[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmrBD-kUUNk87lGb6eLGcDLDp6Etg_s_4BJAjgo2Il5w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Dana-Farber Cancer Institute",[4],820,false,233,16,320385,171,279,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Breast Cancer",116,{"name":18,"count":19},"Prostate Cancer",54,{"name":21,"count":22},"Ovarian Cancer",32,{"name":24,"count":25},"Multiple Myeloma",24,{"name":27,"count":28},"Leukemia",21,{"name":30,"count":28},"Lung Cancer",{"name":32,"count":28},"Cancer",{"name":34,"count":35},"Waldenstrom's Macroglobulinemia",19,[37,42,47,52,56,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT00378105","Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma","2009-07","Bortezomib",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT01366092","Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","2014-10","Interleukin-2",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT01661881","Rituximab\u002FBendamustine + Rituximab\u002FCytarabine for Mantle Cell Lymphoma","2015-02","Rituximab",{"nctId":53,"briefTitle":54,"date":55,"intervention":46},"NCT01937468","Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","2017-08",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT00264602","Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer","2017-09-01","Near Infrared Imaging",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT02158091","A Phase 1b\u002F2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","2017-10","IPI-145",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT02091245","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML","2018-02","KPT-330",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT02326974","T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA","2018-06","T-DM1",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT02919683","Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity","2019-07","Nivolumab",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT02425904","Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders","2020-01","Clofarabine",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,328,441,552,570,999,1195,1278,1401,1491,1577,1631,1657,1696,1722,1755,1777,1804,1822,1840,2159,2310,2531,2611,2777,2980,3086,3151,3238,3313,3458,3527,3572,3616,3735,3775,3842,3879,3923,3966,4009,4261,4419,4511,4548,4587,4622,4648,4675,4703,4732,4754,4885,4960,4986,5044,5076,5104,5141,5167,5193,5226,5256,5292,5317,5346,5372,5394,5416,5438,5456,5474,5492,5510,5537,5566,5584,5611,5638,5656,5674,5692,5710,5728,5746,5764,5782,5806,5824,5842,5860,5878,5896,5914,5932,5957,5975,5999,6017,6041,6059,6077,6110,6128,6146,6164,6182,6200,6218,6243,6261,6279,6297,6315,6333,6359,6377,6395,6420,6446,6464,6482,6500,6518,6536,6554,6572,6590,6737,6763,6820,6852,6878,6904,6930,6957,6979,7008,7026,7044,7062,7080,7098,7116,7134,7158,7176,7194,7212,7230,7248,7266,7284,7302,7320,7338,7356,7374,7392,7419,7437,7455,7481,7511,7529,7554,7572,7623,7645,7671,7695,7717,7767,7814,7858,7901,7944,7974,8004,8040,8066,8088,8110,8132,8154,8176,8208,8226,8244,8262,8285,8303,8321,8344,8362,8380,8451,8541,8594,8662,8716,8767,8828,8870,8916,8954,8995,9038,9068,9106,9145,9186,9216,9242,9270,9299,9349,9375,9401,9435,9461,9500,9522,9551,9577,9599,9621,9643,9671,9698,9720,9749,9780,9807,9839,9861,9885,9907,9940,9962,9994,10016,10038,10060,10082,10109,10134,10160,10182,10204,10226,10248,10270,10293,10317,10335,10353,10376,10394,10412,10430,10448,10466,10484,10502,10520,10538,10556,10579,10597,10615,10633,10658,10676,10694,10716,10734,10752,10774,10796,10814,10832,10856,10874,10903,10921,10944,10962,10980,10998,11016,11038,11062,11087,11109,11127,11145,11163,11184,11206,11224,11248,11272,11297,11315,11333,11351,11375,11400,11424,11442,11460,11484,11505,11529,11547,11570,11588,11606,11629,11647,11665,11688,11713,11734,11758,11776,11794,11812,11833,11854,11872,11890,11908,11929,11947,11965,11987,12014,12032,12054,12072,12095,12113,12137,12155,12173,12191,12214,12232,12259,12277,12295,12319,12337,12355,12379,12397,12420,12438,12456,12477,12498,12519,12537,12558,12576,12594,12612,12635,12656,12677,12695,12713,12734,12752,12781,12806,12828,12850,12877,12895,12917,12935,12956,12974,13000,13018,13036,13054,13076,13094,13112,13130,13148,13175,13193,13211,13229,13253,13271,13289,13307,13325,13348,13366,13384,13407,13425,13443,13461,13482,13500,13521,13543,13566,13584,13608,13632,13655,13673,13691,13709,13730,13751,13769,13787,13805,13823,13841,13859,13877,13898,13920,13938,13956,13974,13992,14019,14037,14055,14073,14091,14113,14135,14153,14171,14193,14217,14239,14257,14282,14305,14327,14345,14369,14394,14412,14434,14462,14484,14508,14529,14550,14572,14590],{"intervention":95,"totalTrials":9,"cells":96},"Prednisone",{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":132,"PHASE3":287,"PHASE4":311,"NA":326},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102,115],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT01741753","BKM120+Abiraterone Acetate for Metastatic CRPC","TERMINATED",[88],"2014-12-29","2016-09-01","2012-11",4,[18],[113,114,95],"BKM120","Abiraterone",{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT01523977","Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL","COMPLETED",[88],"2017-01","2018-11","2011-11",22,[125],"Acute Lymphoblastic Leukemia",[127,95,128,129,130,131],"Everolimus","Vincristine","PEG-Asparaginase","Doxorubicin","Dexrazoxane",{"trials":133,"activeCount":286,"soonestReadout":222},[134,148,159,180,193,204,217,235,246,258,270],{"nctId":135,"briefTitle":136,"status":118,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":145},"NCT04339062","Cemiplimab in AlloSCT\u002FSOT Recipients With CSCC",[88,89],"2023-06-12","2025-03-01","2020-11-03",12,[143,144],"Cutaneous Squamous Cell Carcinoma","Advanced Cancer",[146,127,147,95],"Cemiplimab","Sirolimus",{"nctId":149,"briefTitle":150,"status":118,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":35,"conditions":154,"interventions":156},"NCT00459186","The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer",[88,89],"2012-12","2005-11",[155,18],"Metastatic, Androgen Independent Prostate Cancer",[157,158,95],"RAD001","Docetaxel",{"nctId":160,"briefTitle":161,"status":118,"phases":162,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":168},"NCT00136435","A Study in Adults With Untreated Acute Lymphoblastic Leukemia",[89],"2008-11","2011-05","2002-06",100,[125],[169,170,171,172,173,174,175,176,177,178,179],"prednisone","doxorubicin","vincristine","methotrexate","asparaginase","dexamethasone","leucovorin","cytarabine","hydrocortisone","6-mercaptopurine","e. coli L-asparaginase",{"nctId":181,"briefTitle":182,"status":118,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":189},"NCT02903368","Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy",[89],"2022-04-05","2024-07-10","2016-10-19",118,[18],[190,191,95,192],"Apalutamide","Leuprolide","Abiraterone Acetate",{"nctId":194,"briefTitle":195,"status":118,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":123,"conditions":200,"interventions":202},"NCT00815919","Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease",[89],"2012-01","2013-01","2008-12",[201],"Chronic Graft Versus Host Disease",[203,95],"bortezomib",{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":214},"NCT03141671","Randomized Phase II Study of Salvage XRT + ADT +\u002F- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)","UNKNOWN",[89],"2025-04-05","2025-12-31","2017-11-24",345,[18],[215,216,114,95,190],"GnRH","Bicalutamide",{"nctId":218,"briefTitle":219,"status":220,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":230},"NCT05922761","BElumosudil for Bronchiolitis Obliterans Prevention\u002FTherapy (BEBOP)","RECRUITING",[89],"2027-06-30","2027-12-31","2024-05-31",45,[227,228,229,201],"Bronchiolitis Obliterans Syndrome","Bronchiolitis Obliterans","Lung Diseases",[231,232,233,95,234],"Belumosudil","Fluticasone","Azithromycin","Montelukast",{"nctId":236,"briefTitle":237,"status":105,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},"NCT03093272","A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer",[89],"2019-05-16","2019-12-31","2017-06-23",9,[18],[245,95,158,190],"Leuprolide Acetate",{"nctId":247,"briefTitle":248,"status":118,"phases":249,"primaryCompletion":250,"completion":251,"start":45,"enrollment":252,"conditions":253,"interventions":256},"NCT02268175","Enzalutamide\u002FLeuprolide +\u002F- Abiraterone\u002FPred in Prostate",[89],"2018-01","2021-12",75,[254,18,255],"Prostate Adenocarcinoma","High Risk Prostate Cancer",[257,192,95,245],"Enzalutamide",{"nctId":259,"briefTitle":260,"status":105,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT00361621","Ph II CHOP+Velcade in Mediastinal LBCL",[89],"2007-11","2008-05","2006-07",3,[267],"Non-Hodgkin's Lymphoma",[203,51,269,130,128,95],"Cyclophosphamide",{"nctId":271,"briefTitle":272,"status":105,"phases":273,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT01746173","CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma",[89],"2013-07",5,[277],"T-cell Non-Hodgkin Lymphoma",[269,130,128,279,95,280,281,282,283,284,285],"Etoposide","Filgrastim","Plerixafor","Palifermin","Gemcitabine","Busulfan","Melphalan",1,{"trials":288,"activeCount":99},[289,298],{"nctId":290,"briefTitle":291,"status":105,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":141,"conditions":295,"interventions":296},"NCT03777982","Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT",[90],"2024-02-13","2020-04-20",[18],[95,190,192,297],"LHRH Agonist or Antagonist",{"nctId":299,"briefTitle":300,"status":118,"phases":301,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT00165178","Treatment of Acute Lymphoblastic Leukemia in Children",[90],"2004-12","2000-09",498,[125],[169,174,170,307,171,172,308,309,176,310],"E. coli asparaginase","Leucovorin","Asparaginase","Methotrexate\u002FHydrocortisone",{"trials":312,"activeCount":286,"soonestReadout":318},[313],{"nctId":314,"briefTitle":315,"status":316,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT07426484","Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","NOT_YET_RECRUITING",[91],"2030-12-15","2032-12-15","2026-07",80,[143,323],"Skin Cancer",[325,95,147,127],"Cosibelimab",{"trials":327,"activeCount":99},[],{"intervention":127,"totalTrials":329,"cells":330},10,{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":365,"PHASE3":431,"PHASE4":433,"NA":439},{"trials":332,"activeCount":99},[],{"trials":334,"activeCount":286,"soonestReadout":357},[335,339,352],{"nctId":116,"briefTitle":117,"status":118,"phases":336,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":337,"interventions":338},[88],[125],[127,95,128,129,130,131],{"nctId":340,"briefTitle":341,"status":118,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":349},"NCT01184326","Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer",[88],"2017-03","2011-01",23,[347,348],"Solid Tumor","Kidney Cancer",[350,351],"pazopanib","everolimus",{"nctId":353,"briefTitle":354,"status":355,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":225,"conditions":360,"interventions":362},"NCT03740334","Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL","ACTIVE_NOT_RECRUITING",[88],"2023-03-04","2026-10-01","2019-01-30",[361],"Acute Lymphoblastic Leukemia ALL",[363,364,127],"Ribociclib","Dexamethasone",{"trials":366,"activeCount":99},[367,371,383,397,410,421],{"nctId":135,"briefTitle":136,"status":118,"phases":368,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":369,"interventions":370},[88,89],[143,144],[146,127,147,95],{"nctId":372,"briefTitle":373,"status":118,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT01058655","RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer",[88,89],"2013-09","2015-04","2010-02",56,[380],"Gastrointestinal Cancer",[127,382],"Tivozanib",{"nctId":384,"briefTitle":385,"status":118,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":394},"NCT02871791","Palbociclib With Everolimus + Exemestane In BC",[88,89],"2020-12-03","2021-09","2016-08-24",41,[392,393],"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Hormone Receptor (HR)-Positive Breast Cancer",[395,127,396],"Palbociclib","Exemestane",{"nctId":398,"briefTitle":399,"status":118,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":409},"NCT02201212","Everolimus for Cancer With TSC1 or TSC2 Mutation",[89],"2019-06","2014-09",30,[405,406,407,408],"TSC1","TSC2","Tuberous Sclerosis Complex","MTOR",[127],{"nctId":411,"briefTitle":412,"status":118,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":345,"conditions":416,"interventions":420},"NCT00782626","Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas",[89],"2012-08","2009-06",[417,418,419],"Glioma","Low-grade Glioma","Astrocytoma",[351],{"nctId":422,"briefTitle":423,"status":105,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":430},"NCT01125293","Everolimus, Bortezomib and\u002For Rituximab in Patients With Relapsed\u002FRefractory Waldenstrom's Macroglobulinemia",[88,89],"2013-12","2014-08","2010-04",46,[34],[127,51,41],{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":286,"soonestReadout":318},[435],{"nctId":314,"briefTitle":315,"status":316,"phases":436,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":437,"interventions":438},[91],[143,323],[325,95,147,127],{"trials":440,"activeCount":99},[],{"intervention":147,"totalTrials":329,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":530,"PHASE4":544,"NA":550},{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":99},[],{"trials":448,"activeCount":99},[449,453,467,481,493,503,512,521],{"nctId":135,"briefTitle":136,"status":118,"phases":450,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":451,"interventions":452},[88,89],[143,144],[146,127,147,95],{"nctId":454,"briefTitle":455,"status":118,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":465},"NCT00144703","Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation",[89],"2006-11","2002-07",55,[461,462,125,463,267,464],"Hematologic Malignancies","Myelogenous Leukemia","Myelodysplastic Syndrome","Hodgkin's Disease",[147,466],"Tacrolimus",{"nctId":468,"briefTitle":469,"status":118,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":403,"conditions":473,"interventions":478},"NCT00144677","Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation",[89],"2006-06","2003-11",[474,475,125,476,477,267,464],"Acute Myelogenous Leukemia","Graft Versus Host Disease","Chronic Myelogenous Leukemia","Myelodysplastic Syndromes",[479,480],"sirolimus","tacrolimus",{"nctId":482,"briefTitle":483,"status":118,"phases":484,"primaryCompletion":485,"completion":40,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT00282282","Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation",[89],"2009-01","2006-01",31,[475,489],"GVHD",[480,479,491,492],"fludarabine","busulfex",{"nctId":494,"briefTitle":495,"status":105,"phases":496,"primaryCompletion":375,"completion":375,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT00548717","Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation",[89],"2007-10",15,[500],"Graft-vs-Host Disease",[147,502,41],"Mycophenolate mofetil",{"nctId":504,"briefTitle":505,"status":118,"phases":506,"primaryCompletion":507,"completion":507,"start":458,"enrollment":508,"conditions":509,"interventions":510},"NCT00146614","Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation",[89],"2003-04",105,[475,461],[147,466,511],"Methotrexate",{"nctId":513,"briefTitle":514,"status":118,"phases":515,"primaryCompletion":516,"completion":517,"start":198,"enrollment":518,"conditions":519,"interventions":520},"NCT01754389","Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant",[89],"2016-05","2016-11",138,[475],[466,511,41,147],{"nctId":522,"briefTitle":523,"status":105,"phases":524,"primaryCompletion":516,"completion":516,"start":525,"enrollment":329,"conditions":526,"interventions":529},"NCT02123966","An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease",[89],"2014-07",[527,528],"Chronic Graft-versus-Host-Disease","Oral Mucosal Disease Due to Graft-versus-host Disease",[147],{"trials":531,"activeCount":99},[532],{"nctId":533,"briefTitle":534,"status":118,"phases":535,"primaryCompletion":536,"completion":536,"start":415,"enrollment":537,"conditions":538,"interventions":541},"NCT00928018","Tacrolimus\u002FSirolimus\u002FMethotrexate vs Tacrolimus\u002FMethotrexate or Cyclosporine\u002FMycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma",[90],"2014-11",139,[539,540],"Non-hodgkin Lymphoma","Hodgkin Lymphoma",[147,511,466,542,543],"Cyclosporine","MMF",{"trials":545,"activeCount":286,"soonestReadout":318},[546],{"nctId":314,"briefTitle":315,"status":316,"phases":547,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":548,"interventions":549},[91],[143,323],[325,95,147,127],{"trials":551,"activeCount":99},[],{"intervention":325,"totalTrials":286,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":99},[],{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":286,"soonestReadout":318},[564],{"nctId":314,"briefTitle":315,"status":316,"phases":565,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":566,"interventions":567},[91],[143,323],[325,95,147,127],{"trials":569,"activeCount":99},[],{"intervention":269,"totalTrials":571,"cells":572},33,{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":721,"PHASE3":959,"PHASE4":995,"NA":997},{"trials":574,"activeCount":99},[],{"trials":576,"activeCount":720,"soonestReadout":701},[577,592,615,627,639,654,666,680,697,708],{"nctId":578,"briefTitle":579,"status":118,"phases":580,"primaryCompletion":581,"completion":582,"start":583,"enrollment":275,"conditions":584,"interventions":587},"NCT00005988","Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy",[88],"2001-06-16","2002-03-08","2000-02",[475,27,585,477,586],"Lymphoma","Myeloma",[588,589,590,172,591],"cyclophosphamide","cyclosporine","leucovorin calcium","methylprednisolone",{"nctId":593,"briefTitle":594,"status":355,"phases":595,"primaryCompletion":596,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":613},"NCT03152318","A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2",[88],"2027-01","2028-01","2017-07-18",62,[601,419,602,603,604,605,606,607,608,609,417,610,611,612],"Malignant Glioma of Brain","Malignant Astrocytoma","Oligodendroglioma","Anaplastic Oligodendroglioma of Brain (Diagnosis)","Mixed Oligo-Astrocytoma","Ependymoma","Ganglioglioma","Pylocytic\u002FPylomyxoid Astrocytoma","Brain Tumor","Brain Cancer","Glioblastoma","Glioblastoma Multiforme",[614,269],"rQNestin",{"nctId":616,"briefTitle":617,"status":220,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":498,"conditions":622,"interventions":624},"NCT03219450","A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.",[88],"2027-07-31","2028-07-31","2021-08-18",[623],"Lymphocytic Leukemia",[625,269,626],"NeoVax","Pembrolizumab",{"nctId":628,"briefTitle":629,"status":105,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":265,"conditions":633,"interventions":637},"NCT03132584","Cyclophosphamide and Alemtuzumab In Lymphoma",[88],"2018-01-30","2017-07-30",[634,635,636],"Non Hodgkin Lymphoma","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma",[269,638],"Alemtuzumab",{"nctId":640,"briefTitle":641,"status":118,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":141,"conditions":645,"interventions":650},"NCT04661852","Cabozantinib With Topotecan-Cyclophosphamide",[88],"2022-10-24","2020-12-23",[646,647,648,649],"Relapsed Ewing Sarcoma","Refractory Ewing Sarcoma","Relapsed Osteosarcoma","Refractory Osteosarcoma",[651,652,269,653],"Cabozantinib","Topotecan","Myeloid growth factor",{"nctId":655,"briefTitle":656,"status":118,"phases":657,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT00496665","ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer",[88],"2008-08","2009-03","2007-07",25,[663],"Metastatic Breast Cancer",[665,269,511],"Vandetanib",{"nctId":667,"briefTitle":668,"status":220,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":677},"NCT04024761","A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation",[88],"2026-12-01","2019-08-31",50,[674,477,675,676],"Acute Myeloid Leukemia","Myeloproliferative Neoplasm","Juvenile Myelomonocytic Leukemia",[678,679,269],"CIML NK","Fludarabine",{"nctId":681,"briefTitle":682,"status":220,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":687,"interventions":692},"NCT04678401","IS-free Treg HaploHCT",[88],"2028-08-31","2029-08-31","2021-01-12",[688,689,690,691,477],"Stem Cell Transplant Complications","Graft Vs Host Disease","Myeloid Leukemia, Acute","Myeloid Leukemia in Relapse (Disorder)",[679,693,269,694,695,696,285],"Thiotepa","Mesna","Treg-enriched donor cell","Unmodified donor T Cell",{"nctId":698,"briefTitle":699,"status":355,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":390,"conditions":704,"interventions":705},"NCT03858322","'ADVANCE' (A Pilot Trial)",[88],"2020-11-10","2026-06-30","2019-03-21",[15],[706,269,707],"Paclitaxel","Carboplatin",{"nctId":709,"briefTitle":710,"status":355,"phases":711,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":718},"NCT04608487","Axi-cel in CNS Lymphoma",[88],"2025-06-14","2038-06-14","2020-12-04",18,[585,717],"Lymphoma Cns",[679,269,719],"Axicabtagene Ciloleucel",6,{"trials":722,"activeCount":720,"soonestReadout":64},[723,742,754,763,778,790,800,806,819,829,842,855,868,880,894,905,916,931,935,939,950],{"nctId":724,"briefTitle":725,"status":118,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":730,"interventions":732},"NCT00084838","Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT\u002FRT",[89],"2008-02","2013-03","2003-02",[731],"Central Nervous System Tumor, Pediatric",[733,734,588,176,735,736,737,590,172,738,739,740,741],"filgrastim","cisplatin","dexrazoxane hydrochloride","doxorubicin hydrochloride","etoposide","temozolomide","therapeutic hydrocortisone","vincristine sulfate","Dactinomycin",{"nctId":743,"briefTitle":744,"status":118,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"conditions":749,"interventions":751},"NCT00047281","Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma",[89],"2005-08","2006-02","2004-03",[750],"Brain and Central Nervous System Tumors",[752,588,737,753],"celecoxib","thalidomide",{"nctId":755,"briefTitle":756,"status":105,"phases":757,"primaryCompletion":758,"completion":359,"start":759,"enrollment":459,"conditions":760,"interventions":761},"NCT00925652","Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer",[89],"2015-01-30","2010-09",[15],[762,269,511],"Bevacizumab",{"nctId":764,"briefTitle":765,"status":118,"phases":766,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":771},"NCT00476190","ALL Adult Consortium Trial: Adult ALL Trial",[89],"2020-03","2007-04",112,[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],"Cytarabine","Methylprednisone","Hydrocortisone Sodium Succinate","6-MP","Imatinib","E. coli Asparaginase",{"nctId":779,"briefTitle":780,"status":118,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":787},"NCT00165451","A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer",[89],"2006-10","2001-06",20,[786],"Neoplasms",[788,789,279,269],"Thalidomide","Celecoxib",{"nctId":791,"briefTitle":792,"status":118,"phases":793,"primaryCompletion":74,"completion":794,"start":795,"enrollment":345,"conditions":796,"interventions":797},"NCT01796197","Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa",[89],"2026-01","2013-08",[15],[798,799,706,130,269],"Trastuzumab","Pertuzumab",{"nctId":62,"briefTitle":63,"status":355,"phases":801,"primaryCompletion":64,"completion":320,"start":802,"enrollment":22,"conditions":803,"interventions":805},[88,89],"2014-06-27",[804],"Chronic Lymphocytic Leukemia",[65,679,269,51],{"nctId":807,"briefTitle":808,"status":105,"phases":809,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":813,"interventions":817},"NCT00126191","Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma",[89],"2009-12","2011-06","2005-07",[814,815,816],"Burkitt Lymphoma","Non-Hodgkins Lymphoma","Atypical Burkitt Lymphoma",[51,269,130,128,511,308,818,279,772,694],"Ifosfamide",{"nctId":820,"briefTitle":821,"status":118,"phases":822,"primaryCompletion":427,"completion":823,"start":824,"enrollment":784,"conditions":825,"interventions":828},"NCT00856180","Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies",[89],"2014-01","2009-02",[21,826,827],"Peritoneal Cancer","Fallopian Tube Cancer",[762,269],{"nctId":830,"briefTitle":831,"status":118,"phases":832,"primaryCompletion":833,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":839},"NCT00148681","Preoperative Herceptin and Navelbine for Breast Cancer",[89],"2003-05","2001-05",49,[15,837,838],"Stage II Breast Cancer","Stage III Breast Cancer",[840,841,130,269,706],"Herceptin","Navelbine",{"nctId":843,"briefTitle":844,"status":118,"phases":845,"primaryCompletion":846,"completion":425,"start":847,"enrollment":848,"conditions":849,"interventions":853},"NCT00357500","Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer",[89],"2013-02","2005-01",101,[731,27,585,850,851,852],"Neuroblastoma","Sarcoma","Unspecified Childhood Solid Tumor, Protocol Specific",[752,588,737,854,753],"fenofibrate",{"nctId":856,"briefTitle":857,"status":118,"phases":858,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":861,"interventions":864},"NCT00165139","Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas",[89],"2000-11","1996-01",[850,862,863],"Ewings Sarcoma","Non-rhabdomyosarcoma Soft Tissue Sarcoma",[128,269,865,279,866,707,285,818,867,694],"Adriamycin","Cisplatin","G-CSF",{"nctId":869,"briefTitle":870,"status":355,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":784,"conditions":875,"interventions":877},"NCT05767359","CAR- PRISM (PRecision Intervention Smoldering Myeloma)",[89],"2025-12-15","2040-01-15","2023-04-19",[24,876],"Smoldering Multiple Myeloma",[878,269,879],"Ciltacabtagene Autoleucel","Fludarabine Phosphate",{"nctId":881,"briefTitle":882,"status":118,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":892},"NCT02865135","Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer",[88,89],"2019-10-04","2023-02-06","2017-03-30",11,[889,890,891],"Cancer of Head and Neck","Cancer of Cervix","Cancer of Anus",[893,269],"DPX-E7 vaccine",{"nctId":895,"briefTitle":896,"status":355,"phases":897,"primaryCompletion":898,"completion":899,"start":900,"enrollment":345,"conditions":901,"interventions":903},"NCT02876302","Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer",[89],"2022-12-31","2026-04","2018-01-24",[902],"Inflammatory Breast Cancer (IBC)",[904,706,130,269],"Ruxolitinib",{"nctId":906,"briefTitle":907,"status":118,"phases":908,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":914},"NCT00083031","Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer",[89],"2006-08","2009-08","2003-07",57,[15],[915,588,172],"bevacizumab",{"nctId":917,"briefTitle":918,"status":316,"phases":919,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":923,"interventions":926},"NCT07227584","ALL Backbone in AYAs",[89],"2030-07-31","2035-07-31",67,[125,924,925,27],"Philadelphia Chromosome-Negative Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia (ALL)",[927,928,269,772,364,929,279,930,511,128],"Blinatumomab","Oncaspar","Doxorubicin Hydrochloride","Mercaptopurine",{"nctId":259,"briefTitle":260,"status":105,"phases":932,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":933,"interventions":934},[89],[267],[203,51,269,130,128,95],{"nctId":271,"briefTitle":272,"status":105,"phases":936,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":937,"interventions":938},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"nctId":940,"briefTitle":941,"status":355,"phases":942,"primaryCompletion":943,"completion":944,"start":945,"enrollment":123,"conditions":946,"interventions":948},"NCT02623972","A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer",[89],"2021-05","2026-12","2016-02-26",[947,392],"Inflammatory Breast Cancer",[949,865,269],"Eribulin",{"nctId":951,"briefTitle":952,"status":355,"phases":953,"primaryCompletion":954,"completion":596,"start":45,"enrollment":955,"conditions":956,"interventions":957},"NCT02251548","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",[89],"2025-01",85,[804,27],[958,679,269,51],"Ibrutinib",{"trials":960,"activeCount":286,"soonestReadout":965},[961,983],{"nctId":962,"briefTitle":963,"status":355,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT03020030","Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents",[90],"2026-11-30","2034-11","2017-03-03",560,[970],"Acute Lymphoblastic Leukemia, Pediatric",[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],"Pegaspargase","Erwinia asparaginase","CYTARABINE","DASATINIB","DEXAMETHASONE","ETOPOSIDE","HYDROCORTISONE","LEUCOVORIN CALCIUM","MERCAPTOPURINE","METHOTREXATE","NELARABINE",{"nctId":984,"briefTitle":985,"status":118,"phases":986,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":989,"interventions":991},"NCT00400946","05-001: Treatment of Acute Lymphoblastic Leukemia in Children",[90],"2005-04",800,[990,27],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],"mercaptopurine","pegaspargase","prednisolone",{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[],{"intervention":364,"totalTrials":345,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1035,"PHASE3":1169,"PHASE4":1183,"NA":1185},{"trials":1002,"activeCount":99},[],{"trials":1004,"activeCount":1034,"soonestReadout":357},[1005,1019,1030],{"nctId":1006,"briefTitle":1007,"status":355,"phases":1008,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":345,"conditions":1012,"interventions":1016},"NCT05016947","Venetoclax Plus Inotuzumab for B-ALL",[88],"2023-07-10","2026-12-23","2021-09-24",[1013,1014,1015],"B-cell Acute Lymphoblastic Leukemia","B-Cell Lymphoma","ALL",[1017,364,1018],"Venetoclax","Inotuzumab Ozogamicin",{"nctId":1020,"briefTitle":1021,"status":118,"phases":1022,"primaryCompletion":1023,"completion":388,"start":1024,"enrollment":28,"conditions":1025,"interventions":1027},"NCT01965353","A Phase I Study Of Panobinostat\u002FLenalidomide\u002FBortezomib\u002FDex for Relapsed And Relapsed\u002FRefractory Multiple Myeloma",[88],"2019-03","2013-10",[1026],"Multiple Myeloma in Relapse",[1028,364,1029,41],"Panobinostat","Lenalidomide",{"nctId":353,"briefTitle":354,"status":355,"phases":1031,"primaryCompletion":357,"completion":358,"start":359,"enrollment":225,"conditions":1032,"interventions":1033},[88],[361],[363,364,127],2,{"trials":1036,"activeCount":1034,"soonestReadout":40},[1037,1041,1050,1054,1067,1075,1086,1096,1102,1111,1119,1128,1136,1145,1156,1160],{"nctId":764,"briefTitle":765,"status":118,"phases":1038,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":1039,"interventions":1040},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"nctId":1042,"briefTitle":1043,"status":118,"phases":1044,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":487,"conditions":1047,"interventions":1048},"NCT01470196","Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia",[89],"2016-09","2011-10",[34],[364,1049,51],"Carfilzomib",{"nctId":160,"briefTitle":161,"status":118,"phases":1051,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1052,"interventions":1053},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"nctId":1055,"briefTitle":1056,"status":1057,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":99,"conditions":1062,"interventions":1064},"NCT05050305","Marizomib Central Nervous System (CNS)","WITHDRAWN",[89],"2025-12","2027-12","2024-03",[24,1026,1063],"Multiple Myeloma, Refractory",[1065,1066,364],"Marizomib","Pomalidomide",{"nctId":1068,"briefTitle":1069,"status":118,"phases":1070,"primaryCompletion":1071,"completion":824,"start":1072,"enrollment":345,"conditions":1073,"interventions":1074},"NCT00250926","Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia",[89],"2007-03","2005-10",[34],[41,364,51],{"nctId":1076,"briefTitle":1077,"status":118,"phases":1078,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":1083,"interventions":1084},"NCT02375555","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",[89],"2021-12-15","2024-01-26","2015-05-07",40,[24],[1029,1085,41,364],"Elotuzumab",{"nctId":1087,"briefTitle":1088,"status":118,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT02903381","A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma",[89],"2018-06-28","2021-09-16","2016-10-20",8,[876],[80,1029,364],{"nctId":38,"briefTitle":39,"status":355,"phases":1097,"primaryCompletion":40,"completion":944,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1101},[88,89],"2006-09",68,[24],[41,1029,174],{"nctId":1103,"briefTitle":1104,"status":118,"phases":1105,"primaryCompletion":1106,"completion":1106,"start":376,"enrollment":1107,"conditions":1108,"interventions":1109},"NCT02400437","Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia",[89],"2019-11",26,[34],[1110,364,51],"Ixazomib",{"nctId":1112,"briefTitle":1113,"status":118,"phases":1114,"primaryCompletion":251,"completion":1115,"start":1116,"enrollment":428,"conditions":1117,"interventions":1118},"NCT02441686","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",[89],"2025-10","2015-12",[24],[41,1029,364],{"nctId":1120,"briefTitle":1121,"status":118,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1127},"NCT02916771","Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma",[89],"2025-01-08","2016-10",61,[876],[1110,1029,364],{"nctId":1129,"briefTitle":1130,"status":118,"phases":1131,"primaryCompletion":1132,"completion":1124,"start":909,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT00378209","Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma",[89],"2012-10",65,[24],[41,1029,364],{"nctId":1137,"briefTitle":1138,"status":1057,"phases":1139,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":99,"conditions":1143,"interventions":1144},"NCT03227432","An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma",[89],"2021-12-31","2024-12-31","2018-12",[24],[364,1066,1085,80],{"nctId":1146,"briefTitle":1147,"status":118,"phases":1148,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1155},"NCT02279394","E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma",[89],"2018-12-12","2022-01-26","2014-12-11",51,[1154,876],"Smoldering Myeloma",[1085,1029,364],{"nctId":917,"briefTitle":918,"status":316,"phases":1157,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":1158,"interventions":1159},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"nctId":1161,"briefTitle":1162,"status":118,"phases":1163,"primaryCompletion":1164,"completion":1124,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1168},"NCT00903968","Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed\u002FRefractory Multiple Myeloma",[88,89],"2016-06","2009-06-01",58,[24],[281,203,364],{"trials":1170,"activeCount":286,"soonestReadout":965},[1171,1175,1179],{"nctId":962,"briefTitle":963,"status":355,"phases":1172,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1173,"interventions":1174},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1176,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1177,"interventions":1178},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"nctId":299,"briefTitle":300,"status":118,"phases":1180,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":1181,"interventions":1182},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[1187],{"nctId":1188,"briefTitle":1189,"status":1190,"phases":1191,"conditions":1192,"interventions":1193},"NCT02666209","Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma","NO_LONGER_AVAILABLE",[],[1026,24],[1194,1029,41,364],"Ulocuplumab",{"intervention":772,"totalTrials":141,"cells":1196},{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1230,"PHASE3":1260,"PHASE4":1274,"NA":1276},{"trials":1198,"activeCount":99},[],{"trials":1200,"activeCount":286,"soonestReadout":1205},[1201,1211,1221],{"nctId":1202,"briefTitle":1203,"status":355,"phases":1204,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":672,"conditions":1208,"interventions":1209},"NCT03709758","Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML",[88],"2025-02-23","2026-06-01","2018-10-17",[674],[1017,1210,772],"Daunorubicin",{"nctId":1212,"briefTitle":1213,"status":105,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1034,"conditions":1217,"interventions":1218},"NCT03735446","Prexasertib in Combination With MEC in Relapsed\u002FRefractory AML and High Risk MDS - a Phase I Trial",[88],"2019-03-29","2019-01-18",[674,477],[1219,1220,279,772],"Prexasertib","Mitoxantrone",{"nctId":1222,"briefTitle":1223,"status":118,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":28,"conditions":1227,"interventions":1228},"NCT03654716","Phase 1 Study of the Dual MDM2\u002FMDMX Inhibitor ALRN-6924 in Pediatric Cancer",[88],"2023-07-17","2018-11-01",[27,609,347,585],[1229,772],"ALRN-6924",{"trials":1231,"activeCount":1034,"soonestReadout":50},[1232,1236,1240,1244,1248,1256],{"nctId":724,"briefTitle":725,"status":118,"phases":1233,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":1234,"interventions":1235},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":764,"briefTitle":765,"status":118,"phases":1237,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":1238,"interventions":1239},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"nctId":160,"briefTitle":161,"status":118,"phases":1241,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1242,"interventions":1243},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"nctId":807,"briefTitle":808,"status":105,"phases":1245,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":1246,"interventions":1247},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":48,"briefTitle":49,"status":355,"phases":1249,"primaryCompletion":50,"completion":1250,"start":1251,"enrollment":345,"conditions":1252,"interventions":1254},[89],"2030-04","2012-08-16",[1253],"Mantle Cell Lymphoma",[51,1255,772],"Bendamustine",{"nctId":917,"briefTitle":918,"status":316,"phases":1257,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":1258,"interventions":1259},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"trials":1261,"activeCount":286,"soonestReadout":965},[1262,1266,1270],{"nctId":962,"briefTitle":963,"status":355,"phases":1263,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1264,"interventions":1265},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1267,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1268,"interventions":1269},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"nctId":299,"briefTitle":300,"status":118,"phases":1271,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":1272,"interventions":1273},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":1275,"activeCount":99},[],{"trials":1277,"activeCount":99},[],{"intervention":511,"totalTrials":784,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1302,"PHASE3":1379,"PHASE4":1397,"NA":1399},{"trials":1281,"activeCount":99},[],{"trials":1283,"activeCount":286,"soonestReadout":1292},[1284,1288,1298],{"nctId":578,"briefTitle":579,"status":118,"phases":1285,"primaryCompletion":581,"completion":582,"start":583,"enrollment":275,"conditions":1286,"interventions":1287},[88],[475,27,585,477,586],[588,589,590,172,591],{"nctId":1289,"briefTitle":1290,"status":220,"phases":1291,"primaryCompletion":1292,"completion":222,"start":1293,"enrollment":498,"conditions":1294,"interventions":1296},"NCT06475235","Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL",[88],"2026-12-30","2024-10-18",[585,1295],"Primary Central Nervous System Lymphoma",[626,511,1297,51],"Temozolomide",{"nctId":655,"briefTitle":656,"status":118,"phases":1299,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":1300,"interventions":1301},[88],[663],[665,269,511],{"trials":1303,"activeCount":286,"soonestReadout":920},[1304,1308,1312,1316,1320,1328,1332,1340,1344,1348,1359,1363,1367],{"nctId":724,"briefTitle":725,"status":118,"phases":1305,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":1306,"interventions":1307},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":755,"briefTitle":756,"status":105,"phases":1309,"primaryCompletion":758,"completion":359,"start":759,"enrollment":459,"conditions":1310,"interventions":1311},[89],[15],[762,269,511],{"nctId":764,"briefTitle":765,"status":118,"phases":1313,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":1314,"interventions":1315},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"nctId":160,"briefTitle":161,"status":118,"phases":1317,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1318,"interventions":1319},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"nctId":1321,"briefTitle":1322,"status":118,"phases":1323,"primaryCompletion":1324,"completion":1325,"start":909,"enrollment":225,"conditions":1326,"interventions":1327},"NCT00369226","Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation",[88,89],"2010-07","2011-09",[461],[41,466,511],{"nctId":807,"briefTitle":808,"status":105,"phases":1329,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":1330,"interventions":1331},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":1333,"briefTitle":1334,"status":118,"phases":1335,"primaryCompletion":846,"completion":1336,"start":164,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT01323920","Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors",[89],"2013-11",35,[27,585,463],[41,466,511],{"nctId":504,"briefTitle":505,"status":118,"phases":1341,"primaryCompletion":507,"completion":507,"start":458,"enrollment":508,"conditions":1342,"interventions":1343},[89],[475,461],[147,466,511],{"nctId":513,"briefTitle":514,"status":118,"phases":1345,"primaryCompletion":516,"completion":517,"start":198,"enrollment":518,"conditions":1346,"interventions":1347},[89],[475],[466,511,41,147],{"nctId":1349,"briefTitle":1350,"status":118,"phases":1351,"primaryCompletion":425,"completion":1045,"start":199,"enrollment":1352,"conditions":1353,"interventions":1356},"NCT00808639","Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma",[89],39,[1354,1355],"Bladder Cancer","Muscle-invasive Bladder Cancer",[511,130,1357,734,1358],"vinblastine","Pegfilgrastim",{"nctId":906,"briefTitle":907,"status":118,"phases":1360,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":1361,"interventions":1362},[89],[15],[915,588,172],{"nctId":917,"briefTitle":918,"status":316,"phases":1364,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":1365,"interventions":1366},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"nctId":1368,"briefTitle":1369,"status":105,"phases":1370,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT01773395","GVAX vs. Placebo for MDS\u002FAML After Allo HSCT",[89],"2020-12-11","2021-11-24","2013-01-08",123,[463,674,1376],"Chronic Myelomonocytic Leukemia",[1378,284,679,466,511],"GVAX",{"trials":1380,"activeCount":286,"soonestReadout":965},[1381,1385,1389,1393],{"nctId":962,"briefTitle":963,"status":355,"phases":1382,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1383,"interventions":1384},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1386,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1387,"interventions":1388},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"nctId":299,"briefTitle":300,"status":118,"phases":1390,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":1391,"interventions":1392},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"nctId":533,"briefTitle":534,"status":118,"phases":1394,"primaryCompletion":536,"completion":536,"start":415,"enrollment":537,"conditions":1395,"interventions":1396},[90],[539,540],[147,511,466,542,543],{"trials":1398,"activeCount":99},[],{"trials":1400,"activeCount":99},[],{"intervention":130,"totalTrials":498,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1411,"PHASE3":1460,"PHASE4":1478,"NA":1489},{"trials":1404,"activeCount":99},[],{"trials":1406,"activeCount":99},[1407],{"nctId":116,"briefTitle":117,"status":118,"phases":1408,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":1409,"interventions":1410},[88],[125],[127,95,128,129,130,131],{"trials":1412,"activeCount":286,"soonestReadout":898},[1413,1417,1421,1425,1436,1440,1444,1448,1452,1456],{"nctId":764,"briefTitle":765,"status":118,"phases":1414,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":1415,"interventions":1416},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"nctId":791,"briefTitle":792,"status":118,"phases":1418,"primaryCompletion":74,"completion":794,"start":795,"enrollment":345,"conditions":1419,"interventions":1420},[89],[15],[798,799,706,130,269],{"nctId":160,"briefTitle":161,"status":118,"phases":1422,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1423,"interventions":1424},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"nctId":1426,"briefTitle":1427,"status":118,"phases":1428,"primaryCompletion":486,"completion":486,"start":1429,"enrollment":22,"conditions":1430,"interventions":1434},"NCT00165191","Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus",[89],"1998-08",[1431,1432,1433],"Adenocarcinoma of Stomach","Adenocarcinoma of GE Junction","Adenocarcinoma of Esophagus",[130,866,1435],"5-fluorouracil",{"nctId":807,"briefTitle":808,"status":105,"phases":1437,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":1438,"interventions":1439},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":830,"briefTitle":831,"status":118,"phases":1441,"primaryCompletion":833,"completion":833,"start":834,"enrollment":835,"conditions":1442,"interventions":1443},[89],[15,837,838],[840,841,130,269,706],{"nctId":895,"briefTitle":896,"status":355,"phases":1445,"primaryCompletion":898,"completion":899,"start":900,"enrollment":345,"conditions":1446,"interventions":1447},[89],[902],[904,706,130,269],{"nctId":1349,"briefTitle":1350,"status":118,"phases":1449,"primaryCompletion":425,"completion":1045,"start":199,"enrollment":1352,"conditions":1450,"interventions":1451},[89],[1354,1355],[511,130,1357,734,1358],{"nctId":259,"briefTitle":260,"status":105,"phases":1453,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":1454,"interventions":1455},[89],[267],[203,51,269,130,128,95],{"nctId":271,"briefTitle":272,"status":105,"phases":1457,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":1458,"interventions":1459},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"trials":1461,"activeCount":286,"soonestReadout":965},[1462,1470,1474],{"nctId":1463,"briefTitle":1464,"status":105,"phases":1465,"primaryCompletion":1098,"completion":1098,"start":860,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT00165087","Treatment of Childhood Acute Lymphoblastic Leukemia",[90],491,[125],[173,173,1469,170],"dexrazoxane",{"nctId":962,"briefTitle":963,"status":355,"phases":1471,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1472,"interventions":1473},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":299,"briefTitle":300,"status":118,"phases":1475,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":1476,"interventions":1477},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":1479,"activeCount":99},[1480],{"nctId":1481,"briefTitle":1482,"status":1057,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":99,"conditions":1486,"interventions":1488},"NCT02853500","Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies",[91],"2025-02-03","2016-07",[1487],"Liver Cancer",[130],{"trials":1490,"activeCount":99},[],{"intervention":279,"totalTrials":1492,"cells":1493},14,{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1502,"PHASE3":1563,"PHASE4":1573,"NA":1575},{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[1498],{"nctId":1212,"briefTitle":1213,"status":105,"phases":1499,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1034,"conditions":1500,"interventions":1501},[88],[674,477],[1219,1220,279,772],{"trials":1503,"activeCount":286,"soonestReadout":920},[1504,1508,1512,1516,1520,1524,1537,1541,1545,1549,1553],{"nctId":724,"briefTitle":725,"status":118,"phases":1505,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":1506,"interventions":1507},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":743,"briefTitle":744,"status":118,"phases":1509,"primaryCompletion":746,"completion":747,"start":748,"conditions":1510,"interventions":1511},[89],[750],[752,588,737,753],{"nctId":764,"briefTitle":765,"status":118,"phases":1513,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":1514,"interventions":1515},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"nctId":779,"briefTitle":780,"status":118,"phases":1517,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":1518,"interventions":1519},[89],[786],[788,789,279,269],{"nctId":807,"briefTitle":808,"status":105,"phases":1521,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":1522,"interventions":1523},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":1525,"briefTitle":1526,"status":118,"phases":1527,"primaryCompletion":859,"completion":165,"start":1528,"enrollment":25,"conditions":1529,"interventions":1535},"NCT00003657","High-dose ICE With Amifostine",[89],"1998-07",[1354,750,1530,1531,1532,348,30,21,851,1533,1534],"Carcinoma of Unknown Primary","Extragonadal Germ Cell Tumor","Head and Neck Cancer","Testicular Germ Cell Tumor","Unspecified Adult Solid Tumor, Protocol Specific",[733,1536,707,279,818],"Amifostine",{"nctId":843,"briefTitle":844,"status":118,"phases":1538,"primaryCompletion":846,"completion":425,"start":847,"enrollment":848,"conditions":1539,"interventions":1540},[89],[731,27,585,850,851,852],[752,588,737,854,753],{"nctId":856,"briefTitle":857,"status":118,"phases":1542,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":1543,"interventions":1544},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":917,"briefTitle":918,"status":316,"phases":1546,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":1547,"interventions":1548},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"nctId":271,"briefTitle":272,"status":105,"phases":1550,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":1551,"interventions":1552},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"nctId":1554,"briefTitle":1555,"status":105,"phases":1556,"primaryCompletion":1557,"completion":1132,"start":1558,"enrollment":286,"conditions":1559,"interventions":1562},"NCT01222572","Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer",[88,89],"2012-03","2010-12",[1560,30,1561],"Non-small Cell Lung Cancer","NSCLC",[279,866],{"trials":1564,"activeCount":286,"soonestReadout":965},[1565,1569],{"nctId":962,"briefTitle":963,"status":355,"phases":1566,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1567,"interventions":1568},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1570,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1571,"interventions":1572},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"intervention":128,"totalTrials":329,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1587,"PHASE3":1617,"PHASE4":1627,"NA":1629},{"trials":1580,"activeCount":99},[],{"trials":1582,"activeCount":99},[1583],{"nctId":116,"briefTitle":117,"status":118,"phases":1584,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":1585,"interventions":1586},[88],[125],[127,95,128,129,130,131],{"trials":1588,"activeCount":286,"soonestReadout":920},[1589,1593,1597,1601,1605,1609,1613],{"nctId":764,"briefTitle":765,"status":118,"phases":1590,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":1591,"interventions":1592},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"nctId":160,"briefTitle":161,"status":118,"phases":1594,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1595,"interventions":1596},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"nctId":807,"briefTitle":808,"status":105,"phases":1598,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":1599,"interventions":1600},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":856,"briefTitle":857,"status":118,"phases":1602,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":1603,"interventions":1604},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":917,"briefTitle":918,"status":316,"phases":1606,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":1607,"interventions":1608},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"nctId":259,"briefTitle":260,"status":105,"phases":1610,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":1611,"interventions":1612},[89],[267],[203,51,269,130,128,95],{"nctId":271,"briefTitle":272,"status":105,"phases":1614,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":1615,"interventions":1616},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"trials":1618,"activeCount":286,"soonestReadout":965},[1619,1623],{"nctId":962,"briefTitle":963,"status":355,"phases":1620,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1621,"interventions":1622},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":299,"briefTitle":300,"status":118,"phases":1624,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":1625,"interventions":1626},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":99},[],{"intervention":980,"totalTrials":265,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1653,"NA":1655},{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[],{"trials":1638,"activeCount":286,"soonestReadout":920},[1639],{"nctId":917,"briefTitle":918,"status":316,"phases":1640,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":1641,"interventions":1642},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"trials":1644,"activeCount":286,"soonestReadout":965},[1645,1649],{"nctId":962,"briefTitle":963,"status":355,"phases":1646,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1647,"interventions":1648},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1650,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1651,"interventions":1652},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"intervention":590,"totalTrials":275,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1667,"PHASE3":1682,"PHASE4":1692,"NA":1694},{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[1663],{"nctId":578,"briefTitle":579,"status":118,"phases":1664,"primaryCompletion":581,"completion":582,"start":583,"enrollment":275,"conditions":1665,"interventions":1666},[88],[475,27,585,477,586],[588,589,590,172,591],{"trials":1668,"activeCount":99},[1669,1673],{"nctId":724,"briefTitle":725,"status":118,"phases":1670,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":1671,"interventions":1672},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":1674,"briefTitle":1675,"status":207,"phases":1676,"start":1677,"conditions":1678,"interventions":1679},"NCT00004164","Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx",[89],"1999-08",[1532],[733,734,1680,1681,590],"docetaxel","fluorouracil",{"trials":1683,"activeCount":286,"soonestReadout":965},[1684,1688],{"nctId":962,"briefTitle":963,"status":355,"phases":1685,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1686,"interventions":1687},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1689,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1690,"interventions":1691},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":1693,"activeCount":99},[],{"trials":1695,"activeCount":99},[],{"intervention":131,"totalTrials":265,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1706,"PHASE3":1708,"PHASE4":1718,"NA":1720},{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[1702],{"nctId":116,"briefTitle":117,"status":118,"phases":1703,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":1704,"interventions":1705},[88],[125],[127,95,128,129,130,131],{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":286,"soonestReadout":965},[1710,1714],{"nctId":1463,"briefTitle":1464,"status":105,"phases":1711,"primaryCompletion":1098,"completion":1098,"start":860,"enrollment":1466,"conditions":1712,"interventions":1713},[90],[125],[173,173,1469,170],{"nctId":962,"briefTitle":963,"status":355,"phases":1715,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1716,"interventions":1717},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"trials":1719,"activeCount":99},[],{"trials":1721,"activeCount":99},[],{"intervention":177,"totalTrials":265,"cells":1723},{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1745,"PHASE4":1751,"NA":1753},{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[1730,1741],{"nctId":1731,"briefTitle":1732,"status":105,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":887,"conditions":1736,"interventions":1737},"NCT00953576","Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer",[88,89],"2013-04-11","2009-09-29",[18],[1738,177,1739,1740],"ketoconazole","dutasteride","lapatinib",{"nctId":160,"briefTitle":161,"status":118,"phases":1742,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1743,"interventions":1744},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"trials":1746,"activeCount":286,"soonestReadout":965},[1747],{"nctId":962,"briefTitle":963,"status":355,"phases":1748,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1749,"interventions":1750},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[],{"intervention":972,"totalTrials":1034,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1773,"NA":1775},{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":99},[],{"trials":1762,"activeCount":99},[],{"trials":1764,"activeCount":286,"soonestReadout":965},[1765,1769],{"nctId":962,"briefTitle":963,"status":355,"phases":1766,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1767,"interventions":1768},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"nctId":984,"briefTitle":985,"status":118,"phases":1770,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":1771,"interventions":1772},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"intervention":975,"totalTrials":1034,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1794,"PHASE4":1800,"NA":1802},{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[1785],{"nctId":1786,"briefTitle":1787,"status":105,"phases":1788,"primaryCompletion":198,"completion":1789,"start":1325,"enrollment":275,"conditions":1790,"interventions":1792},"NCT01491633","Dasatinib in Advanced Squamous Cell Lung Cancer",[89],"2013-05",[1791],"Squamous Cell Lung Cancer",[1793],"Dasatinib",{"trials":1795,"activeCount":286,"soonestReadout":965},[1796],{"nctId":962,"briefTitle":963,"status":355,"phases":1797,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1798,"interventions":1799},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[],{"intervention":973,"totalTrials":286,"cells":1805},{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1812,"PHASE4":1818,"NA":1820},{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":286,"soonestReadout":965},[1814],{"nctId":962,"briefTitle":963,"status":355,"phases":1815,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1816,"interventions":1817},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"trials":1819,"activeCount":99},[],{"trials":1821,"activeCount":99},[],{"intervention":982,"totalTrials":286,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1836,"NA":1838},{"trials":1825,"activeCount":99},[],{"trials":1827,"activeCount":99},[],{"trials":1829,"activeCount":99},[],{"trials":1831,"activeCount":286,"soonestReadout":965},[1832],{"nctId":962,"briefTitle":963,"status":355,"phases":1833,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1834,"interventions":1835},[90],[970],[972,973,269,974,975,976,131,130,977,978,979,980,981,982,128],{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[],{"intervention":626,"totalTrials":1841,"cells":1842},29,{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1907,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":1844,"activeCount":99},[],{"trials":1846,"activeCount":275,"soonestReadout":1292},[1847,1857,1861,1872,1876,1888,1897],{"nctId":1848,"briefTitle":1849,"status":118,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":599,"conditions":1853,"interventions":1855},"NCT03239145","Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",[88],"2024-12-13","2018-05-01",[1854],"Advanced Solid Tumor",[626,1856],"Trebananib",{"nctId":1289,"briefTitle":1290,"status":220,"phases":1858,"primaryCompletion":1292,"completion":222,"start":1293,"enrollment":498,"conditions":1859,"interventions":1860},[88],[585,1295],[626,511,1297,51],{"nctId":1862,"briefTitle":1863,"status":355,"phases":1864,"primaryCompletion":1865,"completion":1866,"start":1867,"enrollment":784,"conditions":1868,"interventions":1870},"NCT03361852","Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma",[88],"2026-12-31","2033-12-26","2022-03-14",[1869],"Follicular Lymphoma",[51,1871,626],"Neo Vax",{"nctId":616,"briefTitle":617,"status":220,"phases":1873,"primaryCompletion":619,"completion":620,"start":621,"enrollment":498,"conditions":1874,"interventions":1875},[88],[623],[625,269,626],{"nctId":1877,"briefTitle":1878,"status":355,"phases":1879,"primaryCompletion":223,"completion":1880,"start":1881,"enrollment":329,"conditions":1882,"interventions":1885},"NCT04930783","NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma",[88],"2030-09-30","2022-01-03",[1883,1884],"Melanoma","Metastatic Melanoma",[1886,1887,80,626],"CDX-301","NEOVAX",{"nctId":1889,"briefTitle":1890,"status":118,"phases":1891,"primaryCompletion":1892,"completion":1893,"start":1894,"enrollment":784,"conditions":1895,"interventions":1896},"NCT03032107","A Study Of Pembrolizumab In Combination With Trastuzumab-DM1",[88],"2020-10-29","2024-12-05","2017-02-17",[15],[75,626],{"nctId":1898,"briefTitle":1899,"status":355,"phases":1900,"primaryCompletion":1901,"completion":1902,"start":536,"enrollment":378,"conditions":1903,"interventions":1904},"NCT02287428","Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM",[88],"2027-02","2028-02",[611],[1905,626,1297,1297,1906],"Personalized NeoAntigen Peptides","Poly-ICLC",{"trials":1908,"activeCount":1093,"soonestReadout":2139},[1909,1921,1932,1941,1955,1969,1982,1992,2002,2012,2025,2036,2049,2064,2074,2083,2095,2105,2117,2126,2135,2144],{"nctId":1910,"briefTitle":1911,"status":220,"phases":1912,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":22,"conditions":1916,"interventions":1919},"NCT07465276","Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC",[89],"2028-04-30","2030-04-30","2026-03-26",[1917,1918],"Head and Neck Squamous Cell Carcinoma (HNSCC)","Squamous Cell Carcinoma of the Head and Neck",[1920,626],"Ficerafusp alfa",{"nctId":1922,"briefTitle":1923,"status":118,"phases":1924,"primaryCompletion":1925,"completion":1926,"start":1927,"enrollment":1928,"conditions":1929,"interventions":1930},"NCT03051659","A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer",[89],"2018-10-11","2023-09-05","2017-03-22",90,[15],[1931,626],"Eribulin Mesylate",{"nctId":1933,"briefTitle":1934,"status":105,"phases":1935,"primaryCompletion":1936,"completion":1937,"start":1938,"enrollment":1093,"conditions":1939,"interventions":1940},"NCT03051672","Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC",[89],"2018-09-04","2019-01-11","2017-05-22",[663],[626],{"nctId":1942,"briefTitle":1943,"status":220,"phases":1944,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":22,"conditions":1948,"interventions":1952},"NCT06366347","ALPINE: Maintenance Letrozole\u002FAbemaciclib",[89],"2027-09-01","2029-03-01","2024-09-25",[1949,1950,1951],"Endometrial Cancer","Recurrent Endometrial Cancer","TP53",[1953,1954,626],"Abemaciclib","Letrozole",{"nctId":1956,"briefTitle":1957,"status":220,"phases":1958,"primaryCompletion":223,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1967},"NCT05726370","Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC",[89],"2030-05-20","2023-05-20",28,[1963,1532,1964,1965,1966],"Head and Neck Squamous Cell Carcinoma","Resectable Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Second Primary Squamous Cell Carcinoma of the Head and Neck",[626,1968,707,158],"CISPLATIN",{"nctId":1970,"briefTitle":1971,"status":1057,"phases":1972,"primaryCompletion":1973,"completion":1974,"start":1975,"enrollment":99,"conditions":1976,"interventions":1980},"NCT04703426","Sargramostim (GM-CSF) + PD-1",[89],"2024-06-10","2025-06-09","2021-04-16",[1977,1884,1978,1979],"Unresectable Melanoma","Stage III Melanoma","Stage IV Melanoma",[1981,626],"Sargramostim",{"nctId":1983,"briefTitle":1984,"status":118,"phases":1985,"primaryCompletion":251,"completion":1986,"start":1987,"enrollment":1988,"conditions":1989,"interventions":1991},"NCT02919969","Pembrolizumab in Metastatic Anal Cancer",[89],"2023-03","2016-10-11",38,[1990],"Anal Cancer",[626],{"nctId":1993,"briefTitle":1994,"status":118,"phases":1995,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":1999,"conditions":2000,"interventions":2001},"NCT03661723","Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma",[89],"2021-12-09","2024-08-01","2018-09-28",60,[611],[626,762],{"nctId":2003,"briefTitle":2004,"status":118,"phases":2005,"primaryCompletion":2006,"completion":2007,"start":376,"enrollment":2008,"conditions":2009,"interventions":2011},"NCT02362997","Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL",[89],"2021-10-26","2023-06",82,[540,636,2010],"Peripheral T-Cell Lymphoma",[626],{"nctId":2013,"briefTitle":2014,"status":2015,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":715,"conditions":2020,"interventions":2024},"NCT03316573","Pembrolizumab in Neoplasms or Lymphomas","SUSPENDED",[89],"2022-08-18","2026-03-01","2017-12-07",[585,2021,2022,2023],"Histiocytic Sarcoma","Follicular Dendritic Cell Sarcoma","Interdigitating Dendritic Cell Sarcoma",[626],{"nctId":2026,"briefTitle":2027,"status":118,"phases":2028,"primaryCompletion":2029,"completion":2029,"start":2030,"enrollment":912,"conditions":2031,"interventions":2035},"NCT03899805","A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas",[89],"2024-07-16","2019-06-04",[851,2032,2033,2034],"Liposarcoma","Leiomyosarcoma","Undifferentiated Pleomorphic Sarcoma",[949,626],{"nctId":2037,"briefTitle":2038,"status":220,"phases":2039,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2044,"interventions":2048},"NCT04421560","Pembrolizumab, Ibrutinib and Rituximab in PCNSL",[88,89],"2026-12-05","2027-01-05","2020-08-01",37,[1295,2045,2046,2047],"Recurrent Cancer","Refractory Cancer","Relapsed Cancer",[958,626,51],{"nctId":2050,"briefTitle":2051,"status":220,"phases":2052,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":2056,"conditions":2057,"interventions":2061},"NCT04724018","Sacituzumab Govitecan Plus EV in Metastatic UC",[88,89],"2027-02-01","2028-05-01","2021-05-20",106,[2058,2059,2060,1354],"Urothelial Cancer","Metastatic Urothelial Carcinoma","Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",[2062,2063,626],"Sacituzumab Govitecan","Enfortumab vedotin-ejfv",{"nctId":2065,"briefTitle":2066,"status":118,"phases":2067,"primaryCompletion":2068,"completion":2069,"start":2070,"enrollment":225,"conditions":2071,"interventions":2072},"NCT03093428","Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC",[89],"2020-04-09","2025-02-28","2017-06-09",[18],[2073,626],"Radium-223",{"nctId":2075,"briefTitle":2076,"status":118,"phases":2077,"primaryCompletion":2078,"completion":2078,"start":2079,"enrollment":28,"conditions":2080,"interventions":2082},"NCT03087019","Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma",[89],"2020-08-04","2017-04-25",[2081],"Adenoid Cystic Carcinoma",[626],{"nctId":2084,"briefTitle":2085,"status":118,"phases":2086,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":835,"conditions":2090,"interventions":2094},"NCT02971956","Pembrolizumab in Refractory Advanced Esophageal Cancer",[89],"2019-07-23","2020-05-13","2017-01-18",[2091,2092,2093],"Esophageal Cancer","Squamous Cell Esophagus Cancer","Adenocarcinoma Esophagus",[626],{"nctId":2096,"briefTitle":2097,"status":118,"phases":2098,"primaryCompletion":2099,"completion":2100,"start":2101,"enrollment":1107,"conditions":2102,"interventions":2103},"NCT02865811","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",[89],"2020-08","2022-03","2016-09-15",[21,827,826],[626,2104],"Pegylated Liposomal Doxorubicin",{"nctId":2106,"briefTitle":2107,"status":220,"phases":2108,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2116},"NCT04468061","Sacituzumab Govitecan +\u002F- Pembrolizumab in Metastatic TNBC",[89],"2027-04-01","2029-04-01","2020-07-20",110,[15,2114,2115],"Triple Negative Breast Cancer","PD-L1 Negative",[2062,626],{"nctId":2118,"briefTitle":2119,"status":118,"phases":2120,"primaryCompletion":2121,"completion":2122,"start":2123,"enrollment":321,"conditions":2124,"interventions":2125},"NCT02337491","Pembrolizumab +\u002F- Bevacizumab for Recurrent GBM",[89],"2016-08-28","2020-09-14","2015-02-09",[611],[626,762],{"nctId":2127,"briefTitle":2128,"status":355,"phases":2129,"primaryCompletion":2130,"completion":2053,"start":2131,"enrollment":715,"conditions":2132,"interventions":2133},"NCT03835819","A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)",[89],"2024-06-04","2020-01-02",[1949],[626,2134],"IMGN853",{"nctId":2136,"briefTitle":2137,"status":355,"phases":2138,"primaryCompletion":2139,"completion":2140,"start":2141,"enrollment":715,"conditions":2142,"interventions":2143},"NCT03085719","Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN",[89],"2022-11-01","2027-10-31","2017-06-30",[1532],[626],{"nctId":2145,"briefTitle":2146,"status":1057,"phases":2147,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":99,"conditions":2151,"interventions":2152},"NCT04118036","Abemaciclib + Pembrolizumab In Glioblastoma",[89],"2023-12-01","2024-12-01","2021-12-01",[611],[626,1953],{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[],{"trials":2158,"activeCount":99},[],{"intervention":1017,"totalTrials":1492,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2217,"PHASE3":2304,"PHASE4":2306,"NA":2308},{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":275,"soonestReadout":1009},[2165,2169,2173,2184,2195,2208],{"nctId":1202,"briefTitle":1203,"status":355,"phases":2166,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":672,"conditions":2167,"interventions":2168},[88],[674],[1017,1210,772],{"nctId":1006,"briefTitle":1007,"status":355,"phases":2170,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":345,"conditions":2171,"interventions":2172},[88],[1013,1014,1015],[1017,364,1018],{"nctId":2174,"briefTitle":2175,"status":220,"phases":2176,"primaryCompletion":965,"completion":2177,"start":2178,"enrollment":329,"conditions":2179,"interventions":2182},"NCT06152809","CIML NK Cells With Venetoclax for AML",[88],"2027-11-30","2024-02-20",[674,2180,27,2181],"Acute Myeloid Leukemia Recurrent","Leukemia, Myeloid",[2183,46,1017],"Cytokine-Induced Memory-like Natural Killer Cells",{"nctId":2185,"briefTitle":2186,"status":355,"phases":2187,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":1082,"conditions":2191,"interventions":2193},"NCT04843904","Safe Accelerated Venetoclax Escalation in CLL",[88],"2025-06-02","2030-06-02","2021-04-14",[804,2192],"Small Lymphocytic Lymphoma",[1017,2194,51],"Obinutuzumab",{"nctId":2196,"briefTitle":2197,"status":220,"phases":2198,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2205},"NCT03113643","SL-401 in Combination With Azacitidine or Azacitidine\u002FVenetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",[88],"2026-05-31","2027-05-31","2017-06-26",72,[674,463,2204],"Blastic Plasmacytoid Dendritic Cell Neoplasm",[2206,2207,1017],"Azacitidine","SL-401",{"nctId":2209,"briefTitle":2210,"status":118,"phases":2211,"primaryCompletion":2212,"completion":2213,"start":2214,"enrollment":275,"conditions":2215,"interventions":2216},"NCT03485547","Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",[88],"2022-01-10","2025-04-16","2018-08-23",[2204],[1017],{"trials":2218,"activeCount":1093,"soonestReadout":2274},[2219,2229,2239,2248,2259,2270,2281,2294],{"nctId":2220,"briefTitle":2221,"status":355,"phases":2222,"primaryCompletion":2223,"completion":223,"start":2224,"enrollment":2202,"conditions":2225,"interventions":2227},"NCT03580928","Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL",[89],"2024-04-10","2018-08-07",[2226],"Chronic Lymphocytic Leukemia (CLL)",[1017,2194,2228],"Acalabrutinib",{"nctId":2230,"briefTitle":2231,"status":355,"phases":2232,"primaryCompletion":2149,"completion":2233,"start":2234,"enrollment":2235,"conditions":2236,"interventions":2238},"NCT03054896","A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome",[89],"2027-12-01","2017-03-08",69,[2237],"Richter Syndrome",[1017],{"nctId":2240,"briefTitle":2241,"status":355,"phases":2242,"primaryCompletion":2149,"completion":2243,"start":2244,"enrollment":459,"conditions":2245,"interventions":2246},"NCT03534323","Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS",[88,89],"2026-07-01","2018-07-12",[804,2237],[2247,1017],"Duvelisib",{"nctId":2249,"briefTitle":2250,"status":355,"phases":2251,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":428,"conditions":2255,"interventions":2257},"NCT05734495","Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia",[89],"2029-01-25","2033-01-25","2023-05-02",[2256],"Waldenstrom Macroglobulinemia",[2258,1017],"Pirtobrutinib",{"nctId":2260,"briefTitle":2261,"status":220,"phases":2262,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":225,"conditions":2266,"interventions":2268},"NCT05168930","Zanubrutinib and Venetoclax in CLL (ZANU-VEN)",[89],"2026-10-28","2028-10-28","2022-02-18",[2226,2267],"Small Lymphocytic Lymphoma (SLL)",[1017,2269],"Zanubrutinib",{"nctId":2271,"briefTitle":2272,"status":355,"phases":2273,"primaryCompletion":2274,"completion":2275,"start":2276,"enrollment":225,"conditions":2277,"interventions":2279},"NCT04273139","Ibrutinib + Venetoclax in Untreated WM",[89],"2022-06-06","2028-02-01","2020-07-09",[2256,2278],"MYD88 Gene Mutation",[2280,1017],"IBRUTINIB",{"nctId":2282,"briefTitle":2283,"status":355,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2292},"NCT04572763","Copanlisib Plus Venetoclax in R\u002FR DLBCL",[88,89],"2025-07-29","2026-07-29","2021-09-08",48,[636,2290,2291],"Relapsed Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",[2293,1017],"Copanlisib",{"nctId":2295,"briefTitle":2296,"status":355,"phases":2297,"primaryCompletion":2298,"completion":2299,"start":2300,"enrollment":2008,"conditions":2301,"interventions":2302},"NCT03319901","Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed\u002FRefractory ALL",[88,89],"2025-11-25","2028-05-30","2017-10-30",[27],[1017,2303],"Standard Chemotherapy",{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"intervention":80,"totalTrials":123,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2352,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2313,"activeCount":99},[],{"trials":2315,"activeCount":265,"soonestReadout":2320},[2316,2328,2339,2343],{"nctId":2317,"briefTitle":2318,"status":355,"phases":2319,"primaryCompletion":2320,"completion":2321,"start":2322,"enrollment":887,"conditions":2323,"interventions":2325},"NCT03929029","Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma",[88],"2022-12-27","2028-09-30","2020-11-11",[2324],"Cutaneous Melanoma",[80,2326,2327],"NeoVax plus Montanide","Ipilimumab",{"nctId":2329,"briefTitle":2330,"status":105,"phases":2331,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":35,"conditions":2335,"interventions":2337},"NCT04239040","GVAX Plus Checkpoint Blockade in Neuroblastoma",[88],"2024-01-27","2024-02-29","2020-01-29",[850,2336],"Pediatric Solid Tumor",[2338,80,2327],"GVAX vaccine",{"nctId":1877,"briefTitle":1878,"status":355,"phases":2340,"primaryCompletion":223,"completion":1880,"start":1881,"enrollment":329,"conditions":2341,"interventions":2342},[88],[1883,1884],[1886,1887,80,626],{"nctId":2344,"briefTitle":2345,"status":355,"phases":2346,"primaryCompletion":2347,"completion":2348,"start":2349,"enrollment":123,"conditions":2350,"interventions":2351},"NCT04024878","NeoVax With Nivolumab in Patients With Ovarian Cancer",[88],"2025-04-30","2029-04-30","2020-11-20",[21],[80,625],{"trials":2353,"activeCount":1093,"soonestReadout":79},[2354,2363,2378,2387,2391,2399,2411,2415,2424,2435,2451,2460,2471,2480,2484,2493,2505,2515],{"nctId":2355,"briefTitle":2356,"status":118,"phases":2357,"primaryCompletion":2358,"completion":2359,"start":2360,"enrollment":720,"conditions":2361,"interventions":2362},"NCT03894891","Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer",[89],"2022-10-31","2022-12-16","2019-06-11",[1532],[80,866,158],{"nctId":2364,"briefTitle":2365,"status":355,"phases":2366,"primaryCompletion":702,"completion":1865,"start":2367,"enrollment":166,"conditions":2368,"interventions":2377},"NCT03333616","Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",[89],"2017-12-28",[2369,2370,2371,2372,2373,2374,2375,2376],"Genitourinary Cancer","Adrenocortical Carcinoma","Non-urothelial Bladder","Non-urothelial Upper Tract","Penile Cancer","Non-adenocarcinoma Prostate Cancer","Refractory Germ-cell","High Grade Neuroendocrine Carcinoma\u002FSmall Cell Carcinoma",[2327,80],{"nctId":2379,"briefTitle":2380,"status":105,"phases":2381,"primaryCompletion":2382,"completion":2382,"start":2383,"enrollment":286,"conditions":2384,"interventions":2385},"NCT04899921","Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets",[89],"2023-05-29","2021-06-30",[1883,1884],[2327,80,2386],"Troriluzole",{"nctId":77,"briefTitle":78,"status":355,"phases":2388,"primaryCompletion":79,"completion":944,"start":517,"enrollment":403,"conditions":2389,"interventions":2390},[89],[1532],[80,2327],{"nctId":2392,"briefTitle":2393,"status":118,"phases":2394,"primaryCompletion":2395,"completion":2395,"start":2396,"enrollment":715,"conditions":2397,"interventions":2398},"NCT03316586","A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer",[89],"2019-08-30","2017-11-30",[15],[80,651],{"nctId":2400,"briefTitle":2401,"status":355,"phases":2402,"primaryCompletion":2403,"completion":2404,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2410},"NCT04938232","Ipilimumab With or Without Nivolumab in Relapsed\u002FRefractory cHL",[89],"2024-04-01","2026-08-01","2021-06-04",13,[540,2408,2409],"Relapsed Hodgkin's Disease, Adult","Refractory Hodgkin Lymphoma",[80,2327],{"nctId":1087,"briefTitle":1088,"status":118,"phases":2412,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":2413,"interventions":2414},[89],[876],[80,1029,364],{"nctId":2416,"briefTitle":2417,"status":355,"phases":2418,"primaryCompletion":2419,"completion":2420,"start":2421,"enrollment":403,"conditions":2422,"interventions":2423},"NCT03789110","NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer",[89],"2021-09-30","2027-02-28","2019-03-08",[15],[80,2327],{"nctId":2425,"briefTitle":2426,"status":118,"phases":2427,"primaryCompletion":2428,"completion":2429,"start":2430,"enrollment":2431,"conditions":2432,"interventions":2434},"NCT03246958","Nivolumab Plus Ipilimumab in Thyroid Cancer",[89],"2021-01-21","2021-07-31","2017-10-03",53,[2433],"Thyroid Cancer",[80,2327],{"nctId":2436,"briefTitle":2437,"status":355,"phases":2438,"primaryCompletion":2439,"completion":2440,"start":2441,"enrollment":225,"conditions":2442,"interventions":2450},"NCT04416568","Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers",[89],"2025-07-17","2026-06","2020-08-14",[2443,2444,2445,2446,2447,2448,2449],"Malignant Rhabdoid Tumor","Rhabdoid Tumor of the Kidney","Epithelioid Sarcoma","Chordoma (Poorly Differentiated or De-differentiated)","Atypical Teratoid\u002FRhabdoid Tumor","Other INI1 Negative Tumors (With PI Approval)","Other SMARCA4-deficient Malignant Tumors (With PI Approval)",[80,2327],{"nctId":2452,"briefTitle":2453,"status":105,"phases":2454,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":275,"conditions":2458,"interventions":2459},"NCT03425331","Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC",[89],"2020-05-18","2021-11-28","2018-04-10",[1560],[2327,80],{"nctId":2461,"briefTitle":2462,"status":1057,"phases":2463,"primaryCompletion":2464,"completion":2464,"start":2465,"enrollment":99,"conditions":2466,"interventions":2469},"NCT04007588","A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma",[89],"2019-12-19","2019-09-06",[2467,2468],"Melanoma Stage III","Melanoma Stage IV",[80,2470,2327],"BMS-986205",{"nctId":2472,"briefTitle":2473,"status":355,"phases":2474,"primaryCompletion":2475,"completion":2476,"start":631,"enrollment":2477,"conditions":2478,"interventions":2479},"NCT03414684","Carboplatin +\u002F- Nivolumab in Metastatic Triple Negative Breast Cancer",[89],"2021-09-28","2026-07-30",78,[15],[707,80],{"nctId":1137,"briefTitle":1138,"status":1057,"phases":2481,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":99,"conditions":2482,"interventions":2483},[89],[24],[364,1066,1085,80],{"nctId":2485,"briefTitle":2486,"status":355,"phases":2487,"primaryCompletion":2488,"completion":596,"start":2489,"enrollment":2202,"conditions":2490,"interventions":2491},"NCT02873962","A Phase II Study Of Nivolumab\u002F Bevacizumab\u002FRucaparib",[89],"2025-02","2016-11-10",[826,21,827],[762,80,2492],"Rucaparib",{"nctId":2494,"briefTitle":2495,"status":118,"phases":2496,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":35,"conditions":2500,"interventions":2504},"NCT04197310","Cabozantinib and Nivolumab for Carcinoid Tumors",[89],"2023-12-27","2024-01-31","2019-12-26",[2501,2502,2503],"Carcinoid Tumor","Carcinoid Tumor of GI System","Neuroendocrine Tumors",[80,651],{"nctId":2506,"briefTitle":2507,"status":355,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":1841,"conditions":2512,"interventions":2513},"NCT03341936","Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN",[89],"2021-07-06","2026-07-06","2018-03-15",[1918],[80,2514],"Lirilumab",{"nctId":2516,"briefTitle":2517,"status":118,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":571,"conditions":2522,"interventions":2524},"NCT03692325","Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia",[89],"2022-09-01","2024-08-30","2018-12-05",[2523],"Leukoplakia, Oral",[80],{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[],{"intervention":2327,"totalTrials":2406,"cells":2532},{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2567,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":1034,"soonestReadout":2320},[2537,2541,2552,2563],{"nctId":2317,"briefTitle":2318,"status":355,"phases":2538,"primaryCompletion":2320,"completion":2321,"start":2322,"enrollment":887,"conditions":2539,"interventions":2540},[88],[2324],[80,2326,2327],{"nctId":2542,"briefTitle":2543,"status":355,"phases":2544,"primaryCompletion":2545,"completion":1865,"start":2546,"enrollment":661,"conditions":2547,"interventions":2550},"NCT03912064","A Phase 1 Trial of CD25\u002FTreg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT",[88],"2024-05-24","2019-07-10",[674,477,2548,1376,2549],"Myeloproliferative Neoplasms","Myelofibrosis",[2327,2551],"CD25hi Treg depleted DLI",{"nctId":2553,"briefTitle":2554,"status":118,"phases":2555,"primaryCompletion":2556,"completion":2557,"start":2111,"enrollment":887,"conditions":2558,"interventions":2559},"NCT04290546","CIML NK Cell in Head & Neck Cancer",[88],"2024-09-01","2024-12-16",[1918,1965],[2560,2561,2327,2562],"Interleukin-15 Superagonist","CIML NK cell","Cetuximab",{"nctId":2329,"briefTitle":2330,"status":105,"phases":2564,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":35,"conditions":2565,"interventions":2566},[88],[850,2336],[2338,80,2327],{"trials":2568,"activeCount":275,"soonestReadout":79},[2569,2573,2577,2581,2585,2589,2593,2597,2601],{"nctId":2364,"briefTitle":2365,"status":355,"phases":2570,"primaryCompletion":702,"completion":1865,"start":2367,"enrollment":166,"conditions":2571,"interventions":2572},[89],[2369,2370,2371,2372,2373,2374,2375,2376],[2327,80],{"nctId":2379,"briefTitle":2380,"status":105,"phases":2574,"primaryCompletion":2382,"completion":2382,"start":2383,"enrollment":286,"conditions":2575,"interventions":2576},[89],[1883,1884],[2327,80,2386],{"nctId":77,"briefTitle":78,"status":355,"phases":2578,"primaryCompletion":79,"completion":944,"start":517,"enrollment":403,"conditions":2579,"interventions":2580},[89],[1532],[80,2327],{"nctId":2400,"briefTitle":2401,"status":355,"phases":2582,"primaryCompletion":2403,"completion":2404,"start":2405,"enrollment":2406,"conditions":2583,"interventions":2584},[89],[540,2408,2409],[80,2327],{"nctId":2416,"briefTitle":2417,"status":355,"phases":2586,"primaryCompletion":2419,"completion":2420,"start":2421,"enrollment":403,"conditions":2587,"interventions":2588},[89],[15],[80,2327],{"nctId":2425,"briefTitle":2426,"status":118,"phases":2590,"primaryCompletion":2428,"completion":2429,"start":2430,"enrollment":2431,"conditions":2591,"interventions":2592},[89],[2433],[80,2327],{"nctId":2436,"briefTitle":2437,"status":355,"phases":2594,"primaryCompletion":2439,"completion":2440,"start":2441,"enrollment":225,"conditions":2595,"interventions":2596},[89],[2443,2444,2445,2446,2447,2448,2449],[80,2327],{"nctId":2452,"briefTitle":2453,"status":105,"phases":2598,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":275,"conditions":2599,"interventions":2600},[89],[1560],[2327,80],{"nctId":2461,"briefTitle":2462,"status":1057,"phases":2602,"primaryCompletion":2464,"completion":2464,"start":2465,"enrollment":99,"conditions":2603,"interventions":2604},[89],[2467,2468],[80,2470,2327],{"trials":2606,"activeCount":99},[],{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[],{"intervention":51,"totalTrials":25,"cells":2612},{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2655,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":265,"soonestReadout":2188},[2617,2624,2628,2632,2639,2643],{"nctId":2618,"briefTitle":2619,"status":105,"phases":2620,"primaryCompletion":415,"completion":152,"start":497,"enrollment":242,"conditions":2621,"interventions":2623},"NCT00543114","Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL\u002FSLL",[88],[804,2622],"Small Lymphocytic Leukemia",[1029,679,51],{"nctId":1289,"briefTitle":1290,"status":220,"phases":2625,"primaryCompletion":1292,"completion":222,"start":1293,"enrollment":498,"conditions":2626,"interventions":2627},[88],[585,1295],[626,511,1297,51],{"nctId":1862,"briefTitle":1863,"status":355,"phases":2629,"primaryCompletion":1865,"completion":1866,"start":1867,"enrollment":784,"conditions":2630,"interventions":2631},[88],[1869],[51,1871,626],{"nctId":2633,"briefTitle":2634,"status":118,"phases":2635,"primaryCompletion":198,"completion":823,"start":2636,"enrollment":1841,"conditions":2637,"interventions":2638},"NCT00330252","Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL",[88],"2006-05",[804],[51,638],{"nctId":2185,"briefTitle":2186,"status":355,"phases":2640,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":1082,"conditions":2641,"interventions":2642},[88],[804,2192],[1017,2194,51],{"nctId":2644,"briefTitle":2645,"status":105,"phases":2646,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":25,"conditions":2650,"interventions":2651},"NCT03636503","Rituximab + Immunotherapy in Follicular Lymphoma",[88],"2021-07-23","2023-07-30","2018-10-30",[1869],[51,2652,2653,2654],"Utomilumab","Avelumab","PF04518600",{"trials":2656,"activeCount":110,"soonestReadout":50},[2657,2667,2671,2682,2686,2690,2694,2698,2702,2706,2715,2724,2728,2737,2741,2749,2753],{"nctId":2658,"briefTitle":2659,"status":118,"phases":2660,"primaryCompletion":2661,"completion":197,"start":2662,"enrollment":1107,"conditions":2663,"interventions":2666},"NCT00117156","Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma",[89],"2008-10","2003-12",[2664,2665],"Lymphoma, Non-Hodgkin","MALT Lymphoma",[679,51],{"nctId":1042,"briefTitle":1043,"status":118,"phases":2668,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":487,"conditions":2669,"interventions":2670},[89],[34],[364,1049,51],{"nctId":2672,"briefTitle":2673,"status":118,"phases":2674,"primaryCompletion":2675,"completion":2676,"start":2677,"enrollment":661,"conditions":2678,"interventions":2680},"NCT02086175","A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma",[89],"2019-07-11","2021-02-01","2014-12",[2679],"Relapsed\u002FRefractory Indolent B Cell Non-Hodgkin Lymphomas",[2681,51],"Imprime PGG",{"nctId":62,"briefTitle":63,"status":355,"phases":2683,"primaryCompletion":64,"completion":320,"start":802,"enrollment":22,"conditions":2684,"interventions":2685},[88,89],[804],[65,679,269,51],{"nctId":807,"briefTitle":808,"status":105,"phases":2687,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":2688,"interventions":2689},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":1068,"briefTitle":1069,"status":118,"phases":2691,"primaryCompletion":1071,"completion":824,"start":1072,"enrollment":345,"conditions":2692,"interventions":2693},[89],[34],[41,364,51],{"nctId":2037,"briefTitle":2038,"status":220,"phases":2695,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2696,"interventions":2697},[88,89],[1295,2045,2046,2047],[958,626,51],{"nctId":1103,"briefTitle":1104,"status":118,"phases":2699,"primaryCompletion":1106,"completion":1106,"start":376,"enrollment":1107,"conditions":2700,"interventions":2701},[89],[34],[1110,364,51],{"nctId":48,"briefTitle":49,"status":355,"phases":2703,"primaryCompletion":50,"completion":1250,"start":1251,"enrollment":345,"conditions":2704,"interventions":2705},[89],[1253],[51,1255,772],{"nctId":2707,"briefTitle":2708,"status":105,"phases":2709,"primaryCompletion":2636,"completion":2710,"start":2711,"enrollment":9,"conditions":2712,"interventions":2713},"NCT00142168","CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia",[89],"2008-04","2004-09",[34],[2714,51],"CC-5103",{"nctId":2716,"briefTitle":2717,"status":118,"phases":2718,"primaryCompletion":2719,"completion":2719,"start":2720,"enrollment":2721,"conditions":2722,"interventions":2723},"NCT00422799","Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)",[89],"2015-10-09","2006-08-30",63,[34],[41,51],{"nctId":259,"briefTitle":260,"status":105,"phases":2725,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":2726,"interventions":2727},[89],[267],[203,51,269,130,128,95],{"nctId":2729,"briefTitle":2730,"status":118,"phases":2731,"primaryCompletion":457,"completion":2732,"start":2733,"enrollment":403,"conditions":2734,"interventions":2736},"NCT00136396","Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease",[88,89],"2010-11","2004-01",[2735],"Graft vs Host Disease",[51],{"nctId":951,"briefTitle":952,"status":355,"phases":2738,"primaryCompletion":954,"completion":596,"start":45,"enrollment":955,"conditions":2739,"interventions":2740},[89],[804,27],[958,679,269,51],{"nctId":2742,"briefTitle":2743,"status":118,"phases":2744,"primaryCompletion":414,"completion":414,"start":1098,"enrollment":1133,"conditions":2745,"interventions":2747},"NCT00379587","Rituximab for Prevention of Chronic GVHD",[88,89],[2746],"Hematological Malignancies",[51,2748],"375 mg\u002Fm2 RRituximab",{"nctId":422,"briefTitle":423,"status":105,"phases":2750,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":2751,"interventions":2752},[88,89],[34],[127,51,41],{"nctId":2754,"briefTitle":2755,"status":118,"phases":2756,"primaryCompletion":2757,"completion":425,"start":2758,"enrollment":403,"conditions":2759,"interventions":2760},"NCT00119730","Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma",[89],"2006-12","2005-02",[1253],[679,1220,51,2761],"Zevalin",{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[2768],{"nctId":2769,"briefTitle":2770,"status":118,"phases":2771,"primaryCompletion":1071,"completion":1071,"start":2772,"enrollment":2773,"conditions":2774,"interventions":2775},"NCT00142155","Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia",[92],"2002-01",300,[34],[51,2776],"monoclonal antibodies",{"intervention":706,"totalTrials":784,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2819,"PHASE3":2964,"PHASE4":2976,"NA":2978},{"trials":2780,"activeCount":99},[],{"trials":2782,"activeCount":1034,"soonestReadout":2810},[2783,2794,2806,2815],{"nctId":2784,"briefTitle":2785,"status":105,"phases":2786,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":720,"conditions":2790,"interventions":2792},"NCT02661815","A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer",[88],"2017-06-28","2017-07-28","2016-06-15",[21,827,2791],"Primary Peritoneal Carcinoma",[706,2793,762],"Ricolinostat",{"nctId":2795,"briefTitle":2796,"status":105,"phases":2797,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":2800,"conditions":2801,"interventions":2803},"NCT00358163","Trial of PTK787\u002FZK 222584 Plus Paclitaxel",[88],"2008-05-29","2006-04-26",7,[2802],"Metastatic Non-hematologic Malignancies",[2804,2805],"PTK787\u002FZK 222584","paclitaxel",{"nctId":2807,"briefTitle":2808,"status":355,"phases":2809,"primaryCompletion":2810,"completion":2811,"start":2812,"enrollment":166,"conditions":2813,"interventions":2814},"NCT03716180","DAPHNe: Paclitaxel\u002FTrastuzumab\u002FPertuzumab in HER2-Positive BC",[88],"2020-10-08","2030-09-01","2018-11-05",[15],[706,798,799],{"nctId":698,"briefTitle":699,"status":355,"phases":2816,"primaryCompletion":701,"completion":702,"start":703,"enrollment":390,"conditions":2817,"interventions":2818},[88],[15],[706,269,707],{"trials":2820,"activeCount":110,"soonestReadout":898},[2821,2833,2837,2849,2858,2869,2882,2886,2896,2903,2911,2915,2933,2942,2952],{"nctId":2822,"briefTitle":2823,"status":118,"phases":2824,"primaryCompletion":2825,"completion":2826,"start":2827,"enrollment":2828,"conditions":2829,"interventions":2831},"NCT02698891","Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer",[89],"2020-12","2021-11","2016-04-07",127,[2830],"Early Stage Breast Cancer",[706,2832],"Neulasta",{"nctId":791,"briefTitle":792,"status":118,"phases":2834,"primaryCompletion":74,"completion":794,"start":795,"enrollment":345,"conditions":2835,"interventions":2836},[89],[15],[798,799,706,130,269],{"nctId":2838,"briefTitle":2839,"status":355,"phases":2840,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":2845,"interventions":2847},"NCT04425018","MARGetuximab Or Trastuzumab (MARGOT)",[89],"2024-10-24","2027-07-01","2020-07-13",174,[15,837,838,2846],"HER2-positive Breast Cancer",[706,799,2848,798],"Margetuximab",{"nctId":2850,"briefTitle":2851,"status":118,"phases":2852,"primaryCompletion":516,"completion":2853,"start":2854,"enrollment":784,"conditions":2855,"interventions":2857},"NCT02041429","Ruxolitinib W\u002F Preop Chemo For Triple Negative Inflammatory Brca",[88,89],"2021-01","2014-02",[2856,663],"Recurrent Breast Cancer",[904,706],{"nctId":2859,"briefTitle":2860,"status":220,"phases":2861,"primaryCompletion":2862,"completion":2054,"start":2863,"enrollment":2864,"conditions":2865,"interventions":2866},"NCT04893109","ATEMPT 2.0: Adjuvant T-DM1 vs TH",[89],"2026-11-01","2021-06-16",500,[15,2846],[2867,2868,706],"trastuzumab-emtansine","Trastuzumab SC",{"nctId":2870,"briefTitle":2871,"status":118,"phases":2872,"primaryCompletion":2873,"completion":1336,"start":2874,"enrollment":1999,"conditions":2875,"interventions":2879},"NCT00520013","Avastin +\u002F- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors",[89],"2010-10","2007-08",[21,827,2876,2877,2878],"Primary Peritoneal Cancer","Papillary Serous Mullerian Tumor","Clear Cell Mullerian Tumor",[915,2880,2805,2881],"erlotinib","carboplatin",{"nctId":830,"briefTitle":831,"status":118,"phases":2883,"primaryCompletion":833,"completion":833,"start":834,"enrollment":835,"conditions":2884,"interventions":2885},[89],[15,837,838],[840,841,130,269,706],{"nctId":2887,"briefTitle":2888,"status":118,"phases":2889,"primaryCompletion":2890,"completion":2891,"start":1789,"enrollment":2892,"conditions":2893,"interventions":2894},"NCT01853748","T-DM1 vs Paclitaxel\u002FTrastuzumab for Breast (ATEMPT Trial)",[89],"2019-08-26","2022-06-15",512,[15],[798,706,2895],"Trastuzumab emtansine",{"nctId":2897,"briefTitle":2898,"status":118,"phases":2899,"primaryCompletion":2874,"completion":2874,"start":2636,"enrollment":225,"conditions":2900,"interventions":2902},"NCT00578149","Bevacizumab and Carboplatin\u002FPaclitaxel and Radiation in Non-Small Cell Lung Cancer",[89],[2901],"Non-Small Cell Lung Cancer",[762,707,706],{"nctId":2904,"briefTitle":2905,"status":105,"phases":2906,"primaryCompletion":2710,"completion":427,"start":2907,"enrollment":141,"conditions":2908,"interventions":2910},"NCT00322881","Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer",[89],"2006-04",[21,2791,827,2909],"Mixed Tumor, Mesodermal",[706,707],{"nctId":895,"briefTitle":896,"status":355,"phases":2912,"primaryCompletion":898,"completion":899,"start":900,"enrollment":345,"conditions":2913,"interventions":2914},[89],[902],[904,706,130,269],{"nctId":2916,"briefTitle":2917,"status":220,"phases":2918,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":2922,"interventions":2927},"NCT06439693","The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer",[89],"2030-03-30","2033-03-30","2024-08-08",[2923,15,2924,2925,2846,2926],"Breast Cancer Female","Breast Cancer Metastatic","Estrogen Receptor-positive Breast Cancer","Stage IV Breast Cancer",[2928,706,158,2929,75,799,2930,2931,2932,798],"Nab-Paclitaxel","Phesgo","Trastuzumab Deruxtecan","Trastuzumab Subcutaneous Subcutaneous","Tucatinib",{"nctId":2934,"briefTitle":2935,"status":118,"phases":2936,"primaryCompletion":2937,"completion":2099,"start":2938,"enrollment":2939,"conditions":2940,"interventions":2941},"NCT01982448","Cisplatin vs Paclitaxel for Triple Negative Breast Cancer",[89],"2019-01","2014-04",147,[2114],[866,706],{"nctId":2943,"briefTitle":2944,"status":118,"phases":2945,"primaryCompletion":2946,"completion":2947,"start":497,"enrollment":2948,"conditions":2949,"interventions":2951},"NCT00542451","Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer",[89],"2014-04-21","2022-08-30",406,[15,2950],"Carcinoma of the Breast",[706,798],{"nctId":2953,"briefTitle":2954,"status":118,"phases":2955,"primaryCompletion":2956,"completion":2957,"start":833,"enrollment":1166,"conditions":2958,"interventions":2963},"NCT00095927","Randomized Amifostine For SCCHN",[89],"2007-06","2008-06",[2959,1532,2960,2961,2962],"Chemotherapeutic Agent Toxicity","Mucositis","Radiation Toxicity","Xerostomia",[1536,707,706],{"trials":2965,"activeCount":99},[2966],{"nctId":2967,"briefTitle":2968,"status":118,"phases":2969,"primaryCompletion":2874,"completion":2970,"start":2971,"enrollment":2972,"conditions":2973,"interventions":2974},"NCT00146549","Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer",[90],"2007-12","2001-08",250,[15,2926],[798,2975,706,158],"Vinorelbine",{"trials":2977,"activeCount":99},[],{"trials":2979,"activeCount":99},[],{"intervention":1953,"totalTrials":329,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":3006,"PHASE3":3080,"PHASE4":3082,"NA":3084},{"trials":2983,"activeCount":99},[],{"trials":2985,"activeCount":99},[2986,2997],{"nctId":2987,"briefTitle":2988,"status":118,"phases":2989,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":887,"conditions":2993,"interventions":2995},"NCT04627064","ABEMA Alone or in COMBO With MK-6482",[88],"2024-02-09","2024-08-04","2020-12-31",[2994],"Clear Cell Renal Cell Carcinoma",[1953,2996],"MK-6482",{"nctId":2998,"briefTitle":2999,"status":1057,"phases":3000,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":99,"conditions":3003,"interventions":3004},"NCT03846583","Tucatinib + Abemaciclib + Herceptin for HER2+ MBC",[88],"2020-09-22","2020-06-28",[15],[2932,1953,798,3005],"Aromatase Inhibitor",{"trials":3007,"activeCount":720,"soonestReadout":3016},[3008,3012,3023,3031,3045,3054,3063,3076],{"nctId":1942,"briefTitle":1943,"status":220,"phases":3009,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":22,"conditions":3010,"interventions":3011},[89],[1949,1950,1951],[1953,1954,626],{"nctId":3013,"briefTitle":3014,"status":355,"phases":3015,"primaryCompletion":3016,"completion":3017,"start":3018,"enrollment":35,"conditions":3019,"interventions":3021},"NCT04751929","Abemaciclib With or Without Atezolizumab for mCRPC",[89],"2024-06-17","2026-04-30","2021-08-20",[18,3020],"Metastatic Castration-resistant Prostate Cancer",[1953,3022],"Atezolizumab",{"nctId":3024,"briefTitle":3025,"status":355,"phases":3026,"primaryCompletion":3027,"completion":702,"start":3028,"enrollment":225,"conditions":3029,"interventions":3030},"NCT02981940","A Study of Abemaciclib in Recurrent Glioblastoma",[89],"2024-06-30","2017-02-09",[611],[1953],{"nctId":3032,"briefTitle":3033,"status":220,"phases":3034,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":3038,"conditions":3039,"interventions":3040},"NCT03675893","RESOLVE: Abemaciclib + Letrozole +\u002F- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer",[89],"2028-08-01","2031-08-01","2018-12-24",180,[1949,21],[1954,1953,3041,3042,3043,3044],"LY3023414","Metformin","Zotatifin","Gedatolisib",{"nctId":3046,"briefTitle":3047,"status":105,"phases":3048,"primaryCompletion":621,"completion":3049,"start":3050,"enrollment":3051,"conditions":3052,"interventions":3053},"NCT03130439","Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",[89],"2022-01-30","2017-05-26",27,[15],[1953],{"nctId":3055,"briefTitle":3056,"status":220,"phases":3057,"primaryCompletion":3058,"completion":3059,"start":3060,"enrollment":1988,"conditions":3061,"interventions":3062},"NCT03310879","Study of the CDK4\u002F6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6",[89],"2027-01-01","2027-09-30","2017-11-21",[32],[1953],{"nctId":3064,"briefTitle":3065,"status":355,"phases":3066,"primaryCompletion":3067,"completion":3058,"start":3068,"enrollment":1928,"conditions":3069,"interventions":3072},"NCT06001762","TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer",[89],"2025-01-22","2023-10-05",[15,3070,3071],"Early-stage Breast Cancer","High Risk Breast Carcinoma",[1953,3073,3074,1954,396,3075],"Tamoxifen","Anastrozole","LHRH Agonist",{"nctId":2145,"briefTitle":2146,"status":1057,"phases":3077,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":99,"conditions":3078,"interventions":3079},[89],[611],[626,1953],{"trials":3081,"activeCount":99},[],{"trials":3083,"activeCount":99},[],{"trials":3085,"activeCount":99},[],{"intervention":679,"totalTrials":887,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3108,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3089,"activeCount":99},[],{"trials":3091,"activeCount":265,"soonestReadout":712},[3092,3096,3100,3104],{"nctId":2618,"briefTitle":2619,"status":105,"phases":3093,"primaryCompletion":415,"completion":152,"start":497,"enrollment":242,"conditions":3094,"interventions":3095},[88],[804,2622],[1029,679,51],{"nctId":667,"briefTitle":668,"status":220,"phases":3097,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":3098,"interventions":3099},[88],[674,477,675,676],[678,679,269],{"nctId":681,"briefTitle":682,"status":220,"phases":3101,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":3102,"interventions":3103},[88],[688,689,690,691,477],[679,693,269,694,695,696,285],{"nctId":709,"briefTitle":710,"status":355,"phases":3105,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":3106,"interventions":3107},[88],[585,717],[679,269,719],{"trials":3109,"activeCount":1034,"soonestReadout":64},[3110,3114,3118,3122,3133,3137,3141],{"nctId":2658,"briefTitle":2659,"status":118,"phases":3111,"primaryCompletion":2661,"completion":197,"start":2662,"enrollment":1107,"conditions":3112,"interventions":3113},[89],[2664,2665],[679,51],{"nctId":62,"briefTitle":63,"status":355,"phases":3115,"primaryCompletion":64,"completion":320,"start":802,"enrollment":22,"conditions":3116,"interventions":3117},[88,89],[804],[65,679,269,51],{"nctId":482,"briefTitle":483,"status":118,"phases":3119,"primaryCompletion":485,"completion":40,"start":486,"enrollment":487,"conditions":3120,"interventions":3121},[89],[475,489],[480,479,491,492],{"nctId":3123,"briefTitle":3124,"status":118,"phases":3125,"primaryCompletion":3126,"completion":40,"start":748,"enrollment":1034,"conditions":3127,"interventions":3131},"NCT00153985","Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies",[89],"2008-03",[3128,3129,3130],"Hemoglobinopathies","Sickle Cell Disease","Thalassemia",[3132,679,638],"Busulfex",{"nctId":951,"briefTitle":952,"status":355,"phases":3134,"primaryCompletion":954,"completion":596,"start":45,"enrollment":955,"conditions":3135,"interventions":3136},[89],[804,27],[958,679,269,51],{"nctId":1368,"briefTitle":1369,"status":105,"phases":3138,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":1374,"conditions":3139,"interventions":3140},[89],[463,674,1376],[1378,284,679,466,511],{"nctId":2754,"briefTitle":2755,"status":118,"phases":3142,"primaryCompletion":2757,"completion":425,"start":2758,"enrollment":403,"conditions":3143,"interventions":3144},[89],[1253],[679,1220,51,2761],{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"intervention":46,"totalTrials":242,"cells":3152},{"EARLY_PHASE1":3153,"PHASE1":3169,"PHASE2":3205,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3154,"activeCount":286,"soonestReadout":2420},[3155],{"nctId":3156,"briefTitle":3157,"status":355,"phases":3158,"primaryCompletion":2420,"completion":3159,"start":3160,"enrollment":275,"conditions":3161,"interventions":3167},"NCT06318871","Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma",[87],"2031-07-28","2024-08-28",[3162,3163,3164,3165,3166],"Renal Carcinoma","Renal Cell Carcinoma","Urothelial Carcinoma","Chromophobe Renal Cell Carcinoma","Translocation Renal Cell Carcinoma",[3168,46],"Cytokine Induced Memory-like Natural Killer (CIML NK) Cells",{"trials":3170,"activeCount":265,"soonestReadout":55},[3171,3178,3184,3188,3196],{"nctId":3172,"briefTitle":3173,"status":118,"phases":3174,"primaryCompletion":811,"completion":3175,"start":2874,"enrollment":1841,"conditions":3176,"interventions":3177},"NCT00529035","Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease",[88],"2020-05-27",[475],[46],{"nctId":53,"briefTitle":54,"status":355,"phases":3179,"primaryCompletion":55,"completion":944,"start":1336,"enrollment":661,"conditions":3180,"interventions":3183},[88],[201,3181,3182],"Chronic GVHD","Complications of Organ Transplant Stem Cells",[46],{"nctId":2174,"briefTitle":2175,"status":220,"phases":3185,"primaryCompletion":965,"completion":2177,"start":2178,"enrollment":329,"conditions":3186,"interventions":3187},[88],[674,2180,27,2181],[2183,46,1017],{"nctId":3189,"briefTitle":3190,"status":118,"phases":3191,"primaryCompletion":64,"completion":3192,"start":50,"enrollment":28,"conditions":3193,"interventions":3195},"NCT02318082","Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD",[88],"2020-04-22",[3194],"Chronic Versus Graft Host Disease",[46],{"nctId":3197,"briefTitle":3198,"status":220,"phases":3199,"primaryCompletion":2420,"completion":2177,"start":3200,"enrollment":498,"conditions":3201,"interventions":3203},"NCT06138587","Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation",[88],"2024-01-24",[674,27,2181,477,675,3202],"Myeloproliferative Disorders",[3204,46],"Cytokine Induced Memory-like Natural Killer Cells",{"trials":3206,"activeCount":286,"soonestReadout":45},[3207,3215,3226],{"nctId":3208,"briefTitle":3209,"status":118,"phases":3210,"primaryCompletion":55,"completion":3211,"start":50,"enrollment":661,"conditions":3212,"interventions":3214},"NCT02340676","A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD",[89],"2025-09",[3213],"Chronic Graft-versus-host-disease",[46],{"nctId":3216,"briefTitle":3217,"status":118,"phases":3218,"primaryCompletion":3219,"completion":3219,"start":3220,"enrollment":403,"conditions":3221,"interventions":3222},"NCT00136448","High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)",[89],"2007-09","1993-02",[474],[3223,3224,3225],"cytosine arabinoside","daunomycin","interleukin-2",{"nctId":43,"briefTitle":44,"status":355,"phases":3227,"primaryCompletion":45,"completion":944,"start":3228,"enrollment":1337,"conditions":3229,"interventions":3231},[89],"2011-07",[3230],"Chronic Graft-versus-host Disease",[46],{"trials":3233,"activeCount":99},[],{"trials":3235,"activeCount":99},[],{"trials":3237,"activeCount":99},[],{"intervention":958,"totalTrials":242,"cells":3239},{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3286,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3241,"activeCount":99},[],{"trials":3243,"activeCount":1034,"soonestReadout":767},[3244,3250,3260,3267,3277],{"nctId":3245,"briefTitle":3246,"status":355,"phases":3247,"primaryCompletion":767,"completion":596,"start":1116,"enrollment":19,"conditions":3248,"interventions":3249},"NCT02537613","A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",[88],[804],[2194,958],{"nctId":3251,"briefTitle":3252,"status":118,"phases":3253,"primaryCompletion":3254,"completion":3255,"start":536,"enrollment":225,"conditions":3256,"interventions":3258},"NCT02268851","A Phase I\u002FIb Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",[88],"2018-05","2022-10",[3257,1253],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[3259,958],"TGR-1202",{"nctId":3261,"briefTitle":3262,"status":105,"phases":3263,"primaryCompletion":898,"completion":898,"start":3264,"enrollment":2406,"conditions":3265,"interventions":3266},"NCT03225716","A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia",[88],"2017-10-20",[34],[1194,958],{"nctId":3268,"briefTitle":3269,"status":355,"phases":3270,"primaryCompletion":899,"completion":3271,"start":516,"enrollment":265,"conditions":3272,"interventions":3274},"NCT02787369","ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL",[88],"2027-04",[3273],"Recurrent Chronic Lymphoid Leukemia",[3275,958,3276],"ACY-1215","Idelalisib",{"nctId":3278,"briefTitle":3279,"status":1057,"phases":3280,"primaryCompletion":3281,"completion":3281,"start":3281,"enrollment":99,"conditions":3282,"interventions":3284},"NCT04043845","ERK 1\u002F2 Signaling in Ibrutinib Resistant B-cell Malignancies",[88],"2020-02-03",[804,2256,1253,3283],"Marginal Zone Lymphoma",[958,3285],"LY3214996",{"trials":3287,"activeCount":265,"soonestReadout":2274},[3288,3295,3299,3303],{"nctId":3289,"briefTitle":3290,"status":118,"phases":3291,"primaryCompletion":2139,"completion":2139,"start":3292,"enrollment":487,"conditions":3293,"interventions":3294},"NCT02604511","Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing",[89],"2016-01",[34],[958],{"nctId":2037,"briefTitle":2038,"status":220,"phases":3296,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":3297,"interventions":3298},[88,89],[1295,2045,2046,2047],[958,626,51],{"nctId":2271,"briefTitle":2272,"status":355,"phases":3300,"primaryCompletion":2274,"completion":2275,"start":2276,"enrollment":225,"conditions":3301,"interventions":3302},[89],[2256,2278],[2280,1017],{"nctId":951,"briefTitle":952,"status":355,"phases":3304,"primaryCompletion":954,"completion":596,"start":45,"enrollment":955,"conditions":3305,"interventions":3306},[89],[804,27],[958,679,269,51],{"trials":3308,"activeCount":99},[],{"trials":3310,"activeCount":99},[],{"trials":3312,"activeCount":99},[],{"intervention":707,"totalTrials":35,"cells":3314},{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3352,"PHASE3":3443,"PHASE4":3454,"NA":3456},{"trials":3316,"activeCount":99},[],{"trials":3318,"activeCount":1034,"soonestReadout":701},[3319,3330,3338,3348],{"nctId":3320,"briefTitle":3321,"status":355,"phases":3322,"primaryCompletion":3323,"completion":3324,"start":3325,"enrollment":2043,"conditions":3326,"interventions":3328},"NCT06303713","LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer",[88],"2026-10-19","2027-03-19","2024-05-22",[18,3327,3020],"Metastatic Prostate Cancer",[707,3329],"177Lu-PSMA-617",{"nctId":3331,"briefTitle":3332,"status":118,"phases":3333,"completion":507,"start":3334,"conditions":3335,"interventions":3336},"NCT00005627","Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[88],"1999-03",[18],[2881,1680,3337],"estramustine phosphate sodium",{"nctId":3339,"briefTitle":3340,"status":118,"phases":3341,"primaryCompletion":3342,"completion":794,"start":3343,"enrollment":1492,"conditions":3344,"interventions":3346},"NCT02133625","A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors",[88],"2016-03","2011-08",[1854,3345],"Metastatic Solid Tumor",[2881,3347],"pioglitazone",{"nctId":698,"briefTitle":699,"status":355,"phases":3349,"primaryCompletion":701,"completion":702,"start":703,"enrollment":390,"conditions":3350,"interventions":3351},[88],[15],[706,269,707],{"trials":3353,"activeCount":1034,"soonestReadout":2475},[3354,3361,3371,3375,3386,3390,3394,3398,3409,3413,3417,3427,3431,3435],{"nctId":3355,"briefTitle":3356,"status":118,"phases":3357,"primaryCompletion":2907,"completion":3358,"start":2733,"enrollment":403,"conditions":3359,"interventions":3360},"NCT00134706","A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer",[89],"2009-09",[18],[158,707],{"nctId":3362,"briefTitle":3363,"status":118,"phases":3364,"primaryCompletion":425,"completion":3365,"start":3366,"enrollment":1988,"conditions":3367,"interventions":3369},"NCT01004172","Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases",[89],"2017-02","2009-11",[663,15,3368],"Progressive Breast Cancer",[2881,915,3370],"herceptin",{"nctId":1956,"briefTitle":1957,"status":220,"phases":3372,"primaryCompletion":223,"completion":1959,"start":1960,"enrollment":1961,"conditions":3373,"interventions":3374},[89],[1963,1532,1964,1965,1966],[626,1968,707,158],{"nctId":3376,"briefTitle":3377,"status":105,"phases":3378,"primaryCompletion":1024,"completion":1024,"start":262,"enrollment":1841,"conditions":3379,"interventions":3383},"NCT00570674","Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck",[88,89],[1918,3380,3381,3382],"Basaloid Squamous Cell Carcinoma","Undifferentiated Carcinoma","Adenosquamous Cell Carcinoma",[3384,3385,707],"Abraxane","Erbitux",{"nctId":2870,"briefTitle":2871,"status":118,"phases":3387,"primaryCompletion":2873,"completion":1336,"start":2874,"enrollment":1999,"conditions":3388,"interventions":3389},[89],[21,827,2876,2877,2878],[915,2880,2805,2881],{"nctId":1525,"briefTitle":1526,"status":118,"phases":3391,"primaryCompletion":859,"completion":165,"start":1528,"enrollment":25,"conditions":3392,"interventions":3393},[89],[1354,750,1530,1531,1532,348,30,21,851,1533,1534],[733,1536,707,279,818],{"nctId":856,"briefTitle":857,"status":118,"phases":3395,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":3396,"interventions":3397},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":3399,"briefTitle":3400,"status":105,"phases":3401,"primaryCompletion":3402,"completion":3403,"start":3228,"enrollment":2800,"conditions":3404,"interventions":3406},"NCT01221753","Docetaxel\u002FCisplatin\u002F5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study",[89],"2012-07","2017-07",[1918,3405],"Human Papilloma Virus",[1680,734,3407,3408,2881],"5-FU","cetuximab",{"nctId":2897,"briefTitle":2898,"status":118,"phases":3410,"primaryCompletion":2874,"completion":2874,"start":2636,"enrollment":225,"conditions":3411,"interventions":3412},[89],[2901],[762,707,706],{"nctId":2904,"briefTitle":2905,"status":105,"phases":3414,"primaryCompletion":2710,"completion":427,"start":2907,"enrollment":141,"conditions":3415,"interventions":3416},[89],[21,2791,827,2909],[706,707],{"nctId":3418,"briefTitle":3419,"status":118,"phases":3420,"primaryCompletion":660,"completion":3421,"start":3422,"enrollment":3423,"conditions":3424,"interventions":3425},"NCT00230542","Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer",[89],"2011-04","2005-09",44,[21,826,827],[707,3426],"Pemetrexed",{"nctId":2472,"briefTitle":2473,"status":355,"phases":3428,"primaryCompletion":2475,"completion":2476,"start":631,"enrollment":2477,"conditions":3429,"interventions":3430},[89],[15],[707,80],{"nctId":2953,"briefTitle":2954,"status":118,"phases":3432,"primaryCompletion":2956,"completion":2957,"start":833,"enrollment":1166,"conditions":3433,"interventions":3434},[89],[2959,1532,2960,2961,2962],[1536,707,706],{"nctId":3436,"briefTitle":3437,"status":105,"phases":3438,"primaryCompletion":198,"completion":3439,"start":415,"enrollment":498,"conditions":3440,"interventions":3441},"NCT00910000","Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer",[88,89],"2015-10",[21,827,826],[3442,707,283],"Vorinostat",{"trials":3444,"activeCount":99},[3445],{"nctId":3446,"briefTitle":3447,"status":118,"phases":3448,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":3451,"conditions":3452,"interventions":3453},"NCT00095875","Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)",[90],"2012-04","2004-08",145,[1532],[2881,734,1680,1681],{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"intervention":1954,"totalTrials":1093,"cells":3459},{"EARLY_PHASE1":3460,"PHASE1":3462,"PHASE2":3464,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3461,"activeCount":99},[],{"trials":3463,"activeCount":99},[],{"trials":3465,"activeCount":110,"soonestReadout":3481},[3466,3473,3477,3488,3499,3503,3510,3514],{"nctId":3467,"briefTitle":3468,"status":118,"phases":3469,"primaryCompletion":658,"completion":728,"start":3470,"enrollment":835,"conditions":3471,"interventions":3472},"NCT00090857","Letrozole in Preventing Breast Cancer in Postmenopausal Women",[89],"2002-02",[15],[1954],{"nctId":1942,"briefTitle":1943,"status":220,"phases":3474,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":22,"conditions":3475,"interventions":3476},[89],[1949,1950,1951],[1953,1954,626],{"nctId":3478,"briefTitle":3479,"status":355,"phases":3480,"primaryCompletion":3481,"completion":3482,"start":3483,"enrollment":3484,"conditions":3485,"interventions":3486},"NCT02764541","Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)",[89],"2022-02","2031-04","2016-05-24",195,[15],[1954,3073,395,3487],"Endocrine Therapy",{"nctId":3489,"briefTitle":3490,"status":118,"phases":3491,"primaryCompletion":525,"completion":402,"start":3492,"enrollment":3493,"conditions":3494,"interventions":3495},"NCT00903162","Extended Endocrine Therapy for Premenopausal Women With Breast Cancer",[89],"2009-05",17,[15],[3496,3497,3498],"leuprolide","letrozole","zoledronic acid",{"nctId":3032,"briefTitle":3033,"status":220,"phases":3500,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":3038,"conditions":3501,"interventions":3502},[89],[1949,21],[1954,1953,3041,3042,3043,3044],{"nctId":3504,"briefTitle":3505,"status":207,"phases":3506,"start":1072,"enrollment":1999,"conditions":3507,"interventions":3509},"NCT00280930","Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer",[89],[3508,15],"Post-Menopausal",[1954],{"nctId":3064,"briefTitle":3065,"status":355,"phases":3511,"primaryCompletion":3067,"completion":3058,"start":3068,"enrollment":1928,"conditions":3512,"interventions":3513},[89],[15,3070,3071],[1953,3073,3074,1954,396,3075],{"nctId":3515,"briefTitle":3516,"status":118,"phases":3517,"primaryCompletion":198,"completion":3518,"start":824,"enrollment":3051,"conditions":3519,"interventions":3520},"NCT00856050","Letrozole in Women With Advanced Estrogen\u002FProgesterone Receptor Positive Uterine Leiomyosarcoma",[89],"2014-03",[2033],[3497],{"trials":3522,"activeCount":99},[],{"trials":3524,"activeCount":99},[],{"trials":3526,"activeCount":99},[],{"intervention":799,"totalTrials":720,"cells":3528},{"EARLY_PHASE1":3529,"PHASE1":3531,"PHASE2":3537,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3530,"activeCount":99},[],{"trials":3532,"activeCount":286,"soonestReadout":2810},[3533],{"nctId":2807,"briefTitle":2808,"status":355,"phases":3534,"primaryCompletion":2810,"completion":2811,"start":2812,"enrollment":166,"conditions":3535,"interventions":3536},[88],[15],[706,798,799],{"trials":3538,"activeCount":265,"soonestReadout":74},[3539,3547,3554,3558,3562],{"nctId":3540,"briefTitle":3541,"status":105,"phases":3542,"primaryCompletion":3543,"completion":3543,"start":375,"enrollment":22,"conditions":3544,"interventions":3545},"NCT01912963","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",[89],"2016-12",[2846,663],[799,798,3546],"eribulin",{"nctId":72,"briefTitle":73,"status":355,"phases":3548,"primaryCompletion":74,"completion":597,"start":3549,"enrollment":3550,"conditions":3551,"interventions":3553},[89],"2015-01",164,[3552,15,837,838],"HER-2 Positive Breast Cancer",[75,799],{"nctId":791,"briefTitle":792,"status":118,"phases":3555,"primaryCompletion":74,"completion":794,"start":795,"enrollment":345,"conditions":3556,"interventions":3557},[89],[15],[798,799,706,130,269],{"nctId":2838,"briefTitle":2839,"status":355,"phases":3559,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":3560,"interventions":3561},[89],[15,837,838,2846],[706,799,2848,798],{"nctId":2916,"briefTitle":2917,"status":220,"phases":3563,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":3564,"interventions":3565},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[],{"trials":3571,"activeCount":99},[],{"intervention":3573,"totalTrials":110,"cells":3574},"Sacituzumab govitecan",{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3576,"activeCount":99},[],{"trials":3578,"activeCount":99},[],{"trials":3580,"activeCount":110,"soonestReadout":1206},[3581,3592,3596,3600],{"nctId":3582,"briefTitle":3583,"status":220,"phases":3584,"primaryCompletion":1206,"completion":3585,"start":3586,"enrollment":3587,"conditions":3588,"interventions":3590},"NCT04986579","Scalp Cooling in MBC",[89],"2028-06-01","2021-10-07",120,[663,3589],"Chemotherapy-induced Alopecia",[949,3573,3591],"Trastuzumab deruxtecan",{"nctId":2050,"briefTitle":2051,"status":220,"phases":3593,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":2056,"conditions":3594,"interventions":3595},[88,89],[2058,2059,2060,1354],[2062,2063,626],{"nctId":2106,"briefTitle":2107,"status":220,"phases":3597,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":2112,"conditions":3598,"interventions":3599},[89],[15,2114,2115],[2062,626],{"nctId":3601,"briefTitle":3602,"status":220,"phases":3603,"primaryCompletion":1292,"completion":3604,"start":3605,"enrollment":1082,"conditions":3606,"interventions":3609},"NCT04434040","Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)",[89],"2027-12-30","2020-07-02",[15,2114,3607,3608],"Residual Cancer","Circulating Tumor DNA",[3022,3573],{"trials":3611,"activeCount":99},[],{"trials":3613,"activeCount":99},[],{"trials":3615,"activeCount":99},[],{"intervention":798,"totalTrials":9,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3642,"PHASE3":3725,"PHASE4":3731,"NA":3733},{"trials":3619,"activeCount":99},[],{"trials":3621,"activeCount":286,"soonestReadout":2810},[3622,3634,3638],{"nctId":3623,"briefTitle":3624,"status":118,"phases":3625,"primaryCompletion":3626,"completion":3627,"start":795,"enrollment":390,"conditions":3628,"interventions":3631},"NCT01921335","ARRY-380 + Trastuzuamab for Breast w\u002F Brain Mets",[88],"2018-03","2023-12-31",[3629,3630],"Brain Metastases From HER2 and Breast Cancer","Advanced HER2-positive Breast Cancer",[3632,3633,798],"ARRY-380 Twice Daily Dosage","ARRY-380 Once Daily",{"nctId":2998,"briefTitle":2999,"status":1057,"phases":3635,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":99,"conditions":3636,"interventions":3637},[88],[15],[2932,1953,798,3005],{"nctId":2807,"briefTitle":2808,"status":355,"phases":3639,"primaryCompletion":2810,"completion":2811,"start":2812,"enrollment":166,"conditions":3640,"interventions":3641},[88],[15],[706,798,799],{"trials":3643,"activeCount":1034,"soonestReadout":2841},[3644,3648,3652,3656,3664,3668,3678,3686,3697,3701,3711,3715],{"nctId":3540,"briefTitle":3541,"status":105,"phases":3645,"primaryCompletion":3543,"completion":3543,"start":375,"enrollment":22,"conditions":3646,"interventions":3647},[89],[2846,663],[799,798,3546],{"nctId":791,"briefTitle":792,"status":118,"phases":3649,"primaryCompletion":74,"completion":794,"start":795,"enrollment":345,"conditions":3650,"interventions":3651},[89],[15],[798,799,706,130,269],{"nctId":2838,"briefTitle":2839,"status":355,"phases":3653,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":3654,"interventions":3655},[89],[15,837,838,2846],[706,799,2848,798],{"nctId":3657,"briefTitle":3658,"status":105,"phases":3659,"primaryCompletion":120,"completion":250,"start":2732,"enrollment":487,"conditions":3660,"interventions":3661},"NCT01185509","Trastuzumab and Vinorelbine in Advanced Breast Cancer",[89],[15,663],[3662,3663],"trastuzumab","vinorelbine",{"nctId":2887,"briefTitle":2888,"status":118,"phases":3665,"primaryCompletion":2890,"completion":2891,"start":1789,"enrollment":2892,"conditions":3666,"interventions":3667},[89],[15],[798,706,2895],{"nctId":3669,"briefTitle":3670,"status":105,"phases":3671,"primaryCompletion":3672,"completion":3673,"start":3674,"enrollment":3493,"conditions":3675,"interventions":3676},"NCT03765983","GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases",[89],"2024-04-29","2024-05-14","2019-02-25",[15],[798,3677],"GDC-0084",{"nctId":3679,"briefTitle":3680,"status":118,"phases":3681,"primaryCompletion":3682,"completion":3682,"start":3683,"enrollment":1492,"conditions":3684,"interventions":3685},"NCT00004163","Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer",[89],"2001-09","1999-10",[1532],[798],{"nctId":3687,"briefTitle":3688,"status":118,"phases":3689,"primaryCompletion":251,"completion":3690,"start":3691,"enrollment":2043,"conditions":3692,"interventions":3694},"NCT01191697","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",[89],"2024-08","2011-02",[2091,3693],"Gastric Cancer",[915,3662,3695,3696],"oxaliplatin","capecitabine",{"nctId":2916,"briefTitle":2917,"status":220,"phases":3698,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":3699,"interventions":3700},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"nctId":3702,"briefTitle":3703,"status":118,"phases":3704,"primaryCompletion":3705,"completion":3706,"start":3707,"enrollment":661,"conditions":3708,"interventions":3709},"NCT02657343","An Open-Label, Phase Ib\u002FII Clinical Trial Of Cdk 4\u002F6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced\u002FMetastatic Her2-Positive Breast Cancer.",[88,89],"2020-08-27","2022-06-30","2016-03-09",[15],[363,75,798,3710],"Fulvestrant",{"nctId":2943,"briefTitle":2944,"status":118,"phases":3712,"primaryCompletion":2946,"completion":2947,"start":497,"enrollment":2948,"conditions":3713,"interventions":3714},[89],[15,2950],[706,798],{"nctId":3716,"briefTitle":3717,"status":118,"phases":3718,"primaryCompletion":3719,"completion":3720,"start":536,"enrollment":3721,"conditions":3722,"interventions":3724},"NCT02260531","Cabozantinib +\u002F- Trastuzumab In Breast Cancer Patients w\u002F Brain Metastases",[89],"2019-01-04","2020-03-17",36,[15,3723],"Brain Tumor - Metastatic",[651,798],{"trials":3726,"activeCount":99},[3727],{"nctId":2967,"briefTitle":2968,"status":118,"phases":3728,"primaryCompletion":2874,"completion":2970,"start":2971,"enrollment":2972,"conditions":3729,"interventions":3730},[90],[15,2926],[798,2975,706,158],{"trials":3732,"activeCount":99},[],{"trials":3734,"activeCount":99},[],{"intervention":75,"totalTrials":275,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3745,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3738,"activeCount":99},[],{"trials":3740,"activeCount":99},[3741],{"nctId":1889,"briefTitle":1890,"status":118,"phases":3742,"primaryCompletion":1892,"completion":1893,"start":1894,"enrollment":784,"conditions":3743,"interventions":3744},[88],[15],[75,626],{"trials":3746,"activeCount":265,"soonestReadout":74},[3747,3751,3761,3765],{"nctId":72,"briefTitle":73,"status":355,"phases":3748,"primaryCompletion":74,"completion":597,"start":3549,"enrollment":3550,"conditions":3749,"interventions":3750},[89],[3552,15,837,838],[75,799],{"nctId":3752,"briefTitle":3753,"status":355,"phases":3754,"primaryCompletion":3755,"completion":3756,"start":3757,"enrollment":3758,"conditions":3759,"interventions":3760},"NCT03587740","ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer",[89],"2025-03-03","2027-08-30","2018-08-22",111,[15],[75],{"nctId":2916,"briefTitle":2917,"status":220,"phases":3762,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":3763,"interventions":3764},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"nctId":3702,"briefTitle":3703,"status":118,"phases":3766,"primaryCompletion":3705,"completion":3706,"start":3707,"enrollment":661,"conditions":3767,"interventions":3768},[88,89],[15],[363,75,798,3710],{"trials":3770,"activeCount":99},[],{"trials":3772,"activeCount":99},[],{"trials":3774,"activeCount":99},[],{"intervention":3776,"totalTrials":275,"cells":3777},"Olaparib",{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3805,"PHASE3":3836,"PHASE4":3838,"NA":3840},{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":1034,"soonestReadout":3799},[3782,3795],{"nctId":3783,"briefTitle":3784,"status":220,"phases":3785,"primaryCompletion":3786,"completion":1946,"start":3787,"enrollment":784,"conditions":3788,"interventions":3793},"NCT06488378","Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1\u002F2 and PALB2- Associated Metastatic HER2-negative Breast Cancer",[88],"2026-09-01","2024-08-13",[15,3789,3790,3791,3792],"PALB2-Mutated Breast Carcinoma","HER2-negative Breast Cancer","BRCA1 Mutation","BRCA2 Mutation",[3794,3776],"Axatilimab",{"nctId":3796,"briefTitle":3797,"status":355,"phases":3798,"primaryCompletion":3799,"completion":3800,"start":3801,"enrollment":329,"conditions":3802,"interventions":3803},"NCT03641755","Olaparib + Sapacitabine in BRCA Mutant Breast Cancer",[88],"2022-04-27","2026-10-22","2018-10-01",[15],[3804,3776],"Sapacitabine",{"trials":3806,"activeCount":286,"soonestReadout":3817},[3807,3813,3824],{"nctId":3808,"briefTitle":3809,"status":1057,"phases":3810,"primaryCompletion":414,"completion":414,"start":414,"enrollment":99,"conditions":3811,"interventions":3812},"NCT01661868","Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer",[89],[21,826,827],[3776],{"nctId":3814,"briefTitle":3815,"status":355,"phases":3816,"primaryCompletion":3817,"completion":1206,"start":3818,"enrollment":2721,"conditions":3819,"interventions":3822},"NCT04417062","Olaparib With Ceralasertib in Recurrent Osteosarcoma",[89],"2025-06-01","2020-11-24",[3820,3821],"Osteosarcoma","Osteosarcoma Recurrent",[3776,3823],"Ceralasertib",{"nctId":3825,"briefTitle":3826,"status":1057,"phases":3827,"primaryCompletion":3828,"completion":3829,"start":3830,"enrollment":99,"conditions":3831,"interventions":3835},"NCT05482074","Olaparib in Unresectable\u002FMetastatic Melanoma With BRCA1\u002F2",[89],"2026-05-01","2027-05-01","2022-10-04",[3832,2324,3833,3834],"Recurrent Metastatic Melanoma","Mucosal Melanoma","Uveal Melanoma",[3776],{"trials":3837,"activeCount":99},[],{"trials":3839,"activeCount":99},[],{"trials":3841,"activeCount":99},[],{"intervention":2194,"totalTrials":110,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3856,"PHASE3":3873,"PHASE4":3875,"NA":3877},{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":1034,"soonestReadout":767},[3848,3852],{"nctId":3245,"briefTitle":3246,"status":355,"phases":3849,"primaryCompletion":767,"completion":596,"start":1116,"enrollment":19,"conditions":3850,"interventions":3851},[88],[804],[2194,958],{"nctId":2185,"briefTitle":2186,"status":355,"phases":3853,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":1082,"conditions":3854,"interventions":3855},[88],[804,2192],[1017,2194,51],{"trials":3857,"activeCount":286,"soonestReadout":2223},[3858,3862],{"nctId":2220,"briefTitle":2221,"status":355,"phases":3859,"primaryCompletion":2223,"completion":223,"start":2224,"enrollment":2202,"conditions":3860,"interventions":3861},[89],[2226],[1017,2194,2228],{"nctId":3863,"briefTitle":3864,"status":118,"phases":3865,"primaryCompletion":3866,"completion":3867,"start":3868,"enrollment":3869,"conditions":3870,"interventions":3872},"NCT02867384","Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation",[89],"2023-11-29","2024-11-14","2016-11-29",181,[3871],"Graft vs. Host Disease",[2194],{"trials":3874,"activeCount":99},[],{"trials":3876,"activeCount":99},[],{"trials":3878,"activeCount":99},[],{"intervention":3880,"totalTrials":265,"cells":3881},"Talazoparib",{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3904,"PHASE3":3917,"PHASE4":3919,"NA":3921},{"trials":3883,"activeCount":99},[],{"trials":3885,"activeCount":1034,"soonestReadout":3899},[3886,3895],{"nctId":3887,"briefTitle":3888,"status":355,"phases":3889,"primaryCompletion":3890,"completion":1292,"start":3891,"enrollment":1337,"conditions":3892,"interventions":3893},"NCT04846478","Phase Ia\u002FIb Talazoparib + Tazemetostat for mCRPC",[88],"2025-09-25","2021-06-28",[3327,3020],[3880,3894],"Tazemetostat",{"nctId":3896,"briefTitle":3897,"status":355,"phases":3898,"primaryCompletion":3899,"completion":3058,"start":3900,"enrollment":2406,"conditions":3901,"interventions":3902},"NCT03974217","Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts",[88],"2025-04-03","2019-08-01",[27],[3880,3903],"Decitabine",{"trials":3905,"activeCount":286,"soonestReadout":3910},[3906],{"nctId":3907,"briefTitle":3908,"status":355,"phases":3909,"primaryCompletion":3910,"completion":3911,"start":3912,"enrollment":2056,"conditions":3913,"interventions":3915},"NCT02912572","Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab\u002FTalazoparib and Avelumab\u002FAxitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer",[89],"2023-11-15","2026-11","2016-11-14",[3914],"Metastatic Endometrial Cancer",[2653,3880,3916],"Axitinib",{"trials":3918,"activeCount":99},[],{"trials":3920,"activeCount":99},[],{"trials":3922,"activeCount":99},[],{"intervention":3924,"totalTrials":265,"cells":3925},"Osimertinib",{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3930,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3927,"activeCount":99},[],{"trials":3929,"activeCount":99},[],{"trials":3931,"activeCount":265,"soonestReadout":702},[3932,3942,3952],{"nctId":3933,"briefTitle":3934,"status":355,"phases":3935,"primaryCompletion":3936,"completion":3937,"start":3938,"enrollment":403,"conditions":3939,"interventions":3941},"NCT03586453","Osimertinib In EGFR Mutant Lung Cancer",[89],"2028-02-28","2028-09-01","2018-08-13",[3940],"Carcinoma, Non-Small-Cell Lung",[3924],{"nctId":3943,"briefTitle":3944,"status":355,"phases":3945,"primaryCompletion":3946,"completion":3947,"start":3948,"enrollment":2288,"conditions":3949,"interventions":3950},"NCT03122717","Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer",[88,89],"2026-10","2027-10","2017-05-09",[2901],[3951,3924],"Gefitinib",{"nctId":3953,"briefTitle":3954,"status":355,"phases":3955,"primaryCompletion":702,"completion":1292,"start":3956,"enrollment":661,"conditions":3957,"interventions":3958},"NCT03392246","A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer",[89],"2018-01-31",[1560],[3924,3959],"Selumetinib",{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[],{"trials":3965,"activeCount":99},[],{"intervention":3073,"totalTrials":110,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3969,"activeCount":99},[],{"trials":3971,"activeCount":99},[],{"trials":3973,"activeCount":265,"soonestReadout":3481},[3974,3978,3992],{"nctId":3478,"briefTitle":3479,"status":355,"phases":3975,"primaryCompletion":3481,"completion":3482,"start":3483,"enrollment":3484,"conditions":3976,"interventions":3977},[89],[15],[1954,3073,395,3487],{"nctId":3979,"briefTitle":3980,"status":316,"phases":3981,"primaryCompletion":3982,"completion":684,"start":3983,"enrollment":3984,"conditions":3985,"interventions":3991},"NCT07499999","Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer",[89],"2027-08-31","2026-09-09",140,[15,3986,3987,3988,3792,3989,3990],"Ductal Carcinoma","Estrogen-receptor-positive Breast Cancer","Atypical Lobular Hyperplasia","CHEK2 Gene Mutation","Ataxia Telangiectasia Mutated Gene Mutation",[396,3073],{"nctId":3064,"briefTitle":3065,"status":355,"phases":3993,"primaryCompletion":3067,"completion":3058,"start":3068,"enrollment":1928,"conditions":3994,"interventions":3995},[89],[15,3070,3071],[1953,3073,3074,1954,396,3075],{"trials":3997,"activeCount":99},[],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[4002],{"nctId":4003,"briefTitle":4004,"status":118,"phases":4005,"primaryCompletion":748,"completion":415,"start":4006,"enrollment":1841,"conditions":4007,"interventions":4008},"NCT00165308","Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors",[92],"2001-04",[464,15],[3073],{"intervention":866,"totalTrials":571,"cells":4010},{"EARLY_PHASE1":4011,"PHASE1":4023,"PHASE2":4105,"PHASE3":4251,"PHASE4":4257,"NA":4259},{"trials":4012,"activeCount":99},[4013],{"nctId":4014,"briefTitle":4015,"status":118,"phases":4016,"primaryCompletion":472,"completion":525,"start":303,"enrollment":661,"conditions":4017,"interventions":4020},"NCT00215514","Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma",[87],[4018,3693,4019],"Stomach Cancer","Gastro-esophageal Junction Cancer",[4021,866,4022],"Epirubicin","5-Fluorouracil",{"trials":4024,"activeCount":286,"soonestReadout":2853},[4025,4032,4040,4048,4058,4068,4079,4094],{"nctId":4026,"briefTitle":4027,"status":105,"phases":4028,"primaryCompletion":4029,"start":377,"enrollment":265,"conditions":4030,"interventions":4031},"NCT01058408","RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer",[88],"2012-02",[1532],[157,734],{"nctId":4033,"briefTitle":4034,"status":118,"phases":4035,"primaryCompletion":40,"completion":40,"start":4036,"enrollment":1841,"conditions":4037,"interventions":4039},"NCT00402545","C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[88],"2007-01",[4038],"Head and Neck Neoplasms",[2562,158,866,4022],{"nctId":4041,"briefTitle":4042,"status":118,"phases":4043,"primaryCompletion":4044,"completion":4045,"start":1132,"enrollment":459,"conditions":4046,"interventions":4047},"NCT01674842","Cisplatin + RT for Triple Negative Breast Cancer",[88],"2018-08","2021-06-08",[15],[866],{"nctId":4049,"briefTitle":4050,"status":118,"phases":4051,"primaryCompletion":3422,"completion":4052,"start":4053,"enrollment":19,"conditions":4054,"interventions":4055},"NCT00215501","Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies",[88],"2008-09","2001-11",[347],[4056,4022,4057,866],"Capecitabine","Irinotecan",{"nctId":4059,"briefTitle":4060,"status":355,"phases":4061,"primaryCompletion":2853,"completion":2440,"start":4062,"enrollment":28,"conditions":4063,"interventions":4067},"NCT02474368","Study Evaluating a Stereotactic Boost\u002FTreatment for Recurrent or Metastatic Cancer of the Head and Neck",[88],"2015-11",[4064,4065,4066],"Recurrent Head and Neck Carcinoma","Head and Neck Cancer Metastatic","Head or Neck Cancer",[866],{"nctId":4069,"briefTitle":4070,"status":118,"phases":4071,"primaryCompletion":4072,"completion":3366,"start":1677,"enrollment":4073,"conditions":4074,"interventions":4077},"NCT00165555","Pleurectomy\u002FDecortication Followed by Intrathoracic\u002FIntraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma",[88],"2002-04",70,[4075,4076],"Pleural Mesothelioma","Malignant Pleural Mesothelioma",[866,4078],"Sodium Thiosulfate",{"nctId":4080,"briefTitle":4081,"status":118,"phases":4082,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":345,"conditions":4086,"interventions":4093},"NCT02113878","Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck",[88],"2019-12-06","2022-01-01","2014-09-29",[4087,4088,4089,4090,4091,4092],"Carcinoma, Squamous Cell of Head and Neck","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Hypopharyngeal Cancer","Early Invasive Cervical Squamous Cell Carcinoma","Carcinoma of Larynx","Cancer of Nasopharynx",[113,866],{"nctId":4095,"briefTitle":4096,"status":118,"phases":4097,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":428,"conditions":4101,"interventions":4102},"NCT00251407","Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies",[88],"2003-01","2009-04","1999-09",[347],[4103,866,4104],"Taxotere","CPT-11",{"trials":4106,"activeCount":286,"soonestReadout":223},[4107,4117,4126,4130,4138,4142,4150,4154,4162,4170,4174,4178,4185,4191,4195,4202,4209,4213,4222,4226,4230,4241,4247],{"nctId":4108,"briefTitle":4109,"status":118,"phases":4110,"primaryCompletion":2757,"completion":2757,"start":4111,"enrollment":1988,"conditions":4112,"interventions":4116},"NCT00139269","Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[88,89],"1998-02",[4113,4114,4115],"Advanced Squamous Cell Carcinoma","Squamous Cell Carcinoma of Head and Neck","SSCHN",[158,866,4022],{"nctId":4118,"briefTitle":4119,"status":118,"phases":4120,"primaryCompletion":486,"completion":486,"start":4121,"enrollment":403,"conditions":4122,"interventions":4125},"NCT00139243","Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck",[88,89],"1997-10",[4123,4124],"Squamous Cell Carcinoma","Carcinoma of Head and\u002For Neck",[4103,866,4022,308],{"nctId":724,"briefTitle":725,"status":118,"phases":4127,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":4128,"interventions":4129},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":4131,"briefTitle":4132,"status":118,"phases":4133,"primaryCompletion":497,"completion":497,"start":458,"enrollment":403,"conditions":4134,"interventions":4137},"NCT00123825","Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer",[89],[4135,4136],"Gallbladder Cancer","Biliary Tract Cancer",[283,866],{"nctId":1956,"briefTitle":1957,"status":220,"phases":4139,"primaryCompletion":223,"completion":1959,"start":1960,"enrollment":1961,"conditions":4140,"interventions":4141},[89],[1963,1532,1964,1965,1966],[626,1968,707,158],{"nctId":4143,"briefTitle":4144,"status":105,"phases":4145,"primaryCompletion":1324,"completion":1324,"start":4146,"enrollment":9,"conditions":4147,"interventions":4148},"NCT00165503","Pleurectomy\u002FDecortication With Intraoperative Intrathoracic\u002FIntraperitoneal Heated Cisplatin With Sodium Thiosulfate",[89],"2004-04",[4075,4076],[866,4078,4149],"ALIMTA",{"nctId":2355,"briefTitle":2356,"status":118,"phases":4151,"primaryCompletion":2358,"completion":2359,"start":2360,"enrollment":720,"conditions":4152,"interventions":4153},[89],[1532],[80,866,158],{"nctId":4155,"briefTitle":4156,"status":118,"phases":4157,"primaryCompletion":2636,"completion":4158,"start":4159,"enrollment":3051,"conditions":4160,"interventions":4161},"NCT00148694","Preoperative Cisplatin in Early Stage Breast Cancer",[89],"2010-05","2004-07",[15],[866],{"nctId":4163,"briefTitle":4164,"status":118,"phases":4165,"primaryCompletion":4166,"completion":4099,"start":2971,"enrollment":19,"conditions":4167,"interventions":4169},"NCT00165464","Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer",[89],"2005-03",[2091,3693,4168],"GE Junction Cancer",[4103,866,4057],{"nctId":1426,"briefTitle":1427,"status":118,"phases":4171,"primaryCompletion":486,"completion":486,"start":1429,"enrollment":22,"conditions":4172,"interventions":4173},[89],[1431,1432,1433],[130,866,1435],{"nctId":1674,"briefTitle":1675,"status":207,"phases":4175,"start":1677,"conditions":4176,"interventions":4177},[89],[1532],[733,734,1680,1681,590],{"nctId":4179,"briefTitle":4180,"status":118,"phases":4181,"primaryCompletion":3449,"completion":795,"start":40,"enrollment":4182,"conditions":4183,"interventions":4184},"NCT00911820","Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",[89],88,[2091,3693,4018],[762,866,4057],{"nctId":4186,"briefTitle":4187,"status":118,"phases":4188,"primaryCompletion":264,"completion":810,"start":2733,"enrollment":955,"conditions":4189,"interventions":4190},"NCT00165516","Extrapleural Pneumonectomy With Intraoperative Intrathoracic\u002FIntraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate",[89],[4075,4076],[866,4078],{"nctId":856,"briefTitle":857,"status":118,"phases":4192,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":4193,"interventions":4194},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":4196,"briefTitle":4197,"status":118,"phases":4198,"primaryCompletion":262,"completion":536,"start":3450,"enrollment":35,"conditions":4199,"interventions":4201},"NCT00165490","Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer",[89],[1433,4200],"Squamous Cell Carcinoma of Esophagus",[2562,866,4057],{"nctId":4203,"briefTitle":4204,"status":118,"phases":4205,"primaryCompletion":3450,"completion":4206,"start":2772,"enrollment":1337,"conditions":4207,"interventions":4208},"NCT00137852","Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer",[89],"2017-09",[2091],[866,4057,789],{"nctId":3399,"briefTitle":3400,"status":105,"phases":4210,"primaryCompletion":3402,"completion":3403,"start":3228,"enrollment":2800,"conditions":4211,"interventions":4212},[89],[1918,3405],[1680,734,3407,3408,2881],{"nctId":4214,"briefTitle":4215,"status":118,"phases":4216,"primaryCompletion":2757,"completion":2757,"start":4217,"enrollment":403,"conditions":4218,"interventions":4220},"NCT00139230","Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[89],"1997-01",[4123,4219],"Carcinoma of Head\u002FNeck",[4103,866,4022,308,867,4221],"Ciprofloxacin",{"nctId":2934,"briefTitle":2935,"status":118,"phases":4223,"primaryCompletion":2937,"completion":2099,"start":2938,"enrollment":2939,"conditions":4224,"interventions":4225},[89],[2114],[866,706],{"nctId":1349,"briefTitle":1350,"status":118,"phases":4227,"primaryCompletion":425,"completion":1045,"start":199,"enrollment":1352,"conditions":4228,"interventions":4229},[89],[1354,1355],[511,130,1357,734,1358],{"nctId":4231,"briefTitle":4232,"status":118,"phases":4233,"primaryCompletion":4234,"completion":4235,"start":2089,"enrollment":4236,"conditions":4237,"interventions":4239},"NCT03012477","CISPLATIN + AZD-1775 In Breast Cancer",[89],"2019-05-07","2020-11-30",34,[4238],"Triple-negative Metastatic Breast Cancer",[866,4240],"AZD1775",{"nctId":4242,"briefTitle":4243,"status":118,"phases":4244,"primaryCompletion":163,"completion":1124,"start":1098,"enrollment":1988,"conditions":4245,"interventions":4246},"NCT00394433","Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",[89],[2091,4018],[762,158,866,4057],{"nctId":1554,"briefTitle":1555,"status":105,"phases":4248,"primaryCompletion":1557,"completion":1132,"start":1558,"enrollment":286,"conditions":4249,"interventions":4250},[88,89],[1560,30,1561],[279,866],{"trials":4252,"activeCount":99},[4253],{"nctId":3446,"briefTitle":3447,"status":118,"phases":4254,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":3451,"conditions":4255,"interventions":4256},[90],[1532],[2881,734,1680,1681],{"trials":4258,"activeCount":99},[],{"trials":4260,"activeCount":99},[],{"intervention":158,"totalTrials":25,"cells":4262},{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4292,"PHASE3":4394,"PHASE4":4415,"NA":4417},{"trials":4264,"activeCount":99},[],{"trials":4266,"activeCount":99},[4267,4271,4275,4283],{"nctId":4033,"briefTitle":4034,"status":118,"phases":4268,"primaryCompletion":40,"completion":40,"start":4036,"enrollment":1841,"conditions":4269,"interventions":4270},[88],[4038],[2562,158,866,4022],{"nctId":3331,"briefTitle":3332,"status":118,"phases":4272,"completion":507,"start":3334,"conditions":4273,"interventions":4274},[88],[18],[2881,1680,3337],{"nctId":4276,"briefTitle":4277,"status":118,"phases":4278,"primaryCompletion":4036,"completion":344,"start":3422,"enrollment":25,"conditions":4279,"interventions":4281},"NCT00268918","Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients",[88],[21,1949,4280,827,826,15],"Cervical Cancer",[158,4282],"PTK787",{"nctId":4284,"briefTitle":4285,"status":118,"phases":4286,"primaryCompletion":4287,"completion":4288,"start":846,"enrollment":1841,"conditions":4289,"interventions":4290},"NCT01783587","Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer",[88],"2017-11-20","2018-06-01",[1918],[4291,158],"Afatinib",{"trials":4293,"activeCount":1034,"soonestReadout":223},[4294,4298,4302,4310,4321,4325,4329,4333,4342,4346,4350,4354,4364,4368,4375,4384,4390],{"nctId":4108,"briefTitle":4109,"status":118,"phases":4295,"primaryCompletion":2757,"completion":2757,"start":4111,"enrollment":1988,"conditions":4296,"interventions":4297},[88,89],[4113,4114,4115],[158,866,4022],{"nctId":3355,"briefTitle":3356,"status":118,"phases":4299,"primaryCompletion":2907,"completion":3358,"start":2733,"enrollment":403,"conditions":4300,"interventions":4301},[89],[18],[158,707],{"nctId":4303,"briefTitle":4304,"status":118,"phases":4305,"primaryCompletion":4306,"completion":4029,"start":1071,"enrollment":403,"conditions":4307,"interventions":4308},"NCT00459043","Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck",[89],"2010-03",[4114],[4309,158],"ZD6474",{"nctId":4311,"briefTitle":4312,"status":118,"phases":4313,"primaryCompletion":4314,"completion":4314,"start":748,"enrollment":599,"conditions":4315,"interventions":4317},"NCT00165399","Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment",[89],"2005-12-31",[4316,18],"Adenocarcinoma of the Prostate",[158,4318,4319,4320],"Estramustine","Casodex","Zoladex",{"nctId":1956,"briefTitle":1957,"status":220,"phases":4322,"primaryCompletion":223,"completion":1959,"start":1960,"enrollment":1961,"conditions":4323,"interventions":4324},[89],[1963,1532,1964,1965,1966],[626,1968,707,158],{"nctId":2355,"briefTitle":2356,"status":118,"phases":4326,"primaryCompletion":2358,"completion":2359,"start":2360,"enrollment":720,"conditions":4327,"interventions":4328},[89],[1532],[80,866,158],{"nctId":149,"briefTitle":150,"status":118,"phases":4330,"primaryCompletion":152,"completion":152,"start":153,"enrollment":35,"conditions":4331,"interventions":4332},[88,89],[155,18],[157,158,95],{"nctId":4334,"briefTitle":4335,"status":118,"phases":4336,"primaryCompletion":2956,"completion":659,"start":4337,"enrollment":22,"conditions":4338,"interventions":4340},"NCT00137761","Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer",[89],"2004-10",[4339],"Metastatic Pancreatic Carcinoma",[4341,158],"ZD 1839",{"nctId":1674,"briefTitle":1675,"status":207,"phases":4343,"start":1677,"conditions":4344,"interventions":4345},[89],[1532],[733,734,1680,1681,590],{"nctId":3399,"briefTitle":3400,"status":105,"phases":4347,"primaryCompletion":3402,"completion":3403,"start":3228,"enrollment":2800,"conditions":4348,"interventions":4349},[89],[1918,3405],[1680,734,3407,3408,2881],{"nctId":236,"briefTitle":237,"status":105,"phases":4351,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":4352,"interventions":4353},[89],[18],[245,95,158,190],{"nctId":4355,"briefTitle":4356,"status":118,"phases":4357,"primaryCompletion":425,"completion":4358,"start":1098,"enrollment":4359,"conditions":4360,"interventions":4362},"NCT00880334","Randomized Study of Docetaxel +\u002F- Vandetanib in Metastatic TCC",[89],"2015-05",149,[4361,1354],"Transitional Cell Carcinoma",[158,4363],"vandetanib",{"nctId":2916,"briefTitle":2917,"status":220,"phases":4365,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":4366,"interventions":4367},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"nctId":4369,"briefTitle":4370,"status":118,"phases":4371,"primaryCompletion":165,"completion":165,"start":4372,"enrollment":35,"conditions":4373,"interventions":4374},"NCT00005096","Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer",[89],"1999-12",[18],[1680],{"nctId":4376,"briefTitle":4377,"status":118,"phases":4378,"primaryCompletion":402,"completion":4379,"start":2957,"enrollment":4380,"conditions":4381,"interventions":4382},"NCT00658697","Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer",[89],"2015-06",42,[18],[158,762,4383,216],"ADT",{"nctId":4385,"briefTitle":4386,"status":118,"phases":4387,"primaryCompletion":1098,"completion":3358,"start":3450,"enrollment":4380,"conditions":4388,"interventions":4389},"NCT00137813","Avastin and Taxotere for Esophagogastric Cancer",[89],[2091,3693],[158,762],{"nctId":4242,"briefTitle":4243,"status":118,"phases":4391,"primaryCompletion":163,"completion":1124,"start":1098,"enrollment":1988,"conditions":4392,"interventions":4393},[89],[2091,4018],[762,158,866,4057],{"trials":4395,"activeCount":99},[4396,4407,4411],{"nctId":4397,"briefTitle":4398,"status":118,"phases":4399,"primaryCompletion":4400,"completion":4400,"start":4401,"enrollment":4402,"conditions":4403,"interventions":4404},"NCT00116142","Hormone Suppression and Radiation Therapy for 6 Months With\u002FWithout Docetaxel for High Risk Prostate Cancer",[90],"2020-06-29","2005-06",350,[18],[158,4405,4406],"Androgen Hormonal Suppression and Radiation","Androgen Suppression Therapy and Radiation Therapy",{"nctId":3446,"briefTitle":3447,"status":118,"phases":4408,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":3451,"conditions":4409,"interventions":4410},[90],[1532],[2881,734,1680,1681],{"nctId":2967,"briefTitle":2968,"status":118,"phases":4412,"primaryCompletion":2874,"completion":2970,"start":2971,"enrollment":2972,"conditions":4413,"interventions":4414},[90],[15,2926],[798,2975,706,158],{"trials":4416,"activeCount":99},[],{"trials":4418,"activeCount":99},[],{"intervention":395,"totalTrials":242,"cells":4420},{"EARLY_PHASE1":4421,"PHASE1":4423,"PHASE2":4455,"PHASE3":4505,"PHASE4":4507,"NA":4509},{"trials":4422,"activeCount":99},[],{"trials":4424,"activeCount":99},[4425,4435,4446],{"nctId":4426,"briefTitle":4427,"status":118,"phases":4428,"primaryCompletion":4429,"completion":2383,"start":823,"enrollment":1999,"conditions":4430,"interventions":4433},"NCT02022982","PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors",[88],"2017-11-01",[4431,4432],"KRAS Mutant Non-Small Cell Lung Cancer","Solid Tumors",[395,4434],"PD-0325901",{"nctId":4436,"briefTitle":4437,"status":2015,"phases":4438,"primaryCompletion":1865,"completion":4439,"start":4440,"enrollment":252,"conditions":4441,"interventions":4445},"NCT03065062","Study of the CDK4\u002F6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K\u002FmTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",[88],"2027-01-31","2017-02-28",[4442,4432,4443,4444],"Lung Cancer Squamous Cell","Head & Neck Cancer","Pancreatic Cancer",[395,3044],{"nctId":4447,"briefTitle":4448,"status":118,"phases":4449,"primaryCompletion":4450,"completion":210,"start":4451,"enrollment":4236,"conditions":4452,"interventions":4453},"NCT03170206","Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer",[88],"2023-02-28","2017-05-31",[30],[4454,395],"Binimetinib",{"trials":4456,"activeCount":1034,"soonestReadout":3481},[4457,4468,4476,4484,4488,4492],{"nctId":4458,"briefTitle":4459,"status":105,"phases":4460,"primaryCompletion":4461,"completion":4461,"start":4462,"enrollment":329,"conditions":4463,"interventions":4466},"NCT04129151","Palbociclib + Ganitumab In Ewing Sarcoma",[89],"2022-12-15","2019-12-05",[4464,4465],"Ewing Sarcoma","Ewing's Sarcoma Recurrent",[395,4467],"Ganitumab",{"nctId":4469,"briefTitle":4470,"status":355,"phases":4471,"primaryCompletion":898,"completion":702,"start":4472,"enrollment":4473,"conditions":4474,"interventions":4475},"NCT03147287","Palbociclib After CDK and Endocrine Therapy (PACE)",[89],"2017-09-05",220,[663],[395,3710,2653],{"nctId":4477,"briefTitle":4478,"status":118,"phases":4479,"primaryCompletion":3254,"completion":4480,"start":823,"enrollment":4481,"conditions":4482,"interventions":4483},"NCT02040857","Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer",[89],"2024-12-27",162,[15],[395,3005],{"nctId":3478,"briefTitle":3479,"status":355,"phases":4485,"primaryCompletion":3481,"completion":3482,"start":3483,"enrollment":3484,"conditions":4486,"interventions":4487},[89],[15],[1954,3073,395,3487],{"nctId":384,"briefTitle":385,"status":118,"phases":4489,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":4490,"interventions":4491},[88,89],[392,393],[395,127,396],{"nctId":4493,"briefTitle":4494,"status":118,"phases":4495,"primaryCompletion":4496,"completion":4497,"start":4498,"enrollment":3721,"conditions":4499,"interventions":4503},"NCT02448771","A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer",[88,89],"2019-08-12","2021-03-03","2015-07-09",[4500,4501,4502],"Breast Cancer Stage IV","Unresectable Locally Advanced Invasive Breast Cancer","Metastatic Invasive Breast Cancer",[395,4504],"Bazedoxifene",{"trials":4506,"activeCount":99},[],{"trials":4508,"activeCount":99},[],{"trials":4510,"activeCount":99},[],{"intervention":949,"totalTrials":275,"cells":4512},{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4517,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4514,"activeCount":99},[],{"trials":4516,"activeCount":99},[],{"trials":4518,"activeCount":1034,"soonestReadout":943},[4519,4523,4527,4531,4538],{"nctId":3540,"briefTitle":3541,"status":105,"phases":4520,"primaryCompletion":3543,"completion":3543,"start":375,"enrollment":22,"conditions":4521,"interventions":4522},[89],[2846,663],[799,798,3546],{"nctId":3582,"briefTitle":3583,"status":220,"phases":4524,"primaryCompletion":1206,"completion":3585,"start":3586,"enrollment":3587,"conditions":4525,"interventions":4526},[89],[663,3589],[949,3573,3591],{"nctId":2026,"briefTitle":2027,"status":118,"phases":4528,"primaryCompletion":2029,"completion":2029,"start":2030,"enrollment":912,"conditions":4529,"interventions":4530},[89],[851,2032,2033,2034],[949,626],{"nctId":4532,"briefTitle":4533,"status":118,"phases":4534,"primaryCompletion":516,"completion":516,"start":1789,"enrollment":4535,"conditions":4536,"interventions":4537},"NCT01827787","Eribulin in HER2 Negative Metastatic BrCa",[89],83,[15],[949],{"nctId":940,"briefTitle":941,"status":355,"phases":4539,"primaryCompletion":943,"completion":944,"start":945,"enrollment":123,"conditions":4540,"interventions":4541},[89],[947,392],[949,865,269],{"trials":4543,"activeCount":99},[],{"trials":4545,"activeCount":99},[],{"trials":4547,"activeCount":99},[],{"intervention":3022,"totalTrials":110,"cells":4549},{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4554,"PHASE3":4581,"PHASE4":4583,"NA":4585},{"trials":4551,"activeCount":99},[],{"trials":4553,"activeCount":99},[],{"trials":4555,"activeCount":1034,"soonestReadout":3016},[4556,4564,4568,4577],{"nctId":4557,"briefTitle":4558,"status":118,"phases":4559,"primaryCompletion":4560,"completion":4561,"start":1852,"enrollment":720,"conditions":4562,"interventions":4563},"NCT03483012","Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis",[89],"2019-11-21","2025-11-12",[15],[3022],{"nctId":3013,"briefTitle":3014,"status":355,"phases":4565,"primaryCompletion":3016,"completion":3017,"start":3018,"enrollment":35,"conditions":4566,"interventions":4567},[89],[18,3020],[1953,3022],{"nctId":4569,"briefTitle":4570,"status":118,"phases":4571,"primaryCompletion":4572,"completion":1141,"start":4573,"enrollment":1133,"conditions":4574,"interventions":4576},"NCT02724878","Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma",[89],"2019-11-13","2016-07-15",[4575],"Advanced Non-Clear Cell Kidney Cancer",[762,3022],{"nctId":3601,"briefTitle":3602,"status":220,"phases":4578,"primaryCompletion":1292,"completion":3604,"start":3605,"enrollment":1082,"conditions":4579,"interventions":4580},[89],[15,2114,3607,3608],[3022,3573],{"trials":4582,"activeCount":99},[],{"trials":4584,"activeCount":99},[],{"trials":4586,"activeCount":99},[],{"intervention":2653,"totalTrials":110,"cells":4588},{"EARLY_PHASE1":4589,"PHASE1":4591,"PHASE2":4597,"PHASE3":4616,"PHASE4":4618,"NA":4620},{"trials":4590,"activeCount":99},[],{"trials":4592,"activeCount":99},[4593],{"nctId":2644,"briefTitle":2645,"status":105,"phases":4594,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":25,"conditions":4595,"interventions":4596},[88],[1869],[51,2652,2653,2654],{"trials":4598,"activeCount":1034,"soonestReadout":898},[4599,4603,4607],{"nctId":4469,"briefTitle":4470,"status":355,"phases":4600,"primaryCompletion":898,"completion":702,"start":4472,"enrollment":4473,"conditions":4601,"interventions":4602},[89],[663],[395,3710,2653],{"nctId":3907,"briefTitle":3908,"status":355,"phases":4604,"primaryCompletion":3910,"completion":3911,"start":3912,"enrollment":2056,"conditions":4605,"interventions":4606},[89],[3914],[2653,3880,3916],{"nctId":4608,"briefTitle":4609,"status":105,"phases":4610,"primaryCompletion":4611,"completion":4611,"start":4612,"enrollment":1492,"conditions":4613,"interventions":4615},"NCT03747419","Avelumab and Radiation in Muscle-Invasive Bladder Cancer",[89],"2025-02-24","2018-12-13",[1354,4614],"Muscle Invasive Bladder Cancer",[2653],{"trials":4617,"activeCount":99},[],{"trials":4619,"activeCount":99},[],{"trials":4621,"activeCount":99},[],{"intervention":396,"totalTrials":265,"cells":4623},{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4642,"PHASE4":4644,"NA":4646},{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":1034,"soonestReadout":3067},[4630,4634,4638],{"nctId":384,"briefTitle":385,"status":118,"phases":4631,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":4632,"interventions":4633},[88,89],[392,393],[395,127,396],{"nctId":3979,"briefTitle":3980,"status":316,"phases":4635,"primaryCompletion":3982,"completion":684,"start":3983,"enrollment":3984,"conditions":4636,"interventions":4637},[89],[15,3986,3987,3988,3792,3989,3990],[396,3073],{"nctId":3064,"briefTitle":3065,"status":355,"phases":4639,"primaryCompletion":3067,"completion":3058,"start":3068,"enrollment":1928,"conditions":4640,"interventions":4641},[89],[15,3070,3071],[1953,3073,3074,1954,396,3075],{"trials":4643,"activeCount":99},[],{"trials":4645,"activeCount":99},[],{"trials":4647,"activeCount":99},[],{"intervention":3329,"totalTrials":1034,"cells":4649},{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4658,"PHASE3":4669,"PHASE4":4671,"NA":4673},{"trials":4651,"activeCount":99},[],{"trials":4653,"activeCount":286,"soonestReadout":3323},[4654],{"nctId":3320,"briefTitle":3321,"status":355,"phases":4655,"primaryCompletion":3323,"completion":3324,"start":3325,"enrollment":2043,"conditions":4656,"interventions":4657},[88],[18,3327,3020],[707,3329],{"trials":4659,"activeCount":286,"soonestReadout":670},[4660],{"nctId":4661,"briefTitle":4662,"status":355,"phases":4663,"primaryCompletion":670,"completion":4664,"start":4665,"enrollment":25,"conditions":4666,"interventions":4668},"NCT06964958","177LuPSMA in Renal Cell Carcinoma",[89],"2028-12-01","2025-07-31",[3163,4667,348],"Advanced Clear Cell Renal Cell Carcinoma",[3329],{"trials":4670,"activeCount":99},[],{"trials":4672,"activeCount":99},[],{"trials":4674,"activeCount":99},[],{"intervention":2228,"totalTrials":1034,"cells":4676},{"EARLY_PHASE1":4677,"PHASE1":4679,"PHASE2":4681,"PHASE3":4697,"PHASE4":4699,"NA":4701},{"trials":4678,"activeCount":99},[],{"trials":4680,"activeCount":99},[],{"trials":4682,"activeCount":1034,"soonestReadout":2223},[4683,4693],{"nctId":4684,"briefTitle":4685,"status":355,"phases":4686,"primaryCompletion":3017,"completion":4439,"start":4687,"enrollment":835,"conditions":4688,"interventions":4692},"NCT04906902","Acalabrutinib in CNSL",[88,89],"2021-08-23",[4689,4690,4691],"Central Nervous System Lymphoma","Refractory Central Nervous System Lymphoma","Recurrent Central Nervous System Lymphoma",[2228],{"nctId":2220,"briefTitle":2221,"status":355,"phases":4694,"primaryCompletion":2223,"completion":223,"start":2224,"enrollment":2202,"conditions":4695,"interventions":4696},[89],[2226],[1017,2194,2228],{"trials":4698,"activeCount":99},[],{"trials":4700,"activeCount":99},[],{"trials":4702,"activeCount":99},[],{"intervention":928,"totalTrials":1034,"cells":4704},{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4726,"PHASE4":4728,"NA":4730},{"trials":4706,"activeCount":99},[],{"trials":4708,"activeCount":99},[],{"trials":4710,"activeCount":1034,"soonestReadout":4715},[4711,4722],{"nctId":4712,"briefTitle":4713,"status":355,"phases":4714,"primaryCompletion":4715,"completion":2842,"start":4716,"enrollment":4717,"conditions":4718,"interventions":4720},"NCT01574274","SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma",[89],"2021-07","2012-06",240,[125,4719],"Lymphoblastic Lymphoma",[4721,928],"SC-PEG",{"nctId":917,"briefTitle":918,"status":316,"phases":4723,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":4724,"interventions":4725},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"trials":4727,"activeCount":99},[],{"trials":4729,"activeCount":99},[],{"trials":4731,"activeCount":99},[],{"intervention":3591,"totalTrials":1034,"cells":4733},{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4738,"PHASE3":4748,"PHASE4":4750,"NA":4752},{"trials":4735,"activeCount":99},[],{"trials":4737,"activeCount":99},[],{"trials":4739,"activeCount":1034,"soonestReadout":1206},[4740,4744],{"nctId":3582,"briefTitle":3583,"status":220,"phases":4741,"primaryCompletion":1206,"completion":3585,"start":3586,"enrollment":3587,"conditions":4742,"interventions":4743},[89],[663,3589],[949,3573,3591],{"nctId":2916,"briefTitle":2917,"status":220,"phases":4745,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":4746,"interventions":4747},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"trials":4749,"activeCount":99},[],{"trials":4751,"activeCount":99},[],{"trials":4753,"activeCount":99},[],{"intervention":41,"totalTrials":123,"cells":4755},{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4782,"PHASE3":4875,"PHASE4":4877,"NA":4879},{"trials":4757,"activeCount":99},[],{"trials":4759,"activeCount":99},[4760,4770,4778],{"nctId":4761,"briefTitle":4762,"status":1057,"phases":4763,"primaryCompletion":4764,"completion":4765,"enrollment":99,"conditions":4766,"interventions":4768},"NCT02658396","GO-203-2C + Bortezomib For Relapsed Or Refractory MM",[88],"2019-05","2022-01",[24,1026,4767],"Refractory Multiple Myeloma",[4769,41],"GO-203-2C",{"nctId":4771,"briefTitle":4772,"status":118,"phases":4773,"primaryCompletion":525,"completion":525,"start":3450,"enrollment":1166,"conditions":4774,"interventions":4776},"NCT00153933","Bortezomib in Combination With CC-5013 in Patients With Relapsed\u002FRefractory Multiple Myeloma",[88],[4767,4775,24],"Relapsed Multiple Myeloma",[41,4777],"CC-5013",{"nctId":1020,"briefTitle":1021,"status":118,"phases":4779,"primaryCompletion":1023,"completion":388,"start":1024,"enrollment":28,"conditions":4780,"interventions":4781},[88],[1026],[1028,364,1029,41],{"trials":4783,"activeCount":1034,"soonestReadout":40},[4784,4797,4804,4808,4812,4816,4820,4824,4828,4832,4836,4844,4851,4855,4859,4863,4867,4871],{"nctId":4785,"briefTitle":4786,"status":316,"phases":4787,"primaryCompletion":4788,"completion":4789,"start":4790,"enrollment":4182,"conditions":4791,"interventions":4793},"NCT07601100","Phase 1b\u002F2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible\u002FDeferred Newly Diagnosed Myeloma",[88,89],"2029-07-01","2034-07-01","2026-06-26",[4792],"Newly Diagnosed Multiple Myeloma",[4794,4795,41,4796],"Isatuximab","Iberdomide","Dexamethesone",{"nctId":4798,"briefTitle":4799,"status":118,"phases":4800,"primaryCompletion":2956,"completion":2956,"start":2662,"enrollment":3051,"conditions":4801,"interventions":4803},"NCT00142129","Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia",[89],[34,4802],"Lymphoplasmacytic Lymphoma",[41],{"nctId":1321,"briefTitle":1322,"status":118,"phases":4805,"primaryCompletion":1324,"completion":1325,"start":909,"enrollment":225,"conditions":4806,"interventions":4807},[88,89],[461],[41,466,511],{"nctId":1333,"briefTitle":1334,"status":118,"phases":4809,"primaryCompletion":846,"completion":1336,"start":164,"enrollment":1337,"conditions":4810,"interventions":4811},[89],[27,585,463],[41,466,511],{"nctId":1068,"briefTitle":1069,"status":118,"phases":4813,"primaryCompletion":1071,"completion":824,"start":1072,"enrollment":345,"conditions":4814,"interventions":4815},[89],[34],[41,364,51],{"nctId":1076,"briefTitle":1077,"status":118,"phases":4817,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":4818,"interventions":4819},[89],[24],[1029,1085,41,364],{"nctId":38,"briefTitle":39,"status":355,"phases":4821,"primaryCompletion":40,"completion":944,"start":1098,"enrollment":1099,"conditions":4822,"interventions":4823},[88,89],[24],[41,1029,174],{"nctId":494,"briefTitle":495,"status":105,"phases":4825,"primaryCompletion":375,"completion":375,"start":497,"enrollment":498,"conditions":4826,"interventions":4827},[89],[500],[147,502,41],{"nctId":1112,"briefTitle":1113,"status":118,"phases":4829,"primaryCompletion":251,"completion":1115,"start":1116,"enrollment":428,"conditions":4830,"interventions":4831},[89],[24],[41,1029,364],{"nctId":194,"briefTitle":195,"status":118,"phases":4833,"primaryCompletion":197,"completion":198,"start":199,"enrollment":123,"conditions":4834,"interventions":4835},[89],[201],[203,95],{"nctId":4837,"briefTitle":4838,"status":118,"phases":4839,"primaryCompletion":344,"completion":4029,"start":4840,"enrollment":2721,"conditions":4841,"interventions":4842},"NCT00483262","Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and\u002For Relapsed\u002FRefractory Multiple Myeloma",[88,89],"2007-05",[24],[4843,41],"CCI-779",{"nctId":4845,"briefTitle":4846,"status":118,"phases":4847,"primaryCompletion":660,"completion":4052,"start":2662,"enrollment":4848,"conditions":4849,"interventions":4850},"NCT00153920","Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma",[89],66,[24],[203],{"nctId":513,"briefTitle":514,"status":118,"phases":4852,"primaryCompletion":516,"completion":517,"start":198,"enrollment":518,"conditions":4853,"interventions":4854},[89],[475],[466,511,41,147],{"nctId":1129,"briefTitle":1130,"status":118,"phases":4856,"primaryCompletion":1132,"completion":1124,"start":909,"enrollment":1133,"conditions":4857,"interventions":4858},[89],[24],[41,1029,364],{"nctId":2716,"briefTitle":2717,"status":118,"phases":4860,"primaryCompletion":2719,"completion":2719,"start":2720,"enrollment":2721,"conditions":4861,"interventions":4862},[89],[34],[41,51],{"nctId":259,"briefTitle":260,"status":105,"phases":4864,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":4865,"interventions":4866},[89],[267],[203,51,269,130,128,95],{"nctId":1161,"briefTitle":1162,"status":118,"phases":4868,"primaryCompletion":1164,"completion":1124,"start":1165,"enrollment":1166,"conditions":4869,"interventions":4870},[88,89],[24],[281,203,364],{"nctId":422,"briefTitle":423,"status":105,"phases":4872,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":4873,"interventions":4874},[88,89],[34],[127,51,41],{"trials":4876,"activeCount":99},[],{"trials":4878,"activeCount":99},[],{"trials":4880,"activeCount":99},[4881],{"nctId":1188,"briefTitle":1189,"status":1190,"phases":4882,"conditions":4883,"interventions":4884},[],[1026,24],[1194,1029,41,364],{"intervention":1029,"totalTrials":141,"cells":4886},{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4899,"PHASE3":4950,"PHASE4":4952,"NA":4954},{"trials":4888,"activeCount":99},[],{"trials":4890,"activeCount":99},[4891,4895],{"nctId":2618,"briefTitle":2619,"status":105,"phases":4892,"primaryCompletion":415,"completion":152,"start":497,"enrollment":242,"conditions":4893,"interventions":4894},[88],[804,2622],[1029,679,51],{"nctId":1020,"briefTitle":1021,"status":118,"phases":4896,"primaryCompletion":1023,"completion":388,"start":1024,"enrollment":28,"conditions":4897,"interventions":4898},[88],[1026],[1028,364,1029,41],{"trials":4900,"activeCount":1034,"soonestReadout":40},[4901,4910,4914,4918,4922,4934,4938,4942,4946],{"nctId":4902,"briefTitle":4903,"status":118,"phases":4904,"primaryCompletion":262,"completion":40,"start":3422,"enrollment":345,"conditions":4905,"interventions":4908},"NCT00165477","Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme",[89],[611,4906,4907],"Gliosarcoma","Malignant Gliomas",[4909],"lenalidomide",{"nctId":1076,"briefTitle":1077,"status":118,"phases":4911,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":4912,"interventions":4913},[89],[24],[1029,1085,41,364],{"nctId":1087,"briefTitle":1088,"status":118,"phases":4915,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":4916,"interventions":4917},[89],[876],[80,1029,364],{"nctId":38,"briefTitle":39,"status":355,"phases":4919,"primaryCompletion":40,"completion":944,"start":1098,"enrollment":1099,"conditions":4920,"interventions":4921},[88,89],[24],[41,1029,174],{"nctId":4923,"briefTitle":4924,"status":355,"phases":4925,"primaryCompletion":4926,"completion":4927,"start":4928,"enrollment":141,"conditions":4929,"interventions":4933},"NCT02523040","Lenalidomide for Adult Histiocyte Disorders",[89],"2024-02","2026-02","2015-08",[4930,4931,4932],"Langerhans Cell Histiocytosis (LCH)","Histiocytoses Erdheim-chester Disease","Histiocytic Sarcoma (HS)",[1029],{"nctId":1112,"briefTitle":1113,"status":118,"phases":4935,"primaryCompletion":251,"completion":1115,"start":1116,"enrollment":428,"conditions":4936,"interventions":4937},[89],[24],[41,1029,364],{"nctId":1120,"briefTitle":1121,"status":118,"phases":4939,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":1125,"conditions":4940,"interventions":4941},[89],[876],[1110,1029,364],{"nctId":1129,"briefTitle":1130,"status":118,"phases":4943,"primaryCompletion":1132,"completion":1124,"start":909,"enrollment":1133,"conditions":4944,"interventions":4945},[89],[24],[41,1029,364],{"nctId":1146,"briefTitle":1147,"status":118,"phases":4947,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":4948,"interventions":4949},[89],[1154,876],[1085,1029,364],{"trials":4951,"activeCount":99},[],{"trials":4953,"activeCount":99},[],{"trials":4955,"activeCount":99},[4956],{"nctId":1188,"briefTitle":1189,"status":1190,"phases":4957,"conditions":4958,"interventions":4959},[],[1026,24],[1194,1029,41,364],{"intervention":736,"totalTrials":265,"cells":4961},{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4966,"PHASE3":4976,"PHASE4":4982,"NA":4984},{"trials":4963,"activeCount":99},[],{"trials":4965,"activeCount":99},[],{"trials":4967,"activeCount":286,"soonestReadout":920},[4968,4972],{"nctId":724,"briefTitle":725,"status":118,"phases":4969,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":4970,"interventions":4971},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":917,"briefTitle":918,"status":316,"phases":4973,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":4974,"interventions":4975},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"trials":4977,"activeCount":99},[4978],{"nctId":984,"briefTitle":985,"status":118,"phases":4979,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":4980,"interventions":4981},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":4983,"activeCount":99},[],{"trials":4985,"activeCount":99},[],{"intervention":3710,"totalTrials":720,"cells":4987},{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":5004,"PHASE3":5038,"PHASE4":5040,"NA":5042},{"trials":4989,"activeCount":99},[],{"trials":4991,"activeCount":99},[4992],{"nctId":4993,"briefTitle":4994,"status":105,"phases":4995,"primaryCompletion":4996,"completion":4996,"start":4997,"enrollment":571,"conditions":4998,"interventions":5002},"NCT03294694","Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer",[88],"2020-10-14","2017-11-08",[4999,5000,5001],"Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer","HER2-Negative Breast Cancer","Metastatic Epithelial Ovarian Cancer",[363,5003,3710],"PDR001",{"trials":5005,"activeCount":286,"soonestReadout":898},[5006,5010,5019,5026,5034],{"nctId":4469,"briefTitle":4470,"status":355,"phases":5007,"primaryCompletion":898,"completion":702,"start":4472,"enrollment":4473,"conditions":5008,"interventions":5009},[89],[663],[395,3710,2653],{"nctId":5011,"briefTitle":5012,"status":105,"phases":5013,"primaryCompletion":5014,"completion":5014,"start":5015,"enrollment":28,"conditions":5016,"interventions":5017},"NCT03289039","Neratinib +\u002F- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer",[89],"2021-07-20","2017-10-25",[15],[5018,3710],"Neratinib",{"nctId":5020,"briefTitle":5021,"status":118,"phases":5022,"primaryCompletion":660,"completion":660,"start":5023,"enrollment":1337,"conditions":5024,"interventions":5025},"NCT00146601","Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer",[89],"2004-06",[15],[3710],{"nctId":5027,"briefTitle":5028,"status":118,"phases":5029,"primaryCompletion":5030,"completion":5030,"start":4716,"enrollment":672,"conditions":5031,"interventions":5032},"NCT01560416","Fulvestrant With or Without Ganetespib in HR+ Breast Cancer",[89],"2016-06-26",[15],[3710,5033],"Ganetespib",{"nctId":3702,"briefTitle":3703,"status":118,"phases":5035,"primaryCompletion":3705,"completion":3706,"start":3707,"enrollment":661,"conditions":5036,"interventions":5037},[88,89],[15],[363,75,798,3710],{"trials":5039,"activeCount":99},[],{"trials":5041,"activeCount":99},[],{"trials":5043,"activeCount":99},[],{"intervention":191,"totalTrials":265,"cells":5045},{"EARLY_PHASE1":5046,"PHASE1":5048,"PHASE2":5050,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5047,"activeCount":99},[],{"trials":5049,"activeCount":99},[],{"trials":5051,"activeCount":286,"soonestReadout":2842},[5052,5056,5060],{"nctId":3489,"briefTitle":3490,"status":118,"phases":5053,"primaryCompletion":525,"completion":402,"start":3492,"enrollment":3493,"conditions":5054,"interventions":5055},[89],[15],[3496,3497,3498],{"nctId":181,"briefTitle":182,"status":118,"phases":5057,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":5058,"interventions":5059},[89],[18],[190,191,95,192],{"nctId":5061,"briefTitle":5062,"status":220,"phases":5063,"primaryCompletion":2842,"completion":5064,"start":5065,"enrollment":2112,"conditions":5066,"interventions":5068},"NCT05765500","RecoverPC: Relugolix vs GnRH Agonist in Quality of Life",[89],"2028-01-01","2024-02-12",[18,5067],"Prostatic Neoplasms",[5069,191],"Relugolix",{"trials":5071,"activeCount":99},[],{"trials":5073,"activeCount":99},[],{"trials":5075,"activeCount":99},[],{"intervention":904,"totalTrials":265,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5098,"PHASE4":5100,"NA":5102},{"trials":5079,"activeCount":99},[],{"trials":5081,"activeCount":99},[],{"trials":5083,"activeCount":286,"soonestReadout":898},[5084,5090,5094],{"nctId":5085,"briefTitle":5086,"status":105,"phases":5087,"primaryCompletion":4379,"completion":1164,"start":4716,"enrollment":28,"conditions":5088,"interventions":5089},"NCT01562873","Ruxolitinib in Patients With Breast Cancer",[89],[15],[904],{"nctId":2850,"briefTitle":2851,"status":118,"phases":5091,"primaryCompletion":516,"completion":2853,"start":2854,"enrollment":784,"conditions":5092,"interventions":5093},[88,89],[2856,663],[904,706],{"nctId":895,"briefTitle":896,"status":355,"phases":5095,"primaryCompletion":898,"completion":899,"start":900,"enrollment":345,"conditions":5096,"interventions":5097},[89],[902],[904,706,130,269],{"trials":5099,"activeCount":99},[],{"trials":5101,"activeCount":99},[],{"trials":5103,"activeCount":99},[],{"intervention":5105,"totalTrials":265,"cells":5106},"Nab-paclitaxel",{"EARLY_PHASE1":5107,"PHASE1":5109,"PHASE2":5129,"PHASE3":5135,"PHASE4":5137,"NA":5139},{"trials":5108,"activeCount":99},[],{"trials":5110,"activeCount":99},[5111,5119],{"nctId":5112,"briefTitle":5113,"status":105,"phases":5114,"primaryCompletion":5115,"completion":5115,"start":2521,"enrollment":3721,"conditions":5116,"interventions":5117},"NCT03520790","Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer",[88],"2024-07-01",[4444],[283,5105,5118],"Paricalcitol",{"nctId":5120,"briefTitle":5121,"status":118,"phases":5122,"primaryCompletion":5123,"completion":5124,"start":5125,"enrollment":1107,"conditions":5126,"interventions":5127},"NCT03316599","Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer",[88],"2020-10-10","2021-07-29","2018-01-17",[4444],[283,5105,5128],"Ficlatuzumab",{"trials":5130,"activeCount":286,"soonestReadout":2919},[5131],{"nctId":2916,"briefTitle":2917,"status":220,"phases":5132,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":5133,"interventions":5134},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"trials":5136,"activeCount":99},[],{"trials":5138,"activeCount":99},[],{"trials":5140,"activeCount":99},[],{"intervention":3042,"totalTrials":1034,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5161,"PHASE4":5163,"NA":5165},{"trials":5144,"activeCount":99},[],{"trials":5146,"activeCount":99},[],{"trials":5148,"activeCount":286,"soonestReadout":3035},[5149,5157],{"nctId":5150,"briefTitle":5151,"status":118,"phases":5152,"primaryCompletion":3292,"completion":5153,"start":164,"enrollment":537,"conditions":5154,"interventions":5156},"NCT01340300","Exercise and Metformin in Colorectal and Breast Cancer Survivors",[89],"2017-12",[5155,15],"Colorectal Cancer",[3042],{"nctId":3032,"briefTitle":3033,"status":220,"phases":5158,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":3038,"conditions":5159,"interventions":5160},[89],[1949,21],[1954,1953,3041,3042,3043,3044],{"trials":5162,"activeCount":99},[],{"trials":5164,"activeCount":99},[],{"trials":5166,"activeCount":99},[],{"intervention":5168,"totalTrials":1034,"cells":5169},"gefitinib",{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5171,"activeCount":99},[],{"trials":5173,"activeCount":99},[],{"trials":5175,"activeCount":286,"soonestReadout":3946},[5176,5183],{"nctId":5177,"briefTitle":5178,"status":118,"phases":5179,"primaryCompletion":262,"completion":262,"start":746,"enrollment":715,"conditions":5180,"interventions":5182},"NCT00130702","Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia",[89],[5181],"Myelogenous Leukemia, Acute",[5168],{"nctId":3943,"briefTitle":3944,"status":355,"phases":5184,"primaryCompletion":3946,"completion":3947,"start":3948,"enrollment":2288,"conditions":5185,"interventions":5186},[88,89],[2901],[3951,3924],{"trials":5188,"activeCount":99},[],{"trials":5190,"activeCount":99},[],{"trials":5192,"activeCount":99},[],{"intervention":5194,"totalTrials":1034,"cells":5195},"Daratumumab",{"EARLY_PHASE1":5196,"PHASE1":5198,"PHASE2":5200,"PHASE3":5220,"PHASE4":5222,"NA":5224},{"trials":5197,"activeCount":99},[],{"trials":5199,"activeCount":99},[],{"trials":5201,"activeCount":286,"soonestReadout":5206},[5202,5211],{"nctId":5203,"briefTitle":5204,"status":355,"phases":5205,"primaryCompletion":5206,"completion":5207,"start":211,"enrollment":4380,"conditions":5208,"interventions":5210},"NCT03236428","Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma",[89],"2021-10-04","2026-10-04",[5209,876],"Monoclonal Gammopathy",[5194],{"nctId":5212,"briefTitle":5213,"status":118,"phases":5214,"primaryCompletion":5215,"completion":1140,"start":5216,"enrollment":2406,"conditions":5217,"interventions":5219},"NCT03187262","A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia",[89],"2021-01-31","2017-11-27",[5218],"Waldenström Macroglobulinemia",[5194],{"trials":5221,"activeCount":99},[],{"trials":5223,"activeCount":99},[],{"trials":5225,"activeCount":99},[],{"intervention":5227,"totalTrials":1034,"cells":5228},"fludarabine phosphate",{"EARLY_PHASE1":5229,"PHASE1":5231,"PHASE2":5244,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5230,"activeCount":99},[],{"trials":5232,"activeCount":99},[5233],{"nctId":5234,"briefTitle":5235,"status":118,"phases":5236,"primaryCompletion":5237,"completion":5238,"start":4401,"enrollment":35,"conditions":5239,"interventions":5240},"NCT00376480","Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant",[88],"2010-06","2018-05-16",[27,477],[5241,5242,5227,591,5243],"anti-thymocyte globulin","peripheral blood lymphocyte therapy","thiotepa",{"trials":5245,"activeCount":286,"soonestReadout":872},[5246],{"nctId":869,"briefTitle":870,"status":355,"phases":5247,"primaryCompletion":872,"completion":873,"start":874,"enrollment":784,"conditions":5248,"interventions":5249},[89],[24,876],[878,269,879],{"trials":5251,"activeCount":99},[],{"trials":5253,"activeCount":99},[],{"trials":5255,"activeCount":99},[],{"intervention":5257,"totalTrials":1034,"cells":5258},"Niraparib",{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5286,"PHASE4":5288,"NA":5290},{"trials":5260,"activeCount":99},[],{"trials":5262,"activeCount":99},[],{"trials":5264,"activeCount":286,"soonestReadout":5269},[5265,5279],{"nctId":5266,"briefTitle":5267,"status":355,"phases":5268,"primaryCompletion":5269,"completion":5270,"start":5271,"enrollment":599,"conditions":5272,"interventions":5277},"NCT04584255","Niraparib + Dostarlimab In BRCA Mutated Breast Cancer",[89],"2025-07-01","2029-07-17","2020-12-18",[5273,837,838,15,3790,5274,5275,5276],"Stage I Breast Cancer","Germline BRCA1 Gene Mutation","Germline BRCA2 Gene Mutation","Deleterious PALB2 Gene Mutation",[5257,5278],"Dostarlimab",{"nctId":5280,"briefTitle":5281,"status":118,"phases":5282,"primaryCompletion":210,"completion":5283,"start":3757,"enrollment":22,"conditions":5284,"interventions":5285},"NCT03601923","Niraparib in Patients With Pancreatic Cancer",[89],"2026-02-28",[4444],[5257],{"trials":5287,"activeCount":99},[],{"trials":5289,"activeCount":99},[],{"trials":5291,"activeCount":99},[],{"intervention":85,"totalTrials":1034,"cells":5293},{"EARLY_PHASE1":5294,"PHASE1":5296,"PHASE2":5298,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5295,"activeCount":99},[],{"trials":5297,"activeCount":99},[],{"trials":5299,"activeCount":286,"soonestReadout":84},[5300,5307],{"nctId":5301,"briefTitle":5302,"status":1057,"phases":5303,"primaryCompletion":64,"enrollment":99,"conditions":5304,"interventions":5306},"NCT01796405","Clofarabine for Langerhans in Pedi",[89],[5305],"Langerhans Cell Histiocytosis",[85],{"nctId":82,"briefTitle":83,"status":355,"phases":5308,"primaryCompletion":84,"completion":2476,"start":4358,"enrollment":661,"conditions":5309,"interventions":5310},[89],[5305],[85],{"trials":5312,"activeCount":99},[],{"trials":5314,"activeCount":99},[],{"trials":5316,"activeCount":99},[],{"intervention":5318,"totalTrials":1034,"cells":5319},"Regorafenib",{"EARLY_PHASE1":5320,"PHASE1":5322,"PHASE2":5332,"PHASE3":5340,"PHASE4":5342,"NA":5344},{"trials":5321,"activeCount":99},[],{"trials":5323,"activeCount":99},[5324],{"nctId":5325,"briefTitle":5326,"status":118,"phases":5327,"primaryCompletion":3543,"completion":943,"start":525,"enrollment":1492,"conditions":5328,"interventions":5330},"NCT02164240","Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and\u002For Unresectable GIST",[88],[5329],"Gastrointestinal Stromal Tumor",[5331,5318],"Sunitinib",{"trials":5333,"activeCount":286,"soonestReadout":1059},[5334],{"nctId":5335,"briefTitle":5336,"status":355,"phases":5337,"primaryCompletion":1059,"completion":1059,"start":3292,"enrollment":1093,"conditions":5338,"interventions":5339},"NCT02657551","A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer",[89],[2433],[5318],{"trials":5341,"activeCount":99},[],{"trials":5343,"activeCount":99},[],{"trials":5345,"activeCount":99},[],{"intervention":4240,"totalTrials":1034,"cells":5347},{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5366,"PHASE4":5368,"NA":5370},{"trials":5349,"activeCount":99},[],{"trials":5351,"activeCount":99},[],{"trials":5353,"activeCount":286,"soonestReadout":2243},[5354,5362],{"nctId":5355,"briefTitle":5356,"status":355,"phases":5357,"primaryCompletion":2243,"completion":2842,"start":5358,"enrollment":835,"conditions":5359,"interventions":5361},"NCT03668340","AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma",[89],"2018-10-22",[5360],"Uterine Cancer",[4240],{"nctId":4231,"briefTitle":4232,"status":118,"phases":5363,"primaryCompletion":4234,"completion":4235,"start":2089,"enrollment":4236,"conditions":5364,"interventions":5365},[89],[4238],[866,4240],{"trials":5367,"activeCount":99},[],{"trials":5369,"activeCount":99},[],{"trials":5371,"activeCount":99},[],{"intervention":3044,"totalTrials":1034,"cells":5373},{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5382,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5375,"activeCount":99},[],{"trials":5377,"activeCount":99},[5378],{"nctId":4436,"briefTitle":4437,"status":2015,"phases":5379,"primaryCompletion":1865,"completion":4439,"start":4440,"enrollment":252,"conditions":5380,"interventions":5381},[88],[4442,4432,4443,4444],[395,3044],{"trials":5383,"activeCount":286,"soonestReadout":3035},[5384],{"nctId":3032,"briefTitle":3033,"status":220,"phases":5385,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":3038,"conditions":5386,"interventions":5387},[89],[1949,21],[1954,1953,3041,3042,3043,3044],{"trials":5389,"activeCount":99},[],{"trials":5391,"activeCount":99},[],{"trials":5393,"activeCount":99},[],{"intervention":865,"totalTrials":1034,"cells":5395},{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5400,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5397,"activeCount":99},[],{"trials":5399,"activeCount":99},[],{"trials":5401,"activeCount":286,"soonestReadout":943},[5402,5406],{"nctId":856,"briefTitle":857,"status":118,"phases":5403,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":5404,"interventions":5405},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":940,"briefTitle":941,"status":355,"phases":5407,"primaryCompletion":943,"completion":944,"start":945,"enrollment":123,"conditions":5408,"interventions":5409},[89],[947,392],[949,865,269],{"trials":5411,"activeCount":99},[],{"trials":5413,"activeCount":99},[],{"trials":5415,"activeCount":99},[],{"intervention":2932,"totalTrials":1034,"cells":5417},{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5426,"PHASE3":5432,"PHASE4":5434,"NA":5436},{"trials":5419,"activeCount":99},[],{"trials":5421,"activeCount":99},[5422],{"nctId":2998,"briefTitle":2999,"status":1057,"phases":5423,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":99,"conditions":5424,"interventions":5425},[88],[15],[2932,1953,798,3005],{"trials":5427,"activeCount":286,"soonestReadout":2919},[5428],{"nctId":2916,"briefTitle":2917,"status":220,"phases":5429,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":5430,"interventions":5431},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"trials":5433,"activeCount":99},[],{"trials":5435,"activeCount":99},[],{"trials":5437,"activeCount":99},[],{"intervention":4794,"totalTrials":286,"cells":5439},{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5441,"activeCount":99},[],{"trials":5443,"activeCount":99},[],{"trials":5445,"activeCount":286,"soonestReadout":4788},[5446],{"nctId":4785,"briefTitle":4786,"status":316,"phases":5447,"primaryCompletion":4788,"completion":4789,"start":4790,"enrollment":4182,"conditions":5448,"interventions":5449},[88,89],[4792],[4794,4795,41,4796],{"trials":5451,"activeCount":99},[],{"trials":5453,"activeCount":99},[],{"trials":5455,"activeCount":99},[],{"intervention":4795,"totalTrials":286,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5459,"activeCount":99},[],{"trials":5461,"activeCount":99},[],{"trials":5463,"activeCount":286,"soonestReadout":4788},[5464],{"nctId":4785,"briefTitle":4786,"status":316,"phases":5465,"primaryCompletion":4788,"completion":4789,"start":4790,"enrollment":4182,"conditions":5466,"interventions":5467},[88,89],[4792],[4794,4795,41,4796],{"trials":5469,"activeCount":99},[],{"trials":5471,"activeCount":99},[],{"trials":5473,"activeCount":99},[],{"intervention":4796,"totalTrials":286,"cells":5475},{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5480,"PHASE3":5486,"PHASE4":5488,"NA":5490},{"trials":5477,"activeCount":99},[],{"trials":5479,"activeCount":99},[],{"trials":5481,"activeCount":286,"soonestReadout":4788},[5482],{"nctId":4785,"briefTitle":4786,"status":316,"phases":5483,"primaryCompletion":4788,"completion":4789,"start":4790,"enrollment":4182,"conditions":5484,"interventions":5485},[88,89],[4792],[4794,4795,41,4796],{"trials":5487,"activeCount":99},[],{"trials":5489,"activeCount":99},[],{"trials":5491,"activeCount":99},[],{"intervention":1920,"totalTrials":286,"cells":5493},{"EARLY_PHASE1":5494,"PHASE1":5496,"PHASE2":5498,"PHASE3":5504,"PHASE4":5506,"NA":5508},{"trials":5495,"activeCount":99},[],{"trials":5497,"activeCount":99},[],{"trials":5499,"activeCount":286,"soonestReadout":1913},[5500],{"nctId":1910,"briefTitle":1911,"status":220,"phases":5501,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":22,"conditions":5502,"interventions":5503},[89],[1917,1918],[1920,626],{"trials":5505,"activeCount":99},[],{"trials":5507,"activeCount":99},[],{"trials":5509,"activeCount":99},[],{"intervention":5511,"totalTrials":286,"cells":5512},"Belzutifan",{"EARLY_PHASE1":5513,"PHASE1":5515,"PHASE2":5517,"PHASE3":5531,"PHASE4":5533,"NA":5535},{"trials":5514,"activeCount":99},[],{"trials":5516,"activeCount":99},[],{"trials":5518,"activeCount":286,"soonestReadout":1292},[5519],{"nctId":5520,"briefTitle":5521,"status":220,"phases":5522,"primaryCompletion":1292,"completion":5523,"start":5524,"enrollment":22,"conditions":5525,"interventions":5530},"NCT06677190","Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin",[89],"2029-06-30","2024-12-20",[21,5526,1949,5360,4280,5527,5528,5529],"Ovarian Carcinoma","Vulvar Cancer","Gynecologic Cancer","Vaginal Cancer",[5511],{"trials":5532,"activeCount":99},[],{"trials":5534,"activeCount":99},[],{"trials":5536,"activeCount":99},[],{"intervention":5538,"totalTrials":286,"cells":5539},"Pertuzumab+TRASTUZUMAB",{"EARLY_PHASE1":5540,"PHASE1":5542,"PHASE2":5544,"PHASE3":5560,"PHASE4":5562,"NA":5564},{"trials":5541,"activeCount":99},[],{"trials":5543,"activeCount":99},[],{"trials":5545,"activeCount":286,"soonestReadout":5550},[5546],{"nctId":5547,"briefTitle":5548,"status":355,"phases":5549,"primaryCompletion":5550,"completion":2811,"start":5551,"enrollment":5552,"conditions":5553,"interventions":5558},"NCT04569747","A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer",[89],"2026-03-23","2021-01-11",393,[2846,5554,15,5555,5556,5557],"Invasive Carcinoma of the Breast","Node Negative Breast Cancer","Micrometastasis Breast Cancer","Hormone Receptor Positive Breast Cancer",[5538,5559],"ADJUVANT ENDOCRINE THERAPY",{"trials":5561,"activeCount":99},[],{"trials":5563,"activeCount":99},[],{"trials":5565,"activeCount":99},[],{"intervention":5559,"totalTrials":286,"cells":5567},{"EARLY_PHASE1":5568,"PHASE1":5570,"PHASE2":5572,"PHASE3":5578,"PHASE4":5580,"NA":5582},{"trials":5569,"activeCount":99},[],{"trials":5571,"activeCount":99},[],{"trials":5573,"activeCount":286,"soonestReadout":5550},[5574],{"nctId":5547,"briefTitle":5548,"status":355,"phases":5575,"primaryCompletion":5550,"completion":2811,"start":5551,"enrollment":5552,"conditions":5576,"interventions":5577},[89],[2846,5554,15,5555,5556,5557],[5538,5559],{"trials":5579,"activeCount":99},[],{"trials":5581,"activeCount":99},[],{"trials":5583,"activeCount":99},[],{"intervention":5585,"totalTrials":286,"cells":5586},"AGuIX",{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5605,"PHASE4":5607,"NA":5609},{"trials":5588,"activeCount":99},[],{"trials":5590,"activeCount":99},[],{"trials":5592,"activeCount":286,"soonestReadout":5597},[5593],{"nctId":5594,"briefTitle":5595,"status":220,"phases":5596,"primaryCompletion":5597,"completion":5598,"start":5599,"enrollment":166,"conditions":5600,"interventions":5604},"NCT04789486","Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer",[88,89],"2028-04-10","2030-04-10","2021-05-27",[1560,5601,5602,5603],"Advanced Pancreatic Adenocarcinoma","Unresectable Pancreatic Cancer","Ductal Adenocarcinoma of the Pancreas",[5585],{"trials":5606,"activeCount":99},[],{"trials":5608,"activeCount":99},[],{"trials":5610,"activeCount":99},[],{"intervention":5612,"totalTrials":286,"cells":5613},"Nivolumab - 240 mg",{"EARLY_PHASE1":5614,"PHASE1":5616,"PHASE2":5618,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5615,"activeCount":99},[],{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":286,"soonestReadout":2149},[5620],{"nctId":5621,"briefTitle":5622,"status":355,"phases":5623,"primaryCompletion":2149,"completion":1206,"start":3342,"enrollment":1082,"conditions":5624,"interventions":5626},"NCT02648997","An Open-Label Phase II Study of Nivolumab or Nivolumab\u002FIpilimumab in Adult Participants With Progessive\u002F Recurrent Meningioma",[89],[5625],"Meningiomas",[5612,5627,5628,5629,5630,5631],"Ipilimumab - 1 mg\u002Fkg","Nivolumab - 480 mg","Nivolumab - 3 mg\u002Fkg","Nivolumab - 1 mg\u002Fkg","Ipilimumab - 3 mg\u002Fkg",{"trials":5633,"activeCount":99},[],{"trials":5635,"activeCount":99},[],{"trials":5637,"activeCount":99},[],{"intervention":5627,"totalTrials":286,"cells":5639},{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5644,"PHASE3":5650,"PHASE4":5652,"NA":5654},{"trials":5641,"activeCount":99},[],{"trials":5643,"activeCount":99},[],{"trials":5645,"activeCount":286,"soonestReadout":2149},[5646],{"nctId":5621,"briefTitle":5622,"status":355,"phases":5647,"primaryCompletion":2149,"completion":1206,"start":3342,"enrollment":1082,"conditions":5648,"interventions":5649},[89],[5625],[5612,5627,5628,5629,5630,5631],{"trials":5651,"activeCount":99},[],{"trials":5653,"activeCount":99},[],{"trials":5655,"activeCount":99},[],{"intervention":5628,"totalTrials":286,"cells":5657},{"EARLY_PHASE1":5658,"PHASE1":5660,"PHASE2":5662,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5659,"activeCount":99},[],{"trials":5661,"activeCount":99},[],{"trials":5663,"activeCount":286,"soonestReadout":2149},[5664],{"nctId":5621,"briefTitle":5622,"status":355,"phases":5665,"primaryCompletion":2149,"completion":1206,"start":3342,"enrollment":1082,"conditions":5666,"interventions":5667},[89],[5625],[5612,5627,5628,5629,5630,5631],{"trials":5669,"activeCount":99},[],{"trials":5671,"activeCount":99},[],{"trials":5673,"activeCount":99},[],{"intervention":5629,"totalTrials":286,"cells":5675},{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5686,"PHASE4":5688,"NA":5690},{"trials":5677,"activeCount":99},[],{"trials":5679,"activeCount":99},[],{"trials":5681,"activeCount":286,"soonestReadout":2149},[5682],{"nctId":5621,"briefTitle":5622,"status":355,"phases":5683,"primaryCompletion":2149,"completion":1206,"start":3342,"enrollment":1082,"conditions":5684,"interventions":5685},[89],[5625],[5612,5627,5628,5629,5630,5631],{"trials":5687,"activeCount":99},[],{"trials":5689,"activeCount":99},[],{"trials":5691,"activeCount":99},[],{"intervention":5630,"totalTrials":286,"cells":5693},{"EARLY_PHASE1":5694,"PHASE1":5696,"PHASE2":5698,"PHASE3":5704,"PHASE4":5706,"NA":5708},{"trials":5695,"activeCount":99},[],{"trials":5697,"activeCount":99},[],{"trials":5699,"activeCount":286,"soonestReadout":2149},[5700],{"nctId":5621,"briefTitle":5622,"status":355,"phases":5701,"primaryCompletion":2149,"completion":1206,"start":3342,"enrollment":1082,"conditions":5702,"interventions":5703},[89],[5625],[5612,5627,5628,5629,5630,5631],{"trials":5705,"activeCount":99},[],{"trials":5707,"activeCount":99},[],{"trials":5709,"activeCount":99},[],{"intervention":5631,"totalTrials":286,"cells":5711},{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5716,"PHASE3":5722,"PHASE4":5724,"NA":5726},{"trials":5713,"activeCount":99},[],{"trials":5715,"activeCount":99},[],{"trials":5717,"activeCount":286,"soonestReadout":2149},[5718],{"nctId":5621,"briefTitle":5622,"status":355,"phases":5719,"primaryCompletion":2149,"completion":1206,"start":3342,"enrollment":1082,"conditions":5720,"interventions":5721},[89],[5625],[5612,5627,5628,5629,5630,5631],{"trials":5723,"activeCount":99},[],{"trials":5725,"activeCount":99},[],{"trials":5727,"activeCount":99},[],{"intervention":5278,"totalTrials":286,"cells":5729},{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5734,"PHASE3":5740,"PHASE4":5742,"NA":5744},{"trials":5731,"activeCount":99},[],{"trials":5733,"activeCount":99},[],{"trials":5735,"activeCount":286,"soonestReadout":5269},[5736],{"nctId":5266,"briefTitle":5267,"status":355,"phases":5737,"primaryCompletion":5269,"completion":5270,"start":5271,"enrollment":599,"conditions":5738,"interventions":5739},[89],[5273,837,838,15,3790,5274,5275,5276],[5257,5278],{"trials":5741,"activeCount":99},[],{"trials":5743,"activeCount":99},[],{"trials":5745,"activeCount":99},[],{"intervention":4721,"totalTrials":286,"cells":5747},{"EARLY_PHASE1":5748,"PHASE1":5750,"PHASE2":5752,"PHASE3":5758,"PHASE4":5760,"NA":5762},{"trials":5749,"activeCount":99},[],{"trials":5751,"activeCount":99},[],{"trials":5753,"activeCount":286,"soonestReadout":4715},[5754],{"nctId":4712,"briefTitle":4713,"status":355,"phases":5755,"primaryCompletion":4715,"completion":2842,"start":4716,"enrollment":4717,"conditions":5756,"interventions":5757},[89],[125,4719],[4721,928],{"trials":5759,"activeCount":99},[],{"trials":5761,"activeCount":99},[],{"trials":5763,"activeCount":99},[],{"intervention":3487,"totalTrials":286,"cells":5765},{"EARLY_PHASE1":5766,"PHASE1":5768,"PHASE2":5770,"PHASE3":5776,"PHASE4":5778,"NA":5780},{"trials":5767,"activeCount":99},[],{"trials":5769,"activeCount":99},[],{"trials":5771,"activeCount":286,"soonestReadout":3481},[5772],{"nctId":3478,"briefTitle":3479,"status":355,"phases":5773,"primaryCompletion":3481,"completion":3482,"start":3483,"enrollment":3484,"conditions":5774,"interventions":5775},[89],[15],[1954,3073,395,3487],{"trials":5777,"activeCount":99},[],{"trials":5779,"activeCount":99},[],{"trials":5781,"activeCount":99},[],{"intervention":5783,"totalTrials":286,"cells":5784},"Pembroluzimab",{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5789,"PHASE3":5800,"PHASE4":5802,"NA":5804},{"trials":5786,"activeCount":99},[],{"trials":5788,"activeCount":99},[],{"trials":5790,"activeCount":286,"soonestReadout":5064},[5791],{"nctId":5792,"briefTitle":5793,"status":316,"phases":5794,"primaryCompletion":5064,"completion":5795,"start":3828,"enrollment":16,"conditions":5796,"interventions":5799},"NCT07513324","Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)",[89],"2030-01-01",[5797,5798],"HPV-positive Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[5783],{"trials":5801,"activeCount":99},[],{"trials":5803,"activeCount":99},[],{"trials":5805,"activeCount":99},[],{"intervention":65,"totalTrials":286,"cells":5807},{"EARLY_PHASE1":5808,"PHASE1":5810,"PHASE2":5812,"PHASE3":5818,"PHASE4":5820,"NA":5822},{"trials":5809,"activeCount":99},[],{"trials":5811,"activeCount":99},[],{"trials":5813,"activeCount":286,"soonestReadout":64},[5814],{"nctId":62,"briefTitle":63,"status":355,"phases":5815,"primaryCompletion":64,"completion":320,"start":802,"enrollment":22,"conditions":5816,"interventions":5817},[88,89],[804],[65,679,269,51],{"trials":5819,"activeCount":99},[],{"trials":5821,"activeCount":99},[],{"trials":5823,"activeCount":99},[],{"intervention":2247,"totalTrials":286,"cells":5825},{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5836,"PHASE4":5838,"NA":5840},{"trials":5827,"activeCount":99},[],{"trials":5829,"activeCount":99},[],{"trials":5831,"activeCount":286,"soonestReadout":2149},[5832],{"nctId":2240,"briefTitle":2241,"status":355,"phases":5833,"primaryCompletion":2149,"completion":2243,"start":2244,"enrollment":459,"conditions":5834,"interventions":5835},[88,89],[804,2237],[2247,1017],{"trials":5837,"activeCount":99},[],{"trials":5839,"activeCount":99},[],{"trials":5841,"activeCount":99},[],{"intervention":3041,"totalTrials":286,"cells":5843},{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5848,"PHASE3":5854,"PHASE4":5856,"NA":5858},{"trials":5845,"activeCount":99},[],{"trials":5847,"activeCount":99},[],{"trials":5849,"activeCount":286,"soonestReadout":3035},[5850],{"nctId":3032,"briefTitle":3033,"status":220,"phases":5851,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":3038,"conditions":5852,"interventions":5853},[89],[1949,21],[1954,1953,3041,3042,3043,3044],{"trials":5855,"activeCount":99},[],{"trials":5857,"activeCount":99},[],{"trials":5859,"activeCount":99},[],{"intervention":3043,"totalTrials":286,"cells":5861},{"EARLY_PHASE1":5862,"PHASE1":5864,"PHASE2":5866,"PHASE3":5872,"PHASE4":5874,"NA":5876},{"trials":5863,"activeCount":99},[],{"trials":5865,"activeCount":99},[],{"trials":5867,"activeCount":286,"soonestReadout":3035},[5868],{"nctId":3032,"briefTitle":3033,"status":220,"phases":5869,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":3038,"conditions":5870,"interventions":5871},[89],[1949,21],[1954,1953,3041,3042,3043,3044],{"trials":5873,"activeCount":99},[],{"trials":5875,"activeCount":99},[],{"trials":5877,"activeCount":99},[],{"intervention":2848,"totalTrials":286,"cells":5879},{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5890,"PHASE4":5892,"NA":5894},{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[],{"trials":5885,"activeCount":286,"soonestReadout":2841},[5886],{"nctId":2838,"briefTitle":2839,"status":355,"phases":5887,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":5888,"interventions":5889},[89],[15,837,838,2846],[706,799,2848,798],{"trials":5891,"activeCount":99},[],{"trials":5893,"activeCount":99},[],{"trials":5895,"activeCount":99},[],{"intervention":2867,"totalTrials":286,"cells":5897},{"EARLY_PHASE1":5898,"PHASE1":5900,"PHASE2":5902,"PHASE3":5908,"PHASE4":5910,"NA":5912},{"trials":5899,"activeCount":99},[],{"trials":5901,"activeCount":99},[],{"trials":5903,"activeCount":286,"soonestReadout":2862},[5904],{"nctId":2859,"briefTitle":2860,"status":220,"phases":5905,"primaryCompletion":2862,"completion":2054,"start":2863,"enrollment":2864,"conditions":5906,"interventions":5907},[89],[15,2846],[2867,2868,706],{"trials":5909,"activeCount":99},[],{"trials":5911,"activeCount":99},[],{"trials":5913,"activeCount":99},[],{"intervention":2868,"totalTrials":286,"cells":5915},{"EARLY_PHASE1":5916,"PHASE1":5918,"PHASE2":5920,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5917,"activeCount":99},[],{"trials":5919,"activeCount":99},[],{"trials":5921,"activeCount":286,"soonestReadout":2862},[5922],{"nctId":2859,"briefTitle":2860,"status":220,"phases":5923,"primaryCompletion":2862,"completion":2054,"start":2863,"enrollment":2864,"conditions":5924,"interventions":5925},[89],[15,2846],[2867,2868,706],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":99},[],{"trials":5931,"activeCount":99},[],{"intervention":5933,"totalTrials":286,"cells":5934},"FHD-286",{"EARLY_PHASE1":5935,"PHASE1":5937,"PHASE2":5939,"PHASE3":5951,"PHASE4":5953,"NA":5955},{"trials":5936,"activeCount":99},[],{"trials":5938,"activeCount":99},[],{"trials":5940,"activeCount":286,"soonestReadout":5945},[5941],{"nctId":5942,"briefTitle":5943,"status":316,"phases":5944,"primaryCompletion":5945,"completion":5946,"start":5947,"enrollment":784,"conditions":5948,"interventions":5950},"NCT07551635","SMARCA4\u002F2 Inhibitor for POU2F3-Positive SCLC",[89],"2028-01-31","2029-01-31","2026-09-04",[5949],"Small Cell Lung Cancer",[5933],{"trials":5952,"activeCount":99},[],{"trials":5954,"activeCount":99},[],{"trials":5956,"activeCount":99},[],{"intervention":1255,"totalTrials":286,"cells":5958},{"EARLY_PHASE1":5959,"PHASE1":5961,"PHASE2":5963,"PHASE3":5969,"PHASE4":5971,"NA":5973},{"trials":5960,"activeCount":99},[],{"trials":5962,"activeCount":99},[],{"trials":5964,"activeCount":286,"soonestReadout":50},[5965],{"nctId":48,"briefTitle":49,"status":355,"phases":5966,"primaryCompletion":50,"completion":1250,"start":1251,"enrollment":345,"conditions":5967,"interventions":5968},[89],[1253],[51,1255,772],{"trials":5970,"activeCount":99},[],{"trials":5972,"activeCount":99},[],{"trials":5974,"activeCount":99},[],{"intervention":5976,"totalTrials":286,"cells":5977},"Pemigatinib",{"EARLY_PHASE1":5978,"PHASE1":5980,"PHASE2":5982,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5979,"activeCount":99},[],{"trials":5981,"activeCount":99},[],{"trials":5983,"activeCount":286,"soonestReadout":5988},[5984],{"nctId":5985,"briefTitle":5986,"status":220,"phases":5987,"primaryCompletion":5988,"completion":2110,"start":5989,"enrollment":25,"conditions":5990,"interventions":5992},"NCT07434843","PH 2 Pemigatinib in SDH-deficient GIST",[89],"2028-10-01","2026-05-19",[5991,5329],"SDH Gene Mutation",[5976],{"trials":5994,"activeCount":99},[],{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[],{"intervention":2063,"totalTrials":286,"cells":6000},{"EARLY_PHASE1":6001,"PHASE1":6003,"PHASE2":6005,"PHASE3":6011,"PHASE4":6013,"NA":6015},{"trials":6002,"activeCount":99},[],{"trials":6004,"activeCount":99},[],{"trials":6006,"activeCount":286,"soonestReadout":2053},[6007],{"nctId":2050,"briefTitle":2051,"status":220,"phases":6008,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":2056,"conditions":6009,"interventions":6010},[88,89],[2058,2059,2060,1354],[2062,2063,626],{"trials":6012,"activeCount":99},[],{"trials":6014,"activeCount":99},[],{"trials":6016,"activeCount":99},[],{"intervention":6018,"totalTrials":286,"cells":6019},"Metformin XR",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6035,"PHASE4":6037,"NA":6039},{"trials":6021,"activeCount":99},[],{"trials":6023,"activeCount":99},[],{"trials":6025,"activeCount":286,"soonestReadout":6030},[6026],{"nctId":6027,"briefTitle":6028,"status":355,"phases":6029,"primaryCompletion":6030,"completion":619,"start":6031,"enrollment":1999,"conditions":6032,"interventions":6034},"NCT04850846","Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma",[89],"2025-01-29","2021-04-27",[6033,876],"Monoclonal Gammopathy of Undetermined Significance",[6018],{"trials":6036,"activeCount":99},[],{"trials":6038,"activeCount":99},[],{"trials":6040,"activeCount":99},[],{"intervention":3916,"totalTrials":286,"cells":6042},{"EARLY_PHASE1":6043,"PHASE1":6045,"PHASE2":6047,"PHASE3":6053,"PHASE4":6055,"NA":6057},{"trials":6044,"activeCount":99},[],{"trials":6046,"activeCount":99},[],{"trials":6048,"activeCount":286,"soonestReadout":3910},[6049],{"nctId":3907,"briefTitle":3908,"status":355,"phases":6050,"primaryCompletion":3910,"completion":3911,"start":3912,"enrollment":2056,"conditions":6051,"interventions":6052},[89],[3914],[2653,3880,3916],{"trials":6054,"activeCount":99},[],{"trials":6056,"activeCount":99},[],{"trials":6058,"activeCount":99},[],{"intervention":878,"totalTrials":286,"cells":6060},{"EARLY_PHASE1":6061,"PHASE1":6063,"PHASE2":6065,"PHASE3":6071,"PHASE4":6073,"NA":6075},{"trials":6062,"activeCount":99},[],{"trials":6064,"activeCount":99},[],{"trials":6066,"activeCount":286,"soonestReadout":872},[6067],{"nctId":869,"briefTitle":870,"status":355,"phases":6068,"primaryCompletion":872,"completion":873,"start":874,"enrollment":784,"conditions":6069,"interventions":6070},[89],[24,876],[878,269,879],{"trials":6072,"activeCount":99},[],{"trials":6074,"activeCount":99},[],{"trials":6076,"activeCount":99},[],{"intervention":6078,"totalTrials":286,"cells":6079},"Elacestrant",{"EARLY_PHASE1":6080,"PHASE1":6082,"PHASE2":6084,"PHASE3":6104,"PHASE4":6106,"NA":6108},{"trials":6081,"activeCount":99},[],{"trials":6083,"activeCount":99},[],{"trials":6085,"activeCount":286,"soonestReadout":6090},[6086],{"nctId":6087,"briefTitle":6088,"status":220,"phases":6089,"primaryCompletion":6090,"completion":6091,"start":6092,"enrollment":403,"conditions":6093,"interventions":6103},"NCT07467772","Ph 2 Elacestrant in ER Positive Uterine Sarcomas",[89],"2027-07","2028-04","2026-03-25",[6094,6095,6096,6097,6098,6099,6100,6101,6102],"Uterine Sarcoma","Uterine Leiomyosarcoma","Endometrial Stromal Sarcoma","ESS","Perivascular Epithelioid Cell Tumors","Uterine Adenosarcoma","Uterine PEComa","Estrogen Receptor Positive Tumor","uLMS",[6078],{"trials":6105,"activeCount":99},[],{"trials":6107,"activeCount":99},[],{"trials":6109,"activeCount":99},[],{"intervention":2258,"totalTrials":286,"cells":6111},{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6122,"PHASE4":6124,"NA":6126},{"trials":6113,"activeCount":99},[],{"trials":6115,"activeCount":99},[],{"trials":6117,"activeCount":286,"soonestReadout":2252},[6118],{"nctId":2249,"briefTitle":2250,"status":355,"phases":6119,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":428,"conditions":6120,"interventions":6121},[89],[2256],[2258,1017],{"trials":6123,"activeCount":99},[],{"trials":6125,"activeCount":99},[],{"trials":6127,"activeCount":99},[],{"intervention":231,"totalTrials":286,"cells":6129},{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6134,"PHASE3":6140,"PHASE4":6142,"NA":6144},{"trials":6131,"activeCount":99},[],{"trials":6133,"activeCount":99},[],{"trials":6135,"activeCount":286,"soonestReadout":222},[6136],{"nctId":218,"briefTitle":219,"status":220,"phases":6137,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":6138,"interventions":6139},[89],[227,228,229,201],[231,232,233,95,234],{"trials":6141,"activeCount":99},[],{"trials":6143,"activeCount":99},[],{"trials":6145,"activeCount":99},[],{"intervention":232,"totalTrials":286,"cells":6147},{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6152,"PHASE3":6158,"PHASE4":6160,"NA":6162},{"trials":6149,"activeCount":99},[],{"trials":6151,"activeCount":99},[],{"trials":6153,"activeCount":286,"soonestReadout":222},[6154],{"nctId":218,"briefTitle":219,"status":220,"phases":6155,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":6156,"interventions":6157},[89],[227,228,229,201],[231,232,233,95,234],{"trials":6159,"activeCount":99},[],{"trials":6161,"activeCount":99},[],{"trials":6163,"activeCount":99},[],{"intervention":233,"totalTrials":286,"cells":6165},{"EARLY_PHASE1":6166,"PHASE1":6168,"PHASE2":6170,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6167,"activeCount":99},[],{"trials":6169,"activeCount":99},[],{"trials":6171,"activeCount":286,"soonestReadout":222},[6172],{"nctId":218,"briefTitle":219,"status":220,"phases":6173,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":6174,"interventions":6175},[89],[227,228,229,201],[231,232,233,95,234],{"trials":6177,"activeCount":99},[],{"trials":6179,"activeCount":99},[],{"trials":6181,"activeCount":99},[],{"intervention":234,"totalTrials":286,"cells":6183},{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6194,"PHASE4":6196,"NA":6198},{"trials":6185,"activeCount":99},[],{"trials":6187,"activeCount":99},[],{"trials":6189,"activeCount":286,"soonestReadout":222},[6190],{"nctId":218,"briefTitle":219,"status":220,"phases":6191,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":6192,"interventions":6193},[89],[227,228,229,201],[231,232,233,95,234],{"trials":6195,"activeCount":99},[],{"trials":6197,"activeCount":99},[],{"trials":6199,"activeCount":99},[],{"intervention":2269,"totalTrials":286,"cells":6201},{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6203,"activeCount":99},[],{"trials":6205,"activeCount":99},[],{"trials":6207,"activeCount":286,"soonestReadout":2263},[6208],{"nctId":2260,"briefTitle":2261,"status":220,"phases":6209,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":225,"conditions":6210,"interventions":6211},[89],[2226,2267],[1017,2269],{"trials":6213,"activeCount":99},[],{"trials":6215,"activeCount":99},[],{"trials":6217,"activeCount":99},[],{"intervention":6219,"totalTrials":286,"cells":6220},"Casdatifan",{"EARLY_PHASE1":6221,"PHASE1":6223,"PHASE2":6225,"PHASE3":6237,"PHASE4":6239,"NA":6241},{"trials":6222,"activeCount":99},[],{"trials":6224,"activeCount":99},[],{"trials":6226,"activeCount":286,"soonestReadout":5945},[6227],{"nctId":6228,"briefTitle":6229,"status":220,"phases":6230,"primaryCompletion":5945,"completion":6231,"start":6232,"enrollment":22,"conditions":6233,"interventions":6235},"NCT07397611","Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC",[89],"2029-09-30","2026-03-09",[3163,348,6234,3162],"Kidney Neoplasm",[6219,6236],"Zimberelimab",{"trials":6238,"activeCount":99},[],{"trials":6240,"activeCount":99},[],{"trials":6242,"activeCount":99},[],{"intervention":6236,"totalTrials":286,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6255,"PHASE4":6257,"NA":6259},{"trials":6246,"activeCount":99},[],{"trials":6248,"activeCount":99},[],{"trials":6250,"activeCount":286,"soonestReadout":5945},[6251],{"nctId":6228,"briefTitle":6229,"status":220,"phases":6252,"primaryCompletion":5945,"completion":6231,"start":6232,"enrollment":22,"conditions":6253,"interventions":6254},[89],[3163,348,6234,3162],[6219,6236],{"trials":6256,"activeCount":99},[],{"trials":6258,"activeCount":99},[],{"trials":6260,"activeCount":99},[],{"intervention":3959,"totalTrials":286,"cells":6262},{"EARLY_PHASE1":6263,"PHASE1":6265,"PHASE2":6267,"PHASE3":6273,"PHASE4":6275,"NA":6277},{"trials":6264,"activeCount":99},[],{"trials":6266,"activeCount":99},[],{"trials":6268,"activeCount":286,"soonestReadout":702},[6269],{"nctId":3953,"briefTitle":3954,"status":355,"phases":6270,"primaryCompletion":702,"completion":1292,"start":3956,"enrollment":661,"conditions":6271,"interventions":6272},[89],[1560],[3924,3959],{"trials":6274,"activeCount":99},[],{"trials":6276,"activeCount":99},[],{"trials":6278,"activeCount":99},[],{"intervention":5069,"totalTrials":286,"cells":6280},{"EARLY_PHASE1":6281,"PHASE1":6283,"PHASE2":6285,"PHASE3":6291,"PHASE4":6293,"NA":6295},{"trials":6282,"activeCount":99},[],{"trials":6284,"activeCount":99},[],{"trials":6286,"activeCount":286,"soonestReadout":2842},[6287],{"nctId":5061,"briefTitle":5062,"status":220,"phases":6288,"primaryCompletion":2842,"completion":5064,"start":5065,"enrollment":2112,"conditions":6289,"interventions":6290},[89],[18,5067],[5069,191],{"trials":6292,"activeCount":99},[],{"trials":6294,"activeCount":99},[],{"trials":6296,"activeCount":99},[],{"intervention":2929,"totalTrials":286,"cells":6298},{"EARLY_PHASE1":6299,"PHASE1":6301,"PHASE2":6303,"PHASE3":6309,"PHASE4":6311,"NA":6313},{"trials":6300,"activeCount":99},[],{"trials":6302,"activeCount":99},[],{"trials":6304,"activeCount":286,"soonestReadout":2919},[6305],{"nctId":2916,"briefTitle":2917,"status":220,"phases":6306,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":6307,"interventions":6308},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"trials":6310,"activeCount":99},[],{"trials":6312,"activeCount":99},[],{"trials":6314,"activeCount":99},[],{"intervention":2931,"totalTrials":286,"cells":6316},{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6321,"PHASE3":6327,"PHASE4":6329,"NA":6331},{"trials":6318,"activeCount":99},[],{"trials":6320,"activeCount":99},[],{"trials":6322,"activeCount":286,"soonestReadout":2919},[6323],{"nctId":2916,"briefTitle":2917,"status":220,"phases":6324,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2202,"conditions":6325,"interventions":6326},[89],[2923,15,2924,2925,2846,2926],[2928,706,158,2929,75,799,2930,2931,2932,798],{"trials":6328,"activeCount":99},[],{"trials":6330,"activeCount":99},[],{"trials":6332,"activeCount":99},[],{"intervention":6334,"totalTrials":286,"cells":6335},"Ado-trastuzumab",{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6340,"PHASE3":6353,"PHASE4":6355,"NA":6357},{"trials":6337,"activeCount":99},[],{"trials":6339,"activeCount":99},[],{"trials":6341,"activeCount":286,"soonestReadout":2275},[6342],{"nctId":6343,"briefTitle":6344,"status":220,"phases":6345,"primaryCompletion":2275,"completion":6346,"start":6347,"enrollment":2043,"conditions":6348,"interventions":6351},"NCT04620187","Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas",[89],"2029-02-01","2020-12-24",[6349,6350],"Salivary Gland Cancer","HER2 Gene Mutation",[6334,6352],"Standard of Care Chemotherapy",{"trials":6354,"activeCount":99},[],{"trials":6356,"activeCount":99},[],{"trials":6358,"activeCount":99},[],{"intervention":6352,"totalTrials":286,"cells":6360},{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6365,"PHASE3":6371,"PHASE4":6373,"NA":6375},{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"trials":6366,"activeCount":286,"soonestReadout":2275},[6367],{"nctId":6343,"briefTitle":6344,"status":220,"phases":6368,"primaryCompletion":2275,"completion":6346,"start":6347,"enrollment":2043,"conditions":6369,"interventions":6370},[89],[6349,6350],[6334,6352],{"trials":6372,"activeCount":99},[],{"trials":6374,"activeCount":99},[],{"trials":6376,"activeCount":99},[],{"intervention":2134,"totalTrials":286,"cells":6378},{"EARLY_PHASE1":6379,"PHASE1":6381,"PHASE2":6383,"PHASE3":6389,"PHASE4":6391,"NA":6393},{"trials":6380,"activeCount":99},[],{"trials":6382,"activeCount":99},[],{"trials":6384,"activeCount":286,"soonestReadout":2130},[6385],{"nctId":2127,"briefTitle":2128,"status":355,"phases":6386,"primaryCompletion":2130,"completion":2053,"start":2131,"enrollment":715,"conditions":6387,"interventions":6388},[89],[1949],[626,2134],{"trials":6390,"activeCount":99},[],{"trials":6392,"activeCount":99},[],{"trials":6394,"activeCount":99},[],{"intervention":6396,"totalTrials":286,"cells":6397},"Stereotactic Body Radiation Therapy",{"EARLY_PHASE1":6398,"PHASE1":6400,"PHASE2":6402,"PHASE3":6414,"PHASE4":6416,"NA":6418},{"trials":6399,"activeCount":99},[],{"trials":6401,"activeCount":99},[],{"trials":6403,"activeCount":286,"soonestReadout":6408},[6404],{"nctId":6405,"briefTitle":6406,"status":355,"phases":6407,"primaryCompletion":6408,"completion":6409,"start":3868,"enrollment":6410,"conditions":6411,"interventions":6413},"NCT02880319","Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone",[89],"2022-05","2027-05",150,[6412],"Bone Cancer",[6396],{"trials":6415,"activeCount":99},[],{"trials":6417,"activeCount":99},[],{"trials":6419,"activeCount":99},[],{"intervention":6421,"totalTrials":286,"cells":6422},"Cannabidiol",{"EARLY_PHASE1":6423,"PHASE1":6425,"PHASE2":6427,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6424,"activeCount":99},[],{"trials":6426,"activeCount":99},[],{"trials":6428,"activeCount":286,"soonestReadout":6433},[6429],{"nctId":6430,"briefTitle":6431,"status":355,"phases":6432,"primaryCompletion":6433,"completion":670,"start":6434,"enrollment":1999,"conditions":6435,"interventions":6439},"NCT04482244","RCT of CBD for Anxiety in Advanced Breast Cancer",[89],"2023-03-01","2022-01-19",[6436,6437,6438],"Advanced Breast Cancer","Anxiety","CBD",[6421],{"trials":6441,"activeCount":99},[],{"trials":6443,"activeCount":99},[],{"trials":6445,"activeCount":99},[],{"intervention":927,"totalTrials":286,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6452,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6449,"activeCount":99},[],{"trials":6451,"activeCount":99},[],{"trials":6453,"activeCount":286,"soonestReadout":920},[6454],{"nctId":917,"briefTitle":918,"status":316,"phases":6455,"primaryCompletion":920,"completion":921,"start":899,"enrollment":922,"conditions":6456,"interventions":6457},[89],[125,924,925,27],[927,928,269,772,364,929,279,930,511,128],{"trials":6459,"activeCount":99},[],{"trials":6461,"activeCount":99},[],{"trials":6463,"activeCount":99},[],{"intervention":2492,"totalTrials":286,"cells":6465},{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6470,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6467,"activeCount":99},[],{"trials":6469,"activeCount":99},[],{"trials":6471,"activeCount":286,"soonestReadout":2488},[6472],{"nctId":2485,"briefTitle":2486,"status":355,"phases":6473,"primaryCompletion":2488,"completion":596,"start":2489,"enrollment":2202,"conditions":6474,"interventions":6475},[89],[826,21,827],[762,80,2492],{"trials":6477,"activeCount":99},[],{"trials":6479,"activeCount":99},[],{"trials":6481,"activeCount":99},[],{"intervention":3823,"totalTrials":286,"cells":6483},{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6494,"PHASE4":6496,"NA":6498},{"trials":6485,"activeCount":99},[],{"trials":6487,"activeCount":99},[],{"trials":6489,"activeCount":286,"soonestReadout":3817},[6490],{"nctId":3814,"briefTitle":3815,"status":355,"phases":6491,"primaryCompletion":3817,"completion":1206,"start":3818,"enrollment":2721,"conditions":6492,"interventions":6493},[89],[3820,3821],[3776,3823],{"trials":6495,"activeCount":99},[],{"trials":6497,"activeCount":99},[],{"trials":6499,"activeCount":99},[],{"intervention":3074,"totalTrials":286,"cells":6501},{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6512,"PHASE4":6514,"NA":6516},{"trials":6503,"activeCount":99},[],{"trials":6505,"activeCount":99},[],{"trials":6507,"activeCount":286,"soonestReadout":3067},[6508],{"nctId":3064,"briefTitle":3065,"status":355,"phases":6509,"primaryCompletion":3067,"completion":3058,"start":3068,"enrollment":1928,"conditions":6510,"interventions":6511},[89],[15,3070,3071],[1953,3073,3074,1954,396,3075],{"trials":6513,"activeCount":99},[],{"trials":6515,"activeCount":99},[],{"trials":6517,"activeCount":99},[],{"intervention":3075,"totalTrials":286,"cells":6519},{"EARLY_PHASE1":6520,"PHASE1":6522,"PHASE2":6524,"PHASE3":6530,"PHASE4":6532,"NA":6534},{"trials":6521,"activeCount":99},[],{"trials":6523,"activeCount":99},[],{"trials":6525,"activeCount":286,"soonestReadout":3067},[6526],{"nctId":3064,"briefTitle":3065,"status":355,"phases":6527,"primaryCompletion":3067,"completion":3058,"start":3068,"enrollment":1928,"conditions":6528,"interventions":6529},[89],[15,3070,3071],[1953,3073,3074,1954,396,3075],{"trials":6531,"activeCount":99},[],{"trials":6533,"activeCount":99},[],{"trials":6535,"activeCount":99},[],{"intervention":2293,"totalTrials":286,"cells":6537},{"EARLY_PHASE1":6538,"PHASE1":6540,"PHASE2":6542,"PHASE3":6548,"PHASE4":6550,"NA":6552},{"trials":6539,"activeCount":99},[],{"trials":6541,"activeCount":99},[],{"trials":6543,"activeCount":286,"soonestReadout":2285},[6544],{"nctId":2282,"briefTitle":2283,"status":355,"phases":6545,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":6546,"interventions":6547},[88,89],[636,2290,2291],[2293,1017],{"trials":6549,"activeCount":99},[],{"trials":6551,"activeCount":99},[],{"trials":6553,"activeCount":99},[],{"intervention":2514,"totalTrials":286,"cells":6555},{"EARLY_PHASE1":6556,"PHASE1":6558,"PHASE2":6560,"PHASE3":6566,"PHASE4":6568,"NA":6570},{"trials":6557,"activeCount":99},[],{"trials":6559,"activeCount":99},[],{"trials":6561,"activeCount":286,"soonestReadout":2509},[6562],{"nctId":2506,"briefTitle":2507,"status":355,"phases":6563,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":1841,"conditions":6564,"interventions":6565},[89],[1918],[80,2514],{"trials":6567,"activeCount":99},[],{"trials":6569,"activeCount":99},[],{"trials":6571,"activeCount":99},[],{"intervention":2303,"totalTrials":286,"cells":6573},{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6575,"activeCount":99},[],{"trials":6577,"activeCount":99},[],{"trials":6579,"activeCount":286,"soonestReadout":2298},[6580],{"nctId":2295,"briefTitle":2296,"status":355,"phases":6581,"primaryCompletion":2298,"completion":2299,"start":2300,"enrollment":2008,"conditions":6582,"interventions":6583},[88,89],[27],[1017,2303],{"trials":6585,"activeCount":99},[],{"trials":6587,"activeCount":99},[],{"trials":6589,"activeCount":99},[],{"intervention":762,"totalTrials":661,"cells":6591},{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6600,"PHASE3":6724,"PHASE4":6726,"NA":6728},{"trials":6593,"activeCount":99},[],{"trials":6595,"activeCount":99},[6596],{"nctId":2784,"briefTitle":2785,"status":105,"phases":6597,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":720,"conditions":6598,"interventions":6599},[88],[21,827,2791],[706,2793,762],{"trials":6601,"activeCount":286,"soonestReadout":2488},[6602,6606,6614,6618,6625,6632,6636,6640,6649,6658,6662,6666,6670,6674,6680,6688,6692,6696,6700,6704,6708,6716,6720],{"nctId":755,"briefTitle":756,"status":105,"phases":6603,"primaryCompletion":758,"completion":359,"start":759,"enrollment":459,"conditions":6604,"interventions":6605},[89],[15],[762,269,511],{"nctId":6607,"briefTitle":6608,"status":118,"phases":6609,"primaryCompletion":660,"completion":660,"start":847,"enrollment":1337,"conditions":6610,"interventions":6612},"NCT00116506","Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer",[89],[5155,6611],"Neoplasm Metastasis",[2880,6613,915],"FOLFOX",{"nctId":3362,"briefTitle":3363,"status":118,"phases":6615,"primaryCompletion":425,"completion":3365,"start":3366,"enrollment":1988,"conditions":6616,"interventions":6617},[89],[663,15,3368],[2881,915,3370],{"nctId":6619,"briefTitle":6620,"status":118,"phases":6621,"primaryCompletion":812,"completion":152,"start":6622,"enrollment":4236,"conditions":6623,"interventions":6624},"NCT00137774","Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors",[89],"2004-11",[2503],[762,1297],{"nctId":6626,"briefTitle":6627,"status":105,"phases":6628,"primaryCompletion":344,"completion":1046,"start":1098,"enrollment":35,"conditions":6629,"interventions":6630},"NCT00418093","Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma",[89],[21,827,2876],[283,6631,762],"Oxaliplatin",{"nctId":1993,"briefTitle":1994,"status":118,"phases":6633,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":1999,"conditions":6634,"interventions":6635},[89],[611],[626,762],{"nctId":4179,"briefTitle":4180,"status":118,"phases":6637,"primaryCompletion":3449,"completion":795,"start":40,"enrollment":4182,"conditions":6638,"interventions":6639},[89],[2091,3693,4018],[762,866,4057],{"nctId":6641,"briefTitle":6642,"status":118,"phases":6643,"primaryCompletion":2677,"completion":1045,"start":2661,"enrollment":6644,"conditions":6645,"interventions":6646},"NCT00776594","Androgen Deprivation Therapy +\u002F- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy",[89],102,[18],[6647,6648,915],"Androgen Deprivation Therapy","bicalutamide",{"nctId":6650,"briefTitle":6651,"status":118,"phases":6652,"primaryCompletion":1071,"completion":40,"start":6653,"enrollment":2043,"conditions":6654,"interventions":6656},"NCT00137826","Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma",[89],"2004-02",[6655],"Mesothelioma",[6657,762],"Erlotinib",{"nctId":820,"briefTitle":821,"status":118,"phases":6659,"primaryCompletion":427,"completion":823,"start":824,"enrollment":784,"conditions":6660,"interventions":6661},[89],[21,826,827],[762,269],{"nctId":2870,"briefTitle":2871,"status":118,"phases":6663,"primaryCompletion":2873,"completion":1336,"start":2874,"enrollment":1999,"conditions":6664,"interventions":6665},[89],[21,827,2876,2877,2878],[915,2880,2805,2881],{"nctId":4569,"briefTitle":4570,"status":118,"phases":6667,"primaryCompletion":4572,"completion":1141,"start":4573,"enrollment":1133,"conditions":6668,"interventions":6669},[89],[4575],[762,3022],{"nctId":3687,"briefTitle":3688,"status":118,"phases":6671,"primaryCompletion":251,"completion":3690,"start":3691,"enrollment":2043,"conditions":6672,"interventions":6673},[89],[2091,3693],[915,3662,3695,3696],{"nctId":6675,"briefTitle":6676,"status":118,"phases":6677,"completion":782,"start":812,"enrollment":784,"conditions":6678,"interventions":6679},"NCT00165568","Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer",[89],[5155,6611],[762],{"nctId":6681,"briefTitle":6682,"status":105,"phases":6683,"primaryCompletion":1997,"completion":1997,"start":2042,"enrollment":498,"conditions":6684,"interventions":6686},"NCT04406272","VB-111 in Surgically Accessible Recurrent\u002FProgressive GBM",[89],[611,6685],"Recurrent Glioblastoma",[6687,762],"VB11",{"nctId":2897,"briefTitle":2898,"status":118,"phases":6689,"primaryCompletion":2874,"completion":2874,"start":2636,"enrollment":225,"conditions":6690,"interventions":6691},[89],[2901],[762,707,706],{"nctId":4376,"briefTitle":4377,"status":118,"phases":6693,"primaryCompletion":402,"completion":4379,"start":2957,"enrollment":4380,"conditions":6694,"interventions":6695},[89],[18],[158,762,4383,216],{"nctId":2118,"briefTitle":2119,"status":118,"phases":6697,"primaryCompletion":2121,"completion":2122,"start":2123,"enrollment":321,"conditions":6698,"interventions":6699},[89],[611],[626,762],{"nctId":906,"briefTitle":907,"status":118,"phases":6701,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":6702,"interventions":6703},[89],[15],[915,588,172],{"nctId":4385,"briefTitle":4386,"status":118,"phases":6705,"primaryCompletion":1098,"completion":3358,"start":3450,"enrollment":4380,"conditions":6706,"interventions":6707},[89],[2091,3693],[158,762],{"nctId":6709,"briefTitle":6710,"status":118,"phases":6711,"primaryCompletion":6712,"completion":120,"start":1558,"enrollment":2288,"conditions":6713,"interventions":6714},"NCT01290263","Amgen 386 for Recurrent Glioblastoma",[88,89],"2015-07",[612],[6715,762],"Amgen 386",{"nctId":4242,"briefTitle":4243,"status":118,"phases":6717,"primaryCompletion":163,"completion":1124,"start":1098,"enrollment":1988,"conditions":6718,"interventions":6719},[89],[2091,4018],[762,158,866,4057],{"nctId":2485,"briefTitle":2486,"status":355,"phases":6721,"primaryCompletion":2488,"completion":596,"start":2489,"enrollment":2202,"conditions":6722,"interventions":6723},[89],[826,21,827],[762,80,2492],{"trials":6725,"activeCount":99},[],{"trials":6727,"activeCount":99},[],{"trials":6729,"activeCount":99},[6730],{"nctId":6731,"briefTitle":6732,"status":105,"phases":6733,"primaryCompletion":759,"completion":759,"start":6734,"enrollment":329,"conditions":6735,"interventions":6736},"NCT00674011","Hypertension in Breast Cancer Patients Receiving Bevacizumab",[],"2008-01",[15],[762],{"intervention":625,"totalTrials":265,"cells":6738},{"EARLY_PHASE1":6739,"PHASE1":6741,"PHASE2":6755,"PHASE3":6757,"PHASE4":6759,"NA":6761},{"trials":6740,"activeCount":99},[],{"trials":6742,"activeCount":265,"soonestReadout":2347},[6743,6747,6751],{"nctId":616,"briefTitle":617,"status":220,"phases":6744,"primaryCompletion":619,"completion":620,"start":621,"enrollment":498,"conditions":6745,"interventions":6746},[88],[623],[625,269,626],{"nctId":1877,"briefTitle":1878,"status":355,"phases":6748,"primaryCompletion":223,"completion":1880,"start":1881,"enrollment":329,"conditions":6749,"interventions":6750},[88],[1883,1884],[1886,1887,80,626],{"nctId":2344,"briefTitle":2345,"status":355,"phases":6752,"primaryCompletion":2347,"completion":2348,"start":2349,"enrollment":123,"conditions":6753,"interventions":6754},[88],[21],[80,625],{"trials":6756,"activeCount":99},[],{"trials":6758,"activeCount":99},[],{"trials":6760,"activeCount":99},[],{"trials":6762,"activeCount":99},[],{"intervention":1297,"totalTrials":1093,"cells":6764},{"EARLY_PHASE1":6765,"PHASE1":6767,"PHASE2":6777,"PHASE3":6814,"PHASE4":6816,"NA":6818},{"trials":6766,"activeCount":99},[],{"trials":6768,"activeCount":1034,"soonestReadout":1292},[6769,6773],{"nctId":1289,"briefTitle":1290,"status":220,"phases":6770,"primaryCompletion":1292,"completion":222,"start":1293,"enrollment":498,"conditions":6771,"interventions":6772},[88],[585,1295],[626,511,1297,51],{"nctId":1898,"briefTitle":1899,"status":355,"phases":6774,"primaryCompletion":1901,"completion":1902,"start":536,"enrollment":378,"conditions":6775,"interventions":6776},[88],[611],[1905,626,1297,1297,1906],{"trials":6778,"activeCount":99},[6779,6783,6787,6793,6800,6808],{"nctId":724,"briefTitle":725,"status":118,"phases":6780,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":6781,"interventions":6782},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":6619,"briefTitle":6620,"status":118,"phases":6784,"primaryCompletion":812,"completion":152,"start":6622,"enrollment":4236,"conditions":6785,"interventions":6786},[89],[2503],[762,1297],{"nctId":6788,"briefTitle":6789,"status":118,"phases":6790,"primaryCompletion":2757,"completion":3358,"start":3682,"enrollment":428,"conditions":6791,"interventions":6792},"NCT00165360","Prolonged Daily Temozolomide for Low-Grade Glioma",[89],[417,419,603],[1297],{"nctId":6794,"briefTitle":6795,"status":118,"phases":6796,"primaryCompletion":5237,"completion":5237,"start":6797,"enrollment":498,"conditions":6798,"interventions":6799},"NCT00098865","Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma",[89],"2002-09",[731,850],[738,753],{"nctId":6801,"briefTitle":6802,"status":118,"phases":6803,"primaryCompletion":1215,"completion":1215,"start":263,"enrollment":6804,"conditions":6805,"interventions":6807},"NCT00576680","RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors",[88,89],43,[6806],"Pancreatic Neuroendocrine Tumor",[157,1297],{"nctId":6809,"briefTitle":6810,"status":118,"phases":6811,"primaryCompletion":4166,"completion":3219,"start":4006,"conditions":6812,"interventions":6813},"NCT00047294","Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89],[750],[752,738,753],{"trials":6815,"activeCount":99},[],{"trials":6817,"activeCount":99},[],{"trials":6819,"activeCount":99},[],{"intervention":2183,"totalTrials":1034,"cells":6821},{"EARLY_PHASE1":6822,"PHASE1":6824,"PHASE2":6844,"PHASE3":6846,"PHASE4":6848,"NA":6850},{"trials":6823,"activeCount":99},[],{"trials":6825,"activeCount":1034,"soonestReadout":965},[6826,6830],{"nctId":2174,"briefTitle":2175,"status":220,"phases":6827,"primaryCompletion":965,"completion":2177,"start":2178,"enrollment":329,"conditions":6828,"interventions":6829},[88],[674,2180,27,2181],[2183,46,1017],{"nctId":6831,"briefTitle":6832,"status":220,"phases":6833,"primaryCompletion":965,"completion":6834,"start":6835,"enrollment":715,"conditions":6836,"interventions":6842},"NCT06321484","Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer",[88],"2031-10-31","2024-10-09",[6837,6838,21,5526,6839,6840,6841],"Platinum-resistant Ovarian Cancer","Recurrent Ovary Cancer","Ovarian Carcinoma, Recurrent","Endometroid Ovarian Carcinoma","Clear Cell Ovarian Carcinoma",[2183,6843],"Interleukin 2",{"trials":6845,"activeCount":99},[],{"trials":6847,"activeCount":99},[],{"trials":6849,"activeCount":99},[],{"trials":6851,"activeCount":99},[],{"intervention":363,"totalTrials":265,"cells":6853},{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6866,"PHASE3":6872,"PHASE4":6874,"NA":6876},{"trials":6855,"activeCount":99},[],{"trials":6857,"activeCount":286,"soonestReadout":357},[6858,6862],{"nctId":4993,"briefTitle":4994,"status":105,"phases":6859,"primaryCompletion":4996,"completion":4996,"start":4997,"enrollment":571,"conditions":6860,"interventions":6861},[88],[4999,5000,5001],[363,5003,3710],{"nctId":353,"briefTitle":354,"status":355,"phases":6863,"primaryCompletion":357,"completion":358,"start":359,"enrollment":225,"conditions":6864,"interventions":6865},[88],[361],[363,364,127],{"trials":6867,"activeCount":99},[6868],{"nctId":3702,"briefTitle":3703,"status":118,"phases":6869,"primaryCompletion":3705,"completion":3706,"start":3707,"enrollment":661,"conditions":6870,"interventions":6871},[88,89],[15],[363,75,798,3710],{"trials":6873,"activeCount":99},[],{"trials":6875,"activeCount":99},[],{"trials":6877,"activeCount":99},[],{"intervention":694,"totalTrials":265,"cells":6879},{"EARLY_PHASE1":6880,"PHASE1":6882,"PHASE2":6888,"PHASE3":6898,"PHASE4":6900,"NA":6902},{"trials":6881,"activeCount":99},[],{"trials":6883,"activeCount":286,"soonestReadout":684},[6884],{"nctId":681,"briefTitle":682,"status":220,"phases":6885,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":6886,"interventions":6887},[88],[688,689,690,691,477],[679,693,269,694,695,696,285],{"trials":6889,"activeCount":99},[6890,6894],{"nctId":807,"briefTitle":808,"status":105,"phases":6891,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":6892,"interventions":6893},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":856,"briefTitle":857,"status":118,"phases":6895,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":6896,"interventions":6897},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"trials":6899,"activeCount":99},[],{"trials":6901,"activeCount":99},[],{"trials":6903,"activeCount":99},[],{"intervention":285,"totalTrials":265,"cells":6905},{"EARLY_PHASE1":6906,"PHASE1":6908,"PHASE2":6914,"PHASE3":6924,"PHASE4":6926,"NA":6928},{"trials":6907,"activeCount":99},[],{"trials":6909,"activeCount":286,"soonestReadout":684},[6910],{"nctId":681,"briefTitle":682,"status":220,"phases":6911,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":6912,"interventions":6913},[88],[688,689,690,691,477],[679,693,269,694,695,696,285],{"trials":6915,"activeCount":99},[6916,6920],{"nctId":856,"briefTitle":857,"status":118,"phases":6917,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":6918,"interventions":6919},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":271,"briefTitle":272,"status":105,"phases":6921,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":6922,"interventions":6923},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"trials":6925,"activeCount":99},[],{"trials":6927,"activeCount":99},[],{"trials":6929,"activeCount":99},[],{"intervention":3276,"totalTrials":1034,"cells":6931},{"EARLY_PHASE1":6932,"PHASE1":6934,"PHASE2":6940,"PHASE3":6951,"PHASE4":6953,"NA":6955},{"trials":6933,"activeCount":99},[],{"trials":6935,"activeCount":286,"soonestReadout":899},[6936],{"nctId":3268,"briefTitle":3269,"status":355,"phases":6937,"primaryCompletion":899,"completion":3271,"start":516,"enrollment":265,"conditions":6938,"interventions":6939},[88],[3273],[3275,958,3276],{"trials":6941,"activeCount":99},[6942],{"nctId":6943,"briefTitle":6944,"status":118,"phases":6945,"primaryCompletion":6946,"completion":6946,"start":6947,"enrollment":3051,"conditions":6948,"interventions":6949},"NCT02135133","A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL\u002FSLL",[89],"2020-10-06","2014-06",[804,2192],[3276,6950],"Ofatumumab",{"trials":6952,"activeCount":99},[],{"trials":6954,"activeCount":99},[],{"trials":6956,"activeCount":99},[],{"intervention":5243,"totalTrials":1034,"cells":6958},{"EARLY_PHASE1":6959,"PHASE1":6961,"PHASE2":6971,"PHASE3":6973,"PHASE4":6975,"NA":6977},{"trials":6960,"activeCount":99},[],{"trials":6962,"activeCount":286,"soonestReadout":684},[6963,6967],{"nctId":5234,"briefTitle":5235,"status":118,"phases":6964,"primaryCompletion":5237,"completion":5238,"start":4401,"enrollment":35,"conditions":6965,"interventions":6966},[88],[27,477],[5241,5242,5227,591,5243],{"nctId":681,"briefTitle":682,"status":220,"phases":6968,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":6969,"interventions":6970},[88],[688,689,690,691,477],[679,693,269,694,695,696,285],{"trials":6972,"activeCount":99},[],{"trials":6974,"activeCount":99},[],{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[],{"intervention":60,"totalTrials":1034,"cells":6980},{"EARLY_PHASE1":6981,"PHASE1":6983,"PHASE2":7000,"PHASE3":7002,"PHASE4":7004,"NA":7006},{"trials":6982,"activeCount":99},[],{"trials":6984,"activeCount":286,"soonestReadout":59},[6985,6994],{"nctId":6986,"briefTitle":6987,"status":118,"phases":6988,"primaryCompletion":6989,"completion":6990,"start":6991,"enrollment":329,"conditions":6992,"interventions":6993},"NCT01808417","NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer",[88],"2014-04-11","2015-04-07","2013-06-21",[2091],[60],{"nctId":57,"briefTitle":58,"status":355,"phases":6995,"primaryCompletion":59,"completion":6996,"start":6997,"enrollment":912,"conditions":6998,"interventions":6999},[88],"2029-12-01","2009-02-18",[30],[60],{"trials":7001,"activeCount":99},[],{"trials":7003,"activeCount":99},[],{"trials":7005,"activeCount":99},[],{"trials":7007,"activeCount":99},[],{"intervention":3894,"totalTrials":286,"cells":7009},{"EARLY_PHASE1":7010,"PHASE1":7012,"PHASE2":7018,"PHASE3":7020,"PHASE4":7022,"NA":7024},{"trials":7011,"activeCount":99},[],{"trials":7013,"activeCount":286,"soonestReadout":3890},[7014],{"nctId":3887,"briefTitle":3888,"status":355,"phases":7015,"primaryCompletion":3890,"completion":1292,"start":3891,"enrollment":1337,"conditions":7016,"interventions":7017},[88],[3327,3020],[3880,3894],{"trials":7019,"activeCount":99},[],{"trials":7021,"activeCount":99},[],{"trials":7023,"activeCount":99},[],{"trials":7025,"activeCount":99},[],{"intervention":2326,"totalTrials":286,"cells":7027},{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7036,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7029,"activeCount":99},[],{"trials":7031,"activeCount":286,"soonestReadout":2320},[7032],{"nctId":2317,"briefTitle":2318,"status":355,"phases":7033,"primaryCompletion":2320,"completion":2321,"start":2322,"enrollment":887,"conditions":7034,"interventions":7035},[88],[2324],[80,2326,2327],{"trials":7037,"activeCount":99},[],{"trials":7039,"activeCount":99},[],{"trials":7041,"activeCount":99},[],{"trials":7043,"activeCount":99},[],{"intervention":1210,"totalTrials":286,"cells":7045},{"EARLY_PHASE1":7046,"PHASE1":7048,"PHASE2":7054,"PHASE3":7056,"PHASE4":7058,"NA":7060},{"trials":7047,"activeCount":99},[],{"trials":7049,"activeCount":286,"soonestReadout":1205},[7050],{"nctId":1202,"briefTitle":1203,"status":355,"phases":7051,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":672,"conditions":7052,"interventions":7053},[88],[674],[1017,1210,772],{"trials":7055,"activeCount":99},[],{"trials":7057,"activeCount":99},[],{"trials":7059,"activeCount":99},[],{"trials":7061,"activeCount":99},[],{"intervention":2551,"totalTrials":286,"cells":7063},{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7072,"PHASE3":7074,"PHASE4":7076,"NA":7078},{"trials":7065,"activeCount":99},[],{"trials":7067,"activeCount":286,"soonestReadout":2545},[7068],{"nctId":2542,"briefTitle":2543,"status":355,"phases":7069,"primaryCompletion":2545,"completion":1865,"start":2546,"enrollment":661,"conditions":7070,"interventions":7071},[88],[674,477,2548,1376,2549],[2327,2551],{"trials":7073,"activeCount":99},[],{"trials":7075,"activeCount":99},[],{"trials":7077,"activeCount":99},[],{"trials":7079,"activeCount":99},[],{"intervention":614,"totalTrials":286,"cells":7081},{"EARLY_PHASE1":7082,"PHASE1":7084,"PHASE2":7090,"PHASE3":7092,"PHASE4":7094,"NA":7096},{"trials":7083,"activeCount":99},[],{"trials":7085,"activeCount":286,"soonestReadout":596},[7086],{"nctId":593,"briefTitle":594,"status":355,"phases":7087,"primaryCompletion":596,"completion":597,"start":598,"enrollment":599,"conditions":7088,"interventions":7089},[88],[601,419,602,603,604,605,606,607,608,609,417,610,611,612],[614,269],{"trials":7091,"activeCount":99},[],{"trials":7093,"activeCount":99},[],{"trials":7095,"activeCount":99},[],{"trials":7097,"activeCount":99},[],{"intervention":1871,"totalTrials":286,"cells":7099},{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7108,"PHASE3":7110,"PHASE4":7112,"NA":7114},{"trials":7101,"activeCount":99},[],{"trials":7103,"activeCount":286,"soonestReadout":1865},[7104],{"nctId":1862,"briefTitle":1863,"status":355,"phases":7105,"primaryCompletion":1865,"completion":1866,"start":1867,"enrollment":784,"conditions":7106,"interventions":7107},[88],[1869],[51,1871,626],{"trials":7109,"activeCount":99},[],{"trials":7111,"activeCount":99},[],{"trials":7113,"activeCount":99},[],{"trials":7115,"activeCount":99},[],{"intervention":1018,"totalTrials":286,"cells":7117},{"EARLY_PHASE1":7118,"PHASE1":7120,"PHASE2":7126,"PHASE3":7128,"PHASE4":7130,"NA":7132},{"trials":7119,"activeCount":99},[],{"trials":7121,"activeCount":286,"soonestReadout":1009},[7122],{"nctId":1006,"briefTitle":1007,"status":355,"phases":7123,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":345,"conditions":7124,"interventions":7125},[88],[1013,1014,1015],[1017,364,1018],{"trials":7127,"activeCount":99},[],{"trials":7129,"activeCount":99},[],{"trials":7131,"activeCount":99},[],{"trials":7133,"activeCount":99},[],{"intervention":7135,"totalTrials":286,"cells":7136},"MK-3475",{"EARLY_PHASE1":7137,"PHASE1":7139,"PHASE2":7150,"PHASE3":7152,"PHASE4":7154,"NA":7156},{"trials":7138,"activeCount":99},[],{"trials":7140,"activeCount":286,"soonestReadout":7145},[7141],{"nctId":7142,"briefTitle":7143,"status":355,"phases":7144,"primaryCompletion":7145,"completion":7146,"start":7147,"enrollment":1999,"conditions":7148,"interventions":7149},"NCT02852655","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent\u002FProgressive Glioblastoma",[88],"2022-06-02","2026-07-31","2016-09-21",[610],[7135],{"trials":7151,"activeCount":99},[],{"trials":7153,"activeCount":99},[],{"trials":7155,"activeCount":99},[],{"trials":7157,"activeCount":99},[],{"intervention":3903,"totalTrials":286,"cells":7159},{"EARLY_PHASE1":7160,"PHASE1":7162,"PHASE2":7168,"PHASE3":7170,"PHASE4":7172,"NA":7174},{"trials":7161,"activeCount":99},[],{"trials":7163,"activeCount":286,"soonestReadout":3899},[7164],{"nctId":3896,"briefTitle":3897,"status":355,"phases":7165,"primaryCompletion":3899,"completion":3058,"start":3900,"enrollment":2406,"conditions":7166,"interventions":7167},[88],[27],[3880,3903],{"trials":7169,"activeCount":99},[],{"trials":7171,"activeCount":99},[],{"trials":7173,"activeCount":99},[],{"trials":7175,"activeCount":99},[],{"intervention":3794,"totalTrials":286,"cells":7177},{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7186,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7179,"activeCount":99},[],{"trials":7181,"activeCount":286,"soonestReadout":3786},[7182],{"nctId":3783,"briefTitle":3784,"status":220,"phases":7183,"primaryCompletion":3786,"completion":1946,"start":3787,"enrollment":784,"conditions":7184,"interventions":7185},[88],[15,3789,3790,3791,3792],[3794,3776],{"trials":7187,"activeCount":99},[],{"trials":7189,"activeCount":99},[],{"trials":7191,"activeCount":99},[],{"trials":7193,"activeCount":99},[],{"intervention":3804,"totalTrials":286,"cells":7195},{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7204,"PHASE3":7206,"PHASE4":7208,"NA":7210},{"trials":7197,"activeCount":99},[],{"trials":7199,"activeCount":286,"soonestReadout":3799},[7200],{"nctId":3796,"briefTitle":3797,"status":355,"phases":7201,"primaryCompletion":3799,"completion":3800,"start":3801,"enrollment":329,"conditions":7202,"interventions":7203},[88],[15],[3804,3776],{"trials":7205,"activeCount":99},[],{"trials":7207,"activeCount":99},[],{"trials":7209,"activeCount":99},[],{"trials":7211,"activeCount":99},[],{"intervention":3275,"totalTrials":286,"cells":7213},{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7222,"PHASE3":7224,"PHASE4":7226,"NA":7228},{"trials":7215,"activeCount":99},[],{"trials":7217,"activeCount":286,"soonestReadout":899},[7218],{"nctId":3268,"briefTitle":3269,"status":355,"phases":7219,"primaryCompletion":899,"completion":3271,"start":516,"enrollment":265,"conditions":7220,"interventions":7221},[88],[3273],[3275,958,3276],{"trials":7223,"activeCount":99},[],{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":99},[],{"intervention":678,"totalTrials":286,"cells":7231},{"EARLY_PHASE1":7232,"PHASE1":7234,"PHASE2":7240,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7233,"activeCount":99},[],{"trials":7235,"activeCount":286,"soonestReadout":670},[7236],{"nctId":667,"briefTitle":668,"status":220,"phases":7237,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":7238,"interventions":7239},[88],[674,477,675,676],[678,679,269],{"trials":7241,"activeCount":99},[],{"trials":7243,"activeCount":99},[],{"trials":7245,"activeCount":99},[],{"trials":7247,"activeCount":99},[],{"intervention":1886,"totalTrials":286,"cells":7249},{"EARLY_PHASE1":7250,"PHASE1":7252,"PHASE2":7258,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7251,"activeCount":99},[],{"trials":7253,"activeCount":286,"soonestReadout":223},[7254],{"nctId":1877,"briefTitle":1878,"status":355,"phases":7255,"primaryCompletion":223,"completion":1880,"start":1881,"enrollment":329,"conditions":7256,"interventions":7257},[88],[1883,1884],[1886,1887,80,626],{"trials":7259,"activeCount":99},[],{"trials":7261,"activeCount":99},[],{"trials":7263,"activeCount":99},[],{"trials":7265,"activeCount":99},[],{"intervention":695,"totalTrials":286,"cells":7267},{"EARLY_PHASE1":7268,"PHASE1":7270,"PHASE2":7276,"PHASE3":7278,"PHASE4":7280,"NA":7282},{"trials":7269,"activeCount":99},[],{"trials":7271,"activeCount":286,"soonestReadout":684},[7272],{"nctId":681,"briefTitle":682,"status":220,"phases":7273,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":7274,"interventions":7275},[88],[688,689,690,691,477],[679,693,269,694,695,696,285],{"trials":7277,"activeCount":99},[],{"trials":7279,"activeCount":99},[],{"trials":7281,"activeCount":99},[],{"trials":7283,"activeCount":99},[],{"intervention":696,"totalTrials":286,"cells":7285},{"EARLY_PHASE1":7286,"PHASE1":7288,"PHASE2":7294,"PHASE3":7296,"PHASE4":7298,"NA":7300},{"trials":7287,"activeCount":99},[],{"trials":7289,"activeCount":286,"soonestReadout":684},[7290],{"nctId":681,"briefTitle":682,"status":220,"phases":7291,"primaryCompletion":684,"completion":685,"start":686,"enrollment":403,"conditions":7292,"interventions":7293},[88],[688,689,690,691,477],[679,693,269,694,695,696,285],{"trials":7295,"activeCount":99},[],{"trials":7297,"activeCount":99},[],{"trials":7299,"activeCount":99},[],{"trials":7301,"activeCount":99},[],{"intervention":6843,"totalTrials":286,"cells":7303},{"EARLY_PHASE1":7304,"PHASE1":7306,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7305,"activeCount":99},[],{"trials":7307,"activeCount":286,"soonestReadout":965},[7308],{"nctId":6831,"briefTitle":6832,"status":220,"phases":7309,"primaryCompletion":965,"completion":6834,"start":6835,"enrollment":715,"conditions":7310,"interventions":7311},[88],[6837,6838,21,5526,6839,6840,6841],[2183,6843],{"trials":7313,"activeCount":99},[],{"trials":7315,"activeCount":99},[],{"trials":7317,"activeCount":99},[],{"trials":7319,"activeCount":99},[],{"intervention":2206,"totalTrials":286,"cells":7321},{"EARLY_PHASE1":7322,"PHASE1":7324,"PHASE2":7330,"PHASE3":7332,"PHASE4":7334,"NA":7336},{"trials":7323,"activeCount":99},[],{"trials":7325,"activeCount":286,"soonestReadout":2199},[7326],{"nctId":2196,"briefTitle":2197,"status":220,"phases":7327,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":7328,"interventions":7329},[88],[674,463,2204],[2206,2207,1017],{"trials":7331,"activeCount":99},[],{"trials":7333,"activeCount":99},[],{"trials":7335,"activeCount":99},[],{"trials":7337,"activeCount":99},[],{"intervention":2207,"totalTrials":286,"cells":7339},{"EARLY_PHASE1":7340,"PHASE1":7342,"PHASE2":7348,"PHASE3":7350,"PHASE4":7352,"NA":7354},{"trials":7341,"activeCount":99},[],{"trials":7343,"activeCount":286,"soonestReadout":2199},[7344],{"nctId":2196,"briefTitle":2197,"status":220,"phases":7345,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":7346,"interventions":7347},[88],[674,463,2204],[2206,2207,1017],{"trials":7349,"activeCount":99},[],{"trials":7351,"activeCount":99},[],{"trials":7353,"activeCount":99},[],{"trials":7355,"activeCount":99},[],{"intervention":3204,"totalTrials":286,"cells":7357},{"EARLY_PHASE1":7358,"PHASE1":7360,"PHASE2":7366,"PHASE3":7368,"PHASE4":7370,"NA":7372},{"trials":7359,"activeCount":99},[],{"trials":7361,"activeCount":286,"soonestReadout":2420},[7362],{"nctId":3197,"briefTitle":3198,"status":220,"phases":7363,"primaryCompletion":2420,"completion":2177,"start":3200,"enrollment":498,"conditions":7364,"interventions":7365},[88],[674,27,2181,477,675,3202],[3204,46],{"trials":7367,"activeCount":99},[],{"trials":7369,"activeCount":99},[],{"trials":7371,"activeCount":99},[],{"trials":7373,"activeCount":99},[],{"intervention":719,"totalTrials":286,"cells":7375},{"EARLY_PHASE1":7376,"PHASE1":7378,"PHASE2":7384,"PHASE3":7386,"PHASE4":7388,"NA":7390},{"trials":7377,"activeCount":99},[],{"trials":7379,"activeCount":286,"soonestReadout":712},[7380],{"nctId":709,"briefTitle":710,"status":355,"phases":7381,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":7382,"interventions":7383},[88],[585,717],[679,269,719],{"trials":7385,"activeCount":99},[],{"trials":7387,"activeCount":99},[],{"trials":7389,"activeCount":99},[],{"trials":7391,"activeCount":99},[],{"intervention":70,"totalTrials":286,"cells":7393},{"EARLY_PHASE1":7394,"PHASE1":7396,"PHASE2":7411,"PHASE3":7413,"PHASE4":7415,"NA":7417},{"trials":7395,"activeCount":99},[],{"trials":7397,"activeCount":286,"soonestReadout":69},[7398],{"nctId":67,"briefTitle":68,"status":355,"phases":7399,"primaryCompletion":69,"completion":944,"start":3518,"enrollment":9,"conditions":7400,"interventions":7410},[88],[7401,7402,7403,7404,7405,7406,7407,7408,7409],"Relapsed Acute Lymphoblastic Leukemia (ALL)","Refractory Acute Lymphoblastic Leukemia (ALL)","Relapsed Acute Myelogenous Leukemia (AML)","Refractory Acute Myelogenous Leukemia (AML)","Relapsed Mixed Lineage Leukemia","Refractory Mixed Lineage Leukemia","Relapsed Biphenotypic Leukemia","Refractory Biphenotypic Leukemia","Chronic Myelogenous Leukemia (CML) in Blast Crisis",[70],{"trials":7412,"activeCount":99},[],{"trials":7414,"activeCount":99},[],{"trials":7416,"activeCount":99},[],{"trials":7418,"activeCount":99},[],{"intervention":1905,"totalTrials":286,"cells":7420},{"EARLY_PHASE1":7421,"PHASE1":7423,"PHASE2":7429,"PHASE3":7431,"PHASE4":7433,"NA":7435},{"trials":7422,"activeCount":99},[],{"trials":7424,"activeCount":286,"soonestReadout":1901},[7425],{"nctId":1898,"briefTitle":1899,"status":355,"phases":7426,"primaryCompletion":1901,"completion":1902,"start":536,"enrollment":378,"conditions":7427,"interventions":7428},[88],[611],[1905,626,1297,1297,1906],{"trials":7430,"activeCount":99},[],{"trials":7432,"activeCount":99},[],{"trials":7434,"activeCount":99},[],{"trials":7436,"activeCount":99},[],{"intervention":1906,"totalTrials":286,"cells":7438},{"EARLY_PHASE1":7439,"PHASE1":7441,"PHASE2":7447,"PHASE3":7449,"PHASE4":7451,"NA":7453},{"trials":7440,"activeCount":99},[],{"trials":7442,"activeCount":286,"soonestReadout":1901},[7443],{"nctId":1898,"briefTitle":1899,"status":355,"phases":7444,"primaryCompletion":1901,"completion":1902,"start":536,"enrollment":378,"conditions":7445,"interventions":7446},[88],[611],[1905,626,1297,1297,1906],{"trials":7448,"activeCount":99},[],{"trials":7450,"activeCount":99},[],{"trials":7452,"activeCount":99},[],{"trials":7454,"activeCount":99},[],{"intervention":7456,"totalTrials":286,"cells":7457},"Vitamin D3",{"EARLY_PHASE1":7458,"PHASE1":7471,"PHASE2":7473,"PHASE3":7475,"PHASE4":7477,"NA":7479},{"trials":7459,"activeCount":286,"soonestReadout":7464},[7460],{"nctId":7461,"briefTitle":7462,"status":220,"phases":7463,"primaryCompletion":7464,"completion":222,"start":7465,"enrollment":321,"conditions":7466,"interventions":7470},"NCT02172651","Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases",[87],"2027-04-15","2014-07-14",[7467,7468,7469],"Stage, Colon Cancer","Stage I-III Colon Cancer","Stage IV Colon Cancer With Resectable Liver Metastases",[7456],{"trials":7472,"activeCount":99},[],{"trials":7474,"activeCount":99},[],{"trials":7476,"activeCount":99},[],{"trials":7478,"activeCount":99},[],{"trials":7480,"activeCount":99},[],{"intervention":7482,"totalTrials":286,"cells":7483},"Magnetic Resonance Imaging",{"EARLY_PHASE1":7484,"PHASE1":7501,"PHASE2":7503,"PHASE3":7505,"PHASE4":7507,"NA":7509},{"trials":7485,"activeCount":286,"soonestReadout":7490},[7486],{"nctId":7487,"briefTitle":7488,"status":220,"phases":7489,"primaryCompletion":7490,"completion":7491,"start":7492,"enrollment":7493,"conditions":7494,"interventions":7499},"NCT06122896","Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals",[87],"2040-10-31","2041-10-31","2023-11-21",5000,[4444,7495,7496,7497,7498],"Pancreatic Ductal Adenocarcinoma","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasm",[7482,7500],"Magnetic Resonance Cholangiopancreatography",{"trials":7502,"activeCount":99},[],{"trials":7504,"activeCount":99},[],{"trials":7506,"activeCount":99},[],{"trials":7508,"activeCount":99},[],{"trials":7510,"activeCount":99},[],{"intervention":7500,"totalTrials":286,"cells":7512},{"EARLY_PHASE1":7513,"PHASE1":7519,"PHASE2":7521,"PHASE3":7523,"PHASE4":7525,"NA":7527},{"trials":7514,"activeCount":286,"soonestReadout":7490},[7515],{"nctId":7487,"briefTitle":7488,"status":220,"phases":7516,"primaryCompletion":7490,"completion":7491,"start":7492,"enrollment":7493,"conditions":7517,"interventions":7518},[87],[4444,7495,7496,7497,7498],[7482,7500],{"trials":7520,"activeCount":99},[],{"trials":7522,"activeCount":99},[],{"trials":7524,"activeCount":99},[],{"trials":7526,"activeCount":99},[],{"trials":7528,"activeCount":99},[],{"intervention":7530,"totalTrials":286,"cells":7531},"Fluzone Trivalent",{"EARLY_PHASE1":7532,"PHASE1":7544,"PHASE2":7546,"PHASE3":7548,"PHASE4":7550,"NA":7552},{"trials":7533,"activeCount":286,"soonestReadout":7538},[7534],{"nctId":7535,"briefTitle":7536,"status":220,"phases":7537,"primaryCompletion":7538,"completion":7538,"start":7539,"enrollment":661,"conditions":7540,"interventions":7543},"NCT06664151","A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision",[87],"2026-08-30","2024-11-26",[323,7541,7542],"Cutaneous Squamous Cell Carcinoma (CSCC)","Cutaneous Squamous Cell Cancer",[7530],{"trials":7545,"activeCount":99},[],{"trials":7547,"activeCount":99},[],{"trials":7549,"activeCount":99},[],{"trials":7551,"activeCount":99},[],{"trials":7553,"activeCount":99},[],{"intervention":3168,"totalTrials":286,"cells":7555},{"EARLY_PHASE1":7556,"PHASE1":7562,"PHASE2":7564,"PHASE3":7566,"PHASE4":7568,"NA":7570},{"trials":7557,"activeCount":286,"soonestReadout":2420},[7558],{"nctId":3156,"briefTitle":3157,"status":355,"phases":7559,"primaryCompletion":2420,"completion":3159,"start":3160,"enrollment":275,"conditions":7560,"interventions":7561},[87],[3162,3163,3164,3165,3166],[3168,46],{"trials":7563,"activeCount":99},[],{"trials":7565,"activeCount":99},[],{"trials":7567,"activeCount":99},[],{"trials":7569,"activeCount":99},[],{"trials":7571,"activeCount":99},[],{"intervention":7573,"totalTrials":265,"cells":7574},"Data and Specimen Collection",{"EARLY_PHASE1":7575,"PHASE1":7577,"PHASE2":7579,"PHASE3":7581,"PHASE4":7583,"NA":7585},{"trials":7576,"activeCount":99},[],{"trials":7578,"activeCount":99},[],{"trials":7580,"activeCount":99},[],{"trials":7582,"activeCount":99},[],{"trials":7584,"activeCount":99},[],{"trials":7586,"activeCount":265,"soonestReadout":7591},[7587,7598,7608],{"nctId":7588,"briefTitle":7589,"status":220,"phases":7590,"primaryCompletion":7591,"completion":7591,"start":7592,"enrollment":2864,"conditions":7593,"interventions":7597},"NCT05265429","Biology of Young Lung Cancer Study: The YOUNG LUNG Study",[],"2027-08-01","2023-01-01",[7594,7595,7596],"Non Small Cell Lung Cancer","Small Cell Lung Carcinoma","NUT Carcinoma",[7573],{"nctId":7599,"briefTitle":7600,"status":220,"phases":7601,"primaryCompletion":7602,"completion":7602,"start":7592,"enrollment":2864,"conditions":7603,"interventions":7607},"NCT05587439","Investigating Hereditary Risk In Thoracic Cancers (INHERIT)",[],"2027-11-01",[30,7604,7605,7606],"Genetic Disease","Genetic Predisposition","Hereditary Diseases",[7573],{"nctId":7609,"briefTitle":7610,"status":220,"phases":7611,"primaryCompletion":7612,"completion":7613,"start":7614,"enrollment":7615,"conditions":7616,"interventions":7622},"NCT04541654","Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress",[],"2030-12-31","2032-12-31","2020-09-15",1500,[7617,7618,7619,7620,7621],"Li-Fraumeni Syndrome","TP53 Gene Mutation","Hereditary Cancer Syndrome","Clonal Hematopoiesis","Mosaicism",[7573],{"intervention":7624,"totalTrials":286,"cells":7625},"•Referral to Genetic Counselor, if indicated",{"EARLY_PHASE1":7626,"PHASE1":7628,"PHASE2":7630,"PHASE3":7632,"PHASE4":7634,"NA":7636},{"trials":7627,"activeCount":99},[],{"trials":7629,"activeCount":99},[],{"trials":7631,"activeCount":99},[],{"trials":7633,"activeCount":99},[],{"trials":7635,"activeCount":99},[],{"trials":7637,"activeCount":286,"soonestReadout":1946},[7638],{"nctId":7639,"briefTitle":7640,"status":220,"phases":7641,"primaryCompletion":1946,"completion":1946,"start":7642,"enrollment":2972,"conditions":7643,"interventions":7644},"NCT02747888","Hereditary Risk Factors for Thyroid Cancer",[92],"2016-03-01",[2433],[7624],{"intervention":7646,"totalTrials":286,"cells":7647},"Leukemia Profiling",{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7649,"activeCount":99},[],{"trials":7651,"activeCount":99},[],{"trials":7653,"activeCount":99},[],{"trials":7655,"activeCount":99},[],{"trials":7657,"activeCount":99},[],{"trials":7659,"activeCount":286,"soonestReadout":7664},[7660],{"nctId":7661,"briefTitle":7662,"status":355,"phases":7663,"primaryCompletion":7664,"completion":5945,"start":7665,"enrollment":7666,"conditions":7667,"interventions":7670},"NCT02670525","Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome",[92],"2022-05-16","2016-08-17",338,[7668,7669],"Recurrent, Refractory, or High Risk Leukemias","Matched Targeted Therapy",[7646],{"intervention":7672,"totalTrials":286,"cells":7673},"Genomic profiling",{"EARLY_PHASE1":7674,"PHASE1":7676,"PHASE2":7678,"PHASE3":7680,"PHASE4":7682,"NA":7684},{"trials":7675,"activeCount":99},[],{"trials":7677,"activeCount":99},[],{"trials":7679,"activeCount":99},[],{"trials":7681,"activeCount":99},[],{"trials":7683,"activeCount":99},[],{"trials":7685,"activeCount":286,"soonestReadout":7690},[7686],{"nctId":7687,"briefTitle":7688,"status":220,"phases":7689,"primaryCompletion":7690,"completion":7690,"start":7691,"enrollment":2773,"conditions":7692,"interventions":7694},"NCT04968834","Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy",[],"2033-06","2021-06-11",[27,477,7693],"Myeloproliferative Syndrome",[7672],{"intervention":7696,"totalTrials":286,"cells":7697},"Genetic testing and GAIN report",{"EARLY_PHASE1":7698,"PHASE1":7700,"PHASE2":7702,"PHASE3":7704,"PHASE4":7706,"NA":7708},{"trials":7699,"activeCount":99},[],{"trials":7701,"activeCount":99},[],{"trials":7703,"activeCount":99},[],{"trials":7705,"activeCount":99},[],{"trials":7707,"activeCount":99},[],{"trials":7709,"activeCount":286,"soonestReadout":2440},[7710],{"nctId":7711,"briefTitle":7712,"status":355,"phases":7713,"primaryCompletion":2440,"completion":3946,"start":3439,"enrollment":7714,"conditions":7715,"interventions":7716},"NCT02520713","The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study",[],825,[2336],[7696],{"intervention":466,"totalTrials":242,"cells":7718},{"EARLY_PHASE1":7719,"PHASE1":7721,"PHASE2":7723,"PHASE3":7757,"PHASE4":7763,"NA":7765},{"trials":7720,"activeCount":99},[],{"trials":7722,"activeCount":99},[],{"trials":7724,"activeCount":99},[7725,7729,7733,7737,7741,7745,7749,7753],{"nctId":454,"briefTitle":455,"status":118,"phases":7726,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":7727,"interventions":7728},[89],[461,462,125,463,267,464],[147,466],{"nctId":468,"briefTitle":469,"status":118,"phases":7730,"primaryCompletion":471,"completion":471,"start":472,"enrollment":403,"conditions":7731,"interventions":7732},[89],[474,475,125,476,477,267,464],[479,480],{"nctId":1321,"briefTitle":1322,"status":118,"phases":7734,"primaryCompletion":1324,"completion":1325,"start":909,"enrollment":225,"conditions":7735,"interventions":7736},[88,89],[461],[41,466,511],{"nctId":482,"briefTitle":483,"status":118,"phases":7738,"primaryCompletion":485,"completion":40,"start":486,"enrollment":487,"conditions":7739,"interventions":7740},[89],[475,489],[480,479,491,492],{"nctId":1333,"briefTitle":1334,"status":118,"phases":7742,"primaryCompletion":846,"completion":1336,"start":164,"enrollment":1337,"conditions":7743,"interventions":7744},[89],[27,585,463],[41,466,511],{"nctId":504,"briefTitle":505,"status":118,"phases":7746,"primaryCompletion":507,"completion":507,"start":458,"enrollment":508,"conditions":7747,"interventions":7748},[89],[475,461],[147,466,511],{"nctId":513,"briefTitle":514,"status":118,"phases":7750,"primaryCompletion":516,"completion":517,"start":198,"enrollment":518,"conditions":7751,"interventions":7752},[89],[475],[466,511,41,147],{"nctId":1368,"briefTitle":1369,"status":105,"phases":7754,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":1374,"conditions":7755,"interventions":7756},[89],[463,674,1376],[1378,284,679,466,511],{"trials":7758,"activeCount":99},[7759],{"nctId":533,"briefTitle":534,"status":118,"phases":7760,"primaryCompletion":536,"completion":536,"start":415,"enrollment":537,"conditions":7761,"interventions":7762},[90],[539,540],[147,511,466,542,543],{"trials":7764,"activeCount":99},[],{"trials":7766,"activeCount":99},[],{"intervention":789,"totalTrials":2800,"cells":7768},{"EARLY_PHASE1":7769,"PHASE1":7771,"PHASE2":7773,"PHASE3":7801,"PHASE4":7810,"NA":7812},{"trials":7770,"activeCount":99},[],{"trials":7772,"activeCount":99},[],{"trials":7774,"activeCount":99},[7775,7779,7785,7789,7793,7797],{"nctId":743,"briefTitle":744,"status":118,"phases":7776,"primaryCompletion":746,"completion":747,"start":748,"conditions":7777,"interventions":7778},[89],[750],[752,588,737,753],{"nctId":7780,"briefTitle":7781,"status":118,"phases":7782,"primaryCompletion":4166,"completion":4166,"start":165,"enrollment":345,"conditions":7783,"interventions":7784},"NCT00052611","Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and\u002For Head and Neck Dysplasia",[89],[1532],[789],{"nctId":779,"briefTitle":780,"status":118,"phases":7786,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":7787,"interventions":7788},[89],[786],[788,789,279,269],{"nctId":843,"briefTitle":844,"status":118,"phases":7790,"primaryCompletion":846,"completion":425,"start":847,"enrollment":848,"conditions":7791,"interventions":7792},[89],[731,27,585,850,851,852],[752,588,737,854,753],{"nctId":4203,"briefTitle":4204,"status":118,"phases":7794,"primaryCompletion":3450,"completion":4206,"start":2772,"enrollment":1337,"conditions":7795,"interventions":7796},[89],[2091],[866,4057,789],{"nctId":6809,"briefTitle":6810,"status":118,"phases":7798,"primaryCompletion":4166,"completion":3219,"start":4006,"conditions":7799,"interventions":7800},[89],[750],[752,738,753],{"trials":7802,"activeCount":99},[7803],{"nctId":7804,"briefTitle":7805,"status":118,"phases":7806,"primaryCompletion":1098,"completion":1098,"start":7807,"enrollment":955,"conditions":7808,"interventions":7809},"NCT00136487","Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer",[89,90],"2002-10",[18],[789],{"trials":7811,"activeCount":99},[],{"trials":7813,"activeCount":99},[],{"intervention":308,"totalTrials":720,"cells":7815},{"EARLY_PHASE1":7816,"PHASE1":7818,"PHASE2":7820,"PHASE3":7848,"PHASE4":7854,"NA":7856},{"trials":7817,"activeCount":99},[],{"trials":7819,"activeCount":99},[],{"trials":7821,"activeCount":99},[7822,7826,7836,7840,7844],{"nctId":4118,"briefTitle":4119,"status":118,"phases":7823,"primaryCompletion":486,"completion":486,"start":4121,"enrollment":403,"conditions":7824,"interventions":7825},[88,89],[4123,4124],[4103,866,4022,308],{"nctId":7827,"briefTitle":7828,"status":118,"phases":7829,"primaryCompletion":3868,"completion":7830,"start":198,"enrollment":7831,"conditions":7832,"interventions":7833},"NCT01747551","FOLFOX +\u002F- Ziv-Aflibercept for Esophageal and Gastric Cancer",[89],"2017-07-26",64,[2091,3693],[6631,308,7834,7835],"Fluorouracil","Ziv-aflibercept",{"nctId":160,"briefTitle":161,"status":118,"phases":7837,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":7838,"interventions":7839},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"nctId":807,"briefTitle":808,"status":105,"phases":7841,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":7842,"interventions":7843},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":4214,"briefTitle":4215,"status":118,"phases":7845,"primaryCompletion":2757,"completion":2757,"start":4217,"enrollment":403,"conditions":7846,"interventions":7847},[89],[4123,4219],[4103,866,4022,308,867,4221],{"trials":7849,"activeCount":99},[7850],{"nctId":299,"briefTitle":300,"status":118,"phases":7851,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":7852,"interventions":7853},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":7855,"activeCount":99},[],{"trials":7857,"activeCount":99},[],{"intervention":2975,"totalTrials":275,"cells":7859},{"EARLY_PHASE1":7860,"PHASE1":7862,"PHASE2":7864,"PHASE3":7891,"PHASE4":7897,"NA":7899},{"trials":7861,"activeCount":99},[],{"trials":7863,"activeCount":99},[],{"trials":7865,"activeCount":99},[7866,7873,7877,7885],{"nctId":7867,"briefTitle":7868,"status":118,"phases":7869,"primaryCompletion":746,"completion":746,"start":7870,"enrollment":22,"conditions":7871,"interventions":7872},"NCT00215462","Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma",[89],"2000-06",[2091,3693,4018],[2975],{"nctId":3657,"briefTitle":3658,"status":105,"phases":7874,"primaryCompletion":120,"completion":250,"start":2732,"enrollment":487,"conditions":7875,"interventions":7876},[89],[15,663],[3662,3663],{"nctId":7878,"briefTitle":7879,"status":118,"phases":7880,"primaryCompletion":2956,"completion":2956,"start":729,"enrollment":1082,"conditions":7881,"interventions":7883},"NCT00134641","Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas",[89],[7882],"Sarcoma, Soft Tissue",[7884,3663],"gemcitabine",{"nctId":7886,"briefTitle":7887,"status":118,"phases":7888,"primaryCompletion":262,"completion":262,"start":4401,"enrollment":2431,"conditions":7889,"interventions":7890},"NCT00165334","Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer",[89],[1560],[2562,2975],{"trials":7892,"activeCount":99},[7893],{"nctId":2967,"briefTitle":2968,"status":118,"phases":7894,"primaryCompletion":2874,"completion":2970,"start":2971,"enrollment":2972,"conditions":7895,"interventions":7896},[90],[15,2926],[798,2975,706,158],{"trials":7898,"activeCount":99},[],{"trials":7900,"activeCount":99},[],{"intervention":591,"totalTrials":275,"cells":7902},{"EARLY_PHASE1":7903,"PHASE1":7905,"PHASE2":7915,"PHASE3":7926,"PHASE4":7940,"NA":7942},{"trials":7904,"activeCount":99},[],{"trials":7906,"activeCount":99},[7907,7911],{"nctId":5234,"briefTitle":5235,"status":118,"phases":7908,"primaryCompletion":5237,"completion":5238,"start":4401,"enrollment":35,"conditions":7909,"interventions":7910},[88],[27,477],[5241,5242,5227,591,5243],{"nctId":578,"briefTitle":579,"status":118,"phases":7912,"primaryCompletion":581,"completion":582,"start":583,"enrollment":275,"conditions":7913,"interventions":7914},[88],[475,27,585,477,586],[588,589,590,172,591],{"trials":7916,"activeCount":99},[7917],{"nctId":7918,"briefTitle":7919,"status":118,"phases":7920,"primaryCompletion":7921,"completion":7921,"start":3549,"enrollment":28,"conditions":7922,"interventions":7923},"NCT02176031","Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD",[89],"2019-02",[475],[7924,7925],"Natalizumab","Methylprednisolone",{"trials":7927,"activeCount":99},[7928,7932],{"nctId":984,"briefTitle":985,"status":118,"phases":7929,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":7930,"interventions":7931},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"nctId":7933,"briefTitle":7934,"status":118,"phases":7935,"primaryCompletion":472,"completion":6622,"start":7936,"enrollment":508,"conditions":7937,"interventions":7938},"NCT00053976","Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease",[90],"2001-01",[475],[7939,591],"Daclizumab",{"trials":7941,"activeCount":99},[],{"trials":7943,"activeCount":99},[],{"intervention":173,"totalTrials":110,"cells":7945},{"EARLY_PHASE1":7946,"PHASE1":7948,"PHASE2":7950,"PHASE3":7956,"PHASE4":7970,"NA":7972},{"trials":7947,"activeCount":99},[],{"trials":7949,"activeCount":99},[],{"trials":7951,"activeCount":99},[7952],{"nctId":160,"briefTitle":161,"status":118,"phases":7953,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":7954,"interventions":7955},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"trials":7957,"activeCount":99},[7958,7962,7966],{"nctId":1463,"briefTitle":1464,"status":105,"phases":7959,"primaryCompletion":1098,"completion":1098,"start":860,"enrollment":1466,"conditions":7960,"interventions":7961},[90],[125],[173,173,1469,170],{"nctId":984,"briefTitle":985,"status":118,"phases":7963,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":7964,"interventions":7965},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"nctId":299,"briefTitle":300,"status":118,"phases":7967,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":7968,"interventions":7969},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":7971,"activeCount":99},[],{"trials":7973,"activeCount":99},[],{"intervention":190,"totalTrials":110,"cells":7975},{"EARLY_PHASE1":7976,"PHASE1":7978,"PHASE2":7980,"PHASE3":7994,"PHASE4":8000,"NA":8002},{"trials":7977,"activeCount":99},[],{"trials":7979,"activeCount":99},[],{"trials":7981,"activeCount":99},[7982,7986,7990],{"nctId":181,"briefTitle":182,"status":118,"phases":7983,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":7984,"interventions":7985},[89],[18],[190,191,95,192],{"nctId":205,"briefTitle":206,"status":207,"phases":7987,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":7988,"interventions":7989},[89],[18],[215,216,114,95,190],{"nctId":236,"briefTitle":237,"status":105,"phases":7991,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":7992,"interventions":7993},[89],[18],[245,95,158,190],{"trials":7995,"activeCount":99},[7996],{"nctId":290,"briefTitle":291,"status":105,"phases":7997,"primaryCompletion":293,"completion":293,"start":294,"enrollment":141,"conditions":7998,"interventions":7999},[90],[18],[95,190,192,297],{"trials":8001,"activeCount":99},[],{"trials":8003,"activeCount":99},[],{"intervention":192,"totalTrials":110,"cells":8005},{"EARLY_PHASE1":8006,"PHASE1":8008,"PHASE2":8010,"PHASE3":8030,"PHASE4":8036,"NA":8038},{"trials":8007,"activeCount":99},[],{"trials":8009,"activeCount":99},[],{"trials":8011,"activeCount":99},[8012,8022,8026],{"nctId":8013,"briefTitle":8014,"status":118,"phases":8015,"primaryCompletion":251,"completion":8016,"start":8017,"enrollment":1999,"conditions":8018,"interventions":8020},"NCT02025010","Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer",[89],"2025-04-07","2014-01-27",[8019],"Castration-resistant Prostate Cancer",[8021],"abiraterone acetate",{"nctId":181,"briefTitle":182,"status":118,"phases":8023,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":8024,"interventions":8025},[89],[18],[190,191,95,192],{"nctId":247,"briefTitle":248,"status":118,"phases":8027,"primaryCompletion":250,"completion":251,"start":45,"enrollment":252,"conditions":8028,"interventions":8029},[89],[254,18,255],[257,192,95,245],{"trials":8031,"activeCount":99},[8032],{"nctId":290,"briefTitle":291,"status":105,"phases":8033,"primaryCompletion":293,"completion":293,"start":294,"enrollment":141,"conditions":8034,"interventions":8035},[90],[18],[95,190,192,297],{"trials":8037,"activeCount":99},[],{"trials":8039,"activeCount":99},[],{"intervention":1681,"totalTrials":265,"cells":8041},{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8046,"PHASE3":8056,"PHASE4":8062,"NA":8064},{"trials":8043,"activeCount":99},[],{"trials":8045,"activeCount":99},[],{"trials":8047,"activeCount":99},[8048,8052],{"nctId":7827,"briefTitle":7828,"status":118,"phases":8049,"primaryCompletion":3868,"completion":7830,"start":198,"enrollment":7831,"conditions":8050,"interventions":8051},[89],[2091,3693],[6631,308,7834,7835],{"nctId":1674,"briefTitle":1675,"status":207,"phases":8053,"start":1677,"conditions":8054,"interventions":8055},[89],[1532],[733,734,1680,1681,590],{"trials":8057,"activeCount":99},[8058],{"nctId":3446,"briefTitle":3447,"status":118,"phases":8059,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":3451,"conditions":8060,"interventions":8061},[90],[1532],[2881,734,1680,1681],{"trials":8063,"activeCount":99},[],{"trials":8065,"activeCount":99},[],{"intervention":735,"totalTrials":1034,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8078,"PHASE4":8084,"NA":8086},{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[],{"trials":8073,"activeCount":99},[8074],{"nctId":724,"briefTitle":725,"status":118,"phases":8075,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":8076,"interventions":8077},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"trials":8079,"activeCount":99},[8080],{"nctId":984,"briefTitle":985,"status":118,"phases":8081,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":8082,"interventions":8083},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":8085,"activeCount":99},[],{"trials":8087,"activeCount":99},[],{"intervention":739,"totalTrials":1034,"cells":8089},{"EARLY_PHASE1":8090,"PHASE1":8092,"PHASE2":8094,"PHASE3":8100,"PHASE4":8106,"NA":8108},{"trials":8091,"activeCount":99},[],{"trials":8093,"activeCount":99},[],{"trials":8095,"activeCount":99},[8096],{"nctId":724,"briefTitle":725,"status":118,"phases":8097,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":8098,"interventions":8099},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"trials":8101,"activeCount":99},[8102],{"nctId":984,"briefTitle":985,"status":118,"phases":8103,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":8104,"interventions":8105},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":8107,"activeCount":99},[],{"trials":8109,"activeCount":99},[],{"intervention":740,"totalTrials":1034,"cells":8111},{"EARLY_PHASE1":8112,"PHASE1":8114,"PHASE2":8116,"PHASE3":8122,"PHASE4":8128,"NA":8130},{"trials":8113,"activeCount":99},[],{"trials":8115,"activeCount":99},[],{"trials":8117,"activeCount":99},[8118],{"nctId":724,"briefTitle":725,"status":118,"phases":8119,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":8120,"interventions":8121},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"trials":8123,"activeCount":99},[8124],{"nctId":984,"briefTitle":985,"status":118,"phases":8125,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":8126,"interventions":8127},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":8129,"activeCount":99},[],{"trials":8131,"activeCount":99},[],{"intervention":777,"totalTrials":1034,"cells":8133},{"EARLY_PHASE1":8134,"PHASE1":8136,"PHASE2":8138,"PHASE3":8144,"PHASE4":8150,"NA":8152},{"trials":8135,"activeCount":99},[],{"trials":8137,"activeCount":99},[],{"trials":8139,"activeCount":99},[8140],{"nctId":764,"briefTitle":765,"status":118,"phases":8141,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":8142,"interventions":8143},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"trials":8145,"activeCount":99},[8146],{"nctId":299,"briefTitle":300,"status":118,"phases":8147,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":8148,"interventions":8149},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":8151,"activeCount":99},[],{"trials":8153,"activeCount":99},[],{"intervention":589,"totalTrials":1034,"cells":8155},{"EARLY_PHASE1":8156,"PHASE1":8158,"PHASE2":8164,"PHASE3":8166,"PHASE4":8172,"NA":8174},{"trials":8157,"activeCount":99},[],{"trials":8159,"activeCount":99},[8160],{"nctId":578,"briefTitle":579,"status":118,"phases":8161,"primaryCompletion":581,"completion":582,"start":583,"enrollment":275,"conditions":8162,"interventions":8163},[88],[475,27,585,477,586],[588,589,590,172,591],{"trials":8165,"activeCount":99},[],{"trials":8167,"activeCount":99},[8168],{"nctId":533,"briefTitle":534,"status":118,"phases":8169,"primaryCompletion":536,"completion":536,"start":415,"enrollment":537,"conditions":8170,"interventions":8171},[90],[539,540],[147,511,466,542,543],{"trials":8173,"activeCount":99},[],{"trials":8175,"activeCount":99},[],{"intervention":8177,"totalTrials":1034,"cells":8178},"ponatinib",{"EARLY_PHASE1":8179,"PHASE1":8181,"PHASE2":8183,"PHASE3":8195,"PHASE4":8204,"NA":8206},{"trials":8180,"activeCount":99},[],{"trials":8182,"activeCount":99},[],{"trials":8184,"activeCount":99},[8185],{"nctId":8186,"briefTitle":8187,"status":118,"phases":8188,"primaryCompletion":8189,"completion":8190,"start":8191,"enrollment":3493,"conditions":8192,"interventions":8193},"NCT02478164","Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma",[89],"2017-07-08","2018-05-09","2015-07-13",[611],[8194],"Ponatinib",{"trials":8196,"activeCount":99},[8197],{"nctId":8198,"briefTitle":8199,"status":105,"phases":8200,"primaryCompletion":6947,"completion":6947,"start":198,"enrollment":265,"conditions":8201,"interventions":8203},"NCT01761747","Ponatinib for Squamous Cell Lung and Head and Neck Cancers",[89,90],[8202],"Non-Small Cell Lung Cancer, Head and Neck Cancer",[8177],{"trials":8205,"activeCount":99},[],{"trials":8207,"activeCount":99},[],{"intervention":297,"totalTrials":286,"cells":8209},{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8214,"PHASE3":8216,"PHASE4":8222,"NA":8224},{"trials":8211,"activeCount":99},[],{"trials":8213,"activeCount":99},[],{"trials":8215,"activeCount":99},[],{"trials":8217,"activeCount":99},[8218],{"nctId":290,"briefTitle":291,"status":105,"phases":8219,"primaryCompletion":293,"completion":293,"start":294,"enrollment":141,"conditions":8220,"interventions":8221},[90],[18],[95,190,192,297],{"trials":8223,"activeCount":99},[],{"trials":8225,"activeCount":99},[],{"intervention":4405,"totalTrials":286,"cells":8227},{"EARLY_PHASE1":8228,"PHASE1":8230,"PHASE2":8232,"PHASE3":8234,"PHASE4":8240,"NA":8242},{"trials":8229,"activeCount":99},[],{"trials":8231,"activeCount":99},[],{"trials":8233,"activeCount":99},[],{"trials":8235,"activeCount":99},[8236],{"nctId":4397,"briefTitle":4398,"status":118,"phases":8237,"primaryCompletion":4400,"completion":4400,"start":4401,"enrollment":4402,"conditions":8238,"interventions":8239},[90],[18],[158,4405,4406],{"trials":8241,"activeCount":99},[],{"trials":8243,"activeCount":99},[],{"intervention":4406,"totalTrials":286,"cells":8245},{"EARLY_PHASE1":8246,"PHASE1":8248,"PHASE2":8250,"PHASE3":8252,"PHASE4":8258,"NA":8260},{"trials":8247,"activeCount":99},[],{"trials":8249,"activeCount":99},[],{"trials":8251,"activeCount":99},[],{"trials":8253,"activeCount":99},[8254],{"nctId":4397,"briefTitle":4398,"status":118,"phases":8255,"primaryCompletion":4400,"completion":4400,"start":4401,"enrollment":4402,"conditions":8256,"interventions":8257},[90],[18],[158,4405,4406],{"trials":8259,"activeCount":99},[],{"trials":8261,"activeCount":99},[],{"intervention":8263,"totalTrials":286,"cells":8264},"naloxone hydrochloride",{"EARLY_PHASE1":8265,"PHASE1":8267,"PHASE2":8269,"PHASE3":8271,"PHASE4":8281,"NA":8283},{"trials":8266,"activeCount":99},[],{"trials":8268,"activeCount":99},[],{"trials":8270,"activeCount":99},[],{"trials":8272,"activeCount":99},[8273],{"nctId":8274,"briefTitle":8275,"status":207,"phases":8276,"start":8277,"conditions":8278,"interventions":8280},"NCT00020605","Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain",[90],"2000-05",[8279,1534],"Constipation, Impaction, and Bowel Obstruction",[8263],{"trials":8282,"activeCount":99},[],{"trials":8284,"activeCount":99},[],{"intervention":994,"totalTrials":286,"cells":8286},{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8291,"PHASE3":8293,"PHASE4":8299,"NA":8301},{"trials":8288,"activeCount":99},[],{"trials":8290,"activeCount":99},[],{"trials":8292,"activeCount":99},[],{"trials":8294,"activeCount":99},[8295],{"nctId":984,"briefTitle":985,"status":118,"phases":8296,"primaryCompletion":426,"completion":401,"start":987,"enrollment":988,"conditions":8297,"interventions":8298},[90],[990,27],[173,588,176,174,735,736,737,590,992,172,591,993,994,739,740],{"trials":8300,"activeCount":99},[],{"trials":8302,"activeCount":99},[],{"intervention":7939,"totalTrials":286,"cells":8304},{"EARLY_PHASE1":8305,"PHASE1":8307,"PHASE2":8309,"PHASE3":8311,"PHASE4":8317,"NA":8319},{"trials":8306,"activeCount":99},[],{"trials":8308,"activeCount":99},[],{"trials":8310,"activeCount":99},[],{"trials":8312,"activeCount":99},[8313],{"nctId":7933,"briefTitle":7934,"status":118,"phases":8314,"primaryCompletion":472,"completion":6622,"start":7936,"enrollment":508,"conditions":8315,"interventions":8316},[90],[475],[7939,591],{"trials":8318,"activeCount":99},[],{"trials":8320,"activeCount":99},[],{"intervention":8322,"totalTrials":286,"cells":8323},"Flutamide (Eulexin) and Lupron or Zoladex",{"EARLY_PHASE1":8324,"PHASE1":8326,"PHASE2":8328,"PHASE3":8330,"PHASE4":8340,"NA":8342},{"trials":8325,"activeCount":99},[],{"trials":8327,"activeCount":99},[],{"trials":8329,"activeCount":99},[],{"trials":8331,"activeCount":99},[8332],{"nctId":8333,"briefTitle":8334,"status":118,"phases":8335,"primaryCompletion":4006,"completion":50,"start":8336,"enrollment":8337,"conditions":8338,"interventions":8339},"NCT00116220","Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer",[90],"1995-09",206,[18],[8322],{"trials":8341,"activeCount":99},[],{"trials":8343,"activeCount":99},[],{"intervention":310,"totalTrials":286,"cells":8345},{"EARLY_PHASE1":8346,"PHASE1":8348,"PHASE2":8350,"PHASE3":8352,"PHASE4":8358,"NA":8360},{"trials":8347,"activeCount":99},[],{"trials":8349,"activeCount":99},[],{"trials":8351,"activeCount":99},[],{"trials":8353,"activeCount":99},[8354],{"nctId":299,"briefTitle":300,"status":118,"phases":8355,"primaryCompletion":302,"completion":164,"start":303,"enrollment":304,"conditions":8356,"interventions":8357},[90],[125],[169,174,170,307,171,172,308,309,176,310],{"trials":8359,"activeCount":99},[],{"trials":8361,"activeCount":99},[],{"intervention":543,"totalTrials":286,"cells":8363},{"EARLY_PHASE1":8364,"PHASE1":8366,"PHASE2":8368,"PHASE3":8370,"PHASE4":8376,"NA":8378},{"trials":8365,"activeCount":99},[],{"trials":8367,"activeCount":99},[],{"trials":8369,"activeCount":99},[],{"trials":8371,"activeCount":99},[8372],{"nctId":533,"briefTitle":534,"status":118,"phases":8373,"primaryCompletion":536,"completion":536,"start":415,"enrollment":537,"conditions":8374,"interventions":8375},[90],[539,540],[147,511,466,542,543],{"trials":8377,"activeCount":99},[],{"trials":8379,"activeCount":99},[],{"intervention":283,"totalTrials":887,"cells":8381},{"EARLY_PHASE1":8382,"PHASE1":8384,"PHASE2":8401,"PHASE3":8445,"PHASE4":8447,"NA":8449},{"trials":8383,"activeCount":99},[],{"trials":8385,"activeCount":99},[8386,8393,8397],{"nctId":8387,"briefTitle":8388,"status":118,"phases":8389,"primaryCompletion":2956,"completion":658,"start":8390,"enrollment":1082,"conditions":8391,"interventions":8392},"NCT00251355","Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer",[88],"1998-01",[4444],[283,4022],{"nctId":5112,"briefTitle":5113,"status":105,"phases":8394,"primaryCompletion":5115,"completion":5115,"start":2521,"enrollment":3721,"conditions":8395,"interventions":8396},[88],[4444],[283,5105,5118],{"nctId":5120,"briefTitle":5121,"status":118,"phases":8398,"primaryCompletion":5123,"completion":5124,"start":5125,"enrollment":1107,"conditions":8399,"interventions":8400},[88],[4444],[283,5105,5128],{"trials":8402,"activeCount":99},[8403,8407,8415,8419,8426,8430,8437,8441],{"nctId":4131,"briefTitle":4132,"status":118,"phases":8404,"primaryCompletion":497,"completion":497,"start":458,"enrollment":403,"conditions":8405,"interventions":8406},[89],[4135,4136],[283,866],{"nctId":8408,"briefTitle":8409,"status":118,"phases":8410,"primaryCompletion":8411,"completion":8411,"start":8412,"enrollment":9,"conditions":8413,"interventions":8414},"NCT00003744","Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery",[89],"2004-05","1998-11",[1532],[7884],{"nctId":6626,"briefTitle":6627,"status":105,"phases":8416,"primaryCompletion":344,"completion":1046,"start":1098,"enrollment":35,"conditions":8417,"interventions":8418},[89],[21,827,2876],[283,6631,762],{"nctId":8420,"briefTitle":8421,"status":118,"phases":8422,"primaryCompletion":1557,"completion":1116,"start":909,"enrollment":784,"conditions":8423,"interventions":8425},"NCT00476086","Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus",[89],[8424],"Mixed Mullerian Tumors of the Uterus",[283,6631],{"nctId":7878,"briefTitle":7879,"status":118,"phases":8427,"primaryCompletion":2956,"completion":2956,"start":729,"enrollment":1082,"conditions":8428,"interventions":8429},[89],[7882],[7884,3663],{"nctId":8431,"briefTitle":8432,"status":1057,"phases":8433,"primaryCompletion":8434,"completion":8434,"start":8434,"enrollment":99,"conditions":8435,"interventions":8436},"NCT01834183","Tivozanib + Gemcitabine in Metastatic RCC",[89],"2013-06",[3163],[382,283],{"nctId":271,"briefTitle":272,"status":105,"phases":8438,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":8439,"interventions":8440},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"nctId":3436,"briefTitle":3437,"status":105,"phases":8442,"primaryCompletion":198,"completion":3439,"start":415,"enrollment":498,"conditions":8443,"interventions":8444},[88,89],[21,827,826],[3442,707,283],{"trials":8446,"activeCount":99},[],{"trials":8448,"activeCount":99},[],{"trials":8450,"activeCount":99},[],{"intervention":4056,"totalTrials":887,"cells":8452},{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8468,"PHASE3":8535,"PHASE4":8537,"NA":8539},{"trials":8454,"activeCount":99},[],{"trials":8456,"activeCount":99},[8457,8461],{"nctId":4049,"briefTitle":4050,"status":118,"phases":8458,"primaryCompletion":3422,"completion":4052,"start":4053,"enrollment":19,"conditions":8459,"interventions":8460},[88],[347],[4056,4022,4057,866],{"nctId":8462,"briefTitle":8463,"status":118,"phases":8464,"primaryCompletion":1325,"completion":1325,"start":8465,"enrollment":1082,"conditions":8466,"interventions":8467},"NCT00153907","Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer",[88],"2002-03",[15],[841,4056],{"trials":8469,"activeCount":99},[8470,8478,8484,8492,8500,8506,8514,8518,8528],{"nctId":8471,"briefTitle":8472,"status":118,"phases":8473,"primaryCompletion":909,"completion":909,"start":8474,"enrollment":22,"conditions":8475,"interventions":8476},"NCT00123851","Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer",[89],"2003-03",[5155,6611],[8477,4056,6631],"Tarceva",{"nctId":8479,"briefTitle":8480,"status":118,"phases":8481,"primaryCompletion":4840,"completion":4840,"start":5023,"enrollment":265,"conditions":8482,"interventions":8483},"NCT00095901","Capecitabine For Nasopharyngeal Cancer",[89],[1532],[4056],{"nctId":8485,"briefTitle":8486,"status":105,"phases":8487,"primaryCompletion":3219,"start":2711,"enrollment":321,"conditions":8488,"interventions":8491},"NCT00148720","Capecitabine in Women With Operable Breast Cancer",[89],[8489,8490,5273,837,838],"Invasive Breast Carcinoma","Primary Invasive Breast Cancer",[4056],{"nctId":8493,"briefTitle":8494,"status":118,"phases":8495,"primaryCompletion":8496,"completion":8496,"start":4053,"enrollment":2043,"conditions":8497,"interventions":8499},"NCT00165217","Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma",[89],"2005-12",[8498],"Colorectal Adenocarcinoma",[4056,788],{"nctId":8501,"briefTitle":8502,"status":105,"phases":8503,"primaryCompletion":1071,"completion":3126,"start":4337,"enrollment":242,"conditions":8504,"interventions":8505},"NCT00101075","Title XELOX FOR SALIVARY GLAND CANCERS",[89],[1532],[4056,6631],{"nctId":8507,"briefTitle":8508,"status":118,"phases":8509,"primaryCompletion":5023,"completion":4052,"start":8510,"enrollment":22,"conditions":8511,"interventions":8512},"NCT00125021","Tarceva and Capecitabine for Pancreatic Cancer",[89],"2003-10",[4444,6611],[4056,8513],"OSI-774",{"nctId":3687,"briefTitle":3688,"status":118,"phases":8515,"primaryCompletion":251,"completion":3690,"start":3691,"enrollment":2043,"conditions":8516,"interventions":8517},[89],[2091,3693],[915,3662,3695,3696],{"nctId":8519,"briefTitle":8520,"status":118,"phases":8521,"primaryCompletion":8522,"completion":8523,"start":4029,"enrollment":3984,"conditions":8524,"interventions":8525},"NCT01494662","HKI-272 for HER2-Positive Breast Cancer and Brain Metastases",[89],"2023-02-01","2024-04-19",[15],[8526,4056,8526,8527],"HKI-272","Ado-Trastuzumab Emtansine",{"nctId":8529,"briefTitle":8530,"status":105,"phases":8531,"primaryCompletion":8532,"completion":8532,"start":810,"enrollment":329,"conditions":8533,"interventions":8534},"NCT00889187","Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer",[88,89],"2011-12-30",[4444],[4056],{"trials":8536,"activeCount":99},[],{"trials":8538,"activeCount":99},[],{"trials":8540,"activeCount":99},[],{"intervention":4022,"totalTrials":242,"cells":8542},{"EARLY_PHASE1":8543,"PHASE1":8549,"PHASE2":8563,"PHASE3":8588,"PHASE4":8590,"NA":8592},{"trials":8544,"activeCount":99},[8545],{"nctId":4014,"briefTitle":4015,"status":118,"phases":8546,"primaryCompletion":472,"completion":525,"start":303,"enrollment":661,"conditions":8547,"interventions":8548},[87],[4018,3693,4019],[4021,866,4022],{"trials":8550,"activeCount":99},[8551,8555,8559],{"nctId":8387,"briefTitle":8388,"status":118,"phases":8552,"primaryCompletion":2956,"completion":658,"start":8390,"enrollment":1082,"conditions":8553,"interventions":8554},[88],[4444],[283,4022],{"nctId":4033,"briefTitle":4034,"status":118,"phases":8556,"primaryCompletion":40,"completion":40,"start":4036,"enrollment":1841,"conditions":8557,"interventions":8558},[88],[4038],[2562,158,866,4022],{"nctId":4049,"briefTitle":4050,"status":118,"phases":8560,"primaryCompletion":3422,"completion":4052,"start":4053,"enrollment":19,"conditions":8561,"interventions":8562},[88],[347],[4056,4022,4057,866],{"trials":8564,"activeCount":99},[8565,8569,8573,8577,8581],{"nctId":4108,"briefTitle":4109,"status":118,"phases":8566,"primaryCompletion":2757,"completion":2757,"start":4111,"enrollment":1988,"conditions":8567,"interventions":8568},[88,89],[4113,4114,4115],[158,866,4022],{"nctId":4118,"briefTitle":4119,"status":118,"phases":8570,"primaryCompletion":486,"completion":486,"start":4121,"enrollment":403,"conditions":8571,"interventions":8572},[88,89],[4123,4124],[4103,866,4022,308],{"nctId":1426,"briefTitle":1427,"status":118,"phases":8574,"primaryCompletion":486,"completion":486,"start":1429,"enrollment":22,"conditions":8575,"interventions":8576},[89],[1431,1432,1433],[130,866,1435],{"nctId":4214,"briefTitle":4215,"status":118,"phases":8578,"primaryCompletion":2757,"completion":2757,"start":4217,"enrollment":403,"conditions":8579,"interventions":8580},[89],[4123,4219],[4103,866,4022,308,867,4221],{"nctId":8582,"briefTitle":8583,"status":105,"phases":8584,"primaryCompletion":152,"completion":1045,"start":263,"enrollment":2406,"conditions":8585,"interventions":8587},"NCT00611858","Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer",[89],[8586],"Rectal Cancer",[2562,4022],{"trials":8589,"activeCount":99},[],{"trials":8591,"activeCount":99},[],{"trials":8593,"activeCount":99},[],{"intervention":157,"totalTrials":242,"cells":8595},{"EARLY_PHASE1":8596,"PHASE1":8598,"PHASE2":8619,"PHASE3":8656,"PHASE4":8658,"NA":8660},{"trials":8597,"activeCount":99},[],{"trials":8599,"activeCount":99},[8600,8604,8612],{"nctId":4026,"briefTitle":4027,"status":105,"phases":8601,"primaryCompletion":4029,"start":377,"enrollment":265,"conditions":8602,"interventions":8603},[88],[1532],[157,734],{"nctId":8605,"briefTitle":8606,"status":118,"phases":8607,"primaryCompletion":402,"completion":376,"start":2661,"enrollment":123,"conditions":8608,"interventions":8610},"NCT00804336","Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors",[88],[8609,2501,6806],"Neuroendocrine Tumor",[8611,157],"SOM230",{"nctId":8613,"briefTitle":8614,"status":118,"phases":8615,"primaryCompletion":728,"completion":728,"start":40,"enrollment":28,"conditions":8616,"interventions":8617},"NCT00942682","Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors",[88],[8609,2501,6806],[8618,157],"Sorafenib",{"trials":8620,"activeCount":99},[8621,8625,8632,8639,8646,8652],{"nctId":149,"briefTitle":150,"status":118,"phases":8622,"primaryCompletion":152,"completion":152,"start":153,"enrollment":35,"conditions":8623,"interventions":8624},[88,89],[155,18],[157,158,95],{"nctId":8626,"briefTitle":8627,"status":118,"phases":8628,"primaryCompletion":8629,"completion":8629,"start":40,"enrollment":672,"conditions":8630,"interventions":8631},"NCT00936858","RAD001 for Patients With Radioiodine Refractory Thyroid Cancer",[89],"2020-02-27",[2433],[157],{"nctId":8633,"briefTitle":8634,"status":118,"phases":8635,"primaryCompletion":1485,"completion":8636,"start":3366,"enrollment":571,"conditions":8637,"interventions":8638},"NCT00976248","Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia",[89],"2018-07",[34],[157],{"nctId":8640,"briefTitle":8641,"status":118,"phases":8642,"primaryCompletion":8643,"completion":8643,"start":727,"enrollment":3721,"conditions":8644,"interventions":8645},"NCT00630344","RAD001 and Bicalutamide for Androgen Independent Prostate Cancer",[89],"2012-05",[18],[157,216],{"nctId":8647,"briefTitle":8648,"status":118,"phases":8649,"primaryCompletion":485,"completion":3492,"start":4036,"enrollment":571,"conditions":8650,"interventions":8651},"NCT00409292","RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer",[89],[4444],[157],{"nctId":6801,"briefTitle":6802,"status":118,"phases":8653,"primaryCompletion":1215,"completion":1215,"start":263,"enrollment":6804,"conditions":8654,"interventions":8655},[88,89],[6806],[157,1297],{"trials":8657,"activeCount":99},[],{"trials":8659,"activeCount":99},[],{"trials":8661,"activeCount":99},[],{"intervention":753,"totalTrials":1093,"cells":8663},{"EARLY_PHASE1":8664,"PHASE1":8666,"PHASE2":8668,"PHASE3":8710,"PHASE4":8712,"NA":8714},{"trials":8665,"activeCount":99},[],{"trials":8667,"activeCount":99},[],{"trials":8669,"activeCount":99},[8670,8674,8678,8682,8686,8694,8702,8706],{"nctId":743,"briefTitle":744,"status":118,"phases":8671,"primaryCompletion":746,"completion":747,"start":748,"conditions":8672,"interventions":8673},[89],[750],[752,588,737,753],{"nctId":779,"briefTitle":780,"status":118,"phases":8675,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":8676,"interventions":8677},[89],[786],[788,789,279,269],{"nctId":843,"briefTitle":844,"status":118,"phases":8679,"primaryCompletion":846,"completion":425,"start":847,"enrollment":848,"conditions":8680,"interventions":8681},[89],[731,27,585,850,851,852],[752,588,737,854,753],{"nctId":8493,"briefTitle":8494,"status":118,"phases":8683,"primaryCompletion":8496,"completion":8496,"start":4053,"enrollment":2043,"conditions":8684,"interventions":8685},[89],[8498],[4056,788],{"nctId":8687,"briefTitle":8688,"status":118,"phases":8689,"completion":4036,"start":8690,"enrollment":141,"conditions":8691,"interventions":8692},"NCT00058487","Epirubicin and Thalidomide in Treating Patients With Liver Cancer",[89],"2001-12",[1487],[8693,753],"epirubicin hydrochloride",{"nctId":8695,"briefTitle":8696,"status":118,"phases":8697,"primaryCompletion":264,"completion":264,"start":8698,"enrollment":22,"conditions":8699,"interventions":8700},"NCT00165230","Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors",[89],"2002-05",[8609],[788,8701],"Temodar",{"nctId":6794,"briefTitle":6795,"status":118,"phases":8703,"primaryCompletion":5237,"completion":5237,"start":6797,"enrollment":498,"conditions":8704,"interventions":8705},[89],[731,850],[738,753],{"nctId":6809,"briefTitle":6810,"status":118,"phases":8707,"primaryCompletion":4166,"completion":3219,"start":4006,"conditions":8708,"interventions":8709},[89],[750],[752,738,753],{"trials":8711,"activeCount":99},[],{"trials":8713,"activeCount":99},[],{"trials":8715,"activeCount":99},[],{"intervention":2562,"totalTrials":1093,"cells":8717},{"EARLY_PHASE1":8718,"PHASE1":8720,"PHASE2":8737,"PHASE3":8761,"PHASE4":8763,"NA":8765},{"trials":8719,"activeCount":99},[],{"trials":8721,"activeCount":99},[8722,8726,8730],{"nctId":4033,"briefTitle":4034,"status":118,"phases":8723,"primaryCompletion":40,"completion":40,"start":4036,"enrollment":1841,"conditions":8724,"interventions":8725},[88],[4038],[2562,158,866,4022],{"nctId":2553,"briefTitle":2554,"status":118,"phases":8727,"primaryCompletion":2556,"completion":2557,"start":2111,"enrollment":887,"conditions":8728,"interventions":8729},[88],[1918,1965],[2560,2561,2327,2562],{"nctId":8731,"briefTitle":8732,"status":118,"phases":8733,"primaryCompletion":4029,"completion":414,"start":8734,"enrollment":428,"conditions":8735,"interventions":8736},"NCT00436072","ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer",[88],"2007-02",[5155],[4309,2562,4057],{"trials":8738,"activeCount":99},[8739,8745,8749,8753,8757],{"nctId":8740,"briefTitle":8741,"status":118,"phases":8742,"primaryCompletion":759,"completion":759,"start":812,"enrollment":6804,"conditions":8743,"interventions":8744},"NCT00130689","Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer",[89],[2091,3693,6611],[2562],{"nctId":4196,"briefTitle":4197,"status":118,"phases":8746,"primaryCompletion":262,"completion":536,"start":3450,"enrollment":35,"conditions":8747,"interventions":8748},[89],[1433,4200],[2562,866,4057],{"nctId":3399,"briefTitle":3400,"status":105,"phases":8750,"primaryCompletion":3402,"completion":3403,"start":3228,"enrollment":2800,"conditions":8751,"interventions":8752},[89],[1918,3405],[1680,734,3407,3408,2881],{"nctId":8582,"briefTitle":8583,"status":105,"phases":8754,"primaryCompletion":152,"completion":1045,"start":263,"enrollment":2406,"conditions":8755,"interventions":8756},[89],[8586],[2562,4022],{"nctId":7886,"briefTitle":7887,"status":118,"phases":8758,"primaryCompletion":262,"completion":262,"start":4401,"enrollment":2431,"conditions":8759,"interventions":8760},[89],[1560],[2562,2975],{"trials":8762,"activeCount":99},[],{"trials":8764,"activeCount":99},[],{"trials":8766,"activeCount":99},[],{"intervention":651,"totalTrials":1093,"cells":8768},{"EARLY_PHASE1":8769,"PHASE1":8771,"PHASE2":8786,"PHASE3":8822,"PHASE4":8824,"NA":8826},{"trials":8770,"activeCount":99},[],{"trials":8772,"activeCount":99},[8773,8777],{"nctId":640,"briefTitle":641,"status":118,"phases":8774,"primaryCompletion":643,"completion":643,"start":644,"enrollment":141,"conditions":8775,"interventions":8776},[88],[646,647,648,649],[651,652,269,653],{"nctId":8778,"briefTitle":8779,"status":118,"phases":8780,"primaryCompletion":8781,"completion":8782,"start":8783,"enrollment":3051,"conditions":8784,"interventions":8785},"NCT01574937","XL-184+Abiraterone in Post-Chemo CRPC",[88],"2014-12-31","2021-07-01","2012-04-03",[18],[651,114],{"trials":8787,"activeCount":99},[8788,8792,8800,8808,8814,8818],{"nctId":2392,"briefTitle":2393,"status":118,"phases":8789,"primaryCompletion":2395,"completion":2395,"start":2396,"enrollment":715,"conditions":8790,"interventions":8791},[89],[15],[80,651],{"nctId":8793,"briefTitle":8794,"status":105,"phases":8795,"primaryCompletion":8796,"completion":1485,"start":2854,"enrollment":1093,"conditions":8797,"interventions":8799},"NCT02036476","Cabozantinib in Recurrent\u002FMetastatic Merkel Cell Carcinoma",[89],"2016-04",[8798,323],"Merkel Cell Carcinoma",[651],{"nctId":8801,"briefTitle":8802,"status":118,"phases":8803,"primaryCompletion":8804,"completion":8805,"start":3402,"enrollment":1125,"conditions":8806,"interventions":8807},"NCT01466036","Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",[89],"2021-08","2023-12",[2501,6806],[651],{"nctId":8809,"briefTitle":8810,"status":118,"phases":8811,"primaryCompletion":4358,"completion":4358,"start":846,"enrollment":1337,"conditions":8812,"interventions":8813},"NCT01738438","Cabozantinib for Metastatic Triple Negative BrCa",[89],[15],[651],{"nctId":2494,"briefTitle":2495,"status":118,"phases":8815,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":35,"conditions":8816,"interventions":8817},[89],[2501,2502,2503],[80,651],{"nctId":3716,"briefTitle":3717,"status":118,"phases":8819,"primaryCompletion":3719,"completion":3720,"start":536,"enrollment":3721,"conditions":8820,"interventions":8821},[89],[15,3723],[651,798],{"trials":8823,"activeCount":99},[],{"trials":8825,"activeCount":99},[],{"trials":8827,"activeCount":99},[],{"intervention":4057,"totalTrials":2800,"cells":8829},{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8842,"PHASE3":8864,"PHASE4":8866,"NA":8868},{"trials":8831,"activeCount":99},[],{"trials":8833,"activeCount":99},[8834,8838],{"nctId":4049,"briefTitle":4050,"status":118,"phases":8835,"primaryCompletion":3422,"completion":4052,"start":4053,"enrollment":19,"conditions":8836,"interventions":8837},[88],[347],[4056,4022,4057,866],{"nctId":8731,"briefTitle":8732,"status":118,"phases":8839,"primaryCompletion":4029,"completion":414,"start":8734,"enrollment":428,"conditions":8840,"interventions":8841},[88],[5155],[4309,2562,4057],{"trials":8843,"activeCount":99},[8844,8848,8852,8856,8860],{"nctId":4163,"briefTitle":4164,"status":118,"phases":8845,"primaryCompletion":4166,"completion":4099,"start":2971,"enrollment":19,"conditions":8846,"interventions":8847},[89],[2091,3693,4168],[4103,866,4057],{"nctId":4179,"briefTitle":4180,"status":118,"phases":8849,"primaryCompletion":3449,"completion":795,"start":40,"enrollment":4182,"conditions":8850,"interventions":8851},[89],[2091,3693,4018],[762,866,4057],{"nctId":4196,"briefTitle":4197,"status":118,"phases":8853,"primaryCompletion":262,"completion":536,"start":3450,"enrollment":35,"conditions":8854,"interventions":8855},[89],[1433,4200],[2562,866,4057],{"nctId":4203,"briefTitle":4204,"status":118,"phases":8857,"primaryCompletion":3450,"completion":4206,"start":2772,"enrollment":1337,"conditions":8858,"interventions":8859},[89],[2091],[866,4057,789],{"nctId":4242,"briefTitle":4243,"status":118,"phases":8861,"primaryCompletion":163,"completion":1124,"start":1098,"enrollment":1988,"conditions":8862,"interventions":8863},[89],[2091,4018],[762,158,866,4057],{"trials":8865,"activeCount":99},[],{"trials":8867,"activeCount":99},[],{"trials":8869,"activeCount":99},[],{"intervention":4103,"totalTrials":720,"cells":8871},{"EARLY_PHASE1":8872,"PHASE1":8874,"PHASE2":8896,"PHASE3":8910,"PHASE4":8912,"NA":8914},{"trials":8873,"activeCount":99},[],{"trials":8875,"activeCount":99},[8876,8885,8889],{"nctId":8877,"briefTitle":8878,"status":118,"phases":8879,"primaryCompletion":8880,"completion":8881,"start":8882,"enrollment":487,"conditions":8883,"interventions":8884},"NCT00006107","Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[88],"2003-07-17","2004-07-03","2000-07-14",[1532],[4103],{"nctId":4095,"briefTitle":4096,"status":118,"phases":8886,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":428,"conditions":8887,"interventions":8888},[88],[347],[4103,866,4104],{"nctId":8890,"briefTitle":8891,"status":118,"phases":8892,"primaryCompletion":782,"completion":2957,"start":8893,"enrollment":123,"conditions":8894,"interventions":8895},"NCT00003200","Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck",[88],"1995-10",[1532],[4103],{"trials":8897,"activeCount":99},[8898,8902,8906],{"nctId":4118,"briefTitle":4119,"status":118,"phases":8899,"primaryCompletion":486,"completion":486,"start":4121,"enrollment":403,"conditions":8900,"interventions":8901},[88,89],[4123,4124],[4103,866,4022,308],{"nctId":4163,"briefTitle":4164,"status":118,"phases":8903,"primaryCompletion":4166,"completion":4099,"start":2971,"enrollment":19,"conditions":8904,"interventions":8905},[89],[2091,3693,4168],[4103,866,4057],{"nctId":4214,"briefTitle":4215,"status":118,"phases":8907,"primaryCompletion":2757,"completion":2757,"start":4217,"enrollment":403,"conditions":8908,"interventions":8909},[89],[4123,4219],[4103,866,4022,308,867,4221],{"trials":8911,"activeCount":99},[],{"trials":8913,"activeCount":99},[],{"trials":8915,"activeCount":99},[],{"intervention":6631,"totalTrials":720,"cells":8917},{"EARLY_PHASE1":8918,"PHASE1":8920,"PHASE2":8922,"PHASE3":8948,"PHASE4":8950,"NA":8952},{"trials":8919,"activeCount":99},[],{"trials":8921,"activeCount":99},[],{"trials":8923,"activeCount":99},[8924,8928,8932,8936,8940,8944],{"nctId":8471,"briefTitle":8472,"status":118,"phases":8925,"primaryCompletion":909,"completion":909,"start":8474,"enrollment":22,"conditions":8926,"interventions":8927},[89],[5155,6611],[8477,4056,6631],{"nctId":7827,"briefTitle":7828,"status":118,"phases":8929,"primaryCompletion":3868,"completion":7830,"start":198,"enrollment":7831,"conditions":8930,"interventions":8931},[89],[2091,3693],[6631,308,7834,7835],{"nctId":6626,"briefTitle":6627,"status":105,"phases":8933,"primaryCompletion":344,"completion":1046,"start":1098,"enrollment":35,"conditions":8934,"interventions":8935},[89],[21,827,2876],[283,6631,762],{"nctId":8420,"briefTitle":8421,"status":118,"phases":8937,"primaryCompletion":1557,"completion":1116,"start":909,"enrollment":784,"conditions":8938,"interventions":8939},[89],[8424],[283,6631],{"nctId":8501,"briefTitle":8502,"status":105,"phases":8941,"primaryCompletion":1071,"completion":3126,"start":4337,"enrollment":242,"conditions":8942,"interventions":8943},[89],[1532],[4056,6631],{"nctId":3687,"briefTitle":3688,"status":118,"phases":8945,"primaryCompletion":251,"completion":3690,"start":3691,"enrollment":2043,"conditions":8946,"interventions":8947},[89],[2091,3693],[915,3662,3695,3696],{"trials":8949,"activeCount":99},[],{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[],{"intervention":6657,"totalTrials":275,"cells":8955},{"EARLY_PHASE1":8956,"PHASE1":8958,"PHASE2":8960,"PHASE3":8989,"PHASE4":8991,"NA":8993},{"trials":8957,"activeCount":99},[],{"trials":8959,"activeCount":99},[],{"trials":8961,"activeCount":99},[8962,8971,8975,8979,8983],{"nctId":8963,"briefTitle":8964,"status":105,"phases":8965,"primaryCompletion":8966,"completion":8967,"start":1164,"enrollment":6804,"conditions":8968,"interventions":8970},"NCT02770014","Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer",[89],"2019-04-16","2019-06-19",[8969,2901],"Epidermal Growth Factor Receptor",[6657],{"nctId":6607,"briefTitle":6608,"status":118,"phases":8972,"primaryCompletion":660,"completion":660,"start":847,"enrollment":1337,"conditions":8973,"interventions":8974},[89],[5155,6611],[2880,6613,915],{"nctId":6650,"briefTitle":6651,"status":118,"phases":8976,"primaryCompletion":1071,"completion":40,"start":6653,"enrollment":2043,"conditions":8977,"interventions":8978},[89],[6655],[6657,762],{"nctId":2870,"briefTitle":2871,"status":118,"phases":8980,"primaryCompletion":2873,"completion":1336,"start":2874,"enrollment":1999,"conditions":8981,"interventions":8982},[89],[21,827,2876,2877,2878],[915,2880,2805,2881],{"nctId":8984,"briefTitle":8985,"status":118,"phases":8986,"primaryCompletion":1132,"completion":1132,"start":2757,"enrollment":390,"conditions":8987,"interventions":8988},"NCT00476476","Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar",[89],[4123],[6657],{"trials":8990,"activeCount":99},[],{"trials":8992,"activeCount":99},[],{"trials":8994,"activeCount":99},[],{"intervention":638,"totalTrials":275,"cells":8996},{"EARLY_PHASE1":8997,"PHASE1":8999,"PHASE2":9016,"PHASE3":9032,"PHASE4":9034,"NA":9036},{"trials":8998,"activeCount":99},[],{"trials":9000,"activeCount":99},[9001,9008,9012],{"nctId":9002,"briefTitle":9003,"status":118,"phases":9004,"primaryCompletion":1046,"completion":1132,"start":660,"enrollment":2406,"conditions":9005,"interventions":9007},"NCT00495755","Campath in Chronic GVHD",[88],[9006],"Chronic Graft-vs.-Host Disease",[638],{"nctId":2633,"briefTitle":2634,"status":118,"phases":9009,"primaryCompletion":198,"completion":823,"start":2636,"enrollment":1841,"conditions":9010,"interventions":9011},[88],[804],[51,638],{"nctId":628,"briefTitle":629,"status":105,"phases":9013,"primaryCompletion":631,"completion":631,"start":632,"enrollment":265,"conditions":9014,"interventions":9015},[88],[634,635,636],[269,638],{"trials":9017,"activeCount":99},[9018,9028],{"nctId":9019,"briefTitle":9020,"status":105,"phases":9021,"primaryCompletion":536,"completion":120,"start":9022,"enrollment":403,"conditions":9023,"interventions":9026},"NCT01465334","Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL",[89],"2011-12",[9024,9025],"CLL","SLL",[6950,9027,638],"High-Dose Methylprednisolone",{"nctId":3123,"briefTitle":3124,"status":118,"phases":9029,"primaryCompletion":3126,"completion":40,"start":748,"enrollment":1034,"conditions":9030,"interventions":9031},[89],[3128,3129,3130],[3132,679,638],{"trials":9033,"activeCount":99},[],{"trials":9035,"activeCount":99},[],{"trials":9037,"activeCount":99},[],{"intervention":733,"totalTrials":110,"cells":9039},{"EARLY_PHASE1":9040,"PHASE1":9042,"PHASE2":9044,"PHASE3":9062,"PHASE4":9064,"NA":9066},{"trials":9041,"activeCount":99},[],{"trials":9043,"activeCount":99},[],{"trials":9045,"activeCount":99},[9046,9050,9054,9058],{"nctId":724,"briefTitle":725,"status":118,"phases":9047,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":9048,"interventions":9049},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"nctId":1674,"briefTitle":1675,"status":207,"phases":9051,"start":1677,"conditions":9052,"interventions":9053},[89],[1532],[733,734,1680,1681,590],{"nctId":1525,"briefTitle":1526,"status":118,"phases":9055,"primaryCompletion":859,"completion":165,"start":1528,"enrollment":25,"conditions":9056,"interventions":9057},[89],[1354,750,1530,1531,1532,348,30,21,851,1533,1534],[733,1536,707,279,818],{"nctId":271,"briefTitle":272,"status":105,"phases":9059,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":9060,"interventions":9061},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"trials":9063,"activeCount":99},[],{"trials":9065,"activeCount":99},[],{"trials":9067,"activeCount":99},[],{"intervention":1536,"totalTrials":110,"cells":9069},{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9083,"PHASE3":9100,"PHASE4":9102,"NA":9104},{"trials":9071,"activeCount":99},[],{"trials":9073,"activeCount":99},[9074],{"nctId":9075,"briefTitle":9076,"status":207,"phases":9077,"start":9078,"enrollment":28,"conditions":9079,"interventions":9081},"NCT00006127","Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia",[88],"2000-04",[9080],"Fanconi's Anemia",[9082],"amifostine",{"trials":9084,"activeCount":99},[9085,9092,9096],{"nctId":9086,"briefTitle":9087,"status":118,"phases":9088,"primaryCompletion":9089,"completion":659,"start":833,"enrollment":252,"conditions":9090,"interventions":9091},"NCT00136474","Amifostine for Head and Neck Irradiation in Lymphoma",[89],"2005-05",[585,464,267],[1536],{"nctId":1525,"briefTitle":1526,"status":118,"phases":9093,"primaryCompletion":859,"completion":165,"start":1528,"enrollment":25,"conditions":9094,"interventions":9095},[89],[1354,750,1530,1531,1532,348,30,21,851,1533,1534],[733,1536,707,279,818],{"nctId":2953,"briefTitle":2954,"status":118,"phases":9097,"primaryCompletion":2956,"completion":2957,"start":833,"enrollment":1166,"conditions":9098,"interventions":9099},[89],[2959,1532,2960,2961,2962],[1536,707,706],{"trials":9101,"activeCount":99},[],{"trials":9103,"activeCount":99},[],{"trials":9105,"activeCount":99},[],{"intervention":5331,"totalTrials":110,"cells":9107},{"EARLY_PHASE1":9108,"PHASE1":9110,"PHASE2":9116,"PHASE3":9139,"PHASE4":9141,"NA":9143},{"trials":9109,"activeCount":99},[],{"trials":9111,"activeCount":99},[9112],{"nctId":5325,"briefTitle":5326,"status":118,"phases":9113,"primaryCompletion":3543,"completion":943,"start":525,"enrollment":1492,"conditions":9114,"interventions":9115},[88],[5329],[5331,5318],{"trials":9117,"activeCount":99},[9118,9124,9133],{"nctId":9119,"briefTitle":9120,"status":118,"phases":9121,"primaryCompletion":8643,"completion":846,"start":4052,"enrollment":3721,"conditions":9122,"interventions":9123},"NCT00768144","Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma",[89],[21,827,826],[5331],{"nctId":9125,"briefTitle":9126,"status":118,"phases":9127,"primaryCompletion":426,"completion":426,"start":2874,"enrollment":9128,"conditions":9129,"interventions":9132},"NCT00577382","SU011248 in Patients With Metastatic Mucosal or Acral\u002FLentiginous Melanoma",[89],52,[9130,9131],"Mucosal Lentiginous Melanoma","Acral Lentiginous Malignant Melanoma",[5331],{"nctId":9134,"briefTitle":9135,"status":118,"phases":9136,"primaryCompletion":55,"completion":250,"start":1789,"enrollment":2406,"conditions":9137,"interventions":9138},"NCT01829217","Sunitinib in Never-Smokers With Lung Adenocarcinoma",[89],[30],[5331],{"trials":9140,"activeCount":99},[],{"trials":9142,"activeCount":99},[],{"trials":9144,"activeCount":99},[],{"intervention":257,"totalTrials":110,"cells":9146},{"EARLY_PHASE1":9147,"PHASE1":9149,"PHASE2":9159,"PHASE3":9180,"PHASE4":9182,"NA":9184},{"trials":9148,"activeCount":99},[],{"trials":9150,"activeCount":99},[9151],{"nctId":9152,"briefTitle":9153,"status":118,"phases":9154,"primaryCompletion":9155,"completion":1881,"start":426,"enrollment":25,"conditions":9156,"interventions":9157},"NCT02207504","Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer",[88],"2018-02-02",[8019],[9158,257],"Crizotinib",{"trials":9160,"activeCount":99},[9161,9168,9172],{"nctId":9162,"briefTitle":9163,"status":118,"phases":9164,"primaryCompletion":64,"completion":250,"start":2854,"enrollment":7831,"conditions":9165,"interventions":9167},"NCT02028988","Enzalutamide + External Beam Rt For Prostate",[89],[9166],"Intermediate Risk Prostate Cancer",[257],{"nctId":247,"briefTitle":248,"status":118,"phases":9169,"primaryCompletion":250,"completion":251,"start":45,"enrollment":252,"conditions":9170,"interventions":9171},[89],[254,18,255],[257,192,95,245],{"nctId":9173,"briefTitle":9174,"status":118,"phases":9175,"primaryCompletion":251,"completion":9176,"start":9177,"enrollment":922,"conditions":9178,"interventions":9179},"NCT01942837","Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer",[89],"2022-09-30","2013-09-13",[3020],[257],{"trials":9181,"activeCount":99},[],{"trials":9183,"activeCount":99},[],{"trials":9185,"activeCount":99},[],{"intervention":216,"totalTrials":110,"cells":9187},{"EARLY_PHASE1":9188,"PHASE1":9190,"PHASE2":9192,"PHASE3":9210,"PHASE4":9212,"NA":9214},{"trials":9189,"activeCount":99},[],{"trials":9191,"activeCount":99},[],{"trials":9193,"activeCount":99},[9194,9198,9202,9206],{"nctId":6641,"briefTitle":6642,"status":118,"phases":9195,"primaryCompletion":2677,"completion":1045,"start":2661,"enrollment":6644,"conditions":9196,"interventions":9197},[89],[18],[6647,6648,915],{"nctId":205,"briefTitle":206,"status":207,"phases":9199,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":9200,"interventions":9201},[89],[18],[215,216,114,95,190],{"nctId":8640,"briefTitle":8641,"status":118,"phases":9203,"primaryCompletion":8643,"completion":8643,"start":727,"enrollment":3721,"conditions":9204,"interventions":9205},[89],[18],[157,216],{"nctId":4376,"briefTitle":4377,"status":118,"phases":9207,"primaryCompletion":402,"completion":4379,"start":2957,"enrollment":4380,"conditions":9208,"interventions":9209},[89],[18],[158,762,4383,216],{"trials":9211,"activeCount":99},[],{"trials":9213,"activeCount":99},[],{"trials":9215,"activeCount":99},[],{"intervention":4078,"totalTrials":265,"cells":9217},{"EARLY_PHASE1":9218,"PHASE1":9220,"PHASE2":9226,"PHASE3":9236,"PHASE4":9238,"NA":9240},{"trials":9219,"activeCount":99},[],{"trials":9221,"activeCount":99},[9222],{"nctId":4069,"briefTitle":4070,"status":118,"phases":9223,"primaryCompletion":4072,"completion":3366,"start":1677,"enrollment":4073,"conditions":9224,"interventions":9225},[88],[4075,4076],[866,4078],{"trials":9227,"activeCount":99},[9228,9232],{"nctId":4143,"briefTitle":4144,"status":105,"phases":9229,"primaryCompletion":1324,"completion":1324,"start":4146,"enrollment":9,"conditions":9230,"interventions":9231},[89],[4075,4076],[866,4078,4149],{"nctId":4186,"briefTitle":4187,"status":118,"phases":9233,"primaryCompletion":264,"completion":810,"start":2733,"enrollment":955,"conditions":9234,"interventions":9235},[89],[4075,4076],[866,4078],{"trials":9237,"activeCount":99},[],{"trials":9239,"activeCount":99},[],{"trials":9241,"activeCount":99},[],{"intervention":382,"totalTrials":265,"cells":9243},{"EARLY_PHASE1":9244,"PHASE1":9246,"PHASE2":9248,"PHASE3":9264,"PHASE4":9266,"NA":9268},{"trials":9245,"activeCount":99},[],{"trials":9247,"activeCount":99},[],{"trials":9249,"activeCount":99},[9250,9256,9260],{"nctId":9251,"briefTitle":9252,"status":105,"phases":9253,"primaryCompletion":6712,"completion":3292,"start":1336,"enrollment":110,"conditions":9254,"interventions":9255},"NCT01972516","Tivozanib As Maintenance Therapy In GYN",[89],[21,827,2791],[382],{"nctId":372,"briefTitle":373,"status":118,"phases":9257,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":9258,"interventions":9259},[88,89],[380],[127,382],{"nctId":8431,"briefTitle":8432,"status":1057,"phases":9261,"primaryCompletion":8434,"completion":8434,"start":8434,"enrollment":99,"conditions":9262,"interventions":9263},[89],[3163],[382,283],{"trials":9265,"activeCount":99},[],{"trials":9267,"activeCount":99},[],{"trials":9269,"activeCount":99},[],{"intervention":113,"totalTrials":265,"cells":9271},{"EARLY_PHASE1":9272,"PHASE1":9274,"PHASE2":9284,"PHASE3":9293,"PHASE4":9295,"NA":9297},{"trials":9273,"activeCount":99},[],{"trials":9275,"activeCount":99},[9276,9280],{"nctId":4080,"briefTitle":4081,"status":118,"phases":9277,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":345,"conditions":9278,"interventions":9279},[88],[4087,4088,4089,4090,4091,4092],[113,866],{"nctId":103,"briefTitle":104,"status":105,"phases":9281,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":9282,"interventions":9283},[88],[18],[113,114,95],{"trials":9285,"activeCount":99},[9286],{"nctId":9287,"briefTitle":9288,"status":118,"phases":9289,"primaryCompletion":9290,"completion":9290,"start":4716,"enrollment":672,"conditions":9291,"interventions":9292},"NCT01790932","BKM120 For Triple Negative Breast Cancer",[89],"2015-09",[15],[113],{"trials":9294,"activeCount":99},[],{"trials":9296,"activeCount":99},[],{"trials":9298,"activeCount":99},[],{"intervention":9300,"totalTrials":265,"cells":9301},"Durvalumab",{"EARLY_PHASE1":9302,"PHASE1":9304,"PHASE2":9333,"PHASE3":9343,"PHASE4":9345,"NA":9347},{"trials":9303,"activeCount":99},[],{"trials":9305,"activeCount":99},[9306,9316],{"nctId":9307,"briefTitle":9308,"status":118,"phases":9309,"primaryCompletion":9310,"completion":9311,"start":9312,"enrollment":141,"conditions":9313,"interventions":9314},"NCT03773666","A Feasibility Study of Durvalumab +\u002F- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)",[88],"2021-02-04","2021-08-02","2019-02-20",[4614],[9300,9315],"Oleclumab",{"nctId":9317,"briefTitle":9318,"status":105,"phases":9319,"primaryCompletion":9320,"completion":9320,"start":4288,"enrollment":9,"conditions":9321,"interventions":9331},"NCT03277482","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",[88],"2022-07-15",[9322,9323,9324,9325,9326,3914,9327,9328,9329,9330,1950],"Recurrent Gynecological Cancer","Metastatic Cervical Cancer","Metastatic Ovarian Cancer","Metastatic Vaginal Cancer","Metastatic Vulvar Cancer","Recurrent Cervical Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Vaginal Cancer","Recurrent Vulvar Cancer",[9300,9332],"Tremelimumab",{"trials":9334,"activeCount":99},[9335],{"nctId":9336,"briefTitle":9337,"status":105,"phases":9338,"primaryCompletion":9339,"completion":2557,"start":9340,"enrollment":35,"conditions":9341,"interventions":9342},"NCT03075527","A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma",[89],"2019-06-07","2017-04-10",[6655],[9332,9300],{"trials":9344,"activeCount":99},[],{"trials":9346,"activeCount":99},[],{"trials":9348,"activeCount":99},[],{"intervention":818,"totalTrials":265,"cells":9350},{"EARLY_PHASE1":9351,"PHASE1":9353,"PHASE2":9355,"PHASE3":9369,"PHASE4":9371,"NA":9373},{"trials":9352,"activeCount":99},[],{"trials":9354,"activeCount":99},[],{"trials":9356,"activeCount":99},[9357,9361,9365],{"nctId":807,"briefTitle":808,"status":105,"phases":9358,"primaryCompletion":810,"completion":811,"start":812,"enrollment":329,"conditions":9359,"interventions":9360},[89],[814,815,816],[51,269,130,128,511,308,818,279,772,694],{"nctId":1525,"briefTitle":1526,"status":118,"phases":9362,"primaryCompletion":859,"completion":165,"start":1528,"enrollment":25,"conditions":9363,"interventions":9364},[89],[1354,750,1530,1531,1532,348,30,21,851,1533,1534],[733,1536,707,279,818],{"nctId":856,"briefTitle":857,"status":118,"phases":9366,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":9367,"interventions":9368},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"trials":9370,"activeCount":99},[],{"trials":9372,"activeCount":99},[],{"trials":9374,"activeCount":99},[],{"intervention":1085,"totalTrials":265,"cells":9376},{"EARLY_PHASE1":9377,"PHASE1":9379,"PHASE2":9381,"PHASE3":9395,"PHASE4":9397,"NA":9399},{"trials":9378,"activeCount":99},[],{"trials":9380,"activeCount":99},[],{"trials":9382,"activeCount":99},[9383,9387,9391],{"nctId":1076,"briefTitle":1077,"status":118,"phases":9384,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":9385,"interventions":9386},[89],[24],[1029,1085,41,364],{"nctId":1137,"briefTitle":1138,"status":1057,"phases":9388,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":99,"conditions":9389,"interventions":9390},[89],[24],[364,1066,1085,80],{"nctId":1146,"briefTitle":1147,"status":118,"phases":9392,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":9393,"interventions":9394},[89],[1154,876],[1085,1029,364],{"trials":9396,"activeCount":99},[],{"trials":9398,"activeCount":99},[],{"trials":9400,"activeCount":99},[],{"intervention":9402,"totalTrials":265,"cells":9403},"Pazopanib",{"EARLY_PHASE1":9404,"PHASE1":9406,"PHASE2":9419,"PHASE3":9429,"PHASE4":9431,"NA":9433},{"trials":9405,"activeCount":99},[],{"trials":9407,"activeCount":99},[9408,9415],{"nctId":9409,"briefTitle":9410,"status":118,"phases":9411,"primaryCompletion":5153,"completion":240,"start":376,"enrollment":403,"conditions":9412,"interventions":9414},"NCT02406521","Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets",[88],[9413],"Metastatic Renal Cell Carcinoma",[9402,8618,2073],{"nctId":340,"briefTitle":341,"status":118,"phases":9416,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":9417,"interventions":9418},[88],[347,348],[350,351],{"trials":9420,"activeCount":99},[9421],{"nctId":9422,"briefTitle":9423,"status":118,"phases":9424,"primaryCompletion":9425,"completion":2677,"start":5237,"enrollment":571,"conditions":9426,"interventions":9428},"NCT01253369","Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer",[89],"2012-09",[5949,30,9427],"SCLC",[9402],{"trials":9430,"activeCount":99},[],{"trials":9432,"activeCount":99},[],{"trials":9434,"activeCount":99},[],{"intervention":114,"totalTrials":265,"cells":9436},{"EARLY_PHASE1":9437,"PHASE1":9439,"PHASE2":9449,"PHASE3":9455,"PHASE4":9457,"NA":9459},{"trials":9438,"activeCount":99},[],{"trials":9440,"activeCount":99},[9441,9445],{"nctId":103,"briefTitle":104,"status":105,"phases":9442,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":9443,"interventions":9444},[88],[18],[113,114,95],{"nctId":8778,"briefTitle":8779,"status":118,"phases":9446,"primaryCompletion":8781,"completion":8782,"start":8783,"enrollment":3051,"conditions":9447,"interventions":9448},[88],[18],[651,114],{"trials":9450,"activeCount":99},[9451],{"nctId":205,"briefTitle":206,"status":207,"phases":9452,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":9453,"interventions":9454},[89],[18],[215,216,114,95,190],{"trials":9456,"activeCount":99},[],{"trials":9458,"activeCount":99},[],{"trials":9460,"activeCount":99},[],{"intervention":9462,"totalTrials":265,"cells":9463},"Imatinib mesylate",{"EARLY_PHASE1":9464,"PHASE1":9466,"PHASE2":9477,"PHASE3":9494,"PHASE4":9496,"NA":9498},{"trials":9465,"activeCount":99},[],{"trials":9467,"activeCount":99},[9468],{"nctId":9469,"briefTitle":9470,"status":118,"phases":9471,"primaryCompletion":4840,"completion":9472,"start":3422,"enrollment":265,"conditions":9473,"interventions":9474},"NCT00301093","Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",[88],"2020-09-10",[27],[9475,9476],"GM-K562 cell vaccine","imatinib mesylate",{"trials":9478,"activeCount":99},[9479,9487],{"nctId":9480,"briefTitle":9481,"status":118,"phases":9482,"primaryCompletion":746,"completion":199,"start":8698,"enrollment":4236,"conditions":9483,"interventions":9486},"NCT00136409","A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)",[89],[2549,9484,9485,1376],"Myeloid Metaplasia","Agnogenic Myeloid Metaplasia",[9462],{"nctId":9488,"briefTitle":9489,"status":118,"phases":9490,"primaryCompletion":1024,"completion":1024,"start":2957,"enrollment":141,"conditions":9491,"interventions":9493},"NCT00684411","Gleevec in Relapsed\u002FRefractory T Cell Non-Hodgkin's Lymphoma",[89],[9492],"T Cell Non-Hodgkin Lymphoma",[9462],{"trials":9495,"activeCount":99},[],{"trials":9497,"activeCount":99},[],{"trials":9499,"activeCount":99},[],{"intervention":6950,"totalTrials":1034,"cells":9501},{"EARLY_PHASE1":9502,"PHASE1":9504,"PHASE2":9506,"PHASE3":9516,"PHASE4":9518,"NA":9520},{"trials":9503,"activeCount":99},[],{"trials":9505,"activeCount":99},[],{"trials":9507,"activeCount":99},[9508,9512],{"nctId":9019,"briefTitle":9020,"status":105,"phases":9509,"primaryCompletion":536,"completion":120,"start":9022,"enrollment":403,"conditions":9510,"interventions":9511},[89],[9024,9025],[6950,9027,638],{"nctId":6943,"briefTitle":6944,"status":118,"phases":9513,"primaryCompletion":6946,"completion":6946,"start":6947,"enrollment":3051,"conditions":9514,"interventions":9515},[89],[804,2192],[3276,6950],{"trials":9517,"activeCount":99},[],{"trials":9519,"activeCount":99},[],{"trials":9521,"activeCount":99},[],{"intervention":9523,"totalTrials":1034,"cells":9524},"LBH589",{"EARLY_PHASE1":9525,"PHASE1":9527,"PHASE2":9537,"PHASE3":9545,"PHASE4":9547,"NA":9549},{"trials":9526,"activeCount":99},[],{"trials":9528,"activeCount":99},[9529],{"nctId":9530,"briefTitle":9531,"status":118,"phases":9532,"primaryCompletion":728,"completion":9533,"start":377,"enrollment":9,"conditions":9534,"interventions":9536},"NCT01065467","Panobinostat (LBH589) in Patients With Metastatic Melanoma",[88],"2017-03-13",[1883,9535],"Malignant Melanoma",[9523],{"trials":9538,"activeCount":99},[9539],{"nctId":9540,"briefTitle":9541,"status":118,"phases":9542,"primaryCompletion":1325,"completion":109,"start":40,"enrollment":1352,"conditions":9543,"interventions":9544},"NCT00936611","LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia",[89],[34],[9523],{"trials":9546,"activeCount":99},[],{"trials":9548,"activeCount":99},[],{"trials":9550,"activeCount":99},[],{"intervention":776,"totalTrials":1034,"cells":9552},{"EARLY_PHASE1":9553,"PHASE1":9555,"PHASE2":9557,"PHASE3":9571,"PHASE4":9573,"NA":9575},{"trials":9554,"activeCount":99},[],{"trials":9556,"activeCount":99},[],{"trials":9558,"activeCount":99},[9559,9567],{"nctId":9560,"briefTitle":9561,"status":118,"phases":9562,"primaryCompletion":3228,"completion":3228,"start":264,"enrollment":25,"conditions":9563,"interventions":9566},"NCT00424515","Imatinib in Patients With Mucosal or Acral\u002FLentiginous Melanoma",[89],[3833,9564,9565],"Acral\u002FLentiginous Melanoma","Chronically Sun Damaged Melanomas",[776],{"nctId":764,"briefTitle":765,"status":118,"phases":9568,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":9569,"interventions":9570},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"trials":9572,"activeCount":99},[],{"trials":9574,"activeCount":99},[],{"trials":9576,"activeCount":99},[],{"intervention":129,"totalTrials":1034,"cells":9578},{"EARLY_PHASE1":9579,"PHASE1":9581,"PHASE2":9587,"PHASE3":9593,"PHASE4":9595,"NA":9597},{"trials":9580,"activeCount":99},[],{"trials":9582,"activeCount":99},[9583],{"nctId":116,"briefTitle":117,"status":118,"phases":9584,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":9585,"interventions":9586},[88],[125],[127,95,128,129,130,131],{"trials":9588,"activeCount":99},[9589],{"nctId":764,"briefTitle":765,"status":118,"phases":9590,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":9591,"interventions":9592},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"trials":9594,"activeCount":99},[],{"trials":9596,"activeCount":99},[],{"trials":9598,"activeCount":99},[],{"intervention":3370,"totalTrials":1034,"cells":9600},{"EARLY_PHASE1":9601,"PHASE1":9603,"PHASE2":9605,"PHASE3":9615,"PHASE4":9617,"NA":9619},{"trials":9602,"activeCount":99},[],{"trials":9604,"activeCount":99},[],{"trials":9606,"activeCount":99},[9607,9611],{"nctId":3362,"briefTitle":3363,"status":118,"phases":9608,"primaryCompletion":425,"completion":3365,"start":3366,"enrollment":1988,"conditions":9609,"interventions":9610},[89],[663,15,3368],[2881,915,3370],{"nctId":830,"briefTitle":831,"status":118,"phases":9612,"primaryCompletion":833,"completion":833,"start":834,"enrollment":835,"conditions":9613,"interventions":9614},[89],[15,837,838],[840,841,130,269,706],{"trials":9616,"activeCount":99},[],{"trials":9618,"activeCount":99},[],{"trials":9620,"activeCount":99},[],{"intervention":4309,"totalTrials":1034,"cells":9622},{"EARLY_PHASE1":9623,"PHASE1":9625,"PHASE2":9631,"PHASE3":9637,"PHASE4":9639,"NA":9641},{"trials":9624,"activeCount":99},[],{"trials":9626,"activeCount":99},[9627],{"nctId":8731,"briefTitle":8732,"status":118,"phases":9628,"primaryCompletion":4029,"completion":414,"start":8734,"enrollment":428,"conditions":9629,"interventions":9630},[88],[5155],[4309,2562,4057],{"trials":9632,"activeCount":99},[9633],{"nctId":4303,"briefTitle":4304,"status":118,"phases":9634,"primaryCompletion":4306,"completion":4029,"start":1071,"enrollment":403,"conditions":9635,"interventions":9636},[89],[4114],[4309,158],{"trials":9638,"activeCount":99},[],{"trials":9640,"activeCount":99},[],{"trials":9642,"activeCount":99},[],{"intervention":146,"totalTrials":1034,"cells":9644},{"EARLY_PHASE1":9645,"PHASE1":9647,"PHASE2":9659,"PHASE3":9665,"PHASE4":9667,"NA":9669},{"trials":9646,"activeCount":99},[],{"trials":9648,"activeCount":99},[9649],{"nctId":9650,"briefTitle":9651,"status":118,"phases":9652,"primaryCompletion":2358,"completion":9653,"start":9654,"enrollment":1492,"conditions":9655,"interventions":9656},"NCT04826393","ASP8374 + Cemiplimab in Recurrent Glioma",[88],"2024-01-01","2022-03-09",[611,6685],[9657,9658],"ASP8374","cemiplimab",{"trials":9660,"activeCount":99},[9661],{"nctId":135,"briefTitle":136,"status":118,"phases":9662,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":9663,"interventions":9664},[88,89],[143,144],[146,127,147,95],{"trials":9666,"activeCount":99},[],{"trials":9668,"activeCount":99},[],{"trials":9670,"activeCount":99},[],{"intervention":7835,"totalTrials":1034,"cells":9672},{"EARLY_PHASE1":9673,"PHASE1":9675,"PHASE2":9677,"PHASE3":9692,"PHASE4":9694,"NA":9696},{"trials":9674,"activeCount":99},[],{"trials":9676,"activeCount":99},[],{"trials":9678,"activeCount":99},[9679,9683],{"nctId":7827,"briefTitle":7828,"status":118,"phases":9680,"primaryCompletion":3868,"completion":7830,"start":198,"enrollment":7831,"conditions":9681,"interventions":9682},[89],[2091,3693],[6631,308,7834,7835],{"nctId":9684,"briefTitle":9685,"status":118,"phases":9686,"primaryCompletion":9687,"completion":9688,"start":9689,"enrollment":35,"conditions":9690,"interventions":9691},"NCT01782443","Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",[89],"2021-03","2021-12-26","2013-02-13",[2501],[7835],{"trials":9693,"activeCount":99},[],{"trials":9695,"activeCount":99},[],{"trials":9697,"activeCount":99},[],{"intervention":3005,"totalTrials":1034,"cells":9699},{"EARLY_PHASE1":9700,"PHASE1":9702,"PHASE2":9708,"PHASE3":9714,"PHASE4":9716,"NA":9718},{"trials":9701,"activeCount":99},[],{"trials":9703,"activeCount":99},[9704],{"nctId":2998,"briefTitle":2999,"status":1057,"phases":9705,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":99,"conditions":9706,"interventions":9707},[88],[15],[2932,1953,798,3005],{"trials":9709,"activeCount":99},[9710],{"nctId":4477,"briefTitle":4478,"status":118,"phases":9711,"primaryCompletion":3254,"completion":4480,"start":823,"enrollment":4481,"conditions":9712,"interventions":9713},[89],[15],[395,3005],{"trials":9715,"activeCount":99},[],{"trials":9717,"activeCount":99},[],{"trials":9719,"activeCount":99},[],{"intervention":9721,"totalTrials":1034,"cells":9722},"Eltrombopag",{"EARLY_PHASE1":9723,"PHASE1":9732,"PHASE2":9734,"PHASE3":9743,"PHASE4":9745,"NA":9747},{"trials":9724,"activeCount":99},[9725],{"nctId":9726,"briefTitle":9727,"status":118,"phases":9728,"primaryCompletion":3543,"completion":1142,"start":9729,"enrollment":35,"conditions":9730,"interventions":9731},"NCT01286675","Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT",[87],"2011-03",[24],[9721],{"trials":9733,"activeCount":99},[],{"trials":9735,"activeCount":99},[9736],{"nctId":9737,"briefTitle":9738,"status":105,"phases":9739,"primaryCompletion":402,"completion":9290,"start":3449,"enrollment":286,"conditions":9740,"interventions":9742},"NCT01484314","Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma",[89],[9741,24],"Thrombocytopenia",[9721],{"trials":9744,"activeCount":99},[],{"trials":9746,"activeCount":99},[],{"trials":9748,"activeCount":99},[],{"intervention":9750,"totalTrials":1034,"cells":9751},"STA-9090",{"EARLY_PHASE1":9752,"PHASE1":9754,"PHASE2":9756,"PHASE3":9774,"PHASE4":9776,"NA":9778},{"trials":9753,"activeCount":99},[],{"trials":9755,"activeCount":99},[],{"trials":9757,"activeCount":99},[9758,9768],{"nctId":9759,"briefTitle":9760,"status":118,"phases":9761,"primaryCompletion":9762,"completion":9763,"start":9764,"enrollment":3493,"conditions":9765,"interventions":9767},"NCT01200238","STA-9090(Ganetespib) in Metastatic Ocular Melanoma",[89],"2014-10-12","2016-11-11","2010-09-17",[9766],"Ocular Melanoma",[9750],{"nctId":9769,"briefTitle":9770,"status":105,"phases":9771,"primaryCompletion":9425,"completion":9425,"start":1325,"enrollment":265,"conditions":9772,"interventions":9773},"NCT01551693","STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma",[89],[1883],[9750],{"trials":9775,"activeCount":99},[],{"trials":9777,"activeCount":99},[],{"trials":9779,"activeCount":99},[],{"intervention":1981,"totalTrials":1034,"cells":9781},{"EARLY_PHASE1":9782,"PHASE1":9784,"PHASE2":9795,"PHASE3":9801,"PHASE4":9803,"NA":9805},{"trials":9783,"activeCount":99},[],{"trials":9785,"activeCount":99},[9786],{"nctId":9787,"briefTitle":9788,"status":118,"phases":9789,"primaryCompletion":909,"completion":658,"start":9790,"conditions":9791,"interventions":9792},"NCT00069940","Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor",[88],"2000-12",[750,5329,851],[9793,9794],"sargramostim","telomerase: 540-548 peptide vaccine",{"trials":9796,"activeCount":99},[9797],{"nctId":1970,"briefTitle":1971,"status":1057,"phases":9798,"primaryCompletion":1973,"completion":1974,"start":1975,"enrollment":99,"conditions":9799,"interventions":9800},[89],[1977,1884,1978,1979],[1981,626],{"trials":9802,"activeCount":99},[],{"trials":9804,"activeCount":99},[],{"trials":9806,"activeCount":99},[],{"intervention":1065,"totalTrials":1034,"cells":9808},{"EARLY_PHASE1":9809,"PHASE1":9811,"PHASE2":9827,"PHASE3":9833,"PHASE4":9835,"NA":9837},{"trials":9810,"activeCount":99},[],{"trials":9812,"activeCount":99},[9813],{"nctId":9814,"briefTitle":9815,"status":105,"phases":9816,"primaryCompletion":9817,"completion":9817,"start":9818,"enrollment":110,"conditions":9819,"interventions":9826},"NCT04341311","Phase I Study of Marizomib + Panobinostat for Children With DIPG",[88],"2024-02-14","2020-08-10",[9820,9821,9822,9823,9824,9825],"Diffuse Intrinsic Pontine Glioma","Pediatric Brainstem Glioma","Pediatric Brainstem Gliosarcoma, Recurrent","Pediatric Cancer","Pediatric Brain Tumor","Diffuse Glioma",[1065,1028],{"trials":9828,"activeCount":99},[9829],{"nctId":1055,"briefTitle":1056,"status":1057,"phases":9830,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":99,"conditions":9831,"interventions":9832},[89],[24,1026,1063],[1065,1066,364],{"trials":9834,"activeCount":99},[],{"trials":9836,"activeCount":99},[],{"trials":9838,"activeCount":99},[],{"intervention":1066,"totalTrials":1034,"cells":9840},{"EARLY_PHASE1":9841,"PHASE1":9843,"PHASE2":9845,"PHASE3":9855,"PHASE4":9857,"NA":9859},{"trials":9842,"activeCount":99},[],{"trials":9844,"activeCount":99},[],{"trials":9846,"activeCount":99},[9847,9851],{"nctId":1055,"briefTitle":1056,"status":1057,"phases":9848,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":99,"conditions":9849,"interventions":9850},[89],[24,1026,1063],[1065,1066,364],{"nctId":1137,"briefTitle":1138,"status":1057,"phases":9852,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":99,"conditions":9853,"interventions":9854},[89],[24],[364,1066,1085,80],{"trials":9856,"activeCount":99},[],{"trials":9858,"activeCount":99},[],{"trials":9860,"activeCount":99},[],{"intervention":3426,"totalTrials":1034,"cells":9862},{"EARLY_PHASE1":9863,"PHASE1":9865,"PHASE2":9867,"PHASE3":9879,"PHASE4":9881,"NA":9883},{"trials":9864,"activeCount":99},[],{"trials":9866,"activeCount":99},[],{"trials":9868,"activeCount":99},[9869,9875],{"nctId":9870,"briefTitle":9871,"status":118,"phases":9872,"primaryCompletion":4036,"completion":4306,"start":8496,"enrollment":22,"conditions":9873,"interventions":9874},"NCT00424723","Pemetrexed in Patients With Advanced Neuroendocrine Tumors",[89],[2503],[3426],{"nctId":3418,"briefTitle":3419,"status":118,"phases":9876,"primaryCompletion":660,"completion":3421,"start":3422,"enrollment":3423,"conditions":9877,"interventions":9878},[89],[21,826,827],[707,3426],{"trials":9880,"activeCount":99},[],{"trials":9882,"activeCount":99},[],{"trials":9884,"activeCount":99},[],{"intervention":9332,"totalTrials":1034,"cells":9886},{"EARLY_PHASE1":9887,"PHASE1":9889,"PHASE2":9895,"PHASE3":9901,"PHASE4":9903,"NA":9905},{"trials":9888,"activeCount":99},[],{"trials":9890,"activeCount":99},[9891],{"nctId":9317,"briefTitle":9318,"status":105,"phases":9892,"primaryCompletion":9320,"completion":9320,"start":4288,"enrollment":9,"conditions":9893,"interventions":9894},[88],[9322,9323,9324,9325,9326,3914,9327,9328,9329,9330,1950],[9300,9332],{"trials":9896,"activeCount":99},[9897],{"nctId":9336,"briefTitle":9337,"status":105,"phases":9898,"primaryCompletion":9339,"completion":2557,"start":9340,"enrollment":35,"conditions":9899,"interventions":9900},[89],[6655],[9332,9300],{"trials":9902,"activeCount":99},[],{"trials":9904,"activeCount":99},[],{"trials":9906,"activeCount":99},[],{"intervention":9908,"totalTrials":1034,"cells":9909},"Rapamycin",{"EARLY_PHASE1":9910,"PHASE1":9912,"PHASE2":9921,"PHASE3":9934,"PHASE4":9936,"NA":9938},{"trials":9911,"activeCount":99},[],{"trials":9913,"activeCount":99},[9914],{"nctId":9915,"briefTitle":9916,"status":118,"phases":9917,"primaryCompletion":3366,"completion":8796,"start":660,"enrollment":720,"conditions":9918,"interventions":9919},"NCT00874562","Rapamycin in Relapsed Acute Lymphoblastic Leukemia",[88],[125],[9920,9908],"Corticosteroid",{"trials":9922,"activeCount":99},[9923],{"nctId":9924,"briefTitle":9925,"status":118,"phases":9926,"primaryCompletion":427,"completion":427,"start":9927,"enrollment":3721,"conditions":9928,"interventions":9933},"NCT00126672","RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS",[89],"2005-12-20",[9929,9930,9931,9932],"Nonmalignant Neoplasm","Tuberous Sclerosis","Lymphangioleimyomatosis","Kidney Angiomyolipoma",[9908],{"trials":9935,"activeCount":99},[],{"trials":9937,"activeCount":99},[],{"trials":9939,"activeCount":99},[],{"intervention":492,"totalTrials":1034,"cells":9941},{"EARLY_PHASE1":9942,"PHASE1":9944,"PHASE2":9946,"PHASE3":9956,"PHASE4":9958,"NA":9960},{"trials":9943,"activeCount":99},[],{"trials":9945,"activeCount":99},[],{"trials":9947,"activeCount":99},[9948,9952],{"nctId":482,"briefTitle":483,"status":118,"phases":9949,"primaryCompletion":485,"completion":40,"start":486,"enrollment":487,"conditions":9950,"interventions":9951},[89],[475,489],[480,479,491,492],{"nctId":3123,"briefTitle":3124,"status":118,"phases":9953,"primaryCompletion":3126,"completion":40,"start":748,"enrollment":1034,"conditions":9954,"interventions":9955},[89],[3128,3129,3130],[3132,679,638],{"trials":9957,"activeCount":99},[],{"trials":9959,"activeCount":99},[],{"trials":9961,"activeCount":99},[],{"intervention":9963,"totalTrials":1034,"cells":9964},"MLN0128",{"EARLY_PHASE1":9965,"PHASE1":9967,"PHASE2":9969,"PHASE3":9988,"PHASE4":9990,"NA":9992},{"trials":9966,"activeCount":99},[],{"trials":9968,"activeCount":99},[],{"trials":9970,"activeCount":99},[9971,9979],{"nctId":9972,"briefTitle":9973,"status":118,"phases":9974,"primaryCompletion":9975,"completion":9976,"start":3439,"enrollment":242,"conditions":9977,"interventions":9978},"NCT02514824","MLN0128 in Recurrent\u002FMetastatic Merkel Cell Carcinoma",[88,89],"2017-04","2017-06",[8798],[9963],{"nctId":9980,"briefTitle":9981,"status":118,"phases":9982,"primaryCompletion":9983,"completion":9983,"start":6712,"enrollment":428,"conditions":9984,"interventions":9987},"NCT02244463","A Phase I\u002FII Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer",[88,89],"2022-04-28",[9985,2433,9986],"Anaplastic Thyroid Cancer","Differentiated Thyroid Cancer",[9963],{"trials":9989,"activeCount":99},[],{"trials":9991,"activeCount":99},[],{"trials":9993,"activeCount":99},[],{"intervention":1110,"totalTrials":1034,"cells":9995},{"EARLY_PHASE1":9996,"PHASE1":9998,"PHASE2":10000,"PHASE3":10010,"PHASE4":10012,"NA":10014},{"trials":9997,"activeCount":99},[],{"trials":9999,"activeCount":99},[],{"trials":10001,"activeCount":99},[10002,10006],{"nctId":1103,"briefTitle":1104,"status":118,"phases":10003,"primaryCompletion":1106,"completion":1106,"start":376,"enrollment":1107,"conditions":10004,"interventions":10005},[89],[34],[1110,364,51],{"nctId":1120,"briefTitle":1121,"status":118,"phases":10007,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":1125,"conditions":10008,"interventions":10009},[89],[876],[1110,1029,364],{"trials":10011,"activeCount":99},[],{"trials":10013,"activeCount":99},[],{"trials":10015,"activeCount":99},[],{"intervention":841,"totalTrials":1034,"cells":10017},{"EARLY_PHASE1":10018,"PHASE1":10020,"PHASE2":10026,"PHASE3":10032,"PHASE4":10034,"NA":10036},{"trials":10019,"activeCount":99},[],{"trials":10021,"activeCount":99},[10022],{"nctId":8462,"briefTitle":8463,"status":118,"phases":10023,"primaryCompletion":1325,"completion":1325,"start":8465,"enrollment":1082,"conditions":10024,"interventions":10025},[88],[15],[841,4056],{"trials":10027,"activeCount":99},[10028],{"nctId":830,"briefTitle":831,"status":118,"phases":10029,"primaryCompletion":833,"completion":833,"start":834,"enrollment":835,"conditions":10030,"interventions":10031},[89],[15,837,838],[840,841,130,269,706],{"trials":10033,"activeCount":99},[],{"trials":10035,"activeCount":99},[],{"trials":10037,"activeCount":99},[],{"intervention":665,"totalTrials":1034,"cells":10039},{"EARLY_PHASE1":10040,"PHASE1":10042,"PHASE2":10048,"PHASE3":10054,"PHASE4":10056,"NA":10058},{"trials":10041,"activeCount":99},[],{"trials":10043,"activeCount":99},[10044],{"nctId":655,"briefTitle":656,"status":118,"phases":10045,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":10046,"interventions":10047},[88],[663],[665,269,511],{"trials":10049,"activeCount":99},[10050],{"nctId":4355,"briefTitle":4356,"status":118,"phases":10051,"primaryCompletion":425,"completion":4358,"start":1098,"enrollment":4359,"conditions":10052,"interventions":10053},[89],[4361,1354],[158,4363],{"trials":10055,"activeCount":99},[],{"trials":10057,"activeCount":99},[],{"trials":10059,"activeCount":99},[],{"intervention":867,"totalTrials":1034,"cells":10061},{"EARLY_PHASE1":10062,"PHASE1":10064,"PHASE2":10066,"PHASE3":10076,"PHASE4":10078,"NA":10080},{"trials":10063,"activeCount":99},[],{"trials":10065,"activeCount":99},[],{"trials":10067,"activeCount":99},[10068,10072],{"nctId":856,"briefTitle":857,"status":118,"phases":10069,"primaryCompletion":859,"completion":824,"start":860,"enrollment":784,"conditions":10070,"interventions":10071},[89],[850,862,863],[128,269,865,279,866,707,285,818,867,694],{"nctId":4214,"briefTitle":4215,"status":118,"phases":10073,"primaryCompletion":2757,"completion":2757,"start":4217,"enrollment":403,"conditions":10074,"interventions":10075},[89],[4123,4219],[4103,866,4022,308,867,4221],{"trials":10077,"activeCount":99},[],{"trials":10079,"activeCount":99},[],{"trials":10081,"activeCount":99},[],{"intervention":10083,"totalTrials":1034,"cells":10084},"vorinostat",{"EARLY_PHASE1":10085,"PHASE1":10087,"PHASE2":10089,"PHASE3":10103,"PHASE4":10105,"NA":10107},{"trials":10086,"activeCount":99},[],{"trials":10088,"activeCount":99},[],{"trials":10090,"activeCount":99},[10091,10099],{"nctId":10092,"briefTitle":10093,"status":105,"phases":10094,"primaryCompletion":45,"completion":45,"start":10095,"enrollment":275,"conditions":10096,"interventions":10098},"NCT01000155","Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease",[89],"2009-10",[3129,10097],"Sickle Cell Anemia",[10083],{"nctId":3436,"briefTitle":3437,"status":105,"phases":10100,"primaryCompletion":198,"completion":3439,"start":415,"enrollment":498,"conditions":10101,"interventions":10102},[88,89],[21,827,826],[3442,707,283],{"trials":10104,"activeCount":99},[],{"trials":10106,"activeCount":99},[],{"trials":10108,"activeCount":99},[],{"intervention":8513,"totalTrials":1034,"cells":10110},{"EARLY_PHASE1":10111,"PHASE1":10113,"PHASE2":10115,"PHASE3":10128,"PHASE4":10130,"NA":10132},{"trials":10112,"activeCount":99},[],{"trials":10114,"activeCount":99},[],{"trials":10116,"activeCount":99},[10117,10121],{"nctId":8507,"briefTitle":8508,"status":118,"phases":10118,"primaryCompletion":5023,"completion":4052,"start":8510,"enrollment":22,"conditions":10119,"interventions":10120},[89],[4444,6611],[4056,8513],{"nctId":10122,"briefTitle":10123,"status":118,"phases":10124,"primaryCompletion":9089,"completion":1071,"start":729,"enrollment":2008,"conditions":10125,"interventions":10127},"NCT00137800","Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients",[89],[10126],"Non-Small-Cell Lung Carcinoma",[8513],{"trials":10129,"activeCount":99},[],{"trials":10131,"activeCount":99},[],{"trials":10133,"activeCount":99},[],{"intervention":1378,"totalTrials":1034,"cells":10135},{"EARLY_PHASE1":10136,"PHASE1":10138,"PHASE2":10148,"PHASE3":10154,"PHASE4":10156,"NA":10158},{"trials":10137,"activeCount":99},[],{"trials":10139,"activeCount":99},[10140],{"nctId":10141,"briefTitle":10142,"status":118,"phases":10143,"primaryCompletion":264,"completion":2825,"start":847,"enrollment":141,"conditions":10144,"interventions":10147},"NCT00258687","Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma",[88],[10145,10146,3163,1883],"Sarcoma, Clear Cell","Sarcoma, Alveolar Soft Part",[1378],{"trials":10149,"activeCount":99},[10150],{"nctId":1368,"briefTitle":1369,"status":105,"phases":10151,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":1374,"conditions":10152,"interventions":10153},[89],[463,674,1376],[1378,284,679,466,511],{"trials":10155,"activeCount":99},[],{"trials":10157,"activeCount":99},[],{"trials":10159,"activeCount":99},[],{"intervention":2073,"totalTrials":1034,"cells":10161},{"EARLY_PHASE1":10162,"PHASE1":10164,"PHASE2":10170,"PHASE3":10176,"PHASE4":10178,"NA":10180},{"trials":10163,"activeCount":99},[],{"trials":10165,"activeCount":99},[10166],{"nctId":9409,"briefTitle":9410,"status":118,"phases":10167,"primaryCompletion":5153,"completion":240,"start":376,"enrollment":403,"conditions":10168,"interventions":10169},[88],[9413],[9402,8618,2073],{"trials":10171,"activeCount":99},[10172],{"nctId":2065,"briefTitle":2066,"status":118,"phases":10173,"primaryCompletion":2068,"completion":2069,"start":2070,"enrollment":225,"conditions":10174,"interventions":10175},[89],[18],[2073,626],{"trials":10177,"activeCount":99},[],{"trials":10179,"activeCount":99},[],{"trials":10181,"activeCount":99},[],{"intervention":1220,"totalTrials":1034,"cells":10183},{"EARLY_PHASE1":10184,"PHASE1":10186,"PHASE2":10192,"PHASE3":10198,"PHASE4":10200,"NA":10202},{"trials":10185,"activeCount":99},[],{"trials":10187,"activeCount":99},[10188],{"nctId":1212,"briefTitle":1213,"status":105,"phases":10189,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1034,"conditions":10190,"interventions":10191},[88],[674,477],[1219,1220,279,772],{"trials":10193,"activeCount":99},[10194],{"nctId":2754,"briefTitle":2755,"status":118,"phases":10195,"primaryCompletion":2757,"completion":425,"start":2758,"enrollment":403,"conditions":10196,"interventions":10197},[89],[1253],[679,1220,51,2761],{"trials":10199,"activeCount":99},[],{"trials":10201,"activeCount":99},[],{"trials":10203,"activeCount":99},[],{"intervention":245,"totalTrials":1034,"cells":10205},{"EARLY_PHASE1":10206,"PHASE1":10208,"PHASE2":10210,"PHASE3":10220,"PHASE4":10222,"NA":10224},{"trials":10207,"activeCount":99},[],{"trials":10209,"activeCount":99},[],{"trials":10211,"activeCount":99},[10212,10216],{"nctId":236,"briefTitle":237,"status":105,"phases":10213,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":10214,"interventions":10215},[89],[18],[245,95,158,190],{"nctId":247,"briefTitle":248,"status":118,"phases":10217,"primaryCompletion":250,"completion":251,"start":45,"enrollment":252,"conditions":10218,"interventions":10219},[89],[254,18,255],[257,192,95,245],{"trials":10221,"activeCount":99},[],{"trials":10223,"activeCount":99},[],{"trials":10225,"activeCount":99},[],{"intervention":281,"totalTrials":1034,"cells":10227},{"EARLY_PHASE1":10228,"PHASE1":10230,"PHASE2":10232,"PHASE3":10242,"PHASE4":10244,"NA":10246},{"trials":10229,"activeCount":99},[],{"trials":10231,"activeCount":99},[],{"trials":10233,"activeCount":99},[10234,10238],{"nctId":1161,"briefTitle":1162,"status":118,"phases":10235,"primaryCompletion":1164,"completion":1124,"start":1165,"enrollment":1166,"conditions":10236,"interventions":10237},[88,89],[24],[281,203,364],{"nctId":271,"briefTitle":272,"status":105,"phases":10239,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":10240,"interventions":10241},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"trials":10243,"activeCount":99},[],{"trials":10245,"activeCount":99},[],{"trials":10247,"activeCount":99},[],{"intervention":284,"totalTrials":1034,"cells":10249},{"EARLY_PHASE1":10250,"PHASE1":10252,"PHASE2":10254,"PHASE3":10264,"PHASE4":10266,"NA":10268},{"trials":10251,"activeCount":99},[],{"trials":10253,"activeCount":99},[],{"trials":10255,"activeCount":99},[10256,10260],{"nctId":271,"briefTitle":272,"status":105,"phases":10257,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":10258,"interventions":10259},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"nctId":1368,"briefTitle":1369,"status":105,"phases":10261,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":1374,"conditions":10262,"interventions":10263},[89],[463,674,1376],[1378,284,679,466,511],{"trials":10265,"activeCount":99},[],{"trials":10267,"activeCount":99},[],{"trials":10269,"activeCount":99},[],{"intervention":10271,"totalTrials":286,"cells":10272},"troglitazone",{"EARLY_PHASE1":10273,"PHASE1":10275,"PHASE2":10277,"PHASE3":10287,"PHASE4":10289,"NA":10291},{"trials":10274,"activeCount":99},[],{"trials":10276,"activeCount":99},[],{"trials":10278,"activeCount":99},[10279],{"nctId":10280,"briefTitle":10281,"status":118,"phases":10282,"primaryCompletion":10283,"completion":10283,"start":10284,"enrollment":955,"conditions":10285,"interventions":10286},"NCT00003058","Troglitazone in Treating Patients With Liposarcoma",[89],"2000-01","1997-06",[851],[10271],{"trials":10288,"activeCount":99},[],{"trials":10290,"activeCount":99},[],{"trials":10292,"activeCount":99},[],{"intervention":10294,"totalTrials":286,"cells":10295},"BAY 1000394",{"EARLY_PHASE1":10296,"PHASE1":10298,"PHASE2":10300,"PHASE3":10311,"PHASE4":10313,"NA":10315},{"trials":10297,"activeCount":99},[],{"trials":10299,"activeCount":99},[],{"trials":10301,"activeCount":99},[10302],{"nctId":10303,"briefTitle":10304,"status":1057,"phases":10305,"primaryCompletion":10306,"completion":10307,"start":10308,"enrollment":99,"conditions":10309,"interventions":10310},"NCT02656849","BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",[89],"2019-10","2023-05","2016-02",[347],[10294],{"trials":10312,"activeCount":99},[],{"trials":10314,"activeCount":99},[],{"trials":10316,"activeCount":99},[],{"intervention":741,"totalTrials":286,"cells":10318},{"EARLY_PHASE1":10319,"PHASE1":10321,"PHASE2":10323,"PHASE3":10329,"PHASE4":10331,"NA":10333},{"trials":10320,"activeCount":99},[],{"trials":10322,"activeCount":99},[],{"trials":10324,"activeCount":99},[10325],{"nctId":724,"briefTitle":725,"status":118,"phases":10326,"primaryCompletion":727,"completion":728,"start":729,"enrollment":661,"conditions":10327,"interventions":10328},[89],[731],[733,734,588,176,735,736,737,590,172,738,739,740,741],{"trials":10330,"activeCount":99},[],{"trials":10332,"activeCount":99},[],{"trials":10334,"activeCount":99},[],{"intervention":9027,"totalTrials":286,"cells":10336},{"EARLY_PHASE1":10337,"PHASE1":10339,"PHASE2":10341,"PHASE3":10347,"PHASE4":10349,"NA":10351},{"trials":10338,"activeCount":99},[],{"trials":10340,"activeCount":99},[],{"trials":10342,"activeCount":99},[10343],{"nctId":9019,"briefTitle":9020,"status":105,"phases":10344,"primaryCompletion":536,"completion":120,"start":9022,"enrollment":403,"conditions":10345,"interventions":10346},[89],[9024,9025],[6950,9027,638],{"trials":10348,"activeCount":99},[],{"trials":10350,"activeCount":99},[],{"trials":10352,"activeCount":99},[],{"intervention":10354,"totalTrials":286,"cells":10355},"Merestinib",{"EARLY_PHASE1":10356,"PHASE1":10358,"PHASE2":10360,"PHASE3":10370,"PHASE4":10372,"NA":10374},{"trials":10357,"activeCount":99},[],{"trials":10359,"activeCount":99},[],{"trials":10361,"activeCount":99},[10362],{"nctId":10363,"briefTitle":10364,"status":105,"phases":10365,"primaryCompletion":10366,"completion":10367,"start":9763,"enrollment":141,"conditions":10368,"interventions":10369},"NCT02920996","Merestinib In Non-Small Cell Lung Cancer And Solid Tumors",[89],"2021-10","2023-10",[3940,347],[10354],{"trials":10371,"activeCount":99},[],{"trials":10373,"activeCount":99},[],{"trials":10375,"activeCount":99},[],{"intervention":8477,"totalTrials":286,"cells":10377},{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10388,"PHASE4":10390,"NA":10392},{"trials":10379,"activeCount":99},[],{"trials":10381,"activeCount":99},[],{"trials":10383,"activeCount":99},[10384],{"nctId":8471,"briefTitle":8472,"status":118,"phases":10385,"primaryCompletion":909,"completion":909,"start":8474,"enrollment":22,"conditions":10386,"interventions":10387},[89],[5155,6611],[8477,4056,6631],{"trials":10389,"activeCount":99},[],{"trials":10391,"activeCount":99},[],{"trials":10393,"activeCount":99},[],{"intervention":6613,"totalTrials":286,"cells":10395},{"EARLY_PHASE1":10396,"PHASE1":10398,"PHASE2":10400,"PHASE3":10406,"PHASE4":10408,"NA":10410},{"trials":10397,"activeCount":99},[],{"trials":10399,"activeCount":99},[],{"trials":10401,"activeCount":99},[10402],{"nctId":6607,"briefTitle":6608,"status":118,"phases":10403,"primaryCompletion":660,"completion":660,"start":847,"enrollment":1337,"conditions":10404,"interventions":10405},[89],[5155,6611],[2880,6613,915],{"trials":10407,"activeCount":99},[],{"trials":10409,"activeCount":99},[],{"trials":10411,"activeCount":99},[],{"intervention":1931,"totalTrials":286,"cells":10413},{"EARLY_PHASE1":10414,"PHASE1":10416,"PHASE2":10418,"PHASE3":10424,"PHASE4":10426,"NA":10428},{"trials":10415,"activeCount":99},[],{"trials":10417,"activeCount":99},[],{"trials":10419,"activeCount":99},[10420],{"nctId":1922,"briefTitle":1923,"status":118,"phases":10421,"primaryCompletion":1925,"completion":1926,"start":1927,"enrollment":1928,"conditions":10422,"interventions":10423},[89],[15],[1931,626],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"trials":10429,"activeCount":99},[],{"intervention":4467,"totalTrials":286,"cells":10431},{"EARLY_PHASE1":10432,"PHASE1":10434,"PHASE2":10436,"PHASE3":10442,"PHASE4":10444,"NA":10446},{"trials":10433,"activeCount":99},[],{"trials":10435,"activeCount":99},[],{"trials":10437,"activeCount":99},[10438],{"nctId":4458,"briefTitle":4459,"status":105,"phases":10439,"primaryCompletion":4461,"completion":4461,"start":4462,"enrollment":329,"conditions":10440,"interventions":10441},[89],[4464,4465],[395,4467],{"trials":10443,"activeCount":99},[],{"trials":10445,"activeCount":99},[],{"trials":10447,"activeCount":99},[],{"intervention":1738,"totalTrials":286,"cells":10449},{"EARLY_PHASE1":10450,"PHASE1":10452,"PHASE2":10454,"PHASE3":10460,"PHASE4":10462,"NA":10464},{"trials":10451,"activeCount":99},[],{"trials":10453,"activeCount":99},[],{"trials":10455,"activeCount":99},[10456],{"nctId":1731,"briefTitle":1732,"status":105,"phases":10457,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":887,"conditions":10458,"interventions":10459},[88,89],[18],[1738,177,1739,1740],{"trials":10461,"activeCount":99},[],{"trials":10463,"activeCount":99},[],{"trials":10465,"activeCount":99},[],{"intervention":1739,"totalTrials":286,"cells":10467},{"EARLY_PHASE1":10468,"PHASE1":10470,"PHASE2":10472,"PHASE3":10478,"PHASE4":10480,"NA":10482},{"trials":10469,"activeCount":99},[],{"trials":10471,"activeCount":99},[],{"trials":10473,"activeCount":99},[10474],{"nctId":1731,"briefTitle":1732,"status":105,"phases":10475,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":887,"conditions":10476,"interventions":10477},[88,89],[18],[1738,177,1739,1740],{"trials":10479,"activeCount":99},[],{"trials":10481,"activeCount":99},[],{"trials":10483,"activeCount":99},[],{"intervention":1740,"totalTrials":286,"cells":10485},{"EARLY_PHASE1":10486,"PHASE1":10488,"PHASE2":10490,"PHASE3":10496,"PHASE4":10498,"NA":10500},{"trials":10487,"activeCount":99},[],{"trials":10489,"activeCount":99},[],{"trials":10491,"activeCount":99},[10492],{"nctId":1731,"briefTitle":1732,"status":105,"phases":10493,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":887,"conditions":10494,"interventions":10495},[88,89],[18],[1738,177,1739,1740],{"trials":10497,"activeCount":99},[],{"trials":10499,"activeCount":99},[],{"trials":10501,"activeCount":99},[],{"intervention":773,"totalTrials":286,"cells":10503},{"EARLY_PHASE1":10504,"PHASE1":10506,"PHASE2":10508,"PHASE3":10514,"PHASE4":10516,"NA":10518},{"trials":10505,"activeCount":99},[],{"trials":10507,"activeCount":99},[],{"trials":10509,"activeCount":99},[10510],{"nctId":764,"briefTitle":765,"status":118,"phases":10511,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":10512,"interventions":10513},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"trials":10515,"activeCount":99},[],{"trials":10517,"activeCount":99},[],{"trials":10519,"activeCount":99},[],{"intervention":774,"totalTrials":286,"cells":10521},{"EARLY_PHASE1":10522,"PHASE1":10524,"PHASE2":10526,"PHASE3":10532,"PHASE4":10534,"NA":10536},{"trials":10523,"activeCount":99},[],{"trials":10525,"activeCount":99},[],{"trials":10527,"activeCount":99},[10528],{"nctId":764,"briefTitle":765,"status":118,"phases":10529,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":10530,"interventions":10531},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"trials":10533,"activeCount":99},[],{"trials":10535,"activeCount":99},[],{"trials":10537,"activeCount":99},[],{"intervention":775,"totalTrials":286,"cells":10539},{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10550,"PHASE4":10552,"NA":10554},{"trials":10541,"activeCount":99},[],{"trials":10543,"activeCount":99},[],{"trials":10545,"activeCount":99},[10546],{"nctId":764,"briefTitle":765,"status":118,"phases":10547,"primaryCompletion":375,"completion":767,"start":768,"enrollment":769,"conditions":10548,"interventions":10549},[89],[125],[130,772,511,128,269,773,774,364,775,129,776,279,777],{"trials":10551,"activeCount":99},[],{"trials":10553,"activeCount":99},[],{"trials":10555,"activeCount":99},[],{"intervention":10557,"totalTrials":286,"cells":10558},"Tretinoin",{"EARLY_PHASE1":10559,"PHASE1":10561,"PHASE2":10563,"PHASE3":10573,"PHASE4":10575,"NA":10577},{"trials":10560,"activeCount":99},[],{"trials":10562,"activeCount":99},[],{"trials":10564,"activeCount":99},[10565],{"nctId":10566,"briefTitle":10567,"status":118,"phases":10568,"primaryCompletion":10569,"completion":10569,"start":10570,"enrollment":715,"conditions":10571,"interventions":10572},"NCT03999684","A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma",[89],"2020-04-15","2019-08-05",[2081],[10557],{"trials":10574,"activeCount":99},[],{"trials":10576,"activeCount":99},[],{"trials":10578,"activeCount":99},[],{"intervention":4318,"totalTrials":286,"cells":10580},{"EARLY_PHASE1":10581,"PHASE1":10583,"PHASE2":10585,"PHASE3":10591,"PHASE4":10593,"NA":10595},{"trials":10582,"activeCount":99},[],{"trials":10584,"activeCount":99},[],{"trials":10586,"activeCount":99},[10587],{"nctId":4311,"briefTitle":4312,"status":118,"phases":10588,"primaryCompletion":4314,"completion":4314,"start":748,"enrollment":599,"conditions":10589,"interventions":10590},[89],[4316,18],[158,4318,4319,4320],{"trials":10592,"activeCount":99},[],{"trials":10594,"activeCount":99},[],{"trials":10596,"activeCount":99},[],{"intervention":4319,"totalTrials":286,"cells":10598},{"EARLY_PHASE1":10599,"PHASE1":10601,"PHASE2":10603,"PHASE3":10609,"PHASE4":10611,"NA":10613},{"trials":10600,"activeCount":99},[],{"trials":10602,"activeCount":99},[],{"trials":10604,"activeCount":99},[10605],{"nctId":4311,"briefTitle":4312,"status":118,"phases":10606,"primaryCompletion":4314,"completion":4314,"start":748,"enrollment":599,"conditions":10607,"interventions":10608},[89],[4316,18],[158,4318,4319,4320],{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[],{"trials":10614,"activeCount":99},[],{"intervention":4320,"totalTrials":286,"cells":10616},{"EARLY_PHASE1":10617,"PHASE1":10619,"PHASE2":10621,"PHASE3":10627,"PHASE4":10629,"NA":10631},{"trials":10618,"activeCount":99},[],{"trials":10620,"activeCount":99},[],{"trials":10622,"activeCount":99},[10623],{"nctId":4311,"briefTitle":4312,"status":118,"phases":10624,"primaryCompletion":4314,"completion":4314,"start":748,"enrollment":599,"conditions":10625,"interventions":10626},[89],[4316,18],[158,4318,4319,4320],{"trials":10628,"activeCount":99},[],{"trials":10630,"activeCount":99},[],{"trials":10632,"activeCount":99},[],{"intervention":10634,"totalTrials":286,"cells":10635},"Vancomycin-polymyxin B",{"EARLY_PHASE1":10636,"PHASE1":10638,"PHASE2":10640,"PHASE3":10652,"PHASE4":10654,"NA":10656},{"trials":10637,"activeCount":99},[],{"trials":10639,"activeCount":99},[],{"trials":10641,"activeCount":99},[10642],{"nctId":10643,"briefTitle":10644,"status":118,"phases":10645,"primaryCompletion":10646,"completion":10647,"start":3342,"enrollment":25,"conditions":10648,"interventions":10651},"NCT02641236","Gut Decontamination In Pediatric Allogeneic Hematopoietic",[89],"2021-04-15","2021-10-28",[10649,10650],"Hematopoietic Stem Cell Transplantation (HSCT)","Acute GVH Disease",[10634],{"trials":10653,"activeCount":99},[],{"trials":10655,"activeCount":99},[],{"trials":10657,"activeCount":99},[],{"intervention":1049,"totalTrials":286,"cells":10659},{"EARLY_PHASE1":10660,"PHASE1":10662,"PHASE2":10664,"PHASE3":10670,"PHASE4":10672,"NA":10674},{"trials":10661,"activeCount":99},[],{"trials":10663,"activeCount":99},[],{"trials":10665,"activeCount":99},[10666],{"nctId":1042,"briefTitle":1043,"status":118,"phases":10667,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":487,"conditions":10668,"interventions":10669},[89],[34],[364,1049,51],{"trials":10671,"activeCount":99},[],{"trials":10673,"activeCount":99},[],{"trials":10675,"activeCount":99},[],{"intervention":4149,"totalTrials":286,"cells":10677},{"EARLY_PHASE1":10678,"PHASE1":10680,"PHASE2":10682,"PHASE3":10688,"PHASE4":10690,"NA":10692},{"trials":10679,"activeCount":99},[],{"trials":10681,"activeCount":99},[],{"trials":10683,"activeCount":99},[10684],{"nctId":4143,"briefTitle":4144,"status":105,"phases":10685,"primaryCompletion":1324,"completion":1324,"start":4146,"enrollment":9,"conditions":10686,"interventions":10687},[89],[4075,4076],[866,4078,4149],{"trials":10689,"activeCount":99},[],{"trials":10691,"activeCount":99},[],{"trials":10693,"activeCount":99},[],{"intervention":10695,"totalTrials":286,"cells":10696},"IL-12",{"EARLY_PHASE1":10697,"PHASE1":10699,"PHASE2":10701,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10698,"activeCount":99},[],{"trials":10700,"activeCount":99},[],{"trials":10702,"activeCount":99},[10703],{"nctId":10704,"briefTitle":10705,"status":118,"phases":10706,"primaryCompletion":859,"completion":9790,"start":10707,"enrollment":2800,"conditions":10708,"interventions":10709},"NCT00004070","Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer",[88,89],"1999-07",[1532],[10695],{"trials":10711,"activeCount":99},[],{"trials":10713,"activeCount":99},[],{"trials":10715,"activeCount":99},[],{"intervention":7924,"totalTrials":286,"cells":10717},{"EARLY_PHASE1":10718,"PHASE1":10720,"PHASE2":10722,"PHASE3":10728,"PHASE4":10730,"NA":10732},{"trials":10719,"activeCount":99},[],{"trials":10721,"activeCount":99},[],{"trials":10723,"activeCount":99},[10724],{"nctId":7918,"briefTitle":7919,"status":118,"phases":10725,"primaryCompletion":7921,"completion":7921,"start":3549,"enrollment":28,"conditions":10726,"interventions":10727},[89],[475],[7924,7925],{"trials":10729,"activeCount":99},[],{"trials":10731,"activeCount":99},[],{"trials":10733,"activeCount":99},[],{"intervention":2832,"totalTrials":286,"cells":10735},{"EARLY_PHASE1":10736,"PHASE1":10738,"PHASE2":10740,"PHASE3":10746,"PHASE4":10748,"NA":10750},{"trials":10737,"activeCount":99},[],{"trials":10739,"activeCount":99},[],{"trials":10741,"activeCount":99},[10742],{"nctId":2822,"briefTitle":2823,"status":118,"phases":10743,"primaryCompletion":2825,"completion":2826,"start":2827,"enrollment":2828,"conditions":10744,"interventions":10745},[89],[2830],[706,2832],{"trials":10747,"activeCount":99},[],{"trials":10749,"activeCount":99},[],{"trials":10751,"activeCount":99},[],{"intervention":10753,"totalTrials":286,"cells":10754},"pyrimethamine",{"EARLY_PHASE1":10755,"PHASE1":10757,"PHASE2":10759,"PHASE3":10768,"PHASE4":10770,"NA":10772},{"trials":10756,"activeCount":99},[],{"trials":10758,"activeCount":99},[],{"trials":10760,"activeCount":99},[10761],{"nctId":10762,"briefTitle":10763,"status":118,"phases":10764,"primaryCompletion":3481,"completion":10765,"start":4306,"enrollment":784,"conditions":10766,"interventions":10767},"NCT01066663","Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[88,89],"2023-01",[804,2622],[10753],{"trials":10769,"activeCount":99},[],{"trials":10771,"activeCount":99},[],{"trials":10773,"activeCount":99},[],{"intervention":10775,"totalTrials":286,"cells":10776},"Rituxan",{"EARLY_PHASE1":10777,"PHASE1":10779,"PHASE2":10781,"PHASE3":10790,"PHASE4":10792,"NA":10794},{"trials":10778,"activeCount":99},[],{"trials":10780,"activeCount":99},[],{"trials":10782,"activeCount":99},[10783],{"nctId":10784,"briefTitle":10785,"status":118,"phases":10786,"primaryCompletion":2757,"completion":40,"start":4159,"enrollment":403,"conditions":10787,"interventions":10788},"NCT00251394","Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma",[89],[267],[10775,10789],"1018 ISS",{"trials":10791,"activeCount":99},[],{"trials":10793,"activeCount":99},[],{"trials":10795,"activeCount":99},[],{"intervention":10789,"totalTrials":286,"cells":10797},{"EARLY_PHASE1":10798,"PHASE1":10800,"PHASE2":10802,"PHASE3":10808,"PHASE4":10810,"NA":10812},{"trials":10799,"activeCount":99},[],{"trials":10801,"activeCount":99},[],{"trials":10803,"activeCount":99},[10804],{"nctId":10784,"briefTitle":10785,"status":118,"phases":10805,"primaryCompletion":2757,"completion":40,"start":4159,"enrollment":403,"conditions":10806,"interventions":10807},[89],[267],[10775,10789],{"trials":10809,"activeCount":99},[],{"trials":10811,"activeCount":99},[],{"trials":10813,"activeCount":99},[],{"intervention":5018,"totalTrials":286,"cells":10815},{"EARLY_PHASE1":10816,"PHASE1":10818,"PHASE2":10820,"PHASE3":10826,"PHASE4":10828,"NA":10830},{"trials":10817,"activeCount":99},[],{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[10822],{"nctId":5011,"briefTitle":5012,"status":105,"phases":10823,"primaryCompletion":5014,"completion":5014,"start":5015,"enrollment":28,"conditions":10824,"interventions":10825},[89],[15],[5018,3710],{"trials":10827,"activeCount":99},[],{"trials":10829,"activeCount":99},[],{"trials":10831,"activeCount":99},[],{"intervention":10833,"totalTrials":286,"cells":10834},"All-trans retinoic acid",{"EARLY_PHASE1":10835,"PHASE1":10837,"PHASE2":10839,"PHASE3":10850,"PHASE4":10852,"NA":10854},{"trials":10836,"activeCount":99},[],{"trials":10838,"activeCount":99},[],{"trials":10840,"activeCount":99},[10841],{"nctId":10842,"briefTitle":10843,"status":118,"phases":10844,"primaryCompletion":10845,"completion":10845,"start":10846,"enrollment":1082,"conditions":10847,"interventions":10848},"NCT00136461","A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",[89],"2000-08","1997-05",[474,463],[10833,10849],"Bryostatin 1",{"trials":10851,"activeCount":99},[],{"trials":10853,"activeCount":99},[],{"trials":10855,"activeCount":99},[],{"intervention":10849,"totalTrials":286,"cells":10857},{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10862,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10859,"activeCount":99},[],{"trials":10861,"activeCount":99},[],{"trials":10863,"activeCount":99},[10864],{"nctId":10842,"briefTitle":10843,"status":118,"phases":10865,"primaryCompletion":10845,"completion":10845,"start":10846,"enrollment":1082,"conditions":10866,"interventions":10867},[89],[474,463],[10833,10849],{"trials":10869,"activeCount":99},[],{"trials":10871,"activeCount":99},[],{"trials":10873,"activeCount":99},[],{"intervention":10875,"totalTrials":286,"cells":10876},"Naltrexone",{"EARLY_PHASE1":10877,"PHASE1":10879,"PHASE2":10881,"PHASE3":10897,"PHASE4":10899,"NA":10901},{"trials":10878,"activeCount":99},[],{"trials":10880,"activeCount":99},[],{"trials":10882,"activeCount":99},[10883],{"nctId":10884,"briefTitle":10885,"status":105,"phases":10886,"primaryCompletion":10887,"completion":10887,"start":10888,"enrollment":265,"conditions":10889,"interventions":10895},"NCT02137252","Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer",[89],"2015-08-01","2014-05",[10890,10891,10892,10893,10894],"Invasive Breast Cancer (Stage I-III)","Ductal Carcinoma in Situ","Lobular Carcinoma in Situ","Lobular Carcinoma","Fatigue Related to Cancer Treatment",[10875,10896],"Sugar Pill",{"trials":10898,"activeCount":99},[],{"trials":10900,"activeCount":99},[],{"trials":10902,"activeCount":99},[],{"intervention":10896,"totalTrials":286,"cells":10904},{"EARLY_PHASE1":10905,"PHASE1":10907,"PHASE2":10909,"PHASE3":10915,"PHASE4":10917,"NA":10919},{"trials":10906,"activeCount":99},[],{"trials":10908,"activeCount":99},[],{"trials":10910,"activeCount":99},[10911],{"nctId":10884,"briefTitle":10885,"status":105,"phases":10912,"primaryCompletion":10887,"completion":10887,"start":10888,"enrollment":265,"conditions":10913,"interventions":10914},[89],[10890,10891,10892,10893,10894],[10875,10896],{"trials":10916,"activeCount":99},[],{"trials":10918,"activeCount":99},[],{"trials":10920,"activeCount":99},[],{"intervention":10922,"totalTrials":286,"cells":10923},"defibrotide",{"EARLY_PHASE1":10924,"PHASE1":10926,"PHASE2":10928,"PHASE3":10938,"PHASE4":10940,"NA":10942},{"trials":10925,"activeCount":99},[],{"trials":10927,"activeCount":99},[],{"trials":10929,"activeCount":99},[10930],{"nctId":10931,"briefTitle":10932,"status":118,"phases":10933,"primaryCompletion":747,"completion":2907,"start":9078,"enrollment":10934,"conditions":10935,"interventions":10937},"NCT00003966","Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation",[89],151,[10936],"Veno-occlusive Disease",[10922],{"trials":10939,"activeCount":99},[],{"trials":10941,"activeCount":99},[],{"trials":10943,"activeCount":99},[],{"intervention":178,"totalTrials":286,"cells":10945},{"EARLY_PHASE1":10946,"PHASE1":10948,"PHASE2":10950,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10947,"activeCount":99},[],{"trials":10949,"activeCount":99},[],{"trials":10951,"activeCount":99},[10952],{"nctId":160,"briefTitle":161,"status":118,"phases":10953,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":10954,"interventions":10955},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"trials":10957,"activeCount":99},[],{"trials":10959,"activeCount":99},[],{"trials":10961,"activeCount":99},[],{"intervention":179,"totalTrials":286,"cells":10963},{"EARLY_PHASE1":10964,"PHASE1":10966,"PHASE2":10968,"PHASE3":10974,"PHASE4":10976,"NA":10978},{"trials":10965,"activeCount":99},[],{"trials":10967,"activeCount":99},[],{"trials":10969,"activeCount":99},[10970],{"nctId":160,"briefTitle":161,"status":118,"phases":10971,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":10972,"interventions":10973},[89],[125],[169,170,171,172,173,174,175,176,177,178,179],{"trials":10975,"activeCount":99},[],{"trials":10977,"activeCount":99},[],{"trials":10979,"activeCount":99},[],{"intervention":2386,"totalTrials":286,"cells":10981},{"EARLY_PHASE1":10982,"PHASE1":10984,"PHASE2":10986,"PHASE3":10992,"PHASE4":10994,"NA":10996},{"trials":10983,"activeCount":99},[],{"trials":10985,"activeCount":99},[],{"trials":10987,"activeCount":99},[10988],{"nctId":2379,"briefTitle":2380,"status":105,"phases":10989,"primaryCompletion":2382,"completion":2382,"start":2383,"enrollment":286,"conditions":10990,"interventions":10991},[89],[1883,1884],[2327,80,2386],{"trials":10993,"activeCount":99},[],{"trials":10995,"activeCount":99},[],{"trials":10997,"activeCount":99},[],{"intervention":3498,"totalTrials":286,"cells":10999},{"EARLY_PHASE1":11000,"PHASE1":11002,"PHASE2":11004,"PHASE3":11010,"PHASE4":11012,"NA":11014},{"trials":11001,"activeCount":99},[],{"trials":11003,"activeCount":99},[],{"trials":11005,"activeCount":99},[11006],{"nctId":3489,"briefTitle":3490,"status":118,"phases":11007,"primaryCompletion":525,"completion":402,"start":3492,"enrollment":3493,"conditions":11008,"interventions":11009},[89],[15],[3496,3497,3498],{"trials":11011,"activeCount":99},[],{"trials":11013,"activeCount":99},[],{"trials":11015,"activeCount":99},[],{"intervention":11017,"totalTrials":286,"cells":11018},"MK-2206",{"EARLY_PHASE1":11019,"PHASE1":11021,"PHASE2":11023,"PHASE3":11032,"PHASE4":11034,"NA":11036},{"trials":11020,"activeCount":99},[],{"trials":11022,"activeCount":99},[],{"trials":11024,"activeCount":99},[11025],{"nctId":11026,"briefTitle":11027,"status":1057,"phases":11028,"enrollment":99,"conditions":11029,"interventions":11031},"NCT01249105","MK-2206 for Recurrent Malignant Glioma",[89],[11030],"Malignant Glioma",[11017],{"trials":11033,"activeCount":99},[],{"trials":11035,"activeCount":99},[],{"trials":11037,"activeCount":99},[],{"intervention":11039,"totalTrials":286,"cells":11040},"Tibolone",{"EARLY_PHASE1":11041,"PHASE1":11043,"PHASE2":11045,"PHASE3":11056,"PHASE4":11058,"NA":11060},{"trials":11042,"activeCount":99},[],{"trials":11044,"activeCount":99},[],{"trials":11046,"activeCount":99},[11047],{"nctId":11048,"briefTitle":11049,"status":118,"phases":11050,"primaryCompletion":11051,"completion":11051,"start":4146,"enrollment":672,"conditions":11052,"interventions":11055},"NCT00165204","Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy",[89],"2006-03",[11053,11054,15],"Menopause","Postmenopausal Bone Loss",[11039],{"trials":11057,"activeCount":99},[],{"trials":11059,"activeCount":99},[],{"trials":11061,"activeCount":99},[],{"intervention":11063,"totalTrials":286,"cells":11064},"SPF 30 or Higher Suncreen",{"EARLY_PHASE1":11065,"PHASE1":11067,"PHASE2":11069,"PHASE3":11081,"PHASE4":11083,"NA":11085},{"trials":11066,"activeCount":99},[],{"trials":11068,"activeCount":99},[],{"trials":11070,"activeCount":99},[11071],{"nctId":11072,"briefTitle":11073,"status":118,"phases":11074,"primaryCompletion":9653,"completion":11075,"start":11076,"enrollment":1492,"conditions":11077,"interventions":11080},"NCT04479514","Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy",[89],"2025-02-15","2020-10-01",[9823,11078,11079],"CNS Tumor, Childhood","Skin Inflammation",[11063],{"trials":11082,"activeCount":99},[],{"trials":11084,"activeCount":99},[],{"trials":11086,"activeCount":99},[],{"intervention":11088,"totalTrials":286,"cells":11089},"Rogaratinib",{"EARLY_PHASE1":11090,"PHASE1":11092,"PHASE2":11094,"PHASE3":11103,"PHASE4":11105,"NA":11107},{"trials":11091,"activeCount":99},[],{"trials":11093,"activeCount":99},[],{"trials":11095,"activeCount":99},[11096],{"nctId":11097,"briefTitle":11098,"status":1057,"phases":11099,"primaryCompletion":11100,"completion":11100,"start":11100,"enrollment":99,"conditions":11101,"interventions":11102},"NCT04040725","Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1\u002F2 Overexpression",[89],"2019-11-27",[1354],[11088],{"trials":11104,"activeCount":99},[],{"trials":11106,"activeCount":99},[],{"trials":11108,"activeCount":99},[],{"intervention":3384,"totalTrials":286,"cells":11110},{"EARLY_PHASE1":11111,"PHASE1":11113,"PHASE2":11115,"PHASE3":11121,"PHASE4":11123,"NA":11125},{"trials":11112,"activeCount":99},[],{"trials":11114,"activeCount":99},[],{"trials":11116,"activeCount":99},[11117],{"nctId":3376,"briefTitle":3377,"status":105,"phases":11118,"primaryCompletion":1024,"completion":1024,"start":262,"enrollment":1841,"conditions":11119,"interventions":11120},[88,89],[1918,3380,3381,3382],[3384,3385,707],{"trials":11122,"activeCount":99},[],{"trials":11124,"activeCount":99},[],{"trials":11126,"activeCount":99},[],{"intervention":3385,"totalTrials":286,"cells":11128},{"EARLY_PHASE1":11129,"PHASE1":11131,"PHASE2":11133,"PHASE3":11139,"PHASE4":11141,"NA":11143},{"trials":11130,"activeCount":99},[],{"trials":11132,"activeCount":99},[],{"trials":11134,"activeCount":99},[11135],{"nctId":3376,"briefTitle":3377,"status":105,"phases":11136,"primaryCompletion":1024,"completion":1024,"start":262,"enrollment":1841,"conditions":11137,"interventions":11138},[88,89],[1918,3380,3381,3382],[3384,3385,707],{"trials":11140,"activeCount":99},[],{"trials":11142,"activeCount":99},[],{"trials":11144,"activeCount":99},[],{"intervention":4341,"totalTrials":286,"cells":11146},{"EARLY_PHASE1":11147,"PHASE1":11149,"PHASE2":11151,"PHASE3":11157,"PHASE4":11159,"NA":11161},{"trials":11148,"activeCount":99},[],{"trials":11150,"activeCount":99},[],{"trials":11152,"activeCount":99},[11153],{"nctId":4334,"briefTitle":4335,"status":118,"phases":11154,"primaryCompletion":2956,"completion":659,"start":4337,"enrollment":22,"conditions":11155,"interventions":11156},[89],[4339],[4341,158],{"trials":11158,"activeCount":99},[],{"trials":11160,"activeCount":99},[],{"trials":11162,"activeCount":99},[],{"intervention":11164,"totalTrials":286,"cells":11165},"AMG 479",{"EARLY_PHASE1":11166,"PHASE1":11168,"PHASE2":11170,"PHASE3":11178,"PHASE4":11180,"NA":11182},{"trials":11167,"activeCount":99},[],{"trials":11169,"activeCount":99},[],{"trials":11171,"activeCount":99},[11172],{"nctId":11173,"briefTitle":11174,"status":118,"phases":11175,"primaryCompletion":3292,"completion":120,"start":4306,"enrollment":1999,"conditions":11176,"interventions":11177},"NCT01024387","AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",[89],[8609,2501,6806],[11164],{"trials":11179,"activeCount":99},[],{"trials":11181,"activeCount":99},[],{"trials":11183,"activeCount":99},[],{"intervention":11185,"totalTrials":286,"cells":11186},"Mifepristone",{"EARLY_PHASE1":11187,"PHASE1":11189,"PHASE2":11191,"PHASE3":11200,"PHASE4":11202,"NA":11204},{"trials":11188,"activeCount":99},[],{"trials":11190,"activeCount":99},[],{"trials":11192,"activeCount":99},[11193],{"nctId":11194,"briefTitle":11195,"status":118,"phases":11196,"primaryCompletion":471,"completion":6734,"start":2758,"enrollment":2288,"conditions":11197,"interventions":11199},"NCT00140478","Mifepristone (RU-486) in Androgen Independent Prostate Cancer",[89],[18,11198],"Adenocarcinoma of Prostate",[11185],{"trials":11201,"activeCount":99},[],{"trials":11203,"activeCount":99},[],{"trials":11205,"activeCount":99},[],{"intervention":2681,"totalTrials":286,"cells":11207},{"EARLY_PHASE1":11208,"PHASE1":11210,"PHASE2":11212,"PHASE3":11218,"PHASE4":11220,"NA":11222},{"trials":11209,"activeCount":99},[],{"trials":11211,"activeCount":99},[],{"trials":11213,"activeCount":99},[11214],{"nctId":2672,"briefTitle":2673,"status":118,"phases":11215,"primaryCompletion":2675,"completion":2676,"start":2677,"enrollment":661,"conditions":11216,"interventions":11217},[89],[2679],[2681,51],{"trials":11219,"activeCount":99},[],{"trials":11221,"activeCount":99},[],{"trials":11223,"activeCount":99},[],{"intervention":11225,"totalTrials":286,"cells":11226},"ABT199",{"EARLY_PHASE1":11227,"PHASE1":11229,"PHASE2":11231,"PHASE3":11242,"PHASE4":11244,"NA":11246},{"trials":11228,"activeCount":99},[],{"trials":11230,"activeCount":99},[],{"trials":11232,"activeCount":99},[11233],{"nctId":11234,"briefTitle":11235,"status":118,"phases":11236,"primaryCompletion":11237,"completion":11238,"start":11239,"enrollment":571,"conditions":11240,"interventions":11241},"NCT02677324","Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia",[89],"2020-02-14","2022-02-07","2016-05-09",[2256],[11225],{"trials":11243,"activeCount":99},[],{"trials":11245,"activeCount":99},[],{"trials":11247,"activeCount":99},[],{"intervention":11249,"totalTrials":286,"cells":11250},"Enoxaparin",{"EARLY_PHASE1":11251,"PHASE1":11253,"PHASE2":11255,"PHASE3":11266,"PHASE4":11268,"NA":11270},{"trials":11252,"activeCount":99},[],{"trials":11254,"activeCount":99},[],{"trials":11256,"activeCount":99},[11257],{"nctId":11258,"briefTitle":11259,"status":118,"phases":11260,"primaryCompletion":11261,"completion":11262,"start":8796,"enrollment":672,"conditions":11263,"interventions":11265},"NCT02706249","Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients",[89],"2020-12-07","2021-06-07",[11264],"Venous Thormboembolism",[11249],{"trials":11267,"activeCount":99},[],{"trials":11269,"activeCount":99},[],{"trials":11271,"activeCount":99},[],{"intervention":11273,"totalTrials":286,"cells":11274},"LY3022855",{"EARLY_PHASE1":11275,"PHASE1":11277,"PHASE2":11279,"PHASE3":11291,"PHASE4":11293,"NA":11295},{"trials":11276,"activeCount":99},[],{"trials":11278,"activeCount":99},[],{"trials":11280,"activeCount":99},[11281],{"nctId":11282,"briefTitle":11283,"status":118,"phases":11284,"primaryCompletion":11285,"completion":2322,"start":11286,"enrollment":275,"conditions":11287,"interventions":11288},"NCT03101254","LY3022855 With BRAF\u002FMEK Inhibition in Patients With Melanoma",[88,89],"2020-10-21","2017-06-06",[1883],[11273,11289,11290],"Vemurafenib","Cobimetinib",{"trials":11292,"activeCount":99},[],{"trials":11294,"activeCount":99},[],{"trials":11296,"activeCount":99},[],{"intervention":11289,"totalTrials":286,"cells":11298},{"EARLY_PHASE1":11299,"PHASE1":11301,"PHASE2":11303,"PHASE3":11309,"PHASE4":11311,"NA":11313},{"trials":11300,"activeCount":99},[],{"trials":11302,"activeCount":99},[],{"trials":11304,"activeCount":99},[11305],{"nctId":11282,"briefTitle":11283,"status":118,"phases":11306,"primaryCompletion":11285,"completion":2322,"start":11286,"enrollment":275,"conditions":11307,"interventions":11308},[88,89],[1883],[11273,11289,11290],{"trials":11310,"activeCount":99},[],{"trials":11312,"activeCount":99},[],{"trials":11314,"activeCount":99},[],{"intervention":11290,"totalTrials":286,"cells":11316},{"EARLY_PHASE1":11317,"PHASE1":11319,"PHASE2":11321,"PHASE3":11327,"PHASE4":11329,"NA":11331},{"trials":11318,"activeCount":99},[],{"trials":11320,"activeCount":99},[],{"trials":11322,"activeCount":99},[11323],{"nctId":11282,"briefTitle":11283,"status":118,"phases":11324,"primaryCompletion":11285,"completion":2322,"start":11286,"enrollment":275,"conditions":11325,"interventions":11326},[88,89],[1883],[11273,11289,11290],{"trials":11328,"activeCount":99},[],{"trials":11330,"activeCount":99},[],{"trials":11332,"activeCount":99},[],{"intervention":6647,"totalTrials":286,"cells":11334},{"EARLY_PHASE1":11335,"PHASE1":11337,"PHASE2":11339,"PHASE3":11345,"PHASE4":11347,"NA":11349},{"trials":11336,"activeCount":99},[],{"trials":11338,"activeCount":99},[],{"trials":11340,"activeCount":99},[11341],{"nctId":6641,"briefTitle":6642,"status":118,"phases":11342,"primaryCompletion":2677,"completion":1045,"start":2661,"enrollment":6644,"conditions":11343,"interventions":11344},[89],[18],[6647,6648,915],{"trials":11346,"activeCount":99},[],{"trials":11348,"activeCount":99},[],{"trials":11350,"activeCount":99},[],{"intervention":11352,"totalTrials":286,"cells":11353},"FOLFOX + bevacizumab",{"EARLY_PHASE1":11354,"PHASE1":11356,"PHASE2":11358,"PHASE3":11369,"PHASE4":11371,"NA":11373},{"trials":11355,"activeCount":99},[],{"trials":11357,"activeCount":99},[],{"trials":11359,"activeCount":99},[11360],{"nctId":11361,"briefTitle":11362,"status":118,"phases":11363,"primaryCompletion":11364,"completion":11364,"start":11365,"enrollment":537,"conditions":11366,"interventions":11368},"NCT01516216","Study of Vitamin D in Untreated Metastatic Colorectal Cancer",[89],"2019-11-09","2012-04-13",[11367],"Metastatic Colorectal Cancer",[11352],{"trials":11370,"activeCount":99},[],{"trials":11372,"activeCount":99},[],{"trials":11374,"activeCount":99},[],{"intervention":11376,"totalTrials":286,"cells":11377},"Ivabradine",{"EARLY_PHASE1":11378,"PHASE1":11380,"PHASE2":11382,"PHASE3":11394,"PHASE4":11396,"NA":11398},{"trials":11379,"activeCount":99},[],{"trials":11381,"activeCount":99},[],{"trials":11383,"activeCount":99},[11384],{"nctId":11385,"briefTitle":11386,"status":105,"phases":11387,"primaryCompletion":11388,"completion":11388,"start":11389,"enrollment":345,"conditions":11390,"interventions":11393},"NCT03137537","Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.",[89],"2020-11-18","2018-02-27",[585,11391,11392],"Autonomic Imbalance","Cancer Survivorship",[11376],{"trials":11395,"activeCount":99},[],{"trials":11397,"activeCount":99},[],{"trials":11399,"activeCount":99},[],{"intervention":11401,"totalTrials":286,"cells":11402},"autologous dendritic cell-tumor fusion vaccine",{"EARLY_PHASE1":11403,"PHASE1":11405,"PHASE2":11407,"PHASE3":11418,"PHASE4":11420,"NA":11422},{"trials":11404,"activeCount":99},[],{"trials":11406,"activeCount":99},[],{"trials":11408,"activeCount":99},[11409],{"nctId":11410,"briefTitle":11411,"status":207,"phases":11412,"start":748,"enrollment":1082,"conditions":11413,"interventions":11415},"NCT00085397","Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",[89],[11414],"Melanoma (Skin)",[11401,11416,11417],"gp100 antigen","therapeutic autologous dendritic cells",{"trials":11419,"activeCount":99},[],{"trials":11421,"activeCount":99},[],{"trials":11423,"activeCount":99},[],{"intervention":11416,"totalTrials":286,"cells":11425},{"EARLY_PHASE1":11426,"PHASE1":11428,"PHASE2":11430,"PHASE3":11436,"PHASE4":11438,"NA":11440},{"trials":11427,"activeCount":99},[],{"trials":11429,"activeCount":99},[],{"trials":11431,"activeCount":99},[11432],{"nctId":11410,"briefTitle":11411,"status":207,"phases":11433,"start":748,"enrollment":1082,"conditions":11434,"interventions":11435},[89],[11414],[11401,11416,11417],{"trials":11437,"activeCount":99},[],{"trials":11439,"activeCount":99},[],{"trials":11441,"activeCount":99},[],{"intervention":11417,"totalTrials":286,"cells":11443},{"EARLY_PHASE1":11444,"PHASE1":11446,"PHASE2":11448,"PHASE3":11454,"PHASE4":11456,"NA":11458},{"trials":11445,"activeCount":99},[],{"trials":11447,"activeCount":99},[],{"trials":11449,"activeCount":99},[11450],{"nctId":11410,"briefTitle":11411,"status":207,"phases":11451,"start":748,"enrollment":1082,"conditions":11452,"interventions":11453},[89],[11414],[11401,11416,11417],{"trials":11455,"activeCount":99},[],{"trials":11457,"activeCount":99},[],{"trials":11459,"activeCount":99},[],{"intervention":11461,"totalTrials":286,"cells":11462},"LY2452473",{"EARLY_PHASE1":11463,"PHASE1":11465,"PHASE2":11467,"PHASE3":11478,"PHASE4":11480,"NA":11482},{"trials":11464,"activeCount":99},[],{"trials":11466,"activeCount":99},[],{"trials":11468,"activeCount":99},[11469],{"nctId":11470,"briefTitle":11471,"status":118,"phases":11472,"primaryCompletion":11473,"completion":11473,"start":11474,"enrollment":11475,"conditions":11476,"interventions":11477},"NCT02499497","A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer",[89],"2020-10-31","2016-02-29",114,[18],[11461],{"trials":11479,"activeCount":99},[],{"trials":11481,"activeCount":99},[],{"trials":11483,"activeCount":99},[],{"intervention":11485,"totalTrials":286,"cells":11486},"PTK787\u002FZK222584",{"EARLY_PHASE1":11487,"PHASE1":11489,"PHASE2":11491,"PHASE3":11499,"PHASE4":11501,"NA":11503},{"trials":11488,"activeCount":99},[],{"trials":11490,"activeCount":99},[],{"trials":11492,"activeCount":99},[11493],{"nctId":11494,"briefTitle":11495,"status":118,"phases":11496,"primaryCompletion":782,"completion":782,"start":2662,"enrollment":329,"conditions":11497,"interventions":11498},"NCT00165347","Protein Tyrosine Kinases (PTK) in Multiple Myeloma",[89],[24],[11485],{"trials":11500,"activeCount":99},[],{"trials":11502,"activeCount":99},[],{"trials":11504,"activeCount":99},[],{"intervention":11506,"totalTrials":286,"cells":11507},"LY2606368",{"EARLY_PHASE1":11508,"PHASE1":11510,"PHASE2":11512,"PHASE3":11523,"PHASE4":11525,"NA":11527},{"trials":11509,"activeCount":99},[],{"trials":11511,"activeCount":99},[],{"trials":11513,"activeCount":99},[11514],{"nctId":11515,"briefTitle":11516,"status":118,"phases":11517,"primaryCompletion":11518,"completion":8782,"start":11519,"enrollment":3051,"conditions":11520,"interventions":11522},"NCT02873975","A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency",[89],"2020-09-30","2016-10-12",[11521],"Advanced Cancers",[11506],{"trials":11524,"activeCount":99},[],{"trials":11526,"activeCount":99},[],{"trials":11528,"activeCount":99},[],{"intervention":854,"totalTrials":286,"cells":11530},{"EARLY_PHASE1":11531,"PHASE1":11533,"PHASE2":11535,"PHASE3":11541,"PHASE4":11543,"NA":11545},{"trials":11532,"activeCount":99},[],{"trials":11534,"activeCount":99},[],{"trials":11536,"activeCount":99},[11537],{"nctId":843,"briefTitle":844,"status":118,"phases":11538,"primaryCompletion":846,"completion":425,"start":847,"enrollment":848,"conditions":11539,"interventions":11540},[89],[731,27,585,850,851,852],[752,588,737,854,753],{"trials":11542,"activeCount":99},[],{"trials":11544,"activeCount":99},[],{"trials":11546,"activeCount":99},[],{"intervention":11548,"totalTrials":286,"cells":11549},"GSK1120212",{"EARLY_PHASE1":11550,"PHASE1":11552,"PHASE2":11554,"PHASE3":11564,"PHASE4":11566,"NA":11568},{"trials":11551,"activeCount":99},[],{"trials":11553,"activeCount":99},[],{"trials":11555,"activeCount":99},[11556],{"nctId":11557,"briefTitle":11558,"status":105,"phases":11559,"primaryCompletion":11560,"completion":11560,"start":1024,"enrollment":1492,"conditions":11561,"interventions":11562},"NCT01958112","GSK1120212+GSK2141795 for Cervical Cancer",[89],"2017-11",[4280],[11548,11563],"GSK2141795",{"trials":11565,"activeCount":99},[],{"trials":11567,"activeCount":99},[],{"trials":11569,"activeCount":99},[],{"intervention":11563,"totalTrials":286,"cells":11571},{"EARLY_PHASE1":11572,"PHASE1":11574,"PHASE2":11576,"PHASE3":11582,"PHASE4":11584,"NA":11586},{"trials":11573,"activeCount":99},[],{"trials":11575,"activeCount":99},[],{"trials":11577,"activeCount":99},[11578],{"nctId":11557,"briefTitle":11558,"status":105,"phases":11579,"primaryCompletion":11560,"completion":11560,"start":1024,"enrollment":1492,"conditions":11580,"interventions":11581},[89],[4280],[11548,11563],{"trials":11583,"activeCount":99},[],{"trials":11585,"activeCount":99},[],{"trials":11587,"activeCount":99},[],{"intervention":502,"totalTrials":286,"cells":11589},{"EARLY_PHASE1":11590,"PHASE1":11592,"PHASE2":11594,"PHASE3":11600,"PHASE4":11602,"NA":11604},{"trials":11591,"activeCount":99},[],{"trials":11593,"activeCount":99},[],{"trials":11595,"activeCount":99},[11596],{"nctId":494,"briefTitle":495,"status":105,"phases":11597,"primaryCompletion":375,"completion":375,"start":497,"enrollment":498,"conditions":11598,"interventions":11599},[89],[500],[147,502,41],{"trials":11601,"activeCount":99},[],{"trials":11603,"activeCount":99},[],{"trials":11605,"activeCount":99},[],{"intervention":11607,"totalTrials":286,"cells":11608},"PCI-32765",{"EARLY_PHASE1":11609,"PHASE1":11611,"PHASE2":11613,"PHASE3":11623,"PHASE4":11625,"NA":11627},{"trials":11610,"activeCount":99},[],{"trials":11612,"activeCount":99},[],{"trials":11614,"activeCount":99},[11615],{"nctId":11616,"briefTitle":11617,"status":118,"phases":11618,"primaryCompletion":11619,"completion":11620,"start":8643,"enrollment":2721,"conditions":11621,"interventions":11622},"NCT01614821","Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia",[89],"2016-09-09","2018-09-15",[34],[11607],{"trials":11624,"activeCount":99},[],{"trials":11626,"activeCount":99},[],{"trials":11628,"activeCount":99},[],{"intervention":3223,"totalTrials":286,"cells":11630},{"EARLY_PHASE1":11631,"PHASE1":11633,"PHASE2":11635,"PHASE3":11641,"PHASE4":11643,"NA":11645},{"trials":11632,"activeCount":99},[],{"trials":11634,"activeCount":99},[],{"trials":11636,"activeCount":99},[11637],{"nctId":3216,"briefTitle":3217,"status":118,"phases":11638,"primaryCompletion":3219,"completion":3219,"start":3220,"enrollment":403,"conditions":11639,"interventions":11640},[89],[474],[3223,3224,3225],{"trials":11642,"activeCount":99},[],{"trials":11644,"activeCount":99},[],{"trials":11646,"activeCount":99},[],{"intervention":3224,"totalTrials":286,"cells":11648},{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11653,"PHASE3":11659,"PHASE4":11661,"NA":11663},{"trials":11650,"activeCount":99},[],{"trials":11652,"activeCount":99},[],{"trials":11654,"activeCount":99},[11655],{"nctId":3216,"briefTitle":3217,"status":118,"phases":11656,"primaryCompletion":3219,"completion":3219,"start":3220,"enrollment":403,"conditions":11657,"interventions":11658},[89],[474],[3223,3224,3225],{"trials":11660,"activeCount":99},[],{"trials":11662,"activeCount":99},[],{"trials":11664,"activeCount":99},[],{"intervention":11666,"totalTrials":286,"cells":11667},"3'-Deoxy-3'-18f-Fluorothymidine",{"EARLY_PHASE1":11668,"PHASE1":11670,"PHASE2":11672,"PHASE3":11682,"PHASE4":11684,"NA":11686},{"trials":11669,"activeCount":99},[],{"trials":11671,"activeCount":99},[],{"trials":11673,"activeCount":99},[11674],{"nctId":11675,"briefTitle":11676,"status":118,"phases":11677,"primaryCompletion":10308,"completion":1164,"start":1325,"enrollment":11678,"conditions":11679,"interventions":11681},"NCT01399658","Image-Guided Gynecologic Brachytherapy",[89],93,[4280,5360,5529,11680],"Carcinoma of the Vulva",[11666],{"trials":11683,"activeCount":99},[],{"trials":11685,"activeCount":99},[],{"trials":11687,"activeCount":99},[],{"intervention":11689,"totalTrials":286,"cells":11690},"Topical Tazarotene",{"EARLY_PHASE1":11691,"PHASE1":11693,"PHASE2":11695,"PHASE3":11707,"PHASE4":11709,"NA":11711},{"trials":11692,"activeCount":99},[],{"trials":11694,"activeCount":99},[],{"trials":11696,"activeCount":99},[11697],{"nctId":11698,"briefTitle":11699,"status":105,"phases":11700,"primaryCompletion":11701,"completion":11702,"start":11703,"enrollment":1093,"conditions":11704,"interventions":11706},"NCT04071756","Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions",[89],"2021-06-12","2022-07-14","2019-12-30",[347,11705],"Hand-Foot Skin Reaction (HFSR)",[11689],{"trials":11708,"activeCount":99},[],{"trials":11710,"activeCount":99},[],{"trials":11712,"activeCount":99},[],{"intervention":11714,"totalTrials":286,"cells":11715},"rosiglitazone maleate",{"EARLY_PHASE1":11716,"PHASE1":11718,"PHASE2":11720,"PHASE3":11728,"PHASE4":11730,"NA":11732},{"trials":11717,"activeCount":99},[],{"trials":11719,"activeCount":99},[],{"trials":11721,"activeCount":99},[11722],{"nctId":11723,"briefTitle":11724,"status":118,"phases":11725,"primaryCompletion":11051,"completion":4358,"start":3683,"enrollment":22,"conditions":11726,"interventions":11727},"NCT00004180","Rosiglitazone in Treating Patients With Liposarcoma",[89],[851],[11714],{"trials":11729,"activeCount":99},[],{"trials":11731,"activeCount":99},[],{"trials":11733,"activeCount":99},[],{"intervention":11735,"totalTrials":286,"cells":11736},"BVD-523",{"EARLY_PHASE1":11737,"PHASE1":11739,"PHASE2":11741,"PHASE3":11752,"PHASE4":11754,"NA":11756},{"trials":11738,"activeCount":99},[],{"trials":11740,"activeCount":99},[],{"trials":11742,"activeCount":99},[11743],{"nctId":11744,"briefTitle":11745,"status":105,"phases":11746,"primaryCompletion":11747,"completion":11748,"start":11749,"enrollment":2406,"conditions":11750,"interventions":11751},"NCT03417739","A Phase II Study of BVD-523 in Metastatic Uveal Melanoma",[89],"2020-05-05","2025-07-16","2018-03-26",[3834],[11735],{"trials":11753,"activeCount":99},[],{"trials":11755,"activeCount":99},[],{"trials":11757,"activeCount":99},[],{"intervention":5033,"totalTrials":286,"cells":11759},{"EARLY_PHASE1":11760,"PHASE1":11762,"PHASE2":11764,"PHASE3":11770,"PHASE4":11772,"NA":11774},{"trials":11761,"activeCount":99},[],{"trials":11763,"activeCount":99},[],{"trials":11765,"activeCount":99},[11766],{"nctId":5027,"briefTitle":5028,"status":118,"phases":11767,"primaryCompletion":5030,"completion":5030,"start":4716,"enrollment":672,"conditions":11768,"interventions":11769},[89],[15],[3710,5033],{"trials":11771,"activeCount":99},[],{"trials":11773,"activeCount":99},[],{"trials":11775,"activeCount":99},[],{"intervention":2470,"totalTrials":286,"cells":11777},{"EARLY_PHASE1":11778,"PHASE1":11780,"PHASE2":11782,"PHASE3":11788,"PHASE4":11790,"NA":11792},{"trials":11779,"activeCount":99},[],{"trials":11781,"activeCount":99},[],{"trials":11783,"activeCount":99},[11784],{"nctId":2461,"briefTitle":2462,"status":1057,"phases":11785,"primaryCompletion":2464,"completion":2464,"start":2465,"enrollment":99,"conditions":11786,"interventions":11787},[89],[2467,2468],[80,2470,2327],{"trials":11789,"activeCount":99},[],{"trials":11791,"activeCount":99},[],{"trials":11793,"activeCount":99},[],{"intervention":2895,"totalTrials":286,"cells":11795},{"EARLY_PHASE1":11796,"PHASE1":11798,"PHASE2":11800,"PHASE3":11806,"PHASE4":11808,"NA":11810},{"trials":11797,"activeCount":99},[],{"trials":11799,"activeCount":99},[],{"trials":11801,"activeCount":99},[11802],{"nctId":2887,"briefTitle":2888,"status":118,"phases":11803,"primaryCompletion":2890,"completion":2891,"start":1789,"enrollment":2892,"conditions":11804,"interventions":11805},[89],[15],[798,706,2895],{"trials":11807,"activeCount":99},[],{"trials":11809,"activeCount":99},[],{"trials":11811,"activeCount":99},[],{"intervention":11813,"totalTrials":286,"cells":11814},"Alefacept",{"EARLY_PHASE1":11815,"PHASE1":11817,"PHASE2":11819,"PHASE3":11827,"PHASE4":11829,"NA":11831},{"trials":11816,"activeCount":99},[],{"trials":11818,"activeCount":99},[],{"trials":11820,"activeCount":99},[11821],{"nctId":11822,"briefTitle":11823,"status":105,"phases":11824,"primaryCompletion":414,"completion":414,"start":2873,"enrollment":720,"conditions":11825,"interventions":11826},"NCT01226420","Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease",[89],[3230],[11813],{"trials":11828,"activeCount":99},[],{"trials":11830,"activeCount":99},[],{"trials":11832,"activeCount":99},[],{"intervention":11834,"totalTrials":286,"cells":11835},"Premarin",{"EARLY_PHASE1":11836,"PHASE1":11838,"PHASE2":11840,"PHASE3":11848,"PHASE4":11850,"NA":11852},{"trials":11837,"activeCount":99},[],{"trials":11839,"activeCount":99},[],{"trials":11841,"activeCount":99},[11842],{"nctId":11843,"briefTitle":11844,"status":118,"phases":11845,"primaryCompletion":812,"completion":811,"start":8474,"enrollment":2288,"conditions":11846,"interventions":11847},"NCT00134654","Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer",[89],[18],[11834],{"trials":11849,"activeCount":99},[],{"trials":11851,"activeCount":99},[],{"trials":11853,"activeCount":99},[],{"intervention":4843,"totalTrials":286,"cells":11855},{"EARLY_PHASE1":11856,"PHASE1":11858,"PHASE2":11860,"PHASE3":11866,"PHASE4":11868,"NA":11870},{"trials":11857,"activeCount":99},[],{"trials":11859,"activeCount":99},[],{"trials":11861,"activeCount":99},[11862],{"nctId":4837,"briefTitle":4838,"status":118,"phases":11863,"primaryCompletion":344,"completion":4029,"start":4840,"enrollment":2721,"conditions":11864,"interventions":11865},[88,89],[24],[4843,41],{"trials":11867,"activeCount":99},[],{"trials":11869,"activeCount":99},[],{"trials":11871,"activeCount":99},[],{"intervention":2714,"totalTrials":286,"cells":11873},{"EARLY_PHASE1":11874,"PHASE1":11876,"PHASE2":11878,"PHASE3":11884,"PHASE4":11886,"NA":11888},{"trials":11875,"activeCount":99},[],{"trials":11877,"activeCount":99},[],{"trials":11879,"activeCount":99},[11880],{"nctId":2707,"briefTitle":2708,"status":105,"phases":11881,"primaryCompletion":2636,"completion":2710,"start":2711,"enrollment":9,"conditions":11882,"interventions":11883},[89],[34],[2714,51],{"trials":11885,"activeCount":99},[],{"trials":11887,"activeCount":99},[],{"trials":11889,"activeCount":99},[],{"intervention":215,"totalTrials":286,"cells":11891},{"EARLY_PHASE1":11892,"PHASE1":11894,"PHASE2":11896,"PHASE3":11902,"PHASE4":11904,"NA":11906},{"trials":11893,"activeCount":99},[],{"trials":11895,"activeCount":99},[],{"trials":11897,"activeCount":99},[11898],{"nctId":205,"briefTitle":206,"status":207,"phases":11899,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":11900,"interventions":11901},[89],[18],[215,216,114,95,190],{"trials":11903,"activeCount":99},[],{"trials":11905,"activeCount":99},[],{"trials":11907,"activeCount":99},[],{"intervention":11909,"totalTrials":286,"cells":11910},"Sildenafil citrate",{"EARLY_PHASE1":11911,"PHASE1":11913,"PHASE2":11915,"PHASE3":11923,"PHASE4":11925,"NA":11927},{"trials":11912,"activeCount":99},[],{"trials":11914,"activeCount":99},[],{"trials":11916,"activeCount":99},[11917],{"nctId":11918,"briefTitle":11919,"status":118,"phases":11920,"primaryCompletion":2956,"completion":2956,"start":3422,"enrollment":403,"conditions":11921,"interventions":11922},"NCT00165295","Sildenafil Citrate in Waldenstrom's Macroglobulinemia",[89],[34],[11909],{"trials":11924,"activeCount":99},[],{"trials":11926,"activeCount":99},[],{"trials":11928,"activeCount":99},[],{"intervention":3407,"totalTrials":286,"cells":11930},{"EARLY_PHASE1":11931,"PHASE1":11933,"PHASE2":11935,"PHASE3":11941,"PHASE4":11943,"NA":11945},{"trials":11932,"activeCount":99},[],{"trials":11934,"activeCount":99},[],{"trials":11936,"activeCount":99},[11937],{"nctId":3399,"briefTitle":3400,"status":105,"phases":11938,"primaryCompletion":3402,"completion":3403,"start":3228,"enrollment":2800,"conditions":11939,"interventions":11940},[89],[1918,3405],[1680,734,3407,3408,2881],{"trials":11942,"activeCount":99},[],{"trials":11944,"activeCount":99},[],{"trials":11946,"activeCount":99},[],{"intervention":3677,"totalTrials":286,"cells":11948},{"EARLY_PHASE1":11949,"PHASE1":11951,"PHASE2":11953,"PHASE3":11959,"PHASE4":11961,"NA":11963},{"trials":11950,"activeCount":99},[],{"trials":11952,"activeCount":99},[],{"trials":11954,"activeCount":99},[11955],{"nctId":3669,"briefTitle":3670,"status":105,"phases":11956,"primaryCompletion":3672,"completion":3673,"start":3674,"enrollment":3493,"conditions":11957,"interventions":11958},[89],[15],[798,3677],{"trials":11960,"activeCount":99},[],{"trials":11962,"activeCount":99},[],{"trials":11964,"activeCount":99},[],{"intervention":11966,"totalTrials":286,"cells":11967},"Regadenoson",{"EARLY_PHASE1":11968,"PHASE1":11970,"PHASE2":11972,"PHASE3":11981,"PHASE4":11983,"NA":11985},{"trials":11969,"activeCount":99},[],{"trials":11971,"activeCount":99},[],{"trials":11973,"activeCount":99},[11974],{"nctId":11975,"briefTitle":11976,"status":118,"phases":11977,"primaryCompletion":2489,"completion":11978,"start":274,"enrollment":166,"conditions":11979,"interventions":11980},"NCT01788631","A Phase II Trial of Regadenoson in Sickle Cell Anemia",[89],"2016-12-12",[10097],[11966],{"trials":11982,"activeCount":99},[],{"trials":11984,"activeCount":99},[],{"trials":11986,"activeCount":99},[],{"intervention":11988,"totalTrials":286,"cells":11989},"Alectinib",{"EARLY_PHASE1":11990,"PHASE1":11992,"PHASE2":11994,"PHASE3":12008,"PHASE4":12010,"NA":12012},{"trials":11991,"activeCount":99},[],{"trials":11993,"activeCount":99},[],{"trials":11995,"activeCount":99},[11996],{"nctId":11997,"briefTitle":11998,"status":105,"phases":11999,"primaryCompletion":12000,"completion":12001,"start":12002,"enrollment":275,"conditions":12003,"interventions":12007},"NCT03131206","A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer",[88,89],"2018-11-08","2019-04-08","2017-06-19",[12004,12005,12006],"ALK-positive Non-small Cell Lung Cancer (NSCLC)","RET-positive Non-small Cell Lung Cancer (NSCLC)","RET-positive Thyroid Cancer",[11988],{"trials":12009,"activeCount":99},[],{"trials":12011,"activeCount":99},[],{"trials":12013,"activeCount":99},[],{"intervention":4221,"totalTrials":286,"cells":12015},{"EARLY_PHASE1":12016,"PHASE1":12018,"PHASE2":12020,"PHASE3":12026,"PHASE4":12028,"NA":12030},{"trials":12017,"activeCount":99},[],{"trials":12019,"activeCount":99},[],{"trials":12021,"activeCount":99},[12022],{"nctId":4214,"briefTitle":4215,"status":118,"phases":12023,"primaryCompletion":2757,"completion":2757,"start":4217,"enrollment":403,"conditions":12024,"interventions":12025},[89],[4123,4219],[4103,866,4022,308,867,4221],{"trials":12027,"activeCount":99},[],{"trials":12029,"activeCount":99},[],{"trials":12031,"activeCount":99},[],{"intervention":12033,"totalTrials":286,"cells":12034},"Epstein-Barr Virus Specific Immunotherapy",{"EARLY_PHASE1":12035,"PHASE1":12037,"PHASE2":12039,"PHASE3":12048,"PHASE4":12050,"NA":12052},{"trials":12036,"activeCount":99},[],{"trials":12038,"activeCount":99},[],{"trials":12040,"activeCount":99},[12041],{"nctId":12042,"briefTitle":12043,"status":118,"phases":12044,"primaryCompletion":1557,"completion":3365,"start":4099,"enrollment":715,"conditions":12045,"interventions":12047},"NCT00834093","A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma",[89],[12046],"Nasopharyngeal Carcinoma",[12033],{"trials":12049,"activeCount":99},[],{"trials":12051,"activeCount":99},[],{"trials":12053,"activeCount":99},[],{"intervention":6687,"totalTrials":286,"cells":12055},{"EARLY_PHASE1":12056,"PHASE1":12058,"PHASE2":12060,"PHASE3":12066,"PHASE4":12068,"NA":12070},{"trials":12057,"activeCount":99},[],{"trials":12059,"activeCount":99},[],{"trials":12061,"activeCount":99},[12062],{"nctId":6681,"briefTitle":6682,"status":105,"phases":12063,"primaryCompletion":1997,"completion":1997,"start":2042,"enrollment":498,"conditions":12064,"interventions":12065},[89],[611,6685],[6687,762],{"trials":12067,"activeCount":99},[],{"trials":12069,"activeCount":99},[],{"trials":12071,"activeCount":99},[],{"intervention":12073,"totalTrials":286,"cells":12074},"Nilotinib",{"EARLY_PHASE1":12075,"PHASE1":12077,"PHASE2":12079,"PHASE3":12089,"PHASE4":12091,"NA":12093},{"trials":12076,"activeCount":99},[],{"trials":12078,"activeCount":99},[],{"trials":12080,"activeCount":99},[12081],{"nctId":12082,"briefTitle":12083,"status":118,"phases":12084,"primaryCompletion":3421,"completion":3518,"start":12085,"enrollment":784,"conditions":12086,"interventions":12088},"NCT00788775","Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma",[89],"2009-01-23",[9130,12087,1883],"Acral Melanoma",[12073],{"trials":12090,"activeCount":99},[],{"trials":12092,"activeCount":99},[],{"trials":12094,"activeCount":99},[],{"intervention":893,"totalTrials":286,"cells":12096},{"EARLY_PHASE1":12097,"PHASE1":12099,"PHASE2":12101,"PHASE3":12107,"PHASE4":12109,"NA":12111},{"trials":12098,"activeCount":99},[],{"trials":12100,"activeCount":99},[],{"trials":12102,"activeCount":99},[12103],{"nctId":881,"briefTitle":882,"status":118,"phases":12104,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":12105,"interventions":12106},[88,89],[889,890,891],[893,269],{"trials":12108,"activeCount":99},[],{"trials":12110,"activeCount":99},[],{"trials":12112,"activeCount":99},[],{"intervention":12114,"totalTrials":286,"cells":12115},"Ramucirumab",{"EARLY_PHASE1":12116,"PHASE1":12118,"PHASE2":12120,"PHASE3":12131,"PHASE4":12133,"NA":12135},{"trials":12117,"activeCount":99},[],{"trials":12119,"activeCount":99},[],{"trials":12121,"activeCount":99},[12122],{"nctId":12123,"briefTitle":12124,"status":118,"phases":12125,"primaryCompletion":898,"completion":3627,"start":12126,"enrollment":6804,"conditions":12127,"interventions":12129},"NCT02795858","A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",[89],"2016-06-14",[12128],"Carcinoid Tumors",[12114,12130],"Somatostatin Analog",{"trials":12132,"activeCount":99},[],{"trials":12134,"activeCount":99},[],{"trials":12136,"activeCount":99},[],{"intervention":12130,"totalTrials":286,"cells":12138},{"EARLY_PHASE1":12139,"PHASE1":12141,"PHASE2":12143,"PHASE3":12149,"PHASE4":12151,"NA":12153},{"trials":12140,"activeCount":99},[],{"trials":12142,"activeCount":99},[],{"trials":12144,"activeCount":99},[12145],{"nctId":12123,"briefTitle":12124,"status":118,"phases":12146,"primaryCompletion":898,"completion":3627,"start":12126,"enrollment":6804,"conditions":12147,"interventions":12148},[89],[12128],[12114,12130],{"trials":12150,"activeCount":99},[],{"trials":12152,"activeCount":99},[],{"trials":12154,"activeCount":99},[],{"intervention":2104,"totalTrials":286,"cells":12156},{"EARLY_PHASE1":12157,"PHASE1":12159,"PHASE2":12161,"PHASE3":12167,"PHASE4":12169,"NA":12171},{"trials":12158,"activeCount":99},[],{"trials":12160,"activeCount":99},[],{"trials":12162,"activeCount":99},[12163],{"nctId":2096,"briefTitle":2097,"status":118,"phases":12164,"primaryCompletion":2099,"completion":2100,"start":2101,"enrollment":1107,"conditions":12165,"interventions":12166},[89],[21,827,826],[626,2104],{"trials":12168,"activeCount":99},[],{"trials":12170,"activeCount":99},[],{"trials":12172,"activeCount":99},[],{"intervention":8693,"totalTrials":286,"cells":12174},{"EARLY_PHASE1":12175,"PHASE1":12177,"PHASE2":12179,"PHASE3":12185,"PHASE4":12187,"NA":12189},{"trials":12176,"activeCount":99},[],{"trials":12178,"activeCount":99},[],{"trials":12180,"activeCount":99},[12181],{"nctId":8687,"briefTitle":8688,"status":118,"phases":12182,"completion":4036,"start":8690,"enrollment":141,"conditions":12183,"interventions":12184},[89],[1487],[8693,753],{"trials":12186,"activeCount":99},[],{"trials":12188,"activeCount":99},[],{"trials":12190,"activeCount":99},[],{"intervention":12192,"totalTrials":286,"cells":12193},"Gemcitabine, Erlotinib, OSI-906",{"EARLY_PHASE1":12194,"PHASE1":12196,"PHASE2":12198,"PHASE3":12208,"PHASE4":12210,"NA":12212},{"trials":12195,"activeCount":99},[],{"trials":12197,"activeCount":99},[],{"trials":12199,"activeCount":99},[12200],{"nctId":12201,"briefTitle":12202,"status":1057,"phases":12203,"enrollment":99,"conditions":12204,"interventions":12206},"NCT01600807","OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas",[88,89],[12205],"Pancreatic Cancer, Metastatic",[12192,12207],"Gemcitabine, Erlotinib",{"trials":12209,"activeCount":99},[],{"trials":12211,"activeCount":99},[],{"trials":12213,"activeCount":99},[],{"intervention":12207,"totalTrials":286,"cells":12215},{"EARLY_PHASE1":12216,"PHASE1":12218,"PHASE2":12220,"PHASE3":12226,"PHASE4":12228,"NA":12230},{"trials":12217,"activeCount":99},[],{"trials":12219,"activeCount":99},[],{"trials":12221,"activeCount":99},[12222],{"nctId":12201,"briefTitle":12202,"status":1057,"phases":12223,"enrollment":99,"conditions":12224,"interventions":12225},[88,89],[12205],[12192,12207],{"trials":12227,"activeCount":99},[],{"trials":12229,"activeCount":99},[],{"trials":12231,"activeCount":99},[],{"intervention":12233,"totalTrials":286,"cells":12234},"Perampanel",{"EARLY_PHASE1":12235,"PHASE1":12237,"PHASE2":12239,"PHASE3":12253,"PHASE4":12255,"NA":12257},{"trials":12236,"activeCount":99},[],{"trials":12238,"activeCount":99},[],{"trials":12240,"activeCount":99},[12241],{"nctId":12242,"briefTitle":12243,"status":118,"phases":12244,"primaryCompletion":12245,"completion":12245,"start":12246,"enrollment":141,"conditions":12247,"interventions":12251},"NCT04497142","Effect of Perampanel on Peritumoral Hyperexcitability in HGG",[88,89],"2023-05-16","2020-11-05",[12248,12249,12250],"Glioma, Malignant","Surgery","Seizures",[12233,12252],"Standard of Care",{"trials":12254,"activeCount":99},[],{"trials":12256,"activeCount":99},[],{"trials":12258,"activeCount":99},[],{"intervention":12252,"totalTrials":286,"cells":12260},{"EARLY_PHASE1":12261,"PHASE1":12263,"PHASE2":12265,"PHASE3":12271,"PHASE4":12273,"NA":12275},{"trials":12262,"activeCount":99},[],{"trials":12264,"activeCount":99},[],{"trials":12266,"activeCount":99},[12267],{"nctId":12242,"briefTitle":12243,"status":118,"phases":12268,"primaryCompletion":12245,"completion":12245,"start":12246,"enrollment":141,"conditions":12269,"interventions":12270},[88,89],[12248,12249,12250],[12233,12252],{"trials":12272,"activeCount":99},[],{"trials":12274,"activeCount":99},[],{"trials":12276,"activeCount":99},[],{"intervention":4383,"totalTrials":286,"cells":12278},{"EARLY_PHASE1":12279,"PHASE1":12281,"PHASE2":12283,"PHASE3":12289,"PHASE4":12291,"NA":12293},{"trials":12280,"activeCount":99},[],{"trials":12282,"activeCount":99},[],{"trials":12284,"activeCount":99},[12285],{"nctId":4376,"briefTitle":4377,"status":118,"phases":12286,"primaryCompletion":402,"completion":4379,"start":2957,"enrollment":4380,"conditions":12287,"interventions":12288},[89],[18],[158,762,4383,216],{"trials":12290,"activeCount":99},[],{"trials":12292,"activeCount":99},[],{"trials":12294,"activeCount":99},[],{"intervention":12296,"totalTrials":286,"cells":12297},"MCS110",{"EARLY_PHASE1":12298,"PHASE1":12300,"PHASE2":12302,"PHASE3":12313,"PHASE4":12315,"NA":12317},{"trials":12299,"activeCount":99},[],{"trials":12301,"activeCount":99},[],{"trials":12303,"activeCount":99},[12304],{"nctId":12305,"briefTitle":12306,"status":118,"phases":12307,"primaryCompletion":1926,"completion":1926,"start":12308,"enrollment":720,"conditions":12309,"interventions":12310},"NCT03455764","MCS110 With BRAF\u002FMEK Inhibition in Patients With Melanoma",[88,89],"2018-09-10",[1883],[12296,12311,12312],"Dabrafenib","Trametinib",{"trials":12314,"activeCount":99},[],{"trials":12316,"activeCount":99},[],{"trials":12318,"activeCount":99},[],{"intervention":12311,"totalTrials":286,"cells":12320},{"EARLY_PHASE1":12321,"PHASE1":12323,"PHASE2":12325,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12322,"activeCount":99},[],{"trials":12324,"activeCount":99},[],{"trials":12326,"activeCount":99},[12327],{"nctId":12305,"briefTitle":12306,"status":118,"phases":12328,"primaryCompletion":1926,"completion":1926,"start":12308,"enrollment":720,"conditions":12329,"interventions":12330},[88,89],[1883],[12296,12311,12312],{"trials":12332,"activeCount":99},[],{"trials":12334,"activeCount":99},[],{"trials":12336,"activeCount":99},[],{"intervention":12312,"totalTrials":286,"cells":12338},{"EARLY_PHASE1":12339,"PHASE1":12341,"PHASE2":12343,"PHASE3":12349,"PHASE4":12351,"NA":12353},{"trials":12340,"activeCount":99},[],{"trials":12342,"activeCount":99},[],{"trials":12344,"activeCount":99},[12345],{"nctId":12305,"briefTitle":12306,"status":118,"phases":12346,"primaryCompletion":1926,"completion":1926,"start":12308,"enrollment":720,"conditions":12347,"interventions":12348},[88,89],[1883],[12296,12311,12312],{"trials":12350,"activeCount":99},[],{"trials":12352,"activeCount":99},[],{"trials":12354,"activeCount":99},[],{"intervention":12356,"totalTrials":286,"cells":12357},"Testosterone Cypionate 100 MG\u002FML",{"EARLY_PHASE1":12358,"PHASE1":12360,"PHASE2":12362,"PHASE3":12373,"PHASE4":12375,"NA":12377},{"trials":12359,"activeCount":99},[],{"trials":12361,"activeCount":99},[],{"trials":12363,"activeCount":99},[12364],{"nctId":12365,"briefTitle":12366,"status":118,"phases":12367,"primaryCompletion":12368,"completion":11748,"start":12369,"enrollment":12370,"conditions":12371,"interventions":12372},"NCT03716739","Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency",[89],"2025-05-16","2019-03-19",136,[18],[12356],{"trials":12374,"activeCount":99},[],{"trials":12376,"activeCount":99},[],{"trials":12378,"activeCount":99},[],{"intervention":8701,"totalTrials":286,"cells":12380},{"EARLY_PHASE1":12381,"PHASE1":12383,"PHASE2":12385,"PHASE3":12391,"PHASE4":12393,"NA":12395},{"trials":12382,"activeCount":99},[],{"trials":12384,"activeCount":99},[],{"trials":12386,"activeCount":99},[12387],{"nctId":8695,"briefTitle":8696,"status":118,"phases":12388,"primaryCompletion":264,"completion":264,"start":8698,"enrollment":22,"conditions":12389,"interventions":12390},[89],[8609],[788,8701],{"trials":12392,"activeCount":99},[],{"trials":12394,"activeCount":99},[],{"trials":12396,"activeCount":99},[],{"intervention":12398,"totalTrials":286,"cells":12399},"Pancrelipase",{"EARLY_PHASE1":12400,"PHASE1":12402,"PHASE2":12404,"PHASE3":12414,"PHASE4":12416,"NA":12418},{"trials":12401,"activeCount":99},[],{"trials":12403,"activeCount":99},[],{"trials":12405,"activeCount":99},[12406],{"nctId":12407,"briefTitle":12408,"status":105,"phases":12409,"primaryCompletion":12410,"completion":12410,"start":12411,"enrollment":110,"conditions":12412,"interventions":12413},"NCT03469258","Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma",[89],"2019-10-01","2018-04-13",[4444],[12398],{"trials":12415,"activeCount":99},[],{"trials":12417,"activeCount":99},[],{"trials":12419,"activeCount":99},[],{"intervention":1357,"totalTrials":286,"cells":12421},{"EARLY_PHASE1":12422,"PHASE1":12424,"PHASE2":12426,"PHASE3":12432,"PHASE4":12434,"NA":12436},{"trials":12423,"activeCount":99},[],{"trials":12425,"activeCount":99},[],{"trials":12427,"activeCount":99},[12428],{"nctId":1349,"briefTitle":1350,"status":118,"phases":12429,"primaryCompletion":425,"completion":1045,"start":199,"enrollment":1352,"conditions":12430,"interventions":12431},[89],[1354,1355],[511,130,1357,734,1358],{"trials":12433,"activeCount":99},[],{"trials":12435,"activeCount":99},[],{"trials":12437,"activeCount":99},[],{"intervention":1358,"totalTrials":286,"cells":12439},{"EARLY_PHASE1":12440,"PHASE1":12442,"PHASE2":12444,"PHASE3":12450,"PHASE4":12452,"NA":12454},{"trials":12441,"activeCount":99},[],{"trials":12443,"activeCount":99},[],{"trials":12445,"activeCount":99},[12446],{"nctId":1349,"briefTitle":1350,"status":118,"phases":12447,"primaryCompletion":425,"completion":1045,"start":199,"enrollment":1352,"conditions":12448,"interventions":12449},[89],[1354,1355],[511,130,1357,734,1358],{"trials":12451,"activeCount":99},[],{"trials":12453,"activeCount":99},[],{"trials":12455,"activeCount":99},[],{"intervention":12457,"totalTrials":286,"cells":12458},"Perifosine",{"EARLY_PHASE1":12459,"PHASE1":12461,"PHASE2":12463,"PHASE3":12471,"PHASE4":12473,"NA":12475},{"trials":12460,"activeCount":99},[],{"trials":12462,"activeCount":99},[],{"trials":12464,"activeCount":99},[12465],{"nctId":12466,"briefTitle":12467,"status":118,"phases":12468,"primaryCompletion":415,"completion":109,"start":1098,"enrollment":2043,"conditions":12469,"interventions":12470},"NCT00422656","Perifosine in Patients With Relapsed\u002FRefractory Waldenstrom's Macroglobulinemia",[89],[34],[12457],{"trials":12472,"activeCount":99},[],{"trials":12474,"activeCount":99},[],{"trials":12476,"activeCount":99},[],{"intervention":12478,"totalTrials":286,"cells":12479},"CT-2103",{"EARLY_PHASE1":12480,"PHASE1":12482,"PHASE2":12484,"PHASE3":12492,"PHASE4":12494,"NA":12496},{"trials":12481,"activeCount":99},[],{"trials":12483,"activeCount":99},[],{"trials":12485,"activeCount":99},[12486],{"nctId":12487,"briefTitle":12488,"status":118,"phases":12489,"primaryCompletion":3219,"completion":3219,"start":4337,"enrollment":225,"conditions":12490,"interventions":12491},"NCT00148707","Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer",[89],[15,663],[12478],{"trials":12493,"activeCount":99},[],{"trials":12495,"activeCount":99},[],{"trials":12497,"activeCount":99},[],{"intervention":12499,"totalTrials":286,"cells":12500},"GS-1101",{"EARLY_PHASE1":12501,"PHASE1":12503,"PHASE2":12505,"PHASE3":12513,"PHASE4":12515,"NA":12517},{"trials":12502,"activeCount":99},[],{"trials":12504,"activeCount":99},[],{"trials":12506,"activeCount":99},[12507],{"nctId":12508,"briefTitle":12509,"status":105,"phases":12510,"primaryCompletion":8796,"completion":8796,"start":3439,"enrollment":275,"conditions":12511,"interventions":12512},"NCT02439138","Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia",[89],[34],[12499],{"trials":12514,"activeCount":99},[],{"trials":12516,"activeCount":99},[],{"trials":12518,"activeCount":99},[],{"intervention":6715,"totalTrials":286,"cells":12520},{"EARLY_PHASE1":12521,"PHASE1":12523,"PHASE2":12525,"PHASE3":12531,"PHASE4":12533,"NA":12535},{"trials":12522,"activeCount":99},[],{"trials":12524,"activeCount":99},[],{"trials":12526,"activeCount":99},[12527],{"nctId":6709,"briefTitle":6710,"status":118,"phases":12528,"primaryCompletion":6712,"completion":120,"start":1558,"enrollment":2288,"conditions":12529,"interventions":12530},[88,89],[612],[6715,762],{"trials":12532,"activeCount":99},[],{"trials":12534,"activeCount":99},[],{"trials":12536,"activeCount":99},[],{"intervention":12538,"totalTrials":286,"cells":12539},"Campath-1H",{"EARLY_PHASE1":12540,"PHASE1":12542,"PHASE2":12544,"PHASE3":12552,"PHASE4":12554,"NA":12556},{"trials":12541,"activeCount":99},[],{"trials":12543,"activeCount":99},[],{"trials":12545,"activeCount":99},[12546],{"nctId":12547,"briefTitle":12548,"status":118,"phases":12549,"primaryCompletion":1072,"completion":2957,"start":8474,"enrollment":3051,"conditions":12550,"interventions":12551},"NCT00142181","Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia",[89],[4802,34],[12538],{"trials":12553,"activeCount":99},[],{"trials":12555,"activeCount":99},[],{"trials":12557,"activeCount":99},[],{"intervention":8526,"totalTrials":286,"cells":12559},{"EARLY_PHASE1":12560,"PHASE1":12562,"PHASE2":12564,"PHASE3":12570,"PHASE4":12572,"NA":12574},{"trials":12561,"activeCount":99},[],{"trials":12563,"activeCount":99},[],{"trials":12565,"activeCount":99},[12566],{"nctId":8519,"briefTitle":8520,"status":118,"phases":12567,"primaryCompletion":8522,"completion":8523,"start":4029,"enrollment":3984,"conditions":12568,"interventions":12569},[89],[15],[8526,4056,8526,8527],{"trials":12571,"activeCount":99},[],{"trials":12573,"activeCount":99},[],{"trials":12575,"activeCount":99},[],{"intervention":8527,"totalTrials":286,"cells":12577},{"EARLY_PHASE1":12578,"PHASE1":12580,"PHASE2":12582,"PHASE3":12588,"PHASE4":12590,"NA":12592},{"trials":12579,"activeCount":99},[],{"trials":12581,"activeCount":99},[],{"trials":12583,"activeCount":99},[12584],{"nctId":8519,"briefTitle":8520,"status":118,"phases":12585,"primaryCompletion":8522,"completion":8523,"start":4029,"enrollment":3984,"conditions":12586,"interventions":12587},[89],[15],[8526,4056,8526,8527],{"trials":12589,"activeCount":99},[],{"trials":12591,"activeCount":99},[],{"trials":12593,"activeCount":99},[],{"intervention":282,"totalTrials":286,"cells":12595},{"EARLY_PHASE1":12596,"PHASE1":12598,"PHASE2":12600,"PHASE3":12606,"PHASE4":12608,"NA":12610},{"trials":12597,"activeCount":99},[],{"trials":12599,"activeCount":99},[],{"trials":12601,"activeCount":99},[12602],{"nctId":271,"briefTitle":272,"status":105,"phases":12603,"primaryCompletion":45,"completion":45,"start":274,"enrollment":275,"conditions":12604,"interventions":12605},[89],[277],[269,130,128,279,95,280,281,282,283,284,285],{"trials":12607,"activeCount":99},[],{"trials":12609,"activeCount":99},[],{"trials":12611,"activeCount":99},[],{"intervention":12613,"totalTrials":286,"cells":12614},"morphine sulfate",{"EARLY_PHASE1":12615,"PHASE1":12617,"PHASE2":12619,"PHASE3":12629,"PHASE4":12631,"NA":12633},{"trials":12616,"activeCount":99},[],{"trials":12618,"activeCount":99},[],{"trials":12620,"activeCount":99},[12621],{"nctId":12622,"briefTitle":12623,"status":118,"phases":12624,"completion":6653,"start":12625,"conditions":12626,"interventions":12628},"NCT00020618","Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain",[89],"2001-03",[12627,1534],"Pain",[12613],{"trials":12630,"activeCount":99},[],{"trials":12632,"activeCount":99},[],{"trials":12634,"activeCount":99},[],{"intervention":12636,"totalTrials":286,"cells":12637},"Avastin",{"EARLY_PHASE1":12638,"PHASE1":12640,"PHASE2":12642,"PHASE3":12650,"PHASE4":12652,"NA":12654},{"trials":12639,"activeCount":99},[],{"trials":12641,"activeCount":99},[],{"trials":12643,"activeCount":99},[12644],{"nctId":12645,"briefTitle":12646,"status":118,"phases":12647,"primaryCompletion":2732,"completion":1024,"start":4840,"enrollment":28,"conditions":12648,"interventions":12649},"NCT00545792","Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers",[89],[4280,1949,21,5529,11680],[12636],{"trials":12651,"activeCount":99},[],{"trials":12653,"activeCount":99},[],{"trials":12655,"activeCount":99},[],{"intervention":12657,"totalTrials":286,"cells":12658},"Simvastatin",{"EARLY_PHASE1":12659,"PHASE1":12661,"PHASE2":12663,"PHASE3":12671,"PHASE4":12673,"NA":12675},{"trials":12660,"activeCount":99},[],{"trials":12662,"activeCount":99},[],{"trials":12664,"activeCount":99},[12665],{"nctId":12666,"briefTitle":12667,"status":105,"phases":12668,"primaryCompletion":9022,"completion":9022,"start":262,"enrollment":715,"conditions":12669,"interventions":12670},"NCT00575965","Simvastatin in Waldenstrom's Macroglobulinemia",[89],[34],[12657],{"trials":12672,"activeCount":99},[],{"trials":12674,"activeCount":99},[],{"trials":12676,"activeCount":99},[],{"intervention":4504,"totalTrials":286,"cells":12678},{"EARLY_PHASE1":12679,"PHASE1":12681,"PHASE2":12683,"PHASE3":12689,"PHASE4":12691,"NA":12693},{"trials":12680,"activeCount":99},[],{"trials":12682,"activeCount":99},[],{"trials":12684,"activeCount":99},[12685],{"nctId":4493,"briefTitle":4494,"status":118,"phases":12686,"primaryCompletion":4496,"completion":4497,"start":4498,"enrollment":3721,"conditions":12687,"interventions":12688},[88,89],[4500,4501,4502],[395,4504],{"trials":12690,"activeCount":99},[],{"trials":12692,"activeCount":99},[],{"trials":12694,"activeCount":99},[],{"intervention":2748,"totalTrials":286,"cells":12696},{"EARLY_PHASE1":12697,"PHASE1":12699,"PHASE2":12701,"PHASE3":12707,"PHASE4":12709,"NA":12711},{"trials":12698,"activeCount":99},[],{"trials":12700,"activeCount":99},[],{"trials":12702,"activeCount":99},[12703],{"nctId":2742,"briefTitle":2743,"status":118,"phases":12704,"primaryCompletion":414,"completion":414,"start":1098,"enrollment":1133,"conditions":12705,"interventions":12706},[88,89],[2746],[51,2748],{"trials":12708,"activeCount":99},[],{"trials":12710,"activeCount":99},[],{"trials":12712,"activeCount":99},[],{"intervention":12714,"totalTrials":286,"cells":12715},"Hydroxychloroquine",{"EARLY_PHASE1":12716,"PHASE1":12718,"PHASE2":12720,"PHASE3":12728,"PHASE4":12730,"NA":12732},{"trials":12717,"activeCount":99},[],{"trials":12719,"activeCount":99},[],{"trials":12721,"activeCount":99},[12722],{"nctId":12723,"briefTitle":12724,"status":118,"phases":12725,"primaryCompletion":198,"completion":2854,"start":344,"enrollment":784,"conditions":12726,"interventions":12727},"NCT01273805","Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer",[89],[4444],[12714],{"trials":12729,"activeCount":99},[],{"trials":12731,"activeCount":99},[],{"trials":12733,"activeCount":99},[],{"intervention":2761,"totalTrials":286,"cells":12735},{"EARLY_PHASE1":12736,"PHASE1":12738,"PHASE2":12740,"PHASE3":12746,"PHASE4":12748,"NA":12750},{"trials":12737,"activeCount":99},[],{"trials":12739,"activeCount":99},[],{"trials":12741,"activeCount":99},[12742],{"nctId":2754,"briefTitle":2755,"status":118,"phases":12743,"primaryCompletion":2757,"completion":425,"start":2758,"enrollment":403,"conditions":12744,"interventions":12745},[89],[1253],[679,1220,51,2761],{"trials":12747,"activeCount":99},[],{"trials":12749,"activeCount":99},[],{"trials":12751,"activeCount":99},[],{"intervention":12753,"totalTrials":1034,"cells":12754},"Autologous, Lethally Irradiated Breast Cancer Cells",{"EARLY_PHASE1":12755,"PHASE1":12757,"PHASE2":12773,"PHASE3":12775,"PHASE4":12777,"NA":12779},{"trials":12756,"activeCount":99},[],{"trials":12758,"activeCount":99},[12759,12767],{"nctId":12760,"briefTitle":12761,"status":118,"phases":12762,"primaryCompletion":1046,"completion":12763,"start":12764,"enrollment":1093,"conditions":12765,"interventions":12766},"NCT00880464","Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer",[88],"2021-06","2006-01-01",[15],[12753],{"nctId":12768,"briefTitle":12769,"status":118,"phases":12770,"primaryCompletion":263,"completion":12763,"start":12764,"enrollment":498,"conditions":12771,"interventions":12772},"NCT00317603","Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients",[88],[15],[12753],{"trials":12774,"activeCount":99},[],{"trials":12776,"activeCount":99},[],{"trials":12778,"activeCount":99},[],{"trials":12780,"activeCount":99},[],{"intervention":1219,"totalTrials":1034,"cells":12782},{"EARLY_PHASE1":12783,"PHASE1":12785,"PHASE2":12798,"PHASE3":12800,"PHASE4":12802,"NA":12804},{"trials":12784,"activeCount":99},[],{"trials":12786,"activeCount":99},[12787,12794],{"nctId":12788,"briefTitle":12789,"status":118,"phases":12790,"primaryCompletion":2676,"completion":2676,"start":5238,"enrollment":3493,"conditions":12791,"interventions":12792},"NCT03495323","A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors",[88],[32],[12793,1219],"LY3300054",{"nctId":1212,"briefTitle":1213,"status":105,"phases":12795,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1034,"conditions":12796,"interventions":12797},[88],[674,477],[1219,1220,279,772],{"trials":12799,"activeCount":99},[],{"trials":12801,"activeCount":99},[],{"trials":12803,"activeCount":99},[],{"trials":12805,"activeCount":99},[],{"intervention":1028,"totalTrials":1034,"cells":12807},{"EARLY_PHASE1":12808,"PHASE1":12810,"PHASE2":12820,"PHASE3":12822,"PHASE4":12824,"NA":12826},{"trials":12809,"activeCount":99},[],{"trials":12811,"activeCount":99},[12812,12816],{"nctId":1020,"briefTitle":1021,"status":118,"phases":12813,"primaryCompletion":1023,"completion":388,"start":1024,"enrollment":28,"conditions":12814,"interventions":12815},[88],[1026],[1028,364,1029,41],{"nctId":9814,"briefTitle":9815,"status":105,"phases":12817,"primaryCompletion":9817,"completion":9817,"start":9818,"enrollment":110,"conditions":12818,"interventions":12819},[88],[9820,9821,9822,9823,9824,9825],[1065,1028],{"trials":12821,"activeCount":99},[],{"trials":12823,"activeCount":99},[],{"trials":12825,"activeCount":99},[],{"trials":12827,"activeCount":99},[],{"intervention":8618,"totalTrials":1034,"cells":12829},{"EARLY_PHASE1":12830,"PHASE1":12832,"PHASE2":12842,"PHASE3":12844,"PHASE4":12846,"NA":12848},{"trials":12831,"activeCount":99},[],{"trials":12833,"activeCount":99},[12834,12838],{"nctId":9409,"briefTitle":9410,"status":118,"phases":12835,"primaryCompletion":5153,"completion":240,"start":376,"enrollment":403,"conditions":12836,"interventions":12837},[88],[9413],[9402,8618,2073],{"nctId":8613,"briefTitle":8614,"status":118,"phases":12839,"primaryCompletion":728,"completion":728,"start":40,"enrollment":28,"conditions":12840,"interventions":12841},[88],[8609,2501,6806],[8618,157],{"trials":12843,"activeCount":99},[],{"trials":12845,"activeCount":99},[],{"trials":12847,"activeCount":99},[],{"trials":12849,"activeCount":99},[],{"intervention":3285,"totalTrials":1034,"cells":12851},{"EARLY_PHASE1":12852,"PHASE1":12854,"PHASE2":12869,"PHASE3":12871,"PHASE4":12873,"NA":12875},{"trials":12853,"activeCount":99},[],{"trials":12855,"activeCount":99},[12856,12860],{"nctId":3278,"briefTitle":3279,"status":1057,"phases":12857,"primaryCompletion":3281,"completion":3281,"start":3281,"enrollment":99,"conditions":12858,"interventions":12859},[88],[804,2256,1253,3283],[958,3285],{"nctId":12861,"briefTitle":12862,"status":118,"phases":12863,"primaryCompletion":12864,"completion":12865,"start":12866,"enrollment":3493,"conditions":12867,"interventions":12868},"NCT04081259","LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy",[88],"2023-08-03","2023-08-26","2020-07-15",[674],[3285],{"trials":12870,"activeCount":99},[],{"trials":12872,"activeCount":99},[],{"trials":12874,"activeCount":99},[],{"trials":12876,"activeCount":99},[],{"intervention":2793,"totalTrials":286,"cells":12878},{"EARLY_PHASE1":12879,"PHASE1":12881,"PHASE2":12887,"PHASE3":12889,"PHASE4":12891,"NA":12893},{"trials":12880,"activeCount":99},[],{"trials":12882,"activeCount":99},[12883],{"nctId":2784,"briefTitle":2785,"status":105,"phases":12884,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":720,"conditions":12885,"interventions":12886},[88],[21,827,2791],[706,2793,762],{"trials":12888,"activeCount":99},[],{"trials":12890,"activeCount":99},[],{"trials":12892,"activeCount":99},[],{"trials":12894,"activeCount":99},[],{"intervention":12896,"totalTrials":286,"cells":12897},"BKM120 and Olaparib",{"EARLY_PHASE1":12898,"PHASE1":12900,"PHASE2":12909,"PHASE3":12911,"PHASE4":12913,"NA":12915},{"trials":12899,"activeCount":99},[],{"trials":12901,"activeCount":99},[12902],{"nctId":12903,"briefTitle":12904,"status":118,"phases":12905,"primaryCompletion":4764,"completion":2825,"start":9425,"enrollment":187,"conditions":12906,"interventions":12907},"NCT01623349","Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer",[88],[21,15],[12896,12908],"BYL719 and Olaparib",{"trials":12910,"activeCount":99},[],{"trials":12912,"activeCount":99},[],{"trials":12914,"activeCount":99},[],{"trials":12916,"activeCount":99},[],{"intervention":12908,"totalTrials":286,"cells":12918},{"EARLY_PHASE1":12919,"PHASE1":12921,"PHASE2":12927,"PHASE3":12929,"PHASE4":12931,"NA":12933},{"trials":12920,"activeCount":99},[],{"trials":12922,"activeCount":99},[12923],{"nctId":12903,"briefTitle":12904,"status":118,"phases":12924,"primaryCompletion":4764,"completion":2825,"start":9425,"enrollment":187,"conditions":12925,"interventions":12926},[88],[21,15],[12896,12908],{"trials":12928,"activeCount":99},[],{"trials":12930,"activeCount":99},[],{"trials":12932,"activeCount":99},[],{"trials":12934,"activeCount":99},[],{"intervention":12936,"totalTrials":286,"cells":12937},"rhEndostatin",{"EARLY_PHASE1":12938,"PHASE1":12940,"PHASE2":12948,"PHASE3":12950,"PHASE4":12952,"NA":12954},{"trials":12939,"activeCount":99},[],{"trials":12941,"activeCount":99},[12942],{"nctId":12943,"briefTitle":12944,"status":105,"phases":12945,"primaryCompletion":847,"completion":847,"start":4098,"enrollment":28,"conditions":12946,"interventions":12947},"NCT00165373","rhEndostatin Protein Involving Pediatric Patients With Cancer",[88],[4432],[12936],{"trials":12949,"activeCount":99},[],{"trials":12951,"activeCount":99},[],{"trials":12953,"activeCount":99},[],{"trials":12955,"activeCount":99},[],{"intervention":4769,"totalTrials":286,"cells":12957},{"EARLY_PHASE1":12958,"PHASE1":12960,"PHASE2":12966,"PHASE3":12968,"PHASE4":12970,"NA":12972},{"trials":12959,"activeCount":99},[],{"trials":12961,"activeCount":99},[12962],{"nctId":4761,"briefTitle":4762,"status":1057,"phases":12963,"primaryCompletion":4764,"completion":4765,"enrollment":99,"conditions":12964,"interventions":12965},[88],[24,1026,4767],[4769,41],{"trials":12967,"activeCount":99},[],{"trials":12969,"activeCount":99},[],{"trials":12971,"activeCount":99},[],{"trials":12973,"activeCount":99},[],{"intervention":12975,"totalTrials":286,"cells":12976},"Bevacizumab Plus Ipilimumab Cohort 1",{"EARLY_PHASE1":12977,"PHASE1":12979,"PHASE2":12992,"PHASE3":12994,"PHASE4":12996,"NA":12998},{"trials":12978,"activeCount":99},[],{"trials":12980,"activeCount":99},[12981],{"nctId":12982,"briefTitle":12983,"status":118,"phases":12984,"primaryCompletion":12985,"completion":12985,"start":12986,"enrollment":428,"conditions":12987,"interventions":12988},"NCT00790010","Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma",[88],"2018-06-22","2009-02-26",[1883],[12975,12989,12990,12991],"Bevacizumab Plus Ipilimumab Cohort 2","Bevacizumab Plus Ipilimumab Cohort 3","Bevacizumab Plus Ipilimumab Cohort 4",{"trials":12993,"activeCount":99},[],{"trials":12995,"activeCount":99},[],{"trials":12997,"activeCount":99},[],{"trials":12999,"activeCount":99},[],{"intervention":12989,"totalTrials":286,"cells":13001},{"EARLY_PHASE1":13002,"PHASE1":13004,"PHASE2":13010,"PHASE3":13012,"PHASE4":13014,"NA":13016},{"trials":13003,"activeCount":99},[],{"trials":13005,"activeCount":99},[13006],{"nctId":12982,"briefTitle":12983,"status":118,"phases":13007,"primaryCompletion":12985,"completion":12985,"start":12986,"enrollment":428,"conditions":13008,"interventions":13009},[88],[1883],[12975,12989,12990,12991],{"trials":13011,"activeCount":99},[],{"trials":13013,"activeCount":99},[],{"trials":13015,"activeCount":99},[],{"trials":13017,"activeCount":99},[],{"intervention":12990,"totalTrials":286,"cells":13019},{"EARLY_PHASE1":13020,"PHASE1":13022,"PHASE2":13028,"PHASE3":13030,"PHASE4":13032,"NA":13034},{"trials":13021,"activeCount":99},[],{"trials":13023,"activeCount":99},[13024],{"nctId":12982,"briefTitle":12983,"status":118,"phases":13025,"primaryCompletion":12985,"completion":12985,"start":12986,"enrollment":428,"conditions":13026,"interventions":13027},[88],[1883],[12975,12989,12990,12991],{"trials":13029,"activeCount":99},[],{"trials":13031,"activeCount":99},[],{"trials":13033,"activeCount":99},[],{"trials":13035,"activeCount":99},[],{"intervention":12991,"totalTrials":286,"cells":13037},{"EARLY_PHASE1":13038,"PHASE1":13040,"PHASE2":13046,"PHASE3":13048,"PHASE4":13050,"NA":13052},{"trials":13039,"activeCount":99},[],{"trials":13041,"activeCount":99},[13042],{"nctId":12982,"briefTitle":12983,"status":118,"phases":13043,"primaryCompletion":12985,"completion":12985,"start":12986,"enrollment":428,"conditions":13044,"interventions":13045},[88],[1883],[12975,12989,12990,12991],{"trials":13047,"activeCount":99},[],{"trials":13049,"activeCount":99},[],{"trials":13051,"activeCount":99},[],{"trials":13053,"activeCount":99},[],{"intervention":13055,"totalTrials":286,"cells":13056},"GM-K562 vaccine",{"EARLY_PHASE1":13057,"PHASE1":13059,"PHASE2":13068,"PHASE3":13070,"PHASE4":13072,"NA":13074},{"trials":13058,"activeCount":99},[],{"trials":13060,"activeCount":99},[13061],{"nctId":13062,"briefTitle":13063,"status":118,"phases":13064,"primaryCompletion":2854,"completion":13065,"start":8734,"enrollment":3051,"conditions":13066,"interventions":13067},"NCT00442130","Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination",[88],"2020-04",[804],[13055],{"trials":13069,"activeCount":99},[],{"trials":13071,"activeCount":99},[],{"trials":13073,"activeCount":99},[],{"trials":13075,"activeCount":99},[],{"intervention":5241,"totalTrials":286,"cells":13077},{"EARLY_PHASE1":13078,"PHASE1":13080,"PHASE2":13086,"PHASE3":13088,"PHASE4":13090,"NA":13092},{"trials":13079,"activeCount":99},[],{"trials":13081,"activeCount":99},[13082],{"nctId":5234,"briefTitle":5235,"status":118,"phases":13083,"primaryCompletion":5237,"completion":5238,"start":4401,"enrollment":35,"conditions":13084,"interventions":13085},[88],[27,477],[5241,5242,5227,591,5243],{"trials":13087,"activeCount":99},[],{"trials":13089,"activeCount":99},[],{"trials":13091,"activeCount":99},[],{"trials":13093,"activeCount":99},[],{"intervention":5242,"totalTrials":286,"cells":13095},{"EARLY_PHASE1":13096,"PHASE1":13098,"PHASE2":13104,"PHASE3":13106,"PHASE4":13108,"NA":13110},{"trials":13097,"activeCount":99},[],{"trials":13099,"activeCount":99},[13100],{"nctId":5234,"briefTitle":5235,"status":118,"phases":13101,"primaryCompletion":5237,"completion":5238,"start":4401,"enrollment":35,"conditions":13102,"interventions":13103},[88],[27,477],[5241,5242,5227,591,5243],{"trials":13105,"activeCount":99},[],{"trials":13107,"activeCount":99},[],{"trials":13109,"activeCount":99},[],{"trials":13111,"activeCount":99},[],{"intervention":12793,"totalTrials":286,"cells":13113},{"EARLY_PHASE1":13114,"PHASE1":13116,"PHASE2":13122,"PHASE3":13124,"PHASE4":13126,"NA":13128},{"trials":13115,"activeCount":99},[],{"trials":13117,"activeCount":99},[13118],{"nctId":12788,"briefTitle":12789,"status":118,"phases":13119,"primaryCompletion":2676,"completion":2676,"start":5238,"enrollment":3493,"conditions":13120,"interventions":13121},[88],[32],[12793,1219],{"trials":13123,"activeCount":99},[],{"trials":13125,"activeCount":99},[],{"trials":13127,"activeCount":99},[],{"trials":13129,"activeCount":99},[],{"intervention":1856,"totalTrials":286,"cells":13131},{"EARLY_PHASE1":13132,"PHASE1":13134,"PHASE2":13140,"PHASE3":13142,"PHASE4":13144,"NA":13146},{"trials":13133,"activeCount":99},[],{"trials":13135,"activeCount":99},[13136],{"nctId":1848,"briefTitle":1849,"status":118,"phases":13137,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":599,"conditions":13138,"interventions":13139},[88],[1854],[626,1856],{"trials":13141,"activeCount":99},[],{"trials":13143,"activeCount":99},[],{"trials":13145,"activeCount":99},[],{"trials":13147,"activeCount":99},[],{"intervention":13149,"totalTrials":286,"cells":13150},"Implantable Microdevice",{"EARLY_PHASE1":13151,"PHASE1":13153,"PHASE2":13167,"PHASE3":13169,"PHASE4":13171,"NA":13173},{"trials":13152,"activeCount":99},[],{"trials":13154,"activeCount":99},[13155],{"nctId":13156,"briefTitle":13157,"status":1057,"phases":13158,"primaryCompletion":13159,"completion":3937,"start":10307,"enrollment":99,"conditions":13160,"interventions":13166},"NCT05774886","Implantable Microdevice for TNBC - Pilot Study",[88],"2023-09-01",[2114,13161,13162,15,13163,13164,13165],"Breast Cancer Stage II","Breast Cancer Stage III","Early Stage Triple-Negative Breast Carcinoma","Breast Neoplasms","Breast Carcinoma",[13149],{"trials":13168,"activeCount":99},[],{"trials":13170,"activeCount":99},[],{"trials":13172,"activeCount":99},[],{"trials":13174,"activeCount":99},[],{"intervention":4777,"totalTrials":286,"cells":13176},{"EARLY_PHASE1":13177,"PHASE1":13179,"PHASE2":13185,"PHASE3":13187,"PHASE4":13189,"NA":13191},{"trials":13178,"activeCount":99},[],{"trials":13180,"activeCount":99},[13181],{"nctId":4771,"briefTitle":4772,"status":118,"phases":13182,"primaryCompletion":525,"completion":525,"start":3450,"enrollment":1166,"conditions":13183,"interventions":13184},[88],[4767,4775,24],[41,4777],{"trials":13186,"activeCount":99},[],{"trials":13188,"activeCount":99},[],{"trials":13190,"activeCount":99},[],{"trials":13192,"activeCount":99},[],{"intervention":3632,"totalTrials":286,"cells":13194},{"EARLY_PHASE1":13195,"PHASE1":13197,"PHASE2":13203,"PHASE3":13205,"PHASE4":13207,"NA":13209},{"trials":13196,"activeCount":99},[],{"trials":13198,"activeCount":99},[13199],{"nctId":3623,"briefTitle":3624,"status":118,"phases":13200,"primaryCompletion":3626,"completion":3627,"start":795,"enrollment":390,"conditions":13201,"interventions":13202},[88],[3629,3630],[3632,3633,798],{"trials":13204,"activeCount":99},[],{"trials":13206,"activeCount":99},[],{"trials":13208,"activeCount":99},[],{"trials":13210,"activeCount":99},[],{"intervention":3633,"totalTrials":286,"cells":13212},{"EARLY_PHASE1":13213,"PHASE1":13215,"PHASE2":13221,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13214,"activeCount":99},[],{"trials":13216,"activeCount":99},[13217],{"nctId":3623,"briefTitle":3624,"status":118,"phases":13218,"primaryCompletion":3626,"completion":3627,"start":795,"enrollment":390,"conditions":13219,"interventions":13220},[88],[3629,3630],[3632,3633,798],{"trials":13222,"activeCount":99},[],{"trials":13224,"activeCount":99},[],{"trials":13226,"activeCount":99},[],{"trials":13228,"activeCount":99},[],{"intervention":13230,"totalTrials":286,"cells":13231},"Vitamin D",{"EARLY_PHASE1":13232,"PHASE1":13234,"PHASE2":13245,"PHASE3":13247,"PHASE4":13249,"NA":13251},{"trials":13233,"activeCount":99},[],{"trials":13235,"activeCount":99},[13236],{"nctId":13237,"briefTitle":13238,"status":118,"phases":13239,"primaryCompletion":2873,"completion":425,"start":497,"enrollment":13240,"conditions":13241,"interventions":13244},"NCT00585637","Vitamin D for Chemoprevention",[88],328,[13242,18,13243],"Gastrointestinal Cancers","Hypertension",[13230],{"trials":13246,"activeCount":99},[],{"trials":13248,"activeCount":99},[],{"trials":13250,"activeCount":99},[],{"trials":13252,"activeCount":99},[],{"intervention":5003,"totalTrials":286,"cells":13254},{"EARLY_PHASE1":13255,"PHASE1":13257,"PHASE2":13263,"PHASE3":13265,"PHASE4":13267,"NA":13269},{"trials":13256,"activeCount":99},[],{"trials":13258,"activeCount":99},[13259],{"nctId":4993,"briefTitle":4994,"status":105,"phases":13260,"primaryCompletion":4996,"completion":4996,"start":4997,"enrollment":571,"conditions":13261,"interventions":13262},[88],[4999,5000,5001],[363,5003,3710],{"trials":13264,"activeCount":99},[],{"trials":13266,"activeCount":99},[],{"trials":13268,"activeCount":99},[],{"trials":13270,"activeCount":99},[],{"intervention":2560,"totalTrials":286,"cells":13272},{"EARLY_PHASE1":13273,"PHASE1":13275,"PHASE2":13281,"PHASE3":13283,"PHASE4":13285,"NA":13287},{"trials":13274,"activeCount":99},[],{"trials":13276,"activeCount":99},[13277],{"nctId":2553,"briefTitle":2554,"status":118,"phases":13278,"primaryCompletion":2556,"completion":2557,"start":2111,"enrollment":887,"conditions":13279,"interventions":13280},[88],[1918,1965],[2560,2561,2327,2562],{"trials":13282,"activeCount":99},[],{"trials":13284,"activeCount":99},[],{"trials":13286,"activeCount":99},[],{"trials":13288,"activeCount":99},[],{"intervention":2561,"totalTrials":286,"cells":13290},{"EARLY_PHASE1":13291,"PHASE1":13293,"PHASE2":13299,"PHASE3":13301,"PHASE4":13303,"NA":13305},{"trials":13292,"activeCount":99},[],{"trials":13294,"activeCount":99},[13295],{"nctId":2553,"briefTitle":2554,"status":118,"phases":13296,"primaryCompletion":2556,"completion":2557,"start":2111,"enrollment":887,"conditions":13297,"interventions":13298},[88],[1918,1965],[2560,2561,2327,2562],{"trials":13300,"activeCount":99},[],{"trials":13302,"activeCount":99},[],{"trials":13304,"activeCount":99},[],{"trials":13306,"activeCount":99},[],{"intervention":4434,"totalTrials":286,"cells":13308},{"EARLY_PHASE1":13309,"PHASE1":13311,"PHASE2":13317,"PHASE3":13319,"PHASE4":13321,"NA":13323},{"trials":13310,"activeCount":99},[],{"trials":13312,"activeCount":99},[13313],{"nctId":4426,"briefTitle":4427,"status":118,"phases":13314,"primaryCompletion":4429,"completion":2383,"start":823,"enrollment":1999,"conditions":13315,"interventions":13316},[88],[4431,4432],[395,4434],{"trials":13318,"activeCount":99},[],{"trials":13320,"activeCount":99},[],{"trials":13322,"activeCount":99},[],{"trials":13324,"activeCount":99},[],{"intervention":13326,"totalTrials":286,"cells":13327},"Epstein-Barr virus-specific adoptive T-cells immunotherapy",{"EARLY_PHASE1":13328,"PHASE1":13330,"PHASE2":13340,"PHASE3":13342,"PHASE4":13344,"NA":13346},{"trials":13329,"activeCount":99},[],{"trials":13331,"activeCount":99},[13332],{"nctId":13333,"briefTitle":13334,"status":118,"phases":13335,"primaryCompletion":13336,"completion":13337,"start":8734,"enrollment":1961,"conditions":13338,"interventions":13339},"NCT00431210","Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma",[88],"2015-06-30","2016-01-26",[12046],[13326],{"trials":13341,"activeCount":99},[],{"trials":13343,"activeCount":99},[],{"trials":13345,"activeCount":99},[],{"trials":13347,"activeCount":99},[],{"intervention":9315,"totalTrials":286,"cells":13349},{"EARLY_PHASE1":13350,"PHASE1":13352,"PHASE2":13358,"PHASE3":13360,"PHASE4":13362,"NA":13364},{"trials":13351,"activeCount":99},[],{"trials":13353,"activeCount":99},[13354],{"nctId":9307,"briefTitle":9308,"status":118,"phases":13355,"primaryCompletion":9310,"completion":9311,"start":9312,"enrollment":141,"conditions":13356,"interventions":13357},[88],[4614],[9300,9315],{"trials":13359,"activeCount":99},[],{"trials":13361,"activeCount":99},[],{"trials":13363,"activeCount":99},[],{"trials":13365,"activeCount":99},[],{"intervention":3259,"totalTrials":286,"cells":13367},{"EARLY_PHASE1":13368,"PHASE1":13370,"PHASE2":13376,"PHASE3":13378,"PHASE4":13380,"NA":13382},{"trials":13369,"activeCount":99},[],{"trials":13371,"activeCount":99},[13372],{"nctId":3251,"briefTitle":3252,"status":118,"phases":13373,"primaryCompletion":3254,"completion":3255,"start":536,"enrollment":225,"conditions":13374,"interventions":13375},[88],[3257,1253],[3259,958],{"trials":13377,"activeCount":99},[],{"trials":13379,"activeCount":99},[],{"trials":13381,"activeCount":99},[],{"trials":13383,"activeCount":99},[],{"intervention":13385,"totalTrials":286,"cells":13386},"Infusion of donor dendritic cells",{"EARLY_PHASE1":13387,"PHASE1":13389,"PHASE2":13399,"PHASE3":13401,"PHASE4":13403,"NA":13405},{"trials":13388,"activeCount":99},[],{"trials":13390,"activeCount":99},[13391],{"nctId":13392,"briefTitle":13393,"status":118,"phases":13394,"primaryCompletion":2874,"completion":40,"start":911,"enrollment":661,"conditions":13395,"interventions":13397},"NCT00476177","Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant",[88],[13396],"Hematologic Malignancy",[13385,13398],"Infusion of donor lymphocytes",{"trials":13400,"activeCount":99},[],{"trials":13402,"activeCount":99},[],{"trials":13404,"activeCount":99},[],{"trials":13406,"activeCount":99},[],{"intervention":13398,"totalTrials":286,"cells":13408},{"EARLY_PHASE1":13409,"PHASE1":13411,"PHASE2":13417,"PHASE3":13419,"PHASE4":13421,"NA":13423},{"trials":13410,"activeCount":99},[],{"trials":13412,"activeCount":99},[13413],{"nctId":13392,"briefTitle":13393,"status":118,"phases":13414,"primaryCompletion":2874,"completion":40,"start":911,"enrollment":661,"conditions":13415,"interventions":13416},[88],[13396],[13385,13398],{"trials":13418,"activeCount":99},[],{"trials":13420,"activeCount":99},[],{"trials":13422,"activeCount":99},[],{"trials":13424,"activeCount":99},[],{"intervention":652,"totalTrials":286,"cells":13426},{"EARLY_PHASE1":13427,"PHASE1":13429,"PHASE2":13435,"PHASE3":13437,"PHASE4":13439,"NA":13441},{"trials":13428,"activeCount":99},[],{"trials":13430,"activeCount":99},[13431],{"nctId":640,"briefTitle":641,"status":118,"phases":13432,"primaryCompletion":643,"completion":643,"start":644,"enrollment":141,"conditions":13433,"interventions":13434},[88],[646,647,648,649],[651,652,269,653],{"trials":13436,"activeCount":99},[],{"trials":13438,"activeCount":99},[],{"trials":13440,"activeCount":99},[],{"trials":13442,"activeCount":99},[],{"intervention":653,"totalTrials":286,"cells":13444},{"EARLY_PHASE1":13445,"PHASE1":13447,"PHASE2":13453,"PHASE3":13455,"PHASE4":13457,"NA":13459},{"trials":13446,"activeCount":99},[],{"trials":13448,"activeCount":99},[13449],{"nctId":640,"briefTitle":641,"status":118,"phases":13450,"primaryCompletion":643,"completion":643,"start":644,"enrollment":141,"conditions":13451,"interventions":13452},[88],[646,647,648,649],[651,652,269,653],{"trials":13454,"activeCount":99},[],{"trials":13456,"activeCount":99},[],{"trials":13458,"activeCount":99},[],{"trials":13460,"activeCount":99},[],{"intervention":13462,"totalTrials":286,"cells":13463},"ICG Intervention",{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13474,"PHASE3":13476,"PHASE4":13478,"NA":13480},{"trials":13465,"activeCount":99},[],{"trials":13467,"activeCount":99},[13468],{"nctId":13469,"briefTitle":13470,"status":118,"phases":13471,"primaryCompletion":3449,"completion":3449,"start":759,"enrollment":1107,"conditions":13472,"interventions":13473},"NCT01121718","NIR-Guided Sentinel Lymph Node Mapping in Melanoma",[88],[1883],[13462],{"trials":13475,"activeCount":99},[],{"trials":13477,"activeCount":99},[],{"trials":13479,"activeCount":99},[],{"trials":13481,"activeCount":99},[],{"intervention":9920,"totalTrials":286,"cells":13483},{"EARLY_PHASE1":13484,"PHASE1":13486,"PHASE2":13492,"PHASE3":13494,"PHASE4":13496,"NA":13498},{"trials":13485,"activeCount":99},[],{"trials":13487,"activeCount":99},[13488],{"nctId":9915,"briefTitle":9916,"status":118,"phases":13489,"primaryCompletion":3366,"completion":8796,"start":660,"enrollment":720,"conditions":13490,"interventions":13491},[88],[125],[9920,9908],{"trials":13493,"activeCount":99},[],{"trials":13495,"activeCount":99},[],{"trials":13497,"activeCount":99},[],{"trials":13499,"activeCount":99},[],{"intervention":13501,"totalTrials":286,"cells":13502},"methylphenidate",{"EARLY_PHASE1":13503,"PHASE1":13505,"PHASE2":13513,"PHASE3":13515,"PHASE4":13517,"NA":13519},{"trials":13504,"activeCount":99},[],{"trials":13506,"activeCount":99},[13507],{"nctId":13508,"briefTitle":13509,"status":105,"phases":13510,"primaryCompletion":728,"completion":728,"start":3228,"enrollment":265,"conditions":13511,"interventions":13512},"NCT01164956","Methylphenidate for Cancer-Related Fatigue",[88],[32],[13501],{"trials":13514,"activeCount":99},[],{"trials":13516,"activeCount":99},[],{"trials":13518,"activeCount":99},[],{"trials":13520,"activeCount":99},[],{"intervention":13522,"totalTrials":286,"cells":13523},"WDVAX",{"EARLY_PHASE1":13524,"PHASE1":13526,"PHASE2":13535,"PHASE3":13537,"PHASE4":13539,"NA":13541},{"trials":13525,"activeCount":99},[],{"trials":13527,"activeCount":99},[13528],{"nctId":13529,"briefTitle":13530,"status":118,"phases":13531,"primaryCompletion":13532,"completion":13532,"start":8434,"enrollment":345,"conditions":13533,"interventions":13534},"NCT01753089","Dendritic Cell Activating Scaffold in Melanoma",[88],"2025-08-04",[1883],[13522],{"trials":13536,"activeCount":99},[],{"trials":13538,"activeCount":99},[],{"trials":13540,"activeCount":99},[],{"trials":13542,"activeCount":99},[],{"intervention":13544,"totalTrials":286,"cells":13545},"Magnesium Sulfate",{"EARLY_PHASE1":13546,"PHASE1":13548,"PHASE2":13558,"PHASE3":13560,"PHASE4":13562,"NA":13564},{"trials":13547,"activeCount":99},[],{"trials":13549,"activeCount":99},[13550],{"nctId":13551,"briefTitle":13552,"status":118,"phases":13553,"primaryCompletion":13554,"completion":13554,"start":13555,"enrollment":275,"conditions":13556,"interventions":13557},"NCT04481672","Intravenous Magnesium in Patients Receiving Cisplatin",[88],"2021-12-30","2021-07-30",[6655],[13544],{"trials":13559,"activeCount":99},[],{"trials":13561,"activeCount":99},[],{"trials":13563,"activeCount":99},[],{"trials":13565,"activeCount":99},[],{"intervention":2338,"totalTrials":286,"cells":13567},{"EARLY_PHASE1":13568,"PHASE1":13570,"PHASE2":13576,"PHASE3":13578,"PHASE4":13580,"NA":13582},{"trials":13569,"activeCount":99},[],{"trials":13571,"activeCount":99},[13572],{"nctId":2329,"briefTitle":2330,"status":105,"phases":13573,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":35,"conditions":13574,"interventions":13575},[88],[850,2336],[2338,80,2327],{"trials":13577,"activeCount":99},[],{"trials":13579,"activeCount":99},[],{"trials":13581,"activeCount":99},[],{"trials":13583,"activeCount":99},[],{"intervention":13585,"totalTrials":286,"cells":13586},"Autologous, lethally irradiated melanoma cells",{"EARLY_PHASE1":13587,"PHASE1":13589,"PHASE2":13600,"PHASE3":13602,"PHASE4":13604,"NA":13606},{"trials":13588,"activeCount":99},[],{"trials":13590,"activeCount":99},[13591],{"nctId":13592,"briefTitle":13593,"status":118,"phases":13594,"primaryCompletion":1045,"completion":13595,"start":13596,"enrollment":13597,"conditions":13598,"interventions":13599},"NCT00809588","Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)",[88],"2020-02-25","2003-10-16",84,[1883],[13585],{"trials":13601,"activeCount":99},[],{"trials":13603,"activeCount":99},[],{"trials":13605,"activeCount":99},[],{"trials":13607,"activeCount":99},[],{"intervention":13609,"totalTrials":286,"cells":13610},"9-Aminocamptothecin",{"EARLY_PHASE1":13611,"PHASE1":13613,"PHASE2":13624,"PHASE3":13626,"PHASE4":13628,"NA":13630},{"trials":13612,"activeCount":99},[],{"trials":13614,"activeCount":99},[13615],{"nctId":13616,"briefTitle":13617,"status":118,"phases":13618,"primaryCompletion":3219,"completion":3219,"start":13619,"enrollment":9128,"conditions":13620,"interventions":13623},"NCT00251368","Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia",[88],"1995-01",[13621,13622],"Leukemia, Myelocytic, Acute","Acute Lymphocytic Leukemia",[13609],{"trials":13625,"activeCount":99},[],{"trials":13627,"activeCount":99},[],{"trials":13629,"activeCount":99},[],{"trials":13631,"activeCount":99},[],{"intervention":13633,"totalTrials":286,"cells":13634},"therapeutic autologous lymphocytes",{"EARLY_PHASE1":13635,"PHASE1":13637,"PHASE2":13647,"PHASE3":13649,"PHASE4":13651,"NA":13653},{"trials":13636,"activeCount":99},[],{"trials":13638,"activeCount":99},[13639],{"nctId":13640,"briefTitle":13641,"status":118,"phases":13642,"primaryCompletion":3691,"completion":198,"start":2874,"enrollment":242,"conditions":13643,"interventions":13644},"NCT00512889","Adoptive Transfer of MART1\u002FMelan-A CTL for Malignant Melanoma",[88],[11414],[13633,13645,13646],"Use of an artificial antigen presenting cell (aAPC) to generate CTL","GM-CSF",{"trials":13648,"activeCount":99},[],{"trials":13650,"activeCount":99},[],{"trials":13652,"activeCount":99},[],{"trials":13654,"activeCount":99},[],{"intervention":13645,"totalTrials":286,"cells":13656},{"EARLY_PHASE1":13657,"PHASE1":13659,"PHASE2":13665,"PHASE3":13667,"PHASE4":13669,"NA":13671},{"trials":13658,"activeCount":99},[],{"trials":13660,"activeCount":99},[13661],{"nctId":13640,"briefTitle":13641,"status":118,"phases":13662,"primaryCompletion":3691,"completion":198,"start":2874,"enrollment":242,"conditions":13663,"interventions":13664},[88],[11414],[13633,13645,13646],{"trials":13666,"activeCount":99},[],{"trials":13668,"activeCount":99},[],{"trials":13670,"activeCount":99},[],{"trials":13672,"activeCount":99},[],{"intervention":13646,"totalTrials":286,"cells":13674},{"EARLY_PHASE1":13675,"PHASE1":13677,"PHASE2":13683,"PHASE3":13685,"PHASE4":13687,"NA":13689},{"trials":13676,"activeCount":99},[],{"trials":13678,"activeCount":99},[13679],{"nctId":13640,"briefTitle":13641,"status":118,"phases":13680,"primaryCompletion":3691,"completion":198,"start":2874,"enrollment":242,"conditions":13681,"interventions":13682},[88],[11414],[13633,13645,13646],{"trials":13684,"activeCount":99},[],{"trials":13686,"activeCount":99},[],{"trials":13688,"activeCount":99},[],{"trials":13690,"activeCount":99},[],{"intervention":4104,"totalTrials":286,"cells":13692},{"EARLY_PHASE1":13693,"PHASE1":13695,"PHASE2":13701,"PHASE3":13703,"PHASE4":13705,"NA":13707},{"trials":13694,"activeCount":99},[],{"trials":13696,"activeCount":99},[13697],{"nctId":4095,"briefTitle":4096,"status":118,"phases":13698,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":428,"conditions":13699,"interventions":13700},[88],[347],[4103,866,4104],{"trials":13702,"activeCount":99},[],{"trials":13704,"activeCount":99},[],{"trials":13706,"activeCount":99},[],{"trials":13708,"activeCount":99},[],{"intervention":13710,"totalTrials":286,"cells":13711},"CUDC-907",{"EARLY_PHASE1":13712,"PHASE1":13714,"PHASE2":13722,"PHASE3":13724,"PHASE4":13726,"NA":13728},{"trials":13713,"activeCount":99},[],{"trials":13715,"activeCount":99},[13716],{"nctId":13717,"briefTitle":13718,"status":118,"phases":13719,"primaryCompletion":1059,"completion":1059,"start":1124,"enrollment":1107,"conditions":13720,"interventions":13721},"NCT02909777","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",[88],[585,850,609,347],[13710],{"trials":13723,"activeCount":99},[],{"trials":13725,"activeCount":99},[],{"trials":13727,"activeCount":99},[],{"trials":13729,"activeCount":99},[],{"intervention":13731,"totalTrials":286,"cells":13732},"Lexiscan",{"EARLY_PHASE1":13733,"PHASE1":13735,"PHASE2":13743,"PHASE3":13745,"PHASE4":13747,"NA":13749},{"trials":13734,"activeCount":99},[],{"trials":13736,"activeCount":99},[13737],{"nctId":13738,"briefTitle":13739,"status":118,"phases":13740,"primaryCompletion":846,"completion":728,"start":427,"enrollment":1352,"conditions":13741,"interventions":13742},"NCT01085201","Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease",[88],[3129],[13731],{"trials":13744,"activeCount":99},[],{"trials":13746,"activeCount":99},[],{"trials":13748,"activeCount":99},[],{"trials":13750,"activeCount":99},[],{"intervention":2652,"totalTrials":286,"cells":13752},{"EARLY_PHASE1":13753,"PHASE1":13755,"PHASE2":13761,"PHASE3":13763,"PHASE4":13765,"NA":13767},{"trials":13754,"activeCount":99},[],{"trials":13756,"activeCount":99},[13757],{"nctId":2644,"briefTitle":2645,"status":105,"phases":13758,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":25,"conditions":13759,"interventions":13760},[88],[1869],[51,2652,2653,2654],{"trials":13762,"activeCount":99},[],{"trials":13764,"activeCount":99},[],{"trials":13766,"activeCount":99},[],{"trials":13768,"activeCount":99},[],{"intervention":2654,"totalTrials":286,"cells":13770},{"EARLY_PHASE1":13771,"PHASE1":13773,"PHASE2":13779,"PHASE3":13781,"PHASE4":13783,"NA":13785},{"trials":13772,"activeCount":99},[],{"trials":13774,"activeCount":99},[13775],{"nctId":2644,"briefTitle":2645,"status":105,"phases":13776,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":25,"conditions":13777,"interventions":13778},[88],[1869],[51,2652,2653,2654],{"trials":13780,"activeCount":99},[],{"trials":13782,"activeCount":99},[],{"trials":13784,"activeCount":99},[],{"trials":13786,"activeCount":99},[],{"intervention":3337,"totalTrials":286,"cells":13788},{"EARLY_PHASE1":13789,"PHASE1":13791,"PHASE2":13797,"PHASE3":13799,"PHASE4":13801,"NA":13803},{"trials":13790,"activeCount":99},[],{"trials":13792,"activeCount":99},[13793],{"nctId":3331,"briefTitle":3332,"status":118,"phases":13794,"completion":507,"start":3334,"conditions":13795,"interventions":13796},[88],[18],[2881,1680,3337],{"trials":13798,"activeCount":99},[],{"trials":13800,"activeCount":99},[],{"trials":13802,"activeCount":99},[],{"trials":13804,"activeCount":99},[],{"intervention":4282,"totalTrials":286,"cells":13806},{"EARLY_PHASE1":13807,"PHASE1":13809,"PHASE2":13815,"PHASE3":13817,"PHASE4":13819,"NA":13821},{"trials":13808,"activeCount":99},[],{"trials":13810,"activeCount":99},[13811],{"nctId":4276,"briefTitle":4277,"status":118,"phases":13812,"primaryCompletion":4036,"completion":344,"start":3422,"enrollment":25,"conditions":13813,"interventions":13814},[88],[21,1949,4280,827,826,15],[158,4282],{"trials":13816,"activeCount":99},[],{"trials":13818,"activeCount":99},[],{"trials":13820,"activeCount":99},[],{"trials":13822,"activeCount":99},[],{"intervention":9475,"totalTrials":286,"cells":13824},{"EARLY_PHASE1":13825,"PHASE1":13827,"PHASE2":13833,"PHASE3":13835,"PHASE4":13837,"NA":13839},{"trials":13826,"activeCount":99},[],{"trials":13828,"activeCount":99},[13829],{"nctId":9469,"briefTitle":9470,"status":118,"phases":13830,"primaryCompletion":4840,"completion":9472,"start":3422,"enrollment":265,"conditions":13831,"interventions":13832},[88],[27],[9475,9476],{"trials":13834,"activeCount":99},[],{"trials":13836,"activeCount":99},[],{"trials":13838,"activeCount":99},[],{"trials":13840,"activeCount":99},[],{"intervention":1229,"totalTrials":286,"cells":13842},{"EARLY_PHASE1":13843,"PHASE1":13845,"PHASE2":13851,"PHASE3":13853,"PHASE4":13855,"NA":13857},{"trials":13844,"activeCount":99},[],{"trials":13846,"activeCount":99},[13847],{"nctId":1222,"briefTitle":1223,"status":118,"phases":13848,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":28,"conditions":13849,"interventions":13850},[88],[27,609,347,585],[1229,772],{"trials":13852,"activeCount":99},[],{"trials":13854,"activeCount":99},[],{"trials":13856,"activeCount":99},[],{"trials":13858,"activeCount":99},[],{"intervention":3347,"totalTrials":286,"cells":13860},{"EARLY_PHASE1":13861,"PHASE1":13863,"PHASE2":13869,"PHASE3":13871,"PHASE4":13873,"NA":13875},{"trials":13862,"activeCount":99},[],{"trials":13864,"activeCount":99},[13865],{"nctId":3339,"briefTitle":3340,"status":118,"phases":13866,"primaryCompletion":3342,"completion":794,"start":3343,"enrollment":1492,"conditions":13867,"interventions":13868},[88],[1854,3345],[2881,3347],{"trials":13870,"activeCount":99},[],{"trials":13872,"activeCount":99},[],{"trials":13874,"activeCount":99},[],{"trials":13876,"activeCount":99},[],{"intervention":13878,"totalTrials":286,"cells":13879},"talotrexin ammonium",{"EARLY_PHASE1":13880,"PHASE1":13882,"PHASE2":13890,"PHASE3":13892,"PHASE4":13894,"NA":13896},{"trials":13881,"activeCount":99},[],{"trials":13883,"activeCount":99},[13884],{"nctId":13885,"briefTitle":13886,"status":118,"phases":13887,"primaryCompletion":1071,"completion":164,"start":2662,"enrollment":2431,"conditions":13888,"interventions":13889},"NCT00098514","Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors",[88],[1534],[13878],{"trials":13891,"activeCount":99},[],{"trials":13893,"activeCount":99},[],{"trials":13895,"activeCount":99},[],{"trials":13897,"activeCount":99},[],{"intervention":13899,"totalTrials":286,"cells":13900},"GM-K562\u002Fleukemia cell vaccine",{"EARLY_PHASE1":13901,"PHASE1":13903,"PHASE2":13912,"PHASE3":13914,"PHASE4":13916,"NA":13918},{"trials":13902,"activeCount":99},[],{"trials":13904,"activeCount":99},[13905],{"nctId":13906,"briefTitle":13907,"status":118,"phases":13908,"primaryCompletion":164,"completion":84,"start":163,"enrollment":571,"conditions":13909,"interventions":13911},"NCT00809250","Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation",[88],[674,1376,13910],"Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts",[13899],{"trials":13913,"activeCount":99},[],{"trials":13915,"activeCount":99},[],{"trials":13917,"activeCount":99},[],{"trials":13919,"activeCount":99},[],{"intervention":4454,"totalTrials":286,"cells":13921},{"EARLY_PHASE1":13922,"PHASE1":13924,"PHASE2":13930,"PHASE3":13932,"PHASE4":13934,"NA":13936},{"trials":13923,"activeCount":99},[],{"trials":13925,"activeCount":99},[13926],{"nctId":4447,"briefTitle":4448,"status":118,"phases":13927,"primaryCompletion":4450,"completion":210,"start":4451,"enrollment":4236,"conditions":13928,"interventions":13929},[88],[30],[4454,395],{"trials":13931,"activeCount":99},[],{"trials":13933,"activeCount":99},[],{"trials":13935,"activeCount":99},[],{"trials":13937,"activeCount":99},[],{"intervention":8611,"totalTrials":286,"cells":13939},{"EARLY_PHASE1":13940,"PHASE1":13942,"PHASE2":13948,"PHASE3":13950,"PHASE4":13952,"NA":13954},{"trials":13941,"activeCount":99},[],{"trials":13943,"activeCount":99},[13944],{"nctId":8605,"briefTitle":8606,"status":118,"phases":13945,"primaryCompletion":402,"completion":376,"start":2661,"enrollment":123,"conditions":13946,"interventions":13947},[88],[8609,2501,6806],[8611,157],{"trials":13949,"activeCount":99},[],{"trials":13951,"activeCount":99},[],{"trials":13953,"activeCount":99},[],{"trials":13955,"activeCount":99},[],{"intervention":2996,"totalTrials":286,"cells":13957},{"EARLY_PHASE1":13958,"PHASE1":13960,"PHASE2":13966,"PHASE3":13968,"PHASE4":13970,"NA":13972},{"trials":13959,"activeCount":99},[],{"trials":13961,"activeCount":99},[13962],{"nctId":2987,"briefTitle":2988,"status":118,"phases":13963,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":887,"conditions":13964,"interventions":13965},[88],[2994],[1953,2996],{"trials":13967,"activeCount":99},[],{"trials":13969,"activeCount":99},[],{"trials":13971,"activeCount":99},[],{"trials":13973,"activeCount":99},[],{"intervention":2804,"totalTrials":286,"cells":13975},{"EARLY_PHASE1":13976,"PHASE1":13978,"PHASE2":13984,"PHASE3":13986,"PHASE4":13988,"NA":13990},{"trials":13977,"activeCount":99},[],{"trials":13979,"activeCount":99},[13980],{"nctId":2795,"briefTitle":2796,"status":105,"phases":13981,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":2800,"conditions":13982,"interventions":13983},[88],[2802],[2804,2805],{"trials":13985,"activeCount":99},[],{"trials":13987,"activeCount":99},[],{"trials":13989,"activeCount":99},[],{"trials":13991,"activeCount":99},[],{"intervention":13993,"totalTrials":286,"cells":13994},"BMS-986158",{"EARLY_PHASE1":13995,"PHASE1":13997,"PHASE2":14011,"PHASE3":14013,"PHASE4":14015,"NA":14017},{"trials":13996,"activeCount":99},[],{"trials":13998,"activeCount":99},[13999],{"nctId":14000,"briefTitle":14001,"status":118,"phases":14002,"primaryCompletion":14003,"completion":14004,"start":14005,"enrollment":390,"conditions":14006,"interventions":14009},"NCT03936465","Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer",[88],"2024-03-16","2024-10-01","2019-09-27",[14007,585,14008],"Solid Tumor, Childhood","Brain Tumor, Pediatric",[13993,14010],"BMS-986378",{"trials":14012,"activeCount":99},[],{"trials":14014,"activeCount":99},[],{"trials":14016,"activeCount":99},[],{"trials":14018,"activeCount":99},[],{"intervention":14010,"totalTrials":286,"cells":14020},{"EARLY_PHASE1":14021,"PHASE1":14023,"PHASE2":14029,"PHASE3":14031,"PHASE4":14033,"NA":14035},{"trials":14022,"activeCount":99},[],{"trials":14024,"activeCount":99},[14025],{"nctId":14000,"briefTitle":14001,"status":118,"phases":14026,"primaryCompletion":14003,"completion":14004,"start":14005,"enrollment":390,"conditions":14027,"interventions":14028},[88],[14007,585,14008],[13993,14010],{"trials":14030,"activeCount":99},[],{"trials":14032,"activeCount":99},[],{"trials":14034,"activeCount":99},[],{"trials":14036,"activeCount":99},[],{"intervention":4291,"totalTrials":286,"cells":14038},{"EARLY_PHASE1":14039,"PHASE1":14041,"PHASE2":14047,"PHASE3":14049,"PHASE4":14051,"NA":14053},{"trials":14040,"activeCount":99},[],{"trials":14042,"activeCount":99},[14043],{"nctId":4284,"briefTitle":4285,"status":118,"phases":14044,"primaryCompletion":4287,"completion":4288,"start":846,"enrollment":1841,"conditions":14045,"interventions":14046},[88],[1918],[4291,158],{"trials":14048,"activeCount":99},[],{"trials":14050,"activeCount":99},[],{"trials":14052,"activeCount":99},[],{"trials":14054,"activeCount":99},[],{"intervention":9657,"totalTrials":286,"cells":14056},{"EARLY_PHASE1":14057,"PHASE1":14059,"PHASE2":14065,"PHASE3":14067,"PHASE4":14069,"NA":14071},{"trials":14058,"activeCount":99},[],{"trials":14060,"activeCount":99},[14061],{"nctId":9650,"briefTitle":9651,"status":118,"phases":14062,"primaryCompletion":2358,"completion":9653,"start":9654,"enrollment":1492,"conditions":14063,"interventions":14064},[88],[611,6685],[9657,9658],{"trials":14066,"activeCount":99},[],{"trials":14068,"activeCount":99},[],{"trials":14070,"activeCount":99},[],{"trials":14072,"activeCount":99},[],{"intervention":5118,"totalTrials":286,"cells":14074},{"EARLY_PHASE1":14075,"PHASE1":14077,"PHASE2":14083,"PHASE3":14085,"PHASE4":14087,"NA":14089},{"trials":14076,"activeCount":99},[],{"trials":14078,"activeCount":99},[14079],{"nctId":5112,"briefTitle":5113,"status":105,"phases":14080,"primaryCompletion":5115,"completion":5115,"start":2521,"enrollment":3721,"conditions":14081,"interventions":14082},[88],[4444],[283,5105,5118],{"trials":14084,"activeCount":99},[],{"trials":14086,"activeCount":99},[],{"trials":14088,"activeCount":99},[],{"trials":14090,"activeCount":99},[],{"intervention":14092,"totalTrials":286,"cells":14093},"18F-FLT",{"EARLY_PHASE1":14094,"PHASE1":14096,"PHASE2":14105,"PHASE3":14107,"PHASE4":14109,"NA":14111},{"trials":14095,"activeCount":99},[],{"trials":14097,"activeCount":99},[14098],{"nctId":14099,"briefTitle":14100,"status":105,"phases":14101,"primaryCompletion":4306,"completion":4306,"start":3126,"enrollment":1034,"conditions":14102,"interventions":14104},"NCT00633958","A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors",[88],[14103],"Tumors of the Central Nervous System",[14092],{"trials":14106,"activeCount":99},[],{"trials":14108,"activeCount":99},[],{"trials":14110,"activeCount":99},[],{"trials":14112,"activeCount":99},[],{"intervention":14114,"totalTrials":286,"cells":14115},"autologous tumor cells",{"EARLY_PHASE1":14116,"PHASE1":14118,"PHASE2":14127,"PHASE3":14129,"PHASE4":14131,"NA":14133},{"trials":14117,"activeCount":99},[],{"trials":14119,"activeCount":99},[14120],{"nctId":14121,"briefTitle":14122,"status":118,"phases":14123,"primaryCompletion":11051,"completion":11051,"start":10283,"enrollment":403,"conditions":14124,"interventions":14126},"NCT00136422","Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia",[88],[474,14125],"Myelodysplasia",[14114],{"trials":14128,"activeCount":99},[],{"trials":14130,"activeCount":99},[],{"trials":14132,"activeCount":99},[],{"trials":14134,"activeCount":99},[],{"intervention":9794,"totalTrials":286,"cells":14136},{"EARLY_PHASE1":14137,"PHASE1":14139,"PHASE2":14145,"PHASE3":14147,"PHASE4":14149,"NA":14151},{"trials":14138,"activeCount":99},[],{"trials":14140,"activeCount":99},[14141],{"nctId":9787,"briefTitle":9788,"status":118,"phases":14142,"primaryCompletion":909,"completion":658,"start":9790,"conditions":14143,"interventions":14144},[88],[750,5329,851],[9793,9794],{"trials":14146,"activeCount":99},[],{"trials":14148,"activeCount":99},[],{"trials":14150,"activeCount":99},[],{"trials":14152,"activeCount":99},[],{"intervention":5128,"totalTrials":286,"cells":14154},{"EARLY_PHASE1":14155,"PHASE1":14157,"PHASE2":14163,"PHASE3":14165,"PHASE4":14167,"NA":14169},{"trials":14156,"activeCount":99},[],{"trials":14158,"activeCount":99},[14159],{"nctId":5120,"briefTitle":5121,"status":118,"phases":14160,"primaryCompletion":5123,"completion":5124,"start":5125,"enrollment":1107,"conditions":14161,"interventions":14162},[88],[4444],[283,5105,5128],{"trials":14164,"activeCount":99},[],{"trials":14166,"activeCount":99},[],{"trials":14168,"activeCount":99},[],{"trials":14170,"activeCount":99},[],{"intervention":14172,"totalTrials":286,"cells":14173},"Omalizumab",{"EARLY_PHASE1":14174,"PHASE1":14176,"PHASE2":14185,"PHASE3":14187,"PHASE4":14189,"NA":14191},{"trials":14175,"activeCount":99},[],{"trials":14177,"activeCount":99},[14178],{"nctId":14179,"briefTitle":14180,"status":118,"phases":14181,"primaryCompletion":5153,"completion":5153,"start":525,"enrollment":275,"conditions":14182,"interventions":14184},"NCT02118987","Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization",[88],[14183],"Drug Allergy",[14172],{"trials":14186,"activeCount":99},[],{"trials":14188,"activeCount":99},[],{"trials":14190,"activeCount":99},[],{"trials":14192,"activeCount":99},[],{"intervention":14194,"totalTrials":286,"cells":14195},"rV-DF3\u002FMUC1",{"EARLY_PHASE1":14196,"PHASE1":14198,"PHASE2":14209,"PHASE3":14211,"PHASE4":14213,"NA":14215},{"trials":14197,"activeCount":99},[],{"trials":14199,"activeCount":99},[14200],{"nctId":14201,"briefTitle":14202,"status":118,"phases":14203,"primaryCompletion":14204,"completion":14205,"start":14206,"enrollment":784,"conditions":14207,"interventions":14208},"NCT00003761","Vaccine Therapy in Treating Patients With Metastatic Breast Cancer",[88],"2001-04-20","2001-10-19","1999-03-03",[15],[14194],{"trials":14210,"activeCount":99},[],{"trials":14212,"activeCount":99},[],{"trials":14214,"activeCount":99},[],{"trials":14216,"activeCount":99},[],{"intervention":14218,"totalTrials":286,"cells":14219},"Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells",{"EARLY_PHASE1":14220,"PHASE1":14222,"PHASE2":14231,"PHASE3":14233,"PHASE4":14235,"NA":14237},{"trials":14221,"activeCount":99},[],{"trials":14223,"activeCount":99},[14224],{"nctId":14225,"briefTitle":14226,"status":118,"phases":14227,"primaryCompletion":14228,"completion":14228,"start":2956,"enrollment":25,"conditions":14229,"interventions":14230},"NCT00487305","Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma",[88],"2023-07-25",[1869],[14218],{"trials":14232,"activeCount":99},[],{"trials":14234,"activeCount":99},[],{"trials":14236,"activeCount":99},[],{"trials":14238,"activeCount":99},[],{"intervention":9158,"totalTrials":286,"cells":14240},{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14249,"PHASE3":14251,"PHASE4":14253,"NA":14255},{"trials":14242,"activeCount":99},[],{"trials":14244,"activeCount":99},[14245],{"nctId":9152,"briefTitle":9153,"status":118,"phases":14246,"primaryCompletion":9155,"completion":1881,"start":426,"enrollment":25,"conditions":14247,"interventions":14248},[88],[8019],[9158,257],{"trials":14250,"activeCount":99},[],{"trials":14252,"activeCount":99},[],{"trials":14254,"activeCount":99},[],{"trials":14256,"activeCount":99},[],{"intervention":14258,"totalTrials":286,"cells":14259},"Di-Dak-Sol",{"EARLY_PHASE1":14260,"PHASE1":14272,"PHASE2":14274,"PHASE3":14276,"PHASE4":14278,"NA":14280},{"trials":14261,"activeCount":99},[14262],{"nctId":14263,"briefTitle":14264,"status":1057,"phases":14265,"primaryCompletion":14266,"completion":14267,"start":14268,"enrollment":99,"conditions":14269,"interventions":14271},"NCT04851522","Dilute Bleach Compresses for Radiation Dermatitis",[87],"2022-04-01","2023-04-01","2021-06-09",[14270],"Radiation Dermatitis",[14258],{"trials":14273,"activeCount":99},[],{"trials":14275,"activeCount":99},[],{"trials":14277,"activeCount":99},[],{"trials":14279,"activeCount":99},[],{"trials":14281,"activeCount":99},[],{"intervention":14283,"totalTrials":286,"cells":14284},"89Zr-bevacizumab",{"EARLY_PHASE1":14285,"PHASE1":14295,"PHASE2":14297,"PHASE3":14299,"PHASE4":14301,"NA":14303},{"trials":14286,"activeCount":99},[14287],{"nctId":14288,"briefTitle":14289,"status":118,"phases":14290,"primaryCompletion":14291,"completion":14291,"start":4379,"enrollment":1034,"conditions":14292,"interventions":14294},"NCT01894451","Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy",[87],"2017-03-17",[14293],"Inflammatory Breast Carcinoma",[14283],{"trials":14296,"activeCount":99},[],{"trials":14298,"activeCount":99},[],{"trials":14300,"activeCount":99},[],{"trials":14302,"activeCount":99},[],{"trials":14304,"activeCount":99},[],{"intervention":14306,"totalTrials":286,"cells":14307},"Melatonin 3 mg",{"EARLY_PHASE1":14308,"PHASE1":14317,"PHASE2":14319,"PHASE3":14321,"PHASE4":14323,"NA":14325},{"trials":14309,"activeCount":99},[14310],{"nctId":14311,"briefTitle":14312,"status":118,"phases":14313,"primaryCompletion":40,"completion":40,"start":782,"enrollment":14314,"conditions":14315,"interventions":14316},"NCT01805089","Melatonin Versus Placebo in Breast Cancer",[87],95,[15],[14306],{"trials":14318,"activeCount":99},[],{"trials":14320,"activeCount":99},[],{"trials":14322,"activeCount":99},[],{"trials":14324,"activeCount":99},[],{"trials":14326,"activeCount":99},[],{"intervention":4021,"totalTrials":286,"cells":14328},{"EARLY_PHASE1":14329,"PHASE1":14335,"PHASE2":14337,"PHASE3":14339,"PHASE4":14341,"NA":14343},{"trials":14330,"activeCount":99},[14331],{"nctId":4014,"briefTitle":4015,"status":118,"phases":14332,"primaryCompletion":472,"completion":525,"start":303,"enrollment":661,"conditions":14333,"interventions":14334},[87],[4018,3693,4019],[4021,866,4022],{"trials":14336,"activeCount":99},[],{"trials":14338,"activeCount":99},[],{"trials":14340,"activeCount":99},[],{"trials":14342,"activeCount":99},[],{"trials":14344,"activeCount":99},[],{"intervention":14346,"totalTrials":286,"cells":14347},"CD 40",{"EARLY_PHASE1":14348,"PHASE1":14359,"PHASE2":14361,"PHASE3":14363,"PHASE4":14365,"NA":14367},{"trials":14349,"activeCount":99},[14350],{"nctId":14351,"briefTitle":14352,"status":105,"phases":14353,"primaryCompletion":14354,"completion":14355,"start":14356,"enrollment":242,"conditions":14357,"interventions":14358},"NCT00020670","Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia",[87],"2003-04-01","2003-07-01","2001-02-20",[27],[14346],{"trials":14360,"activeCount":99},[],{"trials":14362,"activeCount":99},[],{"trials":14364,"activeCount":99},[],{"trials":14366,"activeCount":99},[],{"trials":14368,"activeCount":99},[],{"intervention":14370,"totalTrials":286,"cells":14371},"PEG-L-asparaginase",{"EARLY_PHASE1":14372,"PHASE1":14384,"PHASE2":14386,"PHASE3":14388,"PHASE4":14390,"NA":14392},{"trials":14373,"activeCount":99},[14374],{"nctId":14375,"briefTitle":14376,"status":105,"phases":14377,"primaryCompletion":3365,"completion":3365,"start":274,"enrollment":1034,"conditions":14378,"interventions":14382},"NCT01878708","A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma",[87],[14379,14380,14381],"T-Cell Lymphoma","Relapsed T-Cell Lymphoma","Refractory T-Cell Lymphoma",[14370,14383],"Dexamethasone acetate",{"trials":14385,"activeCount":99},[],{"trials":14387,"activeCount":99},[],{"trials":14389,"activeCount":99},[],{"trials":14391,"activeCount":99},[],{"trials":14393,"activeCount":99},[],{"intervention":14383,"totalTrials":286,"cells":14395},{"EARLY_PHASE1":14396,"PHASE1":14402,"PHASE2":14404,"PHASE3":14406,"PHASE4":14408,"NA":14410},{"trials":14397,"activeCount":99},[14398],{"nctId":14375,"briefTitle":14376,"status":105,"phases":14399,"primaryCompletion":3365,"completion":3365,"start":274,"enrollment":1034,"conditions":14400,"interventions":14401},[87],[14379,14380,14381],[14370,14383],{"trials":14403,"activeCount":99},[],{"trials":14405,"activeCount":99},[],{"trials":14407,"activeCount":99},[],{"trials":14409,"activeCount":99},[],{"trials":14411,"activeCount":99},[],{"intervention":1194,"totalTrials":1034,"cells":14413},{"EARLY_PHASE1":14414,"PHASE1":14416,"PHASE2":14422,"PHASE3":14424,"PHASE4":14426,"NA":14428},{"trials":14415,"activeCount":99},[],{"trials":14417,"activeCount":99},[14418],{"nctId":3261,"briefTitle":3262,"status":105,"phases":14419,"primaryCompletion":898,"completion":898,"start":3264,"enrollment":2406,"conditions":14420,"interventions":14421},[88],[34],[1194,958],{"trials":14423,"activeCount":99},[],{"trials":14425,"activeCount":99},[],{"trials":14427,"activeCount":99},[],{"trials":14429,"activeCount":99},[14430],{"nctId":1188,"briefTitle":1189,"status":1190,"phases":14431,"conditions":14432,"interventions":14433},[],[1026,24],[1194,1029,41,364],{"intervention":14435,"totalTrials":1034,"cells":14436},"Ferumoxytol",{"EARLY_PHASE1":14437,"PHASE1":14439,"PHASE2":14447,"PHASE3":14449,"PHASE4":14451,"NA":14453},{"trials":14438,"activeCount":99},[],{"trials":14440,"activeCount":99},[14441],{"nctId":14442,"briefTitle":14443,"status":1057,"phases":14444,"primaryCompletion":516,"completion":516,"start":516,"enrollment":99,"conditions":14445,"interventions":14446},"NCT02689401","MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer",[88],[2091],[14435],{"trials":14448,"activeCount":99},[],{"trials":14450,"activeCount":99},[],{"trials":14452,"activeCount":99},[],{"trials":14454,"activeCount":99},[14455],{"nctId":14456,"briefTitle":14457,"status":1057,"phases":14458,"primaryCompletion":517,"completion":517,"start":9425,"enrollment":99,"conditions":14459,"interventions":14461},"NCT01663090","Ferumoxytol-Enhanced MRI in Adult\u002FPedi Sarcomas",[92],[14460],"Soft Tissue Sarcoma",[14435],{"intervention":14463,"totalTrials":286,"cells":14464},"Indocyanine green",{"EARLY_PHASE1":14465,"PHASE1":14467,"PHASE2":14469,"PHASE3":14471,"PHASE4":14473,"NA":14475},{"trials":14466,"activeCount":99},[],{"trials":14468,"activeCount":99},[],{"trials":14470,"activeCount":99},[],{"trials":14472,"activeCount":99},[],{"trials":14474,"activeCount":99},[],{"trials":14476,"activeCount":99},[14477],{"nctId":14478,"briefTitle":14479,"status":1057,"phases":14480,"primaryCompletion":14481,"completion":14481,"start":4358,"enrollment":99,"conditions":14482,"interventions":14483},"NCT02423148","Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer",[92],"2016-11-03",[30],[14463],{"intervention":14485,"totalTrials":286,"cells":14486},"GM-CSF secreting leukemia vaccine",{"EARLY_PHASE1":14487,"PHASE1":14489,"PHASE2":14491,"PHASE3":14493,"PHASE4":14495,"NA":14497},{"trials":14488,"activeCount":99},[],{"trials":14490,"activeCount":99},[],{"trials":14492,"activeCount":99},[],{"trials":14494,"activeCount":99},[],{"trials":14496,"activeCount":99},[],{"trials":14498,"activeCount":99},[14499],{"nctId":14500,"briefTitle":14501,"status":118,"phases":14502,"primaryCompletion":3219,"completion":3358,"start":5023,"enrollment":1961,"conditions":14503,"interventions":14507},"NCT00426205","GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies",[92],[14504,14505,14506],"Myelodysplastic Syndrome RAEB-I or RAEB-II","Refractory Acute Myeloid Leukemia","Refractory CML Myeloid Blast Crisis",[14485],{"intervention":14509,"totalTrials":286,"cells":14510},"deferoxamine",{"EARLY_PHASE1":14511,"PHASE1":14513,"PHASE2":14515,"PHASE3":14517,"PHASE4":14519,"NA":14521},{"trials":14512,"activeCount":99},[],{"trials":14514,"activeCount":99},[],{"trials":14516,"activeCount":99},[],{"trials":14518,"activeCount":99},[],{"trials":14520,"activeCount":99},[],{"trials":14522,"activeCount":99},[14523],{"nctId":14524,"briefTitle":14525,"status":105,"phases":14526,"primaryCompletion":9022,"completion":9022,"start":658,"enrollment":275,"conditions":14527,"interventions":14528},"NCT00658411","Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation",[92],[674,125,463],[14509],{"intervention":14530,"totalTrials":286,"cells":14531},"valdecoxib",{"EARLY_PHASE1":14532,"PHASE1":14534,"PHASE2":14536,"PHASE3":14538,"PHASE4":14540,"NA":14542},{"trials":14533,"activeCount":99},[],{"trials":14535,"activeCount":99},[],{"trials":14537,"activeCount":99},[],{"trials":14539,"activeCount":99},[],{"trials":14541,"activeCount":99},[],{"trials":14543,"activeCount":99},[14544],{"nctId":14545,"briefTitle":14546,"status":118,"phases":14547,"completion":6653,"start":7936,"conditions":14548,"interventions":14549},"NCT00021996","Valdecoxib in Treating Chronic Pain in Cancer Patients",[92],[12627,1534],[14530],{"intervention":14551,"totalTrials":286,"cells":14552},"3'-deoxy-3'-(18) F-fluorothymidine",{"EARLY_PHASE1":14553,"PHASE1":14555,"PHASE2":14557,"PHASE3":14559,"PHASE4":14561,"NA":14563},{"trials":14554,"activeCount":99},[],{"trials":14556,"activeCount":99},[],{"trials":14558,"activeCount":99},[],{"trials":14560,"activeCount":99},[],{"trials":14562,"activeCount":99},[],{"trials":14564,"activeCount":99},[14565],{"nctId":14566,"briefTitle":14567,"status":118,"phases":14568,"primaryCompletion":728,"completion":728,"start":14569,"enrollment":275,"conditions":14570,"interventions":14571},"NCT01243619","FLT PET\u002FCT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer",[92],"2010-08",[2091],[14551],{"intervention":2776,"totalTrials":286,"cells":14573},{"EARLY_PHASE1":14574,"PHASE1":14576,"PHASE2":14578,"PHASE3":14580,"PHASE4":14582,"NA":14584},{"trials":14575,"activeCount":99},[],{"trials":14577,"activeCount":99},[],{"trials":14579,"activeCount":99},[],{"trials":14581,"activeCount":99},[],{"trials":14583,"activeCount":99},[],{"trials":14585,"activeCount":99},[14586],{"nctId":2769,"briefTitle":2770,"status":118,"phases":14587,"primaryCompletion":1071,"completion":1071,"start":2772,"enrollment":2773,"conditions":14588,"interventions":14589},[92],[34],[51,2776],{"intervention":14591,"totalTrials":286,"cells":14592},"Darbepoetin alfa",{"EARLY_PHASE1":14593,"PHASE1":14595,"PHASE2":14597,"PHASE3":14599,"PHASE4":14601,"NA":14603},{"trials":14594,"activeCount":99},[],{"trials":14596,"activeCount":99},[],{"trials":14598,"activeCount":99},[],{"trials":14600,"activeCount":99},[],{"trials":14602,"activeCount":99},[],{"trials":14604,"activeCount":99},[14605],{"nctId":14606,"briefTitle":14607,"status":118,"phases":14608,"primaryCompletion":2874,"completion":2874,"start":471,"enrollment":487,"conditions":14609,"interventions":14610},"NCT00355407","Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation",[92],[461],[14591]]